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Summary
This report updates and combines into one document earlier versions of guidelines for preventing and treating opportunistic 
infections (OIs) among HIV-exposed and HIV-infected children, last published in 2002 and 2004, respectively. These guidelines 
are intended for use by clinicians and other health-care workers providing medical care for HIV-exposed and HIV-infected chil-
dren in the United States. The guidelines discuss opportunistic pathogens that occur in the United States and one that might be 
acquired during international travel (i.e., malaria). Topic areas covered for each OI include a brief description of the epidemiology, 
clinical presentation, and diagnosis of the OI in children; prevention of exposure; prevention of disease by chemoprophylaxis and/
or vaccination; discontinuation of primary prophylaxis after immune reconstitution; treatment of disease; monitoring for adverse 
effects during treatment; management of treatment failure; prevention of disease recurrence; and discontinuation of secondary pro-
phylaxis after immune reconstitution. A separate document about preventing and treating of OIs among HIV-infected adults and 
postpubertal adolescents (Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults 
and Adolescents) was prepared by a working group of adult HIV and infectious disease specialists.
The guidelines were developed by a panel of specialists in pediatric HIV infection and infectious diseases (the Pediatric 
Opportunistic Infections Working Group) from the U.S. government and academic institutions. For each OI, a pediatric special-
ist with content-matter expertise reviewed the literature for new information since the last guidelines were published; they then 
proposed revised recommendations at a meeting at the National Institutes of Health (NIH) in June 2007. After these presentations 
and discussions, the guidelines underwent further revision, with review and approval by the Working Group, and final endorse-
ment by NIH, CDC, the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), the Pediatric 
Infectious Disease Society (PIDS), and the American Academy of Pediatrics (AAP). The recommendations are rated by a letter that 
indicates the strength of the recommendation and a Roman 
numeral that indicates the quality of the evidence supporting 
the recommendation so readers can ascertain how best to apply 
the recommendations in their practice environments.
An important mode of acquisition of OIs, as well as HIV 
infection among children, is from their infected mother; HIV-
infected women coinfected with opportunistic pathogens might 
be more likely than women without HIV infection to transmit 
The material in this report originated in the National Center for 
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these infections to their infants. In addition, HIV-infected women or HIV-infected family members coinfected with certain oppor-
tunistic pathogens might be more likely to transmit these infections horizontally to their children, resulting in increased likelihood 
of primary acquisition of such infections in the young child. Therefore, infections with opportunistic pathogens might affect not just 
HIV-infected infants but also HIV-exposed but uninfected infants who become infected by the pathogen because of transmission from 
HIV-infected mothers or family members with coinfections. These guidelines for treating OIs in children therefore consider treatment 
of infections among all children, both HIV-infected and uninfected, born to HIV-infected women.
Additionally, HIV infection is increasingly seen among adolescents with perinatal infection now surviving into their teens and 
among youth with behaviorally acquired HIV infection. Although guidelines for postpubertal adolescents can be found in the adult 
OI guidelines, drug pharmacokinetics and response to treatment may differ for younger prepubertal or pubertal adolescents. Therefore, 
these guidelines also apply to treatment of HIV-infected youth who have not yet completed pubertal development.
Major changes in the guidelines include 1) greater emphasis on the importance of antiretroviral therapy for preventing and treat-
ing OIs, especially those OIs for which no specific therapy exists; 2) information about the diagnosis and management of immune 
reconstitution inflammatory syndromes; 3) information about managing antiretroviral therapy in children with OIs, including 
potential drug–drug interactions; 4) new guidance on diagnosing of HIV infection and presumptively excluding HIV infection 
in infants that affect the need for initiation of prophylaxis to prevent Pneumocystis jirovecii pneumonia (PCP) in neonates; 
5) updated immunization recommendations for HIV-exposed and HIV-infected children, including hepatitis A, human papillo-
mavirus, meningococcal, and rotavirus vaccines; 6) addition of sections on aspergillosis; bartonella; human herpes virus-6, -7, and 
-8; malaria; and progressive multifocal leukodystrophy (PML); and 7) new recommendations on discontinuation of OI prophylaxis 
after immune reconstitution in children. The report includes six tables pertinent to preventing and treating OIs in children and 
two figures describing immunization recommendations for children aged 0–6 years and 7–18 years.
Because treatment of OIs is an evolving science, and availability of new agents or clinical data on existing agents might 
change therapeutic options and preferences, these recommendations will be periodically updated and will be available at 
http://AIDSInfo.nih.gov.
from 3.3 to 0.4 per 100 child-years; herpes zoster from 2.9 to 
1.1 per 100 child-years; disseminated Mycobacterium avium 
complex (MAC) from 1.8 to 0.14 per 100 child-years; and 
Pneumocystis jirovecii pneumonia (PCP) from 1.3 to 0.09 per 
100 child-years.
Despite this progress, prevention and management of OIs 
remain critical components of care for HIV-infected children. 
OIs continue to be the presenting symptom of HIV infection 
among children whose HIV-exposure status is not known (e.g., 
because of lack of maternal antenatal HIV testing). For children 
with known HIV infection, barriers such as parental substance 
abuse may limit links to appropriate care where indications 
for prophylaxis would be evaluated. HIV-infected children 
eligible for primary or secondary OI prophylaxis might fail to 
be treated because they are receiving suboptimal medical care. 
Additionally, adherence to multiple drugs (antiretroviral drugs 
and concomitant OI prophylactic drugs) may prove difficult 
for the child or family. Multiple drug-drug interactions of OI, 
antiretroviral, and other drugs resulting in increased adverse 
events and decreased treatment efficacy may limit the choice 
and continuation of both HAART and prophylactic regimens. 
OIs continue to occur in children in whom drug resistance 
causes virologic and immunologic failure. In PACTG 219, lack 
of a sustained response to HAART predicted OIs in children 
(5). Finally, immune reconstitution inflammatory syndrome 
Background
Opportunistic Infections 
in HIV-Infected Children 
in the Era of Potent 
Antiretroviral Therapy 
In the pre-antiretroviral era and before development of 
potent combination highly active antiretroviral treatment 
(HAART) regimens, opportunistic infections (OIs) were the 
primary cause of death in human immuno deficiency virus 
(HIV)-infected children (1). Current HAART regimens sup-
press viral replication, provide significant immune reconstitu-
tion, and have resulted in a substantial and dramatic decrease 
in acquired immuno deficiency syndrome (AIDS)-related OIs 
and deaths in both adults and children (2–4). In an observa-
tional study from pediatric clinical trial sites in the United 
States, Pediatric AIDS Clinical Trials Group (PACTG) 219, 
the incidence of the most common initial OIs in children 
during the potent HAART era (study period 2000–2004) was 
substantially lower than the incidence in children followed 
at the same sites during the pre-HAART era (study period 
1988–1998) (1,3). For example, the incidence for bacterial 
pneumonia decreased from 11.1 per 100 child-years during 
the pre-HAART era to 2.2 during the HAART era; bacteremia 
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(IRIS), initially described in HIV-infected adults but also seen 
in HIV-infected children, can complicate treatment of OIs 
when HAART is started or when optimization of a failing regi-
men is attempted in a patient with acute OI. Thus, preventing 
and treating OIs in HIV-infected children remains important 
even in an era of potent HAART.
History of the Guidelines
In 1995, the U.S. Public Health Service and the Infectious 
Diseases Society of America (IDSA) developed guidelines 
for preventing OIs among adults, adolescents, and children 
infected with HIV (6). These guidelines, developed for health-
care providers and their HIV-infected patients, were revised in 
1997, 1999, and 2002 (7,8). In 2001, the National Institutes 
of Health, IDSA, and CDC convened a working group to 
develop guidelines for treating HIV-associated OIs, with a 
goal of providing evidence-based guidelines on treatment 
and prophylaxis. In recognition of unique considerations for 
HIV-infected infants, children, and adolescents—including 
differences between adults and children in mode of acquisi-
tion, natural history, diagnosis, and treatment of HIV-related 
OIs—a separate pediatric OI guidelines writing group was 
established. The pediatric OI treatment guidelines were initially 
published in December 2004 (9).
The current document combines recommendations for pre-
venting and treating OIs in HIV-exposed and HIV-infected 
children into one document; it accompanies a similar docu-
ment on preventing and treating OIs among HIV-infected 
adults prepared by a separate group of adult HIV and infectious 
disease specialists. Both sets of guidelines were prepared by the 
Opportunistic Infections Working Group under the auspices of 
the Office of AIDS Research (OAR) of the National Institutes 
of Health. Pediatric specialists with expertise in specific OIs 
reviewed the literature since the last publication of the preven-
tion and treatment guidelines, conferred over several months, 
and produced draft guidelines. The Pediatric OI Working 
Group reviewed and discussed recommendations at a meet-
ing in Bethesda, Maryland, on June 25–26, 2007. After the 
meeting, the document was revised, then reviewed and elec-
tronically approved by the writing group members. The final 
report was further reviewed by the core Writing Group, the 
Office of AIDS Research, experts at CDC, the HIV Medicine 
Association of IDSA, the Pediatric Infectious Diseases Society, 
and the American Academy of Pediatrics before final approval 
and publication.
Why Pediatric Prevention 
and Treatment Guidelines?
Mother-to-child transmission is an important mode of acqui-
sition of OIs and HIV infection in children. HIV-infected 
women coinfected with opportunistic pathogens might be 
more likely than women without HIV infection to transmit 
these infections to their infants. For example, greater rates 
of perinatal transmission of hepatitis C and cytomegalovirus 
(CMV) have been reported from HIV-infected than HIV-
uninfected women (10,11). In addition, HIV-infected women 
or HIV-infected family members coinfected with certain 
opportunistic pathogens might be more likely to transmit 
these infections horizontally to their children, increasing the 
likelihood of primary acquisition of such infections in the 
young child. For example, Mycobacterium tuberculosis infection 
among children primarily reflects acquisition from family mem-
bers who have active tuberculosis (TB) disease, and increased 
incidence and prevalence of TB among HIV-infected persons 
is well documented. HIV-exposed or -infected children in 
the United States might have a higher risk for exposure to 
M. tuberculosis than would comparably aged children in the 
general U.S. population because of residence in households 
with HIV-infected adults (12). Therefore, OIs might affect 
not only HIV-infected infants but also HIV-exposed but 
uninfected infants who become infected with opportunistic 
pathogens because of transmission from HIV-infected mothers 
or family members with coinfections. Guidelines for treating 
OIs in children must consider treatment of infections among 
all children—both HIV-infected and HIV-uninfected—born 
to HIV-infected women.
The natural history of OIs among children might differ 
from that among HIV-infected adults. Many OIs in adults are 
secondary to reactivation of opportunistic pathogens, which 
often were acquired before HIV infection when host immunity 
was intact. However, OIs among HIV-infected children more 
often reflect primary infection with the pathogen. In addition, 
among children with perinatal HIV infection, the primary 
infection with the opportunistic pathogen occurs after HIV 
infection is established and the child’s immune system already 
might be compromised. This can lead to different manifesta-
tions of specific OIs in children than in adults. For example, 
young children with TB are more likely than adults to have 
nonpulmonic and disseminated infection, even without con-
current HIV infection.
Multiple difficulties exist in making laboratory diagnoses of 
various infections in children. A child’s inability to describe the 
symptoms of disease often makes diagnosis more difficult. For 
infections for which diagnosis is made by laboratory detection 
of specific antibodies (e.g., the hepatitis viruses and CMV), 
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transplacental transfer of maternal antibodies that can persist 
in the infant for up to 18 months complicates the ability to 
make a diagnosis in young infants. Assays capable of directly 
detecting the pathogen are required to diagnose such infections 
definitively in infants. In addition, diagnosing the etiology of 
lung infections in children can be difficult because children 
usually do not produce sputum, and more invasive procedures, 
such as bronchoscopy or lung biopsy, might be needed to make 
a more definitive diagnosis.
Data related to the efficacy of various therapies for OIs in 
adults usually can be extrapolated to children, but issues related 
to drug pharmacokinetics, formulation, ease of administration, 
and dosing and toxicity require special considerations for chil-
dren. Young children in particular metabolize drugs differently 
from adults and older children, and the volume of distribution 
differs. Unfortunately, data often are lacking on appropriate 
drug dosing recommendations for children aged <2 years.
The prevalence of different opportunistic pathogens among 
HIV-infected children during the pre-HAART era varied by 
child age, previous OI, immunologic status, and pathogen (1). 
During the pre-HAART era, the most common OIs among 
children in the United States (event rates >1.0 per 100 child-
years) were serious bacterial infections (most commonly pneu-
monia, often presumptively diagnosed, and bacteremia), herpes 
zoster, disseminated MAC, PCP, and candidiasis (esophageal 
and tracheobronchial disease). Less commonly observed OIs 
(event rate <1.0 per 100 child-years) included CMV disease, 
cryptosporidiosis, TB, systemic fungal infections, and toxoplas-
mosis (3,4). History of a previous AIDS-defining OI predicted 
development of a new infection. Although most infections 
occurred among substantially immuno compromised children, 
serious bacterial infections, herpes zoster, and TB occurred 
across the spectrum of immune status.
Descriptions of pediatric OIs in children receiving HAART 
have been limited. As with HIV-infected adults, substantial 
decreases in mortality and morbidity, including OIs, have been 
observed among children receiving HAART (2). Although the 
number of OIs has substantially decreased during the HAART 
era, HIV-associated OIs and other related infections continue 
to occur among HIV-infected children (3,13).
In contrast to recurrent serious bacterial infections, some of 
the protozoan, fungal, or viral OIs complicating HIV are not 
curable with available treatments. Sustained, effective HAART, 
resulting in improved immune status, has been established 
as the most important factor in controlling OIs among both 
HIV-infected adults and children (14). For many OIs, after 
treatment of the initial infectious episode, secondary prophy-
laxis in the form of suppressive therapy is indicated to prevent 
recurrent clinical disease from reactivation or reinfection (15).
These guidelines are a companion to the Guidelines for 
Prevention and Treatment of Opportunistic Infections in HIV-
Infected Adults and Adolescents (16). Treatment of OIs is an 
evolving science, and availability of new agents or clinical 
data on existing agents might change therapeutic options and 
preferences. As a result, these recommendations will need to 
be periodically updated.
Because the guidelines target HIV-exposed and -infected 
children in the United States, the opportunistic pathogens 
discussed are those common to the United States and do not 
include certain pathogens (e.g., Penicillium marneffei) that 
might be seen more frequently in resource-limited countries 
or that are common but seldom cause chronic infection (e.g., 
chronic parvovirus B19 infection). The document is organized 
to provide information about the epidemiology, clinical pre-
sentation, diagnosis, and treatment for each pathogen. The 
most critical treatment recommendation is accompanied by 
a rating that includes a letter and a roman numeral and is 
similar to the rating systems used in other U.S. Public Health 
Service/Infectious Diseases Society of America guidelines (17). 
Recommendations unrelated to treatment were not graded, 
with some exceptions. The letter indicates the strength of 
the recommendation, which is based on the opinion of the 
Working Group, and the roman numeral reflects the nature 
of the evidence supporting the recommendation (Box 1). 
Because licensure of drugs for children often relies on efficacy 
data from adult trials and safety data in children, recommenda-
tions sometimes may need to rely on data from clinical trials 
or studies in adults.
Tables at the end of this document summarize recommenda-
tions for preventing OIs in children (Tables 1–3); treatment 
of OIs in children (Table 4); drug preparation and toxicity 
information for children (Table 5); drug-drug interactions 
(Table 6), and vaccination recommendations for HIV-infected 
children and adolescents (Figures 1 and 2).
Diagnosis of HIV Infection 
and Presumptive Lack 
of HIV Infection in Children 
with Perinatal HIV Exposure
Because maternal antibody persists in children up to 18 
months of age, virologic tests (usually HIV DNA or RNA 
assays) are needed to determine infection status in children 
aged <18 months. The CDC surveillance definition states a 
child is considered definitively infected if he or she has posi-
tive virologic results on two separate specimens or is aged >18 
months and has either a positive virologic test or a positive 
confirmed HIV-antibody test.
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CDC has revised laboratory criteria to allow presumptive 
exclusion of HIV infection at an earlier age for surveillance 
(Box 2) (http://www.cdc.gov/mmwr/preview/mmwrhtml/
rr5710a1.htm). A child who has not been breast-fed is pre-
sumed to be uninfected if he or she has no clinical or laboratory 
evidence of HIV infection and has two negative virologic tests 
both obtained at >2 weeks of age and one obtained at >4 weeks 
of age and no positive viralogic tests; or one negative virologic 
test at >8 weeks of age and no positive virologic tests; or one 
negative HIV-antibody test at >6 months of age. Definitive 
lack of infection is confirmed by two negative viral tests, both 
of which were obtained at >1 month of age and one of which 
was obtained at >4 months of age, or at least two negative HIV-
antibody tests from separate specimens obtained at >6 months 
of age. The new presumptive definition of “uninfected” may 
allow clinicians to avoid starting PCP prophylaxis in some 
HIV-exposed infants at age 6 weeks (see PCP section).
Antiretroviral Therapy 
and Management 
of Opportunistic Infections
Studies in adults and children have demonstrated that 
HAART reduces the incidence of OIs and improves sur-
vival, independent of the use of OI antimicrobial prophy-
laxis. HAART can improve or resolve certain OIs, such as 
cryptosporidiosis or microsporidiosis infection, for which 
effective specific treatments are not available. However, potent 
HAART does not replace the need for OI prophylaxis in chil-
dren with severe immune suppression. Additionally, initiation 
of HAART in persons with an acute or latent OI can lead to 
IRIS, an exaggerated inflammatory reaction that can clinically 
worsen disease and require use of anti-inflammatory drugs (see 
IRIS section below).
Specific data are limited to guide recommendations for when 
to start HAART in children with an acute OI and how to 
manage HAART when an acute OI occurs in a child already 
receiving HAART. The decision of when to start HAART in 
a child with an acute or latent OI needs to be individualized 
and will vary by the degree of immunologic suppression in 
the child before he or she starts HAART. Similarly, in a child 
already receiving HAART who develops an OI, management 
will need to account for the child’s clinical, viral, and immune 
status on HAART and the potential drug-drug interactions 
between HAART and the required OI drug regimen.
Immune Reconstitution Inflammatory 
Syndrome
As in adults, antiretroviral therapy improves immune func-
tion and CD4 cell count in HIV-infected children; within 
the first few months after starting treatment, HIV viral load 
sharply decreases and the CD4 count rapidly increases. This 
BOX 1. Rating scheme for prevention and treatment recommendations for HIV-exposed and HIV-infected infants and children — 
United States
Category Definition
Strength of the recommendation
A Strong evidence for efficacy and substantial clinical benefit both support recommendations for use. 
Always should be offered.
B Moderate evidence for efficacy—or strong evidence for efficacy but only limited clinical benefit—support 
recommendations for use. Generally should be offered.
C Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy 
might not outweigh adverse consequences (e.g., drug toxicity, drug interactions) or cost of the treatment 
under consideration. Optional.
D Moderate evidence for lack of efficacy or for adverse outcomes supports a recommendation against use. 
Generally should not be offered.
E Good evidence for lack of efficacy or for adverse outcomes supports a recommendation against use. 
Never should be offered.
Quality of evidence supporting the recommendation
I Evidence from at least one properly designed randomized, controlled trial.
II Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled 
studies (preferably from more than one center), or from multiple time-series studies; or dramatic results 
from uncontrolled experiments.
III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports 
of expert committees.
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results in increased capacity to mount inflammatory reactions. 
After initiation of HAART, some patients develop a paradoxical 
inflammatory response by their reconstituted immune system 
to infectious or noninfectious antigens, resulting in apparent 
clinical worsening. This is referred to as IRIS, and although 
primarily reported in adults initiating therapy, it also has been 
reported in children (18–28).
IRIS can occur after initiation of HAART because of wors-
ening of an existing active, latent, or occult OI, where infec-
tious pathogens previously not recognized by the immune 
system now evoke an immune response. This inflammatory 
response often is exaggerated in comparison with the response 
in patients who have normal immune systems (referred to by 
some experts as immune reconstitution disease). An example is 
activation of latent or occult TB after initiation of antiretroviral 
therapy (referred to by some experts as “unmasking IRIS”). 
Alternatively, clinical recrudescence of a successfully treated 
infection can occur, with paradoxical, symptomatic relapse 
Definitive infection:
Positive virologic results on two separate specimens •	
at any age
OR
Age >18 months and either a positive virologic test •	
or a positive confirmed HIV-antibody test
Presumptive exclusion of infection in nonbreastfed 
infant:
No clinical or laboratory evidence of HIV infection•	
AND
Two negative virologic tests, both obtained •	
at >2 weeks of age and one obtained at >4 weeks of 
age and no positive virologic tests 
OR
One negative virologic test at •	 >8 weeks of age and 
no positive virologic test
OR
One negative HIV antibody test at •	 >6 months of age
Definitive exclusion of infection in nonbreastfed infant:
No clinical or laboratory evidence of HIV infection•	
AND
Two negative virologic tests, both obtained •	
at >1 month of age and one obtained at >4 months 
of age and no positive virologic tests 
OR
Two or more negative HIV antibody tests •	
at >6 months of age
BOX 2. Diagnosis of HIV infection and presumptive lack of HIV 
infection in children with known exposure to perinatal HIV
despite microbiologic treatment success and sterile cultures 
(referred to as “paradoxical IRIS”). In this case, reconstitution 
of antigen-specific T-cell–mediated immunity occurs with 
activation of the immune system after initiation of HAART 
against persisting antigens, whether present as dead, intact 
organisms or as debris.
The pathologic process of IRIS is inflammatory and not 
microbiologic in etiology. Thus, distinguishing IRIS from 
treatment failure, antimicrobial resistance, or noncompliance 
is important. In therapeutic failure, a microbiologic culture 
should reveal the continued presence of an infectious organism, 
whereas in paradoxical IRIS, follow-up cultures are most often 
sterile. However, with “unmasking” IRIS, viable pathogens 
may be isolated.
IRIS is described primarily on the basis of reports of cases in 
adults. A proposed clinical definition is worsening symptoms 
of inflammation or infection temporally related to starting 
HAART that are not explained by newly acquired infection 
or disease, the usual course of a previously acquired disease, or 
HAART toxicity in a patient with >1 log10 decrease in plasma 
HIV RNA (29).
The timing of IRIS after initiation of HAART in adults has 
varied, with most cases occurring during the first 2–3 months 
after initiation; however, as many as 30% of IRIS cases can 
present beyond the first 3 months of treatment. Later-onset 
IRIS may result from an immune reaction against persistent 
noninfectious antigen. The onset of antigen clearance varies, 
but antigen or antigen debris might persist long after micro-
biologic sterility. For example, after pneumococcal bacteremia, 
the C-polysaccharide antigen can be identified in the urine of 
40% of HIV-infected adults 1 month after successful treat-
ment; similarly, mycobacterial DNA can persist several months 
past culture viability.
In adults, IRIS most frequently has been observed after 
initiation of therapy in persons with mycobacterial infections 
(including MAC and M. tuberculosis), PCP, cryptococcal 
infection, CMV, varicella zoster or herpes virus infections, 
hepatitis B and C infections, toxoplasmosis, and progres-
sive multifocal leukoencephalopathy (PML). Reactions also 
have been described in children who had received bacille 
Calmette-Guérin (BCG) vaccine and later initiated HAART 
(22,25,26,28). In a study of 153 symptomatic children with 
CD4 <15% at initiation of therapy in Thailand, the incidence 
of IRIS was 19%, with a median time of onset of 4 weeks after 
start of HAART; children who developed IRIS had lower base-
line CD4 percentage than did children who did not develop 
IRIS (24).
No randomized controlled trials have been published evalu-
ating treatment of IRIS. Treatment has been based on severity 
of disease (CIII). For mild cases, observation alone with close 
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clinical and laboratory monitoring may be sufficient. For mod-
erate cases, nonsteroidal anti-inflammatory drugs have been 
used to ameliorate symptoms. For severe cases, corticosteroids, 
such as dexamethasone, have been used. However, the optimal 
dosing and duration of therapy are unknown, and inflamma-
tion can take weeks to months to subside. During this time, 
HAART should be continued.
Initiation of HAART for an Acute OI 
in Treatment-Naïve Children
The ideal time to initiate HAART for an acute OI is 
unknown. The benefit of initiating HAART is improved 
immune function, which could result in faster resolution of 
the OI. This is particularly important for OIs for which effec-
tive therapeutic options are limited or not available, such as 
for cryptosporidiosis, microsporidiosis, PML, and Kaposi sar-
coma (KS). However, potential problems exist when HAART 
and treatment for the OI are initiated simultaneously. These 
include drug-drug interactions between the antiretroviral and 
antimicrobial drugs, particularly given the limited repertoire 
of antiretroviral drugs available for children than for adults; 
issues related to toxicity, including potential additive toxicity 
of antiretroviral and OI drugs and difficulty in distinguishing 
HAART toxicity from OI treatment toxicity; and the potential 
for IRIS to complicate OI management.
The primary consideration in delaying HAART until after 
initial treatment of the acute OI is risk for death during the 
delay. Although the short-term risk for death in the United 
States during a 2-month HAART delay may be relatively low, 
mortality in resource-limited countries is significant. IRIS is 
more likely to occur in persons with advanced HIV infection 
and higher OI-specific antigenic burdens, such as those who 
have disseminated infections or a shorter time from an acute 
OI onset to start of HAART. However, in the absence of an 
OI with central nervous system (CNS) involvement, such as 
cryptococcal meningitis, most IRIS events, while potentially 
resulting in significant morbidity, do not result in death. 
With CNS IRIS or in resource-limited countries, significant 
IRIS-related death may occur with simultaneous initiation of 
HAART and OI treatment; however, significant mortality also 
occurs in the absence of HAART.
Because no randomized trials exist in either adults or children 
to address the optimal time for starting HAART when an acute 
OI is present, decisions need to be individualized for each 
child. The timing is a complex decision based on the severity 
of HIV disease, efficacy of standard OI-specific treatment, 
social support system, medical resource availability, potential 
drug-drug interactions, and risk for IRIS. Most experts believe 
that for children who have OIs that lack effective treatment 
(e.g., cryptosporidiosis, microsporidiosis, PML, KS), the early 
benefit of potent HAART outweighs any increased risk, and 
potent HAART should begin as soon as possible (AIII). For 
other OIs, such as TB, MAC, PCP, and cryptococcal menin-
gitis, awaiting a response to therapy may be warranted before 
initiating HAART (CIII).
Management of Acute OIs in HIV-Infected 
Children Receiving HAART
OIs in HIV-infected children soon after initiation of HAART 
(within 12 weeks) may be subclinical infections unmasked 
by HAART-related improvement in immune function, also 
known as “unmasking IRIS” and occurring usually in chil-
dren who have more severe immune suppression at initiation 
of HAART. This does not represent a failure of HAART but 
rather a sign of immune reconstitution (see IRIS section). In 
such situations, HAART should be continued and treatment 
for the OI initiated (AIII). Assessing the potential for drug-
drug interactions between the antiretroviral and antimicrobial 
drugs and whether treatment modifications need to be made 
is important.
In children who develop an OI after receiving >12 weeks of 
HAART with virologic and immunologic response to therapy, 
it can be difficult to distinguish between later-onset IRIS 
(such as a “paradoxical IRIS” reaction where the reconstituted 
immune system demonstrates an inflammatory reaction to a 
noninfectious antigen) and incomplete immune reconstitu-
tion with HAART allowing occurrence of a new OI. In such 
situations, HAART should be continued, and if microbiologic 
evaluation demonstrates organisms by stain or culture, specific 
OI-related therapy should be initiated (AII).
OIs also can occur in HIV-infected children experiencing 
virologic and immunologic failure on HAART and represent 
clinical failure of therapy. In this situation, treatment of the OI 
should be initiated, viral resistance testing performed, and the 
child’s HAART regimen reassessed, as described in pediatric 
antiretroviral guidelines (14).
Preventing Vaccine-Preventable 
Diseases in HIV-Infected Children 
and Adolescents
Vaccines are an extremely effective primary prevention tool, 
and vaccines that protect against 16 diseases are recommended 
for routine use in children and adolescents in the United States. 
Vaccination schedules for children aged 0–6 years and 7–18 
years are published annually (http://www.cdc.gov/vaccines/
recs/schedules/default.htm). These schedules are compiled 
from approved vaccine-specific policy recommendations and 
are standardized among the major vaccine policy-setting and 
vaccine-delivery organizations (e.g., Advisory Committee 
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on Immunization Practices [ACIP], American Academy of 
Pediatrics, American Association of Family Physicians).
HIV-infected children should be protected from vaccine-
preventable diseases. Most vaccines recommended for routine 
use can be administered safely to HIV-exposed or HIV-infected 
children. The recommended vaccination schedules for 2009 for 
HIV-exposed and HIV-infected children aged 0–6 years and 
7–18 years were approved by the ACIP through October 2008 
(Figures 1 and 2). These schedules will be updated periodically 
to reflect additional ACIP-approved vaccine recommendations 
that pertain to HIV-exposed or HIV-infected children.
All inactivated vaccines can be administered safely to per-
sons with altered immunocompetence whether the vaccine is 
a killed whole organism or a recombinant, subunit, toxoid, 
polysaccharide, or polysaccharide protein-conjugate vaccine. 
If inactivated vaccines are indicated for persons with altered 
immunocompetence, the usual doses and schedules are recom-
mended. However, the effectiveness of such vaccinations might 
be suboptimal (30).
Persons with severe cell-mediated immune deficiency should 
not receive live attenuated vaccines. However, children with 
HIV infection are at higher risk than immunocompetent chil-
dren for complications of varicella, herpes zoster, and measles. 
On the basis of limited safety, immunogenicity, and efficacy 
data among HIV-infected children, varicella and measles-
mumps-rubella vaccines can be considered for HIV-infected 
children who are not severely immunosuppressed (i.e., those 
with age-specific CD4 cell percentages of >15%) (30–32). 
Practitioners should consider the potential risks and benefits 
of administering rotavirus vaccine to infants with known or 
suspected altered immunocompetence; consultation with an 
immunologist or infectious diseases specialist is advised. There 
are no safety or efficacy data related to the administration of 
rotavirus vaccine to infants who are potentially immuno-
compromised, including those who are HIV-infected (33). 
However, two considerations support vaccination of HIV-
exposed or -infected infants: first, the HIV diagnosis may not 
be established in infants born to HIV-infected mothers before 
the age of the first rotavirus vaccine dose (only 1.5%–3.0% of 
HIV-exposed infants in the United States will be determined 
to be HIV-infected); and second, vaccine strains of rotavirus 
are considerably attenuated.
Consult the specific ACIP statements (available at http://
www.cdc.gov/vaccines/pubs/ACIP-list.htm) for more detail 
regarding recommendations, precautions, and contraindica-
tions for use of specific vaccines (http://www.cdc.gov/mmwr/
PDF/rr/rr4608.pdf and http://www.cdc.gov/mmwr/pdf/rr/
rr5602.pdf ) (31–44).
Bacterial Infections
Bacterial Infections, 
Serious and Recurrent
Epidemiology
During the pre-HAART era, serious bacterial infections were 
the most commonly diagnosed OIs in HIV-infected children, 
with an event rate of 15 per 100 child-years (1). Pneumonia was 
the most common bacterial infection (11 per 100 child-years), 
followed by bacteremia (3 per 100 child-years), and urinary 
tract infection (2 per 100 child-years). Other serious bacterial 
infections, including osteomyelitis, meningitis, abscess, and 
septic arthritis, occurred at rates <0.2 per 100 child-years. More 
minor bacterial infections such as otitis media and sinusitis 
were particularly common (17–85 per 100 child-years) in 
untreated HIV-infected children (45).
With the advent of HAART, the rate of pneumonia has 
decreased to 2.2–3.1 per 100 child-years (3,46), similar to the 
rate of 3–4 per 100 child-years in HIV-uninfected children 
(47,48). The rate of bacteremia/sepsis during the HAART era 
also has decreased dramatically to 0.35–0.37 per 100 child-
years (3,4,46), but this rate remains substantially higher than 
the rate of <0.01 per 100 child-years in HIV-uninfected chil-
dren (49,50). Sinusitis and otitis rates among HAART-treated 
children are substantially lower (2.9–3.5 per 100 child-years) 
but remain higher than rates in children who do not have HIV 
infection (46).
Acute pneumonia, often presumptively diagnosed in 
children, was associated with increased risk for long-term 
mortality among HIV-infected children in one study dur-
ing the pre-HAART era (51). HIV-infected children with 
pneumonia are more likely to be bacteremic and to die than 
are HIV-uninfected children with pneumonia (52). Chronic 
lung disease might predispose persons to development of acute 
pneumonia; in one study, the incidence of acute lower respi-
ratory tract infection in HIV-infected children with chronic 
lymphoid interstitial pneumonitis was approximately 10-fold 
higher than in a community-based study of HIV-uninfected 
children (53). Chronically abnormal airways probably are 
more susceptible to infectious exacerbations (similar to those 
in children and adults with bronchiectasis or cystic fibrosis) 
caused by typical respiratory bacteria (Streptococcus pneumoniae, 
nontypeable Haemophilus influenzae) and Pseudomonas spp.
S. pneumoniae was the most prominent invasive bacterial 
pathogen in HIV-infected children both in the United States 
and worldwide, accounting for >50% of bacterial bloodstream 
infections in HIV-infected children (1,4,54–57). HIV-infected 
children have a markedly higher risk for pneumococcal infec-
tion than do HIV-uninfected children (58,59). In the absence 
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of HAART, the incidence of invasive pneumococcal disease 
was 6.1 per 100 child-years among HIV-infected children 
through age 7 years (60), whereas among children treated with 
HAART, the rate of invasive pneumococcal disease decreased 
by about half, to 3.3 per 100 child-years (46). This is consis-
tent with the halving of invasive pneumococcal disease rates 
in HIV-infected adults receiving HAART compared with 
rates in those not receiving HAART (61). Among children 
with invasive pneumococcal infections, study results vary on 
whether penicillin-resistant pneumococcal strains are more 
commonly isolated from HIV-infected than HIV-uninfected 
persons (56,60,62–64). Reports among children without HIV 
infection have not demonstrated a difference in the case-fatality 
rate between those with penicillin-susceptible and those with 
nonsusceptible pneumococcal infections (case-fatality rate was 
associated with severity of disease and underlying illness) (65). 
Invasive disease caused by penicillin-nonsusceptible pneumo-
coccus was associated with longer fever and hospitalization but 
not with greater risk for complications or poorer outcome in 
a study of HIV-uninfected children (66). Since routine use of 
seven-valent pneumococcal conjugate vaccine (PCV) in 2000, 
the overall incidence of drug-resistant pneumococcal infections 
has stabilized or decreased.
H. influenzae type b (Hib) also has been reported to have 
been more common in HIV-infected children before the avail-
ability of Hib vaccine. In a study in South African children 
who had not received Hib conjugate vaccine, the estimated 
relative annual rate of overall invasive Hib disease in children 
aged <1 year was 5.9 times greater among HIV-infected than 
HIV-uninfected children, and HIV-infected children were at 
greater risk for bacteremic pneumonia (67). However, Hib is 
unlikely to occur in HIV-infected children in most U.S. com-
munities, where high rates of Hib vaccination result in very low 
rates of Hib nasopharyngeal colonization among contacts.
HIV-related immune dysfunction may increase the risk for 
invasive meningococcal disease in HIV-infected patients, but 
few cases have been reported (68–72). In a population-based 
study of invasive meningococcal disease in Atlanta, Georgia 
(72), as expected, the annual rate of disease was higher for 
18- to 24-year-olds (1.17 per 100,000) than for all adults (0.5 
per 100,000), but the estimated annual rate for HIV-infected 
adults was substantially higher (11.2 per 100,000). Risk for 
invasive meningococcal disease may be higher in HIV-infected 
adults. Specific data are not available on risk for meningococcal 
disease in younger HIV-infected children.
Although the frequency of gram-negative bacteremia is lower 
than that of gram-positive bacteremia among HIV-infected 
children, gram-negative bacteremia is more common among 
children with advanced HIV disease or immunosuppression 
and among children with central venous catheters. However, 
in children aged <5 years, gram-negative bacteremia also was 
observed among children with milder levels of immune sup-
pression. In a study of 680 HIV-infected children in Miami, 
Florida, through 1997, a total of 72 (10.6%) had 95 episodes of 
gram-negative bacteremia; the predominant organisms identi-
fied in those with gram-negative bacteremia were P. aeruginosa 
(26%), nontyphoidal Salmonella (15%), Escherichia coli (15%), 
and H. influenzae (13%) (73). The relative frequency of the 
organisms varied over time, with the relative frequency of 
P. aeruginosa bacteremia increasing from 13% before 1984 to 
56% during 1995–1997, and of Salmonella from 7% before 
1984 to 22% during 1995–1997. However, H. influenzae was 
not observed after 1990 (presumably decreasing after incorpo-
ration of Hib vaccine into routine childhood vaccinations). The 
overall case-fatality rate for children with gram-negative bac-
teremia was 43%. Among Kenyan children with bacteremia, 
HIV infection increased the risk for nontyphoidal Salmonella 
and E. coli infections (74).
The presence of a central venous catheter increases the risk for 
bacterial infections in HIV-infected children, and the incidence 
is similar to that for children with cancer. The most commonly 
isolated pathogens in catheter-associated bacteremia in HIV-
infected children are similar to those in HIV-negative children 
with indwelling catheters, including coagulase-negative staphy-
lococci, S. aureus, enterococci, P. aeruginosa, gram-negative 
enteric bacilli, Bacillus cereus, and Candida spp. (57,75).
Data conflict about whether infectious morbidity increases 
in children who have been exposed to but not infected with 
HIV. In studies in developing countries, uninfected infants of 
HIV-infected mothers had higher mortality (primarily because 
of bacterial pneumonia and sepsis) than did those born to 
uninfected mothers (76,77). Advanced maternal HIV infection 
was associated with increased risk for infant death (76,77). In a 
study in Latin America and the Caribbean, 60% of 462 unin-
fected infants of HIV-infected mothers experienced infectious 
disease morbidity during the first 6 months of life, with the 
rate of neonatal infections (particularly sepsis) and respiratory 
infections higher than rates in comparable community-based 
studies (78). Among other factors, infections in uninfected 
infants were associated with more advanced maternal HIV 
disease and maternal smoking during pregnancy. However, 
in a study from the United States, the rate of lower respira-
tory tract infections in HIV-exposed, uninfected children was 
within the range reported for healthy children during the first 
year of life (79). In a separate study, the rate of overall morbid-
ity (including but not specific to infections) decreased from 
1990 through 1999 in HIV-exposed, uninfected children (80), 
although rates were not compared with an HIV-unexposed or 
community-based cohort.
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Clinical Manifestations 
Clinical presentation depends on the particular type of 
bacterial infection (e.g., bacteremia/sepsis, osteomyelitis/septic 
arthritis, pneumonia, meningitis, and sinusitis/otitis media) 
(81). HIV-infected children with invasive bacterial infections 
typically have a clinical presentation similar to children without 
HIV infection, with acute presentation and fever (59,60,82). 
HIV-infected children might be less likely than children with-
out HIV infection to have leukocytosis (60).
The classical signs, symptoms, and laboratory test abnor-
malities that usually indicate invasive bacterial infection 
(e.g., fever and elevated white blood cell count) are usually 
present but might be lacking among HIV-infected children 
who have reduced immune competence (59,81). One-third 
of HIV-infected children not receiving HAART who have 
acute pneumonia have recurrent episodes (51). Resulting lung 
damage before initiation of HAART can lead to continued 
recurrent pulmonary infections, even in the presence of effec-
tive HAART.
In studies in Malawian and South African children with acute 
bacterial meningitis, the clinical presentations of children with 
and without HIV infection were similar (83,84). However, 
in the Malawi study, HIV-infected children were 6.4-fold 
more likely to have repeated episodes of meningitis than were 
children without HIV infection, although the study did not 
differentiate recrudescence from new infections (83). In both 
studies, HIV-infected children were more likely to die from 
meningitis than were children without HIV infection.
Diagnosis 
Attempted isolation of a pathogenic organism from normally 
sterile sites (e.g., blood, cerebrospinal fluid [CSF], and pleural 
fluid) is strongly recommended. This is particularly important 
because of an increasing incidence of antimicrobial resistance, 
including penicillin-resistant S. pneumoniae and community-
acquired methicillin-resistant S. aureus (MRSA).
Because of difficulties obtaining appropriate specimens 
(e.g., sputum) from young children, bacterial pneumonia 
is most often a presumptive diagnosis in a child with fever, 
pulmonary symptoms, and an abnormal chest radiograph 
unless an accompanying bacteremia exists. In the absence of 
a laboratory isolate, differentiating viral from bacterial pneu-
monia using clinical criteria can be difficult (85). In a study of 
intravenous immune globulin (IVIG) prophylaxis of bacterial 
infections, only a bacterial pathogen was identified in 12% of 
acute presumed bacterial pneumonia episodes (51). TB and 
PCP must always be considered in HIV-infected children 
with pneumonia. Presence of wheezing makes acute bacterial 
pneumonia less likely than other causes, such as viral patho-
gens, asthma exacerbation, “atypical” bacterial pathogens such 
as Mycoplasma pneumoniae, or aspiration. Sputum induction 
obtained by nebulization with hypertonic (5%) saline was 
evaluated for diagnosis of pneumonia in 210 South African 
infants and children (median age: 6 months), 66% of whom 
had HIV infection (86). The procedure was well-tolerated, 
and identified an etiology in 63% of children with pneumonia 
(identification of bacteria in 101, M. tuberculosis in 19, and 
PCP in 12 children). Blood and, if present, fluid from pleural 
effusion should be cultured.
Among children with bacteremia, a source for the bacteremia 
should be sought. In addition to routine chest radiographs, 
other diagnostic radiologic evaluations (e.g., abdomen, 
ultrasound studies) might be necessary among HIV-infected 
children with compromised immune systems to identify less 
apparent foci of infection (e.g., bronchiectasis, internal organ 
abscesses) (87–89). Among children with central venous cath-
eters, both a peripheral and catheter blood culture should be 
obtained; if the catheter is removed, the catheter tip should be 
sent for culture. Assays for detection of bacterial antigens or 
evidence by molecular biology techniques are important for 
the diagnostic evaluation of HIV-infected children in whom 
unusual pathogens might be involved or difficult to identify 
or culture by standard techniques. For example, Bordetella 
pertussis and Chlamydia pneumoniae can be identified by a 
polymerase chain reaction (PCR) assay of nasopharyngeal 
secretions (85).
Prevention Recommendations
Preventing Exposure
Because S. pneumoniae and H. influenzae are common in 
the community, no effective way exists to eliminate exposure 
to these bacteria. However, routine use of conjugated seven-
valent PCV and Hib vaccine in U.S. infants and young children 
has dramatically reduced vaccine type invasive disease and 
nasopharyngeal colonization, conferring herd protection of 
HIV-infected contacts because of decreased exposure to Hib 
and pneumoccal serotypes included in the vaccine.
Food. To reduce the risk for exposure to potential gastroin-
testinal (GI) bacterial pathogens, health-care providers should 
advise that HIV-infected children avoid eating the following 
raw or undercooked foods (including other foods that 
contain them): eggs, poultry, meat, seafood (especially raw 
shellfish), and raw seed sprouts. Unpasteurized dairy products 
and unpasteurized fruit juices also should be avoided. Of 
particular concern to HIV-infected infants and children is the 
potential for caretakers to handle these raw foods (e.g., during 
meal preparation) and then unknowingly transfer bacteria from 
their hands to the child’s food, milk or formula or directly to 
the child. Hands, cutting boards, counters, and knives and 
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other utensils should be washed thoroughly after contact with 
uncooked foods. Produce should be washed thoroughly before 
being eaten.
Pets. When obtaining a new pet, caregivers should avoid 
dogs or cats aged <6 months or stray animals. HIV-infected 
children and adults should avoid contact with any animals that 
have diarrhea and should wash their hands after handling pets, 
including before eating, and avoid contact with pets’ feces. 
HIV-infected children should avoid contact with reptiles 
(e.g., snakes, lizards, iguanas, and turtles) and with chicks and 
ducklings because of the risk for salmonellosis.
Travel. The risk for foodborne and waterborne infections 
among immunosuppressed, HIV-infected persons is magnified 
during travel to economically developing countries. HIV-infected 
children who travel to such countries should avoid foods and 
beverages that might be contaminated, including raw fruits and 
vegetables, raw or undercooked seafood or meat, tap water, 
ice made with tap water, unpasteurized milk and dairy products, 
and items sold by street vendors. Foods and beverages that are 
usually safe include steaming hot foods, fruits that are peeled by 
the traveler, bottled (including carbonated) beverages, and water 
brought to a rolling boil for 1 minute. Treatment of water with 
iodine or chlorine might not be as effective as boiling and will 
not eliminate Cryptosporidia but can be used when boiling is 
not practical.
Preventing First Episode of Disease
HIV-infected children aged <5 years should receive the 
Hib conjugate vaccine (AII) (Figure 1). Clinicians and other 
health-care providers should consider use of Hib vaccine among 
HIV-infected children >5 years old who have not previously 
received Hib vaccine (AIII) (30,34). For these older children, 
the American Academy of Pediatrics recommends two doses of 
any conjugate Hib vaccine, administered at least 1–2 months 
apart (AIII) (90).
HIV-infected children aged 2–59 months should receive the 
seven-valent PCV (AII). A four-dose series of PCV is recom-
mended for routine administration to infants at ages 2, 4, 6, 
and 12–15 months; two or three doses are recommended for 
previously unvaccinated infants and children aged 7–23 months 
depending on age at first vaccination (36). Incompletely vac-
cinated children aged 24–59 months should receive two doses 
of PCV >8 weeks apart. Children who previously received 
three PCV doses need only one additional dose. Additionally, 
children aged >2 years should receive the 23-valent pneu-
mococcal polysaccharide vaccine (PPSV) (>2 months after 
their last PCV dose), with a single revaccination with PPSV 
5 years later (CIII) (36) (see http://www.cdc.gov/vaccines/recs/
provisional/downloads/pneumo-Oct-2008-508.pdf for the 
most updated recommendations). Data are limited regarding 
efficacy of PCV for children aged >5 years and for adults who 
are at high risk for pneumococcal infection. Administering 
PCV to older children with high-risk conditions (including 
HIV-infected children) is not contraindicated. (Figures 1 
and 2). One study reported that five-valent PCV is immu-
nogenic among HIV-infected children aged 2–9 years (91). A 
multicenter study of pneumococcal vaccination in a group of 
HIV-infected children not administered PCV during infancy 
demonstrated the safety and immunogenicity of two doses of 
PCV followed by one dose of PPSV for HAART-treated HIV-
infected children aged 2–19 years (including some who had 
previously received PPSV) (92). In a placebo-controlled trial 
of a nine-valent PCV among South African children, although 
vaccine efficacy was somewhat lower among children with than 
without HIV infection (65% versus 85%, respectively), the 
incidence of invasive pneumococcal disease was substantially 
lower among HIV-infected vaccine recipients (63).
HIV-infected children probably are at increased risk for 
meningococcal disease, although not to the extent they are 
for invasive S. pneumoniae infection. Although the efficacy of 
conjugated meningococcal vaccine (MCV) and meningococcal 
polysaccharide vaccine (MPSV) among HIV-infected patients 
is unknown, HIV infection is not a contraindication to receiv-
ing these vaccines (30). MCV is currently recommended for 
all children at age 11 or 12 years or at age 13–18 years if not 
previously vaccinated and for previously unvaccinated college 
freshmen living in a dormitory (44). A multicenter safety 
and immunogenicity trial of MCV in HIV-infected 11- to 
24-year-olds is under way. In addition, children at high risk 
for meningococcal disease because of other conditions (e.g., 
terminal complement deficiencies, anatomic or functional 
asplenia) should receive MCV if aged 2–10 years (BIII) (41). 
Although the efficacy of MCV among HIV-infected children is 
unknown, because patients with HIV probably are at increased 
risk for meningococcal disease, HIV-infected children who 
do not fit into the above groups may elect to be vaccinated. 
Revaccination with MCV is indicated for children who had 
been vaccinated >5 years previously with MPSV (CIII).
Because influenza increases the risk for secondary bacterial respi-
ratory infections (93), following guidelines for annual influenza 
vaccination for influenza prevention can be expected to reduce 
the risk for serious bacterial infections in HIV-infected children 
(BIII) (Figures 1 and 2) (35).
To prevent serious bacterial infections among HIV-infected 
children who have hypogammaglobulinemia (IgG <400 mg/dL), 
clinicians should use IVIG (AI). During the pre-HAART era, 
IVIG was effective in preventing serious bacterial infections 
in symptomatic HIV-infected children (54), but this effect 
was most clearly demonstrated only in those not receiving 
daily trimethoprim–sulfamethoxazole (TMP–SMX) for PCP 
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prophylaxis (55). Thus, IVIG is no longer recommended for 
primary prevention of serious bacterial infections in HIV-infected 
children unless hypogammaglobulinemia is present or functional 
antibody deficiency is demonstrated by either poor specific 
antibody titers or recurrent bacterial infections (CII).
TMP–SMX administered daily for PCP prophylaxis is effective 
in reducing the rate of serious bacterial infections (predominantly 
respiratory) in HIV-infected children who do not have access to 
HAART (AII) (55,94). Atovaquone combined with azithro-
mycin, which provides prophylaxis for MAC as well as PCP, 
has been shown in HIV-infected children to be as effective as 
TMP–SMX in preventing serious bacterial infections and is 
similarly tolerated (95). However, indiscriminate use of antibiot-
ics (when not indicated for PCP or MAC prophylaxis or other 
specific reasons) might promote development of drug-resistant 
organisms. Thus, antibiotic prophylaxis is not recommended 
solely for primary prevention of serious bacterial infections 
(DIII).
In developing countries, where endemic deficiency of vitamin 
A and zinc is common, supplementation with vitamin A and zinc 
conferred additional protection against bacterial diarrhea and/or 
pneumonia in HIV-infected children (96,97). However, in the 
United States, although attention to good nutrition including 
standard daily multivitamins is an important component of care 
for HIV-infected children, additional vitamin supplementation 
above the recommended daily amounts is not recommended 
(DIII).
Discontinuation of Primary Prophylaxis
A clinical trial, PACTG 1008, demonstrated that discon-
tinuation of MAC and/or PCP antibiotic prophylaxis in 
HIV-infected children who achieved immune reconstitution 
(CD4 >15%) while receiving ART did not result in excessive 
rates of serious bacterial infections (46).
Treatment Recommendations
Treatment of Disease
The principles of treating serious bacterial infections are the 
same in HIV-infected and HIV-uninfected children. Specimens 
for microbiologic studies should be collected before initiation 
of antibiotic treatment. However, in patients with suspected 
serious bacterial infections, therapy should be administered 
empirically and promptly without waiting for results of such 
studies; therapy can be adjusted once culture results become 
available. The local prevalence of resistance to common infec-
tious agents (i.e., penicillin-resistant S. pneumoniae and MRSA) 
and the recent use of prophylactic or therapeutic antibiotics 
should be considered when initiating empiric therapy. When 
the organism is identified, antibiotic susceptibility testing 
should be performed, and subsequent therapy based on the 
results of susceptibility testing (AII). 
HIV-infected children whose immune systems are not seri-
ously compromised (CDC Immunologic Category I) (98) and 
who are not neutropenic can be expected to respond similarly 
to HIV-uninfected children and should be treated with the 
usual antimicrobial agents recommended for the most likely 
bacterial organisms (AIII). For example, for HIV-infected 
children outside of the neonatal period who have suspected 
community-acquired bacteremia, bacterial pneumonia, or 
meningitis, empiric therapy with an extended-spectrum cepha-
losporin (such as ceftriaxone or cefotaxime) is reasonable until 
culture results are available (AIII) (85,99). The addition of 
azithromycin can be considered for hospitalized patients with 
pneumonia to treat other common community-acquired pneu-
monia pathogens (M. pneumoniae, C. pneumoniae). If MRSA is 
suspected or the prevalence of MRSA is high (i.e., >10%) in the 
community, clindamycin or vancomycin can be added (choice 
based on local susceptibility patterns) (100,101). Neutropenic 
children also should be treated with an antipseudomonal drug 
such as ceftazidime or imipenem, with consideration of add-
ing an aminoglycoside if infection with Pseudomonas spp. is 
thought likely. Severely immuno compromised HIV-infected 
children with invasive or recurrent bacterial infections require 
expanded empiric antimicrobial treatment covering a broad 
range of resistant organisms similar to that chosen for suspected 
catheter sepsis pending results of diagnostic evaluations and 
cultures (AIII).
Initial empiric therapy of HIV-infected children with 
suspected catheter sepsis should include coverage for both 
gram-positive and enteric gram-negative organisms, such as 
ceftazidime, which has anti-Pseudomonas activity, and van-
comycin to cover MRSA (AIII). Factors such as response to 
therapy, clinical status, identification of pathogen, and need 
for ongoing vascular access, will determine the need and tim-
ing of catheter removal.
Monitoring and Adverse Events, Including IRIS
The response to appropriate antibiotic therapy should be 
similar in HIV-infected and HIV-uninfected children, with 
a clinical response usually observed within 2–3 days after 
initiation of appropriate antibiotics; radiologic improvement 
in patients with pneumonia may lag behind clinical response. 
Fatal hemolytic reaction to ceftriaxone has been reported in 
an HIV-infected child with prior ceftriaxone treatment (102). 
Whereas HIV-infected adults experience high rates of adverse 
and even treatment-limiting reactions to TMP–SMX, in HIV-
infected children, serious adverse reactions to TMP–SMX 
appear to be much less of a problem (103).
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IRIS has not been described in association with treatment 
of bacterial infections in children.
Management of Treatment Failure
Prevention of Recurrence 
Status of vaccination against Hib, pneumococcus, meningo-
coccus, and influenza should be reviewed and updated, accord-
ing to the recommendations outlined in the section “Preventing 
First Episode of Disease” (Figures 1 and 2) (AI).
TMP–SMX, administered daily for PCP prophylaxis, and 
azithromycin or atovaquone-azithromycin, administered for 
MAC prophylaxis, also may reduce the incidence of drug-
sensitive serious bacterial infections in children with recur-
rent serious bacterial infections. Although administration of 
antibiotic chemoprophylaxis to HIV-infected children who 
have frequent recurrences of serious bacterial infections may 
be considered, caution is required when using antibiotics solely 
to prevent recurrence of serious bacterial infections because of 
the potential for development of drug-resistant microorgan-
isms and drug toxicity. In rare situations in which antibiotic 
prophylaxis is not effective in preventing frequent recurrent 
serious bacterial infections, IVIG prophylaxis can be considered 
for secondary prophylaxis (BI).
Discontinuation of Secondary Prophylaxis
As noted earlier, PACTG 1008, demonstrated that discon-
tinuation of MAC and/or PCP antibiotic phylaxis in HIV-
infected children who achieved immune reconstitution (CD4 
>15%) while receiving antiretroviral therapy did not result in 
excessive rates of serious bacterial infections (46).
Bartonellosis
Epidemiology
Bartonella is a genus of facultative intracellular bacteria 
including 21 species, only a few of which have been implicated 
as human pathogens (104–106). Of these, Bartonella henselae 
and Bartonella quintana cause a spectrum of diseases specifically 
in immuno compromised hosts, such as those infected with 
HIV (107,108). These diseases include bacillary angiomatosis 
and bacillary peliosis. Immuno compromised persons also are 
susceptible to Bartonella-associated bacteremia and dissemina-
tion to other organ systems. Complications of Bartonella infec-
tion are relatively uncommon in the pediatric HIV-infected 
population (4), although complications in adult immuno-
compromised hosts also can occur in immuno compromised 
children with AIDS. Bartonella infections involve an intra-
erythrocytic phase that appears to provide a protective niche 
for the bartonellae leading to persistent and often relapsing 
infection, particularly in immuno compromised persons (104). 
A feature of infections with the genus Bartonella is the ability 
of the bacteria to cause either acute or chronic infection with 
either vascular proliferative or suppurative manifestations, 
depending on the immune status of the patient (104).
In the general population, B. henselae typically is associated 
with cat-scratch disease. Most cases of cat-scratch disease occur 
in patients aged <20 years (109). A study examining the epide-
miology of cat-scratch disease in the United States estimated 
that 437 pediatric hospitalizations associated with cat-scratch 
disease occurred among children aged <18 years during 2000, 
giving a national hospitalization rate of 0.6 per 100,000 chil-
dren aged <18 years and 0.86 per 100,000 children aged <5 
years (110). Data are lacking on the epidemiology of infection 
with Bartonella spp. in HIV-infected children.
The household cat is a major vector for transmission of 
B. henselae to humans. Transmission of B. henselae from cat to 
cat appears to be facilitated by cat fleas, but data do not suggest 
that B. henselae is efficiently transmitted from cats to humans 
by fleas (111). More than 90% of patients with cat-scratch 
disease have a history of recent contact with cats, often kittens 
(109), and a cat scratch or bite (112) has been implicated as 
the principal mode of cat-to-human transmission. Compared 
with adult cats, kittens (<1 year of age) are more likely to have 
B. henselae bacteremia and to have high levels of bacteremia, 
and more likely to scratch. Despite the evidence against flea-
borne cat-to-human transmission, researchers acknowledge 
the potential for such transmission and the need for further 
investigation (111). Elimination of flea infestation is impor-
tant in preventing transmission because contamination of cat 
claws or of a scratch wound with infected flea feces is a possible 
mechanism for infecting humans (111). Infection occurs more 
often during the autumn and winter (109,112–114). 
B. quintana is globally distributed. The vector for B. quintana 
is the human body louse. Outbreaks of trench fever have been 
associated with poor sanitation and personal hygiene, which 
may predispose individuals to the human body louse (106).
Clinical Manifestations
The clinical manifestations of B. henselae infection are largely 
determined by the host’s immune response. Localized disease 
(e.g., focal suppurative regional lymphadenopathy such as in 
typical cat-scratch disease) appears most common in patients 
with an intact immune system; systemic infection appears 
more commonly in immuno compromised patients, although 
systemic disease has also been reported among otherwise nor-
mal children (115,116). Clinical manifestations of B. henselae 
and B. quintana specific to HIV-infected and other immuno-
compromised patients include bacillary angiomatosis and 
bacillary peliosis.
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Bacillary angiomatosis is a rare disorder that occurs almost 
entirely in severely immuno compromised hosts (117,118). It 
is a vascular proliferative disease that has been reported most 
often in HIV-infected adults who have severe immunosuppres-
sion with a median CD4 count of <50 cells/mm3 in a majority 
of case studies of HIV-infected adults (108,119). The disease 
is characterized by cutaneous and subcutaneous angiomatous 
papules; the lesions of this disease can be confused with KS. 
Lesions are often papular and red with smooth or eroded 
surfaces; they are vascular and bleed if traumatized. Nodules 
may be observed in the subcutaneous tissue and can erode 
through the skin. Less frequently, it may involve organs other 
than the skin.
Bacillary peliosis is characterized by angiomatous masses 
in visceral organs; it mainly occurs in severely immuno-
compromised patients with HIV infection. It is a vasopro-
liferative condition that contains blood-filled cystic spaces. 
The organ most commonly affected is the liver (i.e., peliosis 
hepatis), but the disease also can involve bone marrow, lymph 
nodes, lungs, and CNS (120–122).
Immuno compromised patients infected with B. henselae or 
B. quintana can also present with persisting or relapsing fever 
with bacteremia, and these bacteria should be considered 
in the differential diagnosis of fever of unknown origin in 
immuno compromised children with late-stage AIDS (123). 
Dissemination to almost all organ systems has been described, 
including bone (e.g., osteomyelitis), heart (e.g., subacute 
endocarditis), and CNS (e.g., encephalopathy, seizures, neuro-
retinitis, transverse myelitis) (124). Most patients with visceral 
involvement have nonspecific systemic symptoms, including 
fever, chills, night sweats, anorexia and weight loss, abdominal 
pain, nausea, vomiting, and diarrhea.
Diagnosis
Bartonella spp. are small, gram-negative bacilli. In cases of 
bacillary angiomatosis and bacillary peliosis, diagnosis is usually 
made through biopsy with a characteristic histologic picture: 
clusters of organisms can be demonstrated with Warthin-Starry 
silver stain of affected tissue. The organisms can be isolated 
with difficulty from blood or tissue culture using enriched 
agar; they have been isolated more successfully from speci-
mens from patients with bacillary angiomatosis and peliosis 
than from patients with typical cat-scratch disease (107). 
B. henselae, similar to other Bartonella spp., is a fastidious, 
slow-growing organism; in most cases, colonies first appear 
after 9–40 days; therefore incubation for up to 6 weeks is 
recommended (124).
Serologic tests such as indirect fluorescent antibody (IFA) 
test and enzyme immunoassay (EIA) are also available. The IFA 
is available at many commercial laboratories and state public 
health laboratories and through CDC (109). Unfortunately, 
cross-reactivity among Bartonella spp. and other bacteria, such 
as Chlamydia psittaci (115), is common, and serologic tests 
do not accurately distinguish among them. Additionally, the 
sensitivity of the currently available IFA is lower in immuno-
compromised than immune-competent patients; 25% of 
HIV-infected Bartonella culture-positive patients never develop 
anti-Bartonella (121).
The most sensitive method of diagnosis is with PCR testing 
of clinical specimens; different procedures have been devel-
oped that can discriminate among different Bartonella spp. 
(125,126). PCR assays are available in some commercial and 
research laboratories.
Prevention Recommendations
Preventing Exposure
Prevention of bartonellosis should focus on reducing exposure 
to vectors of the disease, i.e., the body louse (for B. quintana) 
and cats and cat fleas (for B. henselae). Controlling cat flea infes-
tation and avoiding cat scratches are therefore critical strategies 
for preventing B. henselae infections in HIV-infected persons. 
To avoid exposure to B. quintana, HIV-infected patients should 
avoid and treat infestation with body lice (AII).
HIV-infected persons, specifically those with severe immuno-
suppression, should consider the potential risks of cat owner-
ship; risks of cat ownership for HIV-infected children should be 
discussed with caretakers. If a decision is made to acquire a cat, 
cats <1 year of age should be avoided (BII) (109,123). HIV-
infected persons should avoid playing roughly with cats and 
kittens to minimize scratches and bites and should promptly 
wash sites of contact if they are scratched or bitten (BIII) 
(109). Also, cats should not be allowed to lick open wounds 
or cuts (BIII). No evidence indicates any benefit from routine 
culturing or serologic testing of cats for Bartonella infection 
or from antibiotic treatment of healthy, serologically positive 
cats (DII) (109).
Preventing First Episode of Disease
No evidence exists that supports the use of chemoprophylaxis 
for bartonellosis, such as after a cat scratch (CIII).
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
Management of typical cat-scratch disease in immunocom-
petent patients is mainly supportive because the disease usu-
ally is self-limited and resolves spontaneously in 2–4 months. 
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Enlarged, painful lymph nodes may need to be aspirated. 
Cat-scratch disease typically does not respond to antibiotic 
therapy; the localized clinical manifestations of the disease are 
believed to result from an immunologic reaction in the lymph 
nodes with few viable Bartonella present by the time a biopsy is 
performed (104,127). In one double-blind, placebo-controlled 
study in a small number (N=29) of immunocompetent older 
children and adults with uncomplicated cat-scratch disease, 
azithromycin resulted in a more rapid decrease in initial lymph 
node volume by sonography, although clinical outcomes did 
not differ (128). Thus, antibiotic treatment usually is not rec-
ommended for uncomplicated localized disease.
The in vitro and in vivo antibiotic susceptibilities of Bartonella 
do not correlate well for a number of antibiotics; for example, 
penicillin demonstrates in vitro activity but has no in vivo 
efficacy (104,115). Although no systematic clinical trials have 
been conducted, antibiotic treatment of bacillary angiomatosis 
and peliosis hepatis is recommended on the basis of reported 
experience in clinical case series because severe, progressive, 
and disseminated disease can occur, and without appropriate 
therapy, systemic spread can occur and involve virtually any 
organ (104,108). Guidelines for treating Bartonella infections 
have been published (104).
The drug of choice for treating systemic bartonellosis is 
erythromycin or doxycycline (AII) (104,121). Clarithromycin 
or azithromycin treatment has been associated with clinical 
response, and either of these can be an alternative for Bartonella 
treatment (BIII) (129).
For patients with severe disease, intravenous (IV) administra-
tion may be needed initially (AIII) (130). Therapy should be 
administered for 3 months for cutaneous bacillary angiomatosis 
and 4 months for bacillary peliosis, CNS disease, osteomyelitis, 
or severe infections, as treatment must be of sufficient duration 
to prevent relapse (AII) (104,123). Combination therapy with 
the addition of rifampin to either erythromycin or doxycycline 
is recommended for immuno compromised patients with acute, 
life-threatening infections (BIII) (104,123). Because doxy-
cycline has better CNS penetration than does erythromycin, 
the combination of doxycycline and rifampin is preferred for 
treating CNS Bartonella infection, including retinitis (AIII).
Endocarditis is most commonly caused by B. quintana, fol-
lowed by B. hensalae, but also has been linked with infection 
with B. elizabethae, B. vinsonii subspecies Berkhoffii, B. vinsonii 
subspecies Arupensis, B. kohlerae, and B. alsatica (131). For 
suspected (but culture-negative) Bartonella endocarditis, 
14 days of aminoglycoside treatment (AII) accompanied 
by ceftriaxone (to adequately treat other potential causes of 
culture-negative endocarditis) with or without doxycycline 
for 6 weeks is recommended (BII) (104). For documented 
culture-positive Bartonella endocarditis, doxycycline for 6 
weeks plus gentamicin intravenously for the first 14 days is 
recommended (BII) (104,109).
Penicillins and first-generation cephalosporins have no in 
vivo activity and should not be used for treatment of bartonel-
losis (DII) (132). Quinolones and TMP–SMX have variable 
in vitro activity and an inconsistent clinical response in case 
reports (115); as a result, they are not recommended for treat-
ment (DIII).
Monitoring and Adverse Events, Including IRIS
Response to treatment can be dramatic in immuno-
compromised patients. Cutaneous bacillary angiomatosis skin 
lesions usually improve and resolve after a month of treat-
ment. Bacillary peliosis responds more slowly than cutaneous 
angiomatosis, but hepatic lesions should improve after several 
months of therapy.
Some immuno compromised patients develop a potentially 
life-threatening Jarisch-Herxheimer–like reaction within 
hours after institution of antibiotic therapy, and immuno-
compromised patients with severe respiratory or cardiovascular 
compromise should be monitored carefully after institution of 
therapy (104,107).
No cases of Bartonella-associated IRIS have been reported.
Management of Treatment Failure
In immuno compromised patients with relapse, retreatment 
should be continued for 4–6 months; repeated relapses should 
be treated indefinitely (AIII) (128). Among patients whose 
Bartonella infections fail to respond to initial treatment, one 
or more of the second-line regimens should be considered 
(AIII).
Prevention of Recurrence
Relapses in bone and skin have been reported and are more 
common when antibiotics are administered for a shorter time 
(<3 months), especially in severely immuno compromised 
patients. For an immuno compromised HIV-infected adult 
experiencing relapse, long-term suppression of infection with 
doxycycline or a macrolide is recommended as long as the 
CD4 cell count is <200 cells/mm3 (AIII). Although no data 
exist for HIV-infected children, it seems reasonable that similar 
recommendations should be followed (AIII).
Discontinuing Secondary Prophylaxis
No specific data are available regarding the discontinuation 
of secondary prophylaxis.
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Syphilis
Epidemiology
Treponema pallidum can be transmitted from mother to child 
at any stage of pregnancy or during delivery. Among women 
with untreated primary, secondary, early latent, or late latent 
syphilis at delivery, approximately 30%, 60%, 40%, and 7% of 
infants, respectively, will be infected. Treatment of the mother 
for syphilis >30 days before delivery is required for effective 
in utero treatment.
Congenital syphilis has been reported despite adequate 
maternal treatment. Factors that contribute to treatment 
failure include maternal stage of syphilis (early stage, mean-
ing, primary, secondary, or early latent syphilis), advancing 
gestational age at treatment, higher Venereal Disease Research 
Laboratory (VDRL) titers at treatment and delivery, and short 
interval from treatment to delivery (<30 days) (133,134). In 
2005, the rate of congenital syphilis declined to 8 per 100,000 
live-born infants (135), down from 14.3 cases per 100,000 
in 2000 and 27.9 cases per 100,000 in 1997. Overall, cases 
of congenital syphilis have decreased 74% since 1996. The 
continuing decline in the rate of congenital syphilis probably 
reflects the substantially reduced rate of primary and secondary 
syphilis among women during the last decade.
Drug use during pregnancy, particularly cocaine use, has 
been associated with increased risk for maternal syphilis and 
congenital infection (136). Similarly, HIV-infected women 
have a higher prevalence of untreated or inadequately treated 
syphilis during pregnancy, which places their newborns at 
higher risk for congenital syphilis (137). Mother-to-child 
HIV transmission might be higher when syphilis coinfection 
is present during pregnancy (137–139); transmission does not 
appear to be higher if the mother’s syphilis is effectively treated 
before pregnancy (137).
Although approximately two thirds of sexually transmitted 
diseases (STDs) diagnosed annually in the United States occur 
among persons aged <24 years, such individuals account for less 
than 25% of early syphilis cases. Nevertheless, the prevalence 
and incidence of syphilis among HIV-infected youth and of 
HIV infection among youth with syphilis are appreciable; in 
a study of 320 HIV-infected and uninfected U.S. adolescents 
aged 12–19 years, the prevalence of syphilis was 9% among 
HIV-infected girls and 6% among HIV-infected boys (140). In 
a meta-analysis of 30 studies, the median HIV seroprevalence 
among persons infected with syphilis in the United States was 
15.7% (27.5% among men and 12.4% among women with 
syphilis) (141).
Clinical Manifestations
Untreated early syphilis during pregnancy can lead to spon-
taneous abortion, stillbirth, hydrops fetalis, preterm delivery, 
and perinatal death in up to 40% of pregnancies (142). Among 
children with congenital syphilis, two characteristic syndromes 
of clinical disease exist: early and late congenital syphilis. Early 
congenital syphilis refers to clinical manifestations appearing 
within the first 2 years of life. Late congenital syphilis refers to 
clinical manifestations appearing in children >2 years old.
At birth, infected infants may manifest such signs as 
hepatosplenomegaly, jaundice, mucocutaneous lesions (e.g., 
skin rash, nasal discharge, mucous patches, condyloma lata), 
lymphadenopathy, pseudoparalysis of an extremity, anemia, 
thrombocytopenia, pneumonia, and skeletal lesions (e.g., 
osteochondritis, periostitis, or osteitis). In a study of 148 
infants born to mothers with untreated or inadequately treated 
syphilis, 47% had clinical, radiographic, or conventional 
laboratory findings consistent with congenital syphilis, and 
44% had a positive rabbit infectivity test, PCR assay, or IgM 
immunoblot of serum, blood, or CSF (143). However, as many 
as 60% of infants with congenital syphilis do not have any 
clinical signs at birth (144). If untreated, these “asymptomatic” 
infants can develop clinically apparent disease in the ensuing 
3 weeks to 6 months. In addition, fever, nephrotic syndrome, 
and hypopituitarism may occur.
The manifestations of acquired syphilis in older children and 
adolescents are similar to those of adults (see Guidelines for the 
Prevention and Treatment of Opportunistic Infections in HIV-
Infected Adults) (16). HIV-infected persons with acquired early 
syphilis might be at increased risk for neurologic complications 
and uveitis and have higher rates of treatment failure (145).
Diagnosis
The standard serologic tests for syphilis in adults are based 
on the measurement of IgG antibody. Because IgG antibody in 
the infant reflects transplacental passively transferred antibody 
from the mother, interpretation of reactive serologic tests for 
syphilis among infants is difficult. Therefore, the diagnosis 
of neonatal congenital syphilis depends on a combination 
of results from physical, laboratory, radiographic, and direct 
microscopic examinations.
All infants born to women with reactive nontreponemal 
and treponemal test results should be evaluated with a quan-
titative nontreponemal test (e.g., VDRL slide test, rapid 
plasma reagin [RPR], or the automated reagin test). Neonatal 
serum should be tested because of the potential for maternal 
blood contamination of the umbilical cord blood specimens. 
Specific treponemal tests, such as the fluorescent treponemal 
antibody absorption (FTA-ABS) test and T. pallidum particle 
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agglutination (TP-PA) test, are not necessary to evaluate con-
genital syphilis in the neonate. No commercially available IgM 
test is recommended for diagnostic use. (Note: Some labora-
tories use treponemal tests, such as EIA, for initial screening, 
and nontreponemal tests for confirmation of positive specimens 
(146). However, such an approach with congenital syphilis has 
not been published.)
Congenital syphilis can be definitively diagnosed if T. pal-
lidum is detected by using darkfield microscopic examination 
or direct fluorescent antibody staining of lesions or body fluids 
such as umbilical cord, placenta, nasal discharge, or skin lesion 
material from the infant. Failure to detect T. pallidum does not 
definitively rule out infection because false-negative results are 
common. Pathologic examination of placenta and umbilical 
cord with specific fluorescent antitreponemal antibody stain-
ing is recommended.
Evaluation of suspected cases of congenital syphilis should 
include a careful and complete physical examination. Further 
evaluation depends on maternal treatment history for syphilis, 
findings on physical examination, and planned infant treat-
ment and may include a complete blood count and differential 
and platelet count, long bone radiographs, and CSF analysis 
for VDRL, cell count, and protein. HIV-infected infants might 
have increased cell counts and protein concentrations even in 
the absence of neurosyphilis. Other tests should be performed 
as clinically indicated (e.g., chest radiograph, liver-function 
tests, cranial ultrasound, ophthalmologic examination, and 
auditory brainstem response).
A proven case of congenital syphilis requires visualization of 
spirochetes by darkfield microscopy or fluorescent antibody 
testing of body fluid(s). Finding that an infant’s serum quantita-
tive nontreponemal serologic titer that is fourfold higher than 
the mother’s titer suggests infection but is not a criterion in 
the case definition. A presumptive case of syphilis is defined as 
maternal untreated or inadequately treated syphilis at delivery, 
regardless of findings in the infant, or a reactive treponemal test 
result and signs in an infant of congenital syphilis on physical 
examination, laboratory evaluation, long bone radiographs, 
positive CSF VDRL test, or an abnormal CSF finding without 
other cause.
For diagnosis of acquired syphilis, a reactive nontreponemal 
test must be confirmed by a specific treponemal test such as 
FTA-ABS or TP-PA. Treponemal tests usually will remain 
positive for life, even with successful treatment. The prozone 
phenomenon (a weakly reactive or falsely negative) reaction 
might occur more frequently in HIV-infected persons (147). 
Treponemal antibody titers do not correlate with disease activ-
ity and should not be used to monitor treatment response. CSF 
should be evaluated among HIV-infected adolescents with 
acquired syphilis of unknown or <1 year’s duration or if they 
have neurologic or ocular symptoms or signs; many clinicians 
recommend a CSF examination for all HIV-infected patients 
with syphilis (16).
Prevention Recommendations
Preventing Exposure
Congenital Syphilis
Effective prevention and detection of congenital syphilis 
depend on the identification of syphilis in pregnant women 
and, therefore, on the routine serologic screening of pregnant 
women during the first prenatal visit. In communities and 
populations in which the risk for congenital syphilis is high, 
serologic testing and a sexual history also should be obtained 
at 28 weeks’ gestation and at delivery. Moreover, as part of the 
management of pregnant women who have syphilis, infor-
mation about treatment of sex partners should be obtained 
to assess the risk for reinfection. Routine screening of serum 
from newborns or umbilical cord blood is not recommended. 
Serologic testing of the mother’s serum is preferred over test-
ing of the infant’s serum because the serologic tests performed 
on infant serum can be nonreactive if the mother’s serologic 
test result is of low titer or the mother was infected late in 
pregnancy. No HIV-exposed infant should leave the hospital 
unless the maternal serologic status has been documented at 
least once during pregnancy and at delivery in communities 
and populations in which the risk for congenital syphilis is 
high (148,149).
Acquired Syphilis
Primary prevention of syphilis includes routine discussion of 
sexual behaviors that may place persons at risk for infection. 
Providers should discuss risk reduction messages that are client-
centered and provide specific actions that can reduce the risk 
for STD acquisition and HIV transmission (150–152).
Routine serologic screening for syphilis is recommended 
at least annually for all sexually active HIV-infected persons, 
with more frequent screening (3–6 months) depending 
on individual risk behaviors (e.g., multiple partners, sex in 
conjunction with illicit drug use, methamphetamine use, or 
partners that participate in such activities) (153). Syphilis in an 
HIV-infected person indicates high-risk behavior and should 
prompt intensified counseling messages and consideration 
of referral for behavioral intervention. Persons undergoing 
screening or treatment for syphilis also should be evaluated 
for all common STDs (154).
Discontinuing Primary Prophylaxis
Not applicable.
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Treatment Recommendations
Treatment of Disease
Penicillin remains the treatment of choice for syphilis, con-
genital or acquired, regardless of HIV status (AI).
Congenital Syphilis
Data are insufficient to determine whether infants who have 
congenital syphilis and whose mothers are coinfected with HIV 
require different evaluation, therapy, or follow-up for syphilis 
than that recommended for infants born to mothers without 
HIV coinfection. Response to standard treatment may differ 
among HIV-infected mothers. For example, some studies in 
adults have shown a lag in serologic improvement in appro-
priately treated patients with HIV infection (155).
Infants should be treated for congenital syphilis if the mother 
has 1) untreated or inadequately treated syphilis (including 
treatment with erythromycin or any other nonpenicillin 
regimen), 2) no documentation of having received treatment, 
3) receipt of treatment <4 weeks before delivery, 4) treatment 
with penicillin but no fourfold decrease in nontreponemal anti-
body titer, or 5) fourfold or greater increase in nontreponemal 
antibody titer suggesting relapse or reinfection (AII) (154). 
Infants should be treated regardless of maternal treatment 
history if they have an abnormal examination consistent with 
congenital syphilis, positive darkfield or fluorescent antibody 
test of body fluid(s), or serum quantitative nontreponemal 
serologic titer that is at least fourfold greater than maternal 
titer (AII) (154).
Treatment for proven or highly probable congenital syphilis 
(i.e., infants with findings or symptoms or with titers fourfold 
greater than mother’s titer) is aqueous crystalline penicillin G 
at 100,000–150,000 units/kg/day, administered as 50,000 
units/kg/dose intravenously every 12 hours during the first 7 
days of life and every 8 hours thereafter for a total of 10 days 
(AII). If congenital syphilis is diagnosed after 1 month of life, 
the dosage of aqueous penicillin G should be increased to 
50,000 units/kg/dose intravenously every 4–6 hours for 10 
days (AII). An alternative to aqueous penicillin G is procaine 
penicillin G at 50,000 units/kg/dose intramuscularly (IM) 
daily in a single dose for 10 days (BII). However, aqueous 
penicillin G is preferred because of its higher penetration into 
the CSF. No reports have been published of treatment failures 
with ampicillin or studies of the effectiveness of ampicillin for 
treating congenital syphilis.
Asymptomatic infants born to mothers who have had 
adequate treatment and response to therapy, and with a normal 
physical examination and CSF findings, and who have a serum 
quantitative nontreponemal serologic titer that is less than 
fourfold higher than maternal titer might be treated with a 
single dose of benzathine penicillin G 50,000 units/kg/dose IM 
with careful clinical and serologic follow-up (BII). However, 
certain health-care providers would treat such infants with 
the standard 10 days of aqueous penicillin because physical 
examination and laboratory test results cannot definitively 
exclude congenital syphilis in all cases (BII).
Acquired Syphilis
Acquired syphilis in children is treated with a single dose of 
benzathine penicillin G 50,000 units/kg IM (up to the adult 
dose of 2.4 million units) for early-stage disease (e.g., primary, 
secondary, and early latent disease) (AII). For late latent disease, 
three doses of benzathine penicillin G 50,000 units/kg (up to 
the adult dose of 2.4 million units) should be administered 
IM once weekly for three doses (total 150,000 units/kg, up 
to the adult total dose of 7.2 million units) (AIII). Alternative 
therapies (e.g., doxycycline, ceftriaxone, or azithromycin) have 
not been evaluated among HIV-infected patients and should 
not be used as first-line therapy (EIII) (154). Neurosyphilis 
should be treated with aqueous penicillin G 200,000–300,000 
units/kg intravenously every 4–6 hours (maximum dosage: 
18–24 million units/day) for 10–14 days (AII). See Guidelines 
for the Prevention and Treatment of Opportunistic Infections in 
HIV-Infected Adults for dosing recommendations for older 
HIV-infected adolescents with acquired syphilis (16).
Monitoring and Adverse Events, Including IRIS
All seroreactive infants (or infants whose mothers were sero-
reactive at delivery) should receive careful follow-up examina-
tions and serologic testing (i.e., a nontreponemal test) every 
2–3 months until the test becomes nonreactive or the titer 
has decreased fourfold (AIII). Nontreponemal antibody titers 
should decline by age 3 months and should be nonreactive by 
age 6 months if the infant was not infected (i.e., if the reac-
tive test result was caused by passive transfer of maternal IgG 
antibody) or was infected but adequately treated. The serologic 
response after therapy might be slower for infants treated after 
the neonatal period. Whether children with congenital syphilis 
who also are HIV-infected take longer to become nonreactive 
and require retreatment is not known.
Treponemal tests should not be used to evaluate treatment 
response because the results for an infected child can remain 
positive despite effective therapy. Passively transferred maternal 
treponemal antibodies can be present in an infant until age 
15 months. A reactive treponemal test after age 18 months is 
diagnostic of congenital syphilis. If the nontreponemal test is 
nonreactive at this time, no further evaluation or treatment 
is necessary. If the nontreponemal test is reactive at age 18 
months, the infant should be fully (re)evaluated and treated 
for congenital syphilis (AIII).
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Infants whose initial CSF evaluations are abnormal should 
undergo a repeat lumbar puncture approximately every 6 
months until the results are normal (AII). A reactive CSF 
VDRL test or abnormal CSF indices that cannot be attrib-
uted to other ongoing illness requires retreatment for possible 
neurosyphilis.
HIV-infected children and adolescents with acquired early 
syphilis (i.e., primary, secondary, early latent) should have clini-
cal and serologic response monitored at age 3, 6, 9, 12, and 24 
months after therapy (AIII); nontreponemal test titers should 
decline by at least fourfold by 6–12 months after successful 
therapy, with examination of CSF and retreatment strongly 
considered in the absence of such decline. For syphilis of lon-
ger duration, follow-up is indicated at 6, 12, and 24 months; 
fourfold decline should be expected by 12–24 months. If 
initial CSF examination demonstrated a pleocytosis, repeat 
lumbar puncture should be conducted at 6 months after 
therapy, and then every 6 months until the cell count is nor-
mal (AIII). Follow-up CSF examinations also can be used to 
evaluate changes in the VDRL-CSF or CSF protein levels after 
therapy, but changes in these parameters occur more slowly 
than changes in CSF cell counts. Data from HIV-infected 
adults with neurosyphilis suggest that CSF abnormalities 
might persist for extended times, and close clinical follow-up 
is warranted (145).
Syphilis in an HIV-infected child (congenital or acquired) 
manifesting as IRIS has not been reported, and only very rare 
reports of syphilis-associated IRIS in adults (primarily syphilitic 
ocular inflammatory disease) have been reported (156).
Management of Treatment Failure
After treatment of congenital syphilis, children with increas-
ing or stable nontreponmenal titers at age 6–12 months or 
children who are seropostive with any titer at 18 months 
should be evaluated (e.g., including a CSF examination) and 
considered for retreatment with a 10-day course of parenteral 
penicillin (AIII).
The management of failures of treatment of acquired syphilis 
in older children and adolescents is identical to that in adults 
(16). Retreatment of patients with early-stage syphilis should 
be considered for those who 1) do not experience at least a 
fourfold decrease in serum nontreponemal test titers 6–12 
months after therapy, 2) have a sustained fourfold increase 
in serum nontreponemal test titers after an initial reduction 
posttreatment, or 3) have persistent or recurring clinical signs 
or symptoms of disease (BIII). If CSF examination does not 
confirm the diagnosis of neurosyphilis, such patients should 
receive 2.4 million units IM benzathine penicillin G adminis-
tered at 1-week intervals for 3 weeks (BIII). Certain specialists 
have also recommended a course of aqueous penicillin G IV 
or procaine penicillin IM plus probenicid (as described above 
for treatment of neurosyphilis) for all patients with treatment 
failure, although data to support this recommendation are 
lacking (CIII). If titers fail to respond appropriately after 
retreatment, the value of repeat CSF evaluation or retreatment 
has not been established.
Patients with late-latent syphilis should be retreated if they 
1) have clinical signs or symptoms of syphilis, 2) have a fourfold 
increase in serum nontreponemal test titer, or 3) experience 
an inadequate serologic response (less than fourfold decline in 
nontreponemal test titer) within 12–24 months after therapy if 
initial titer was high (>1:32) (BIII). Such patients should have 
a repeat CSF examination. If the repeat CSF examination is 
consistent with CNS involvement, retreatment should follow 
the neurosyphilis recommendations (AIII); those without a 
CSF profile indicating CNS disease should receive a repeat 
course of benzathine penicillin, 2.4 million units IM weekly 
for 3 weeks (BIII), although certain specialists recommend 
following the neurosyphilis recommendations in this situation 
as well (CIII).
Retreatment of neurosyphilis should be considered if the 
CSF white blood cell count has not decreased 6 months after 
completion of treatment or if the CSF-VDRL remains reactive 
2 years after treatment (BIII).
Prevention of Recurrence
No recommendations have been developed for secondary 
prophylaxis or chronic maintenance therapy for syphilis in 
HIV-infected children.
Discontinuing Secondary Prophylaxis 
Not applicable.
Mycobacterial Infections 
Mycobacterium tuberculosis
Epidemiology 
In 2006, of the 13,779 cases of TB reported in the United 
States, 807 (6%) occurred in children younger than 15 years 
(157). Overall, during 1993–2001, 12.9% of adults with TB 
were reported to be coinfected with HIV, compared with 1.1% 
of all children with TB (158). However, the actual rate of HIV 
coinfection in U.S. children with TB is unknown because of 
the very low rate of HIV testing in this population.
Numerous studies have documented the increased risk for 
TB among HIV-infected adults. Domestic and international 
studies have documented a similar increased risk for TB among 
HIV-infected children (159–162). Unlike other AIDS-related 
OIs, CD4 cell count is not a sufficient indicator of increased 
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risk for TB in HIV-infected children. Congenital TB is rare 
but has been reported among children born to HIV-infected 
women with TB (163,164).
Children with TB almost always were infected by an adult 
in their daily environment, and their disease represents the 
progression of primary infection rather than the reactivation 
disease commonly observed among adults (165). Identification 
and treatment of the source patient and evaluation of all 
exposed members of the household are particularly important 
because other secondary TB cases and latent infections with 
M. tuberculosis often are found. All confirmed and suspected 
TB cases must be reported to state and local health depart-
ments, which will assist in contact evaluation.
Disease caused by Mycobacterium bovis recently reemerged 
among children in New York City, and M. bovis is a frequent 
cause of TB in children in San Diego County (166,167). 
Recent cases have been associated with ingestion of unpasteur-
ized fresh cheese from Mexico (166). Most M. bovis cases in 
humans are attributable to ingestion of unpasteurized milk or 
its products, and exposure to this pathogen in the United States 
is unlikely except from privately imported products. However, 
human-to-human airborne transmission from persons with 
pulmonary disease has been confirmed, and its relevance 
might be increased by HIV infection. The distinction between 
M. tuberculosis and M. bovis is important for determining the 
source of infection for a child who has TB and for selecting 
a treatment regimen: almost all M. bovis isolates are resistant 
to pyrazinamide.
Disease associated with bacille Calmette-Guerin (BCG), 
an attenuated version of M. bovis, has been reported in HIV-
infected children vaccinated at birth with BCG (168). IRIS 
associated with BCG also has been reported among children 
initiating HAART (22,168).
Internationally, drug resistance is a growing obstacle to 
controlling TB, but in the United States, effective public 
health approaches to prevention and treatment have reduced 
the rates of drug resistance. In the United States during 
1993–2001, M. tuberculosis resistant to any first-line anti-TB 
drugs was identified in 15.2% of children who had culture-
positive M. tuberculosis, with higher rates among foreign-born 
children (19.2%) than among U.S.-born children (14.1%) 
(158). Multidrug-resistant TB (MDR TB) is unusual among 
U.S.-born children and adults with TB. The prevalence of 
multidrug resistance (e.g., at least isoniazid and rifampin) was 
lower: 2.8% in foreign-born children and 1.4% in U.S.-born 
children with TB. However, the fraction of adult TB patients 
in the United States that is foreign born is increasing, and such 
persons are a potential source of drug-resistant infection for 
their U.S.-born children.
Clinical Manifestations 
Once infected, children aged <4 years and all HIV-infected 
children are more likely to develop active TB disease. Usually 
the clinical features of TB among HIV-infected children 
are similar to those among children without HIV infection, 
although the disease usually is more severe (169,170) and can 
be difficult to differentiate from illnesses caused by other OIs. 
Pulmonary involvement is evident in most cases and can be 
characterized by localized alveolar consolidation, pneumonitis, 
and hilar and mediastinal adenopathy. Concomitant atelectasis 
might result from hilar adenopathy compressing bronchi or 
from endobronchial granulomas. HIV-infected children with 
TB are more likely to be symptomatic (with fever and cough) 
and have atypical findings, such as multilobar infiltrates and 
diffuse interstitial disease. Rapidly progressive disease, includ-
ing meningitis or mycobacterial sepsis, can occur without obvi-
ous pulmonary findings. Both HIV infection and young age 
increase the rate of miliary disease and TB meningitis. Older 
HIV-infected children and adolescents have clinical features 
more similar to those in HIV-infected adults, with the typical 
apical lung infiltrates and late cavitation (171). Approximately 
25% of HIV-uninfected children with TB include extrapulmo-
nary disease as a sole or concomitant site, and HIV-infected 
children may have an even higher rate. The most common 
sites of extrapulmonary disease among children include the 
lymph nodes, blood (miliary), CNS, bone, pericardium, and 
peritoneum (169,172–174).
Diagnosis 
The cornerstone of diagnostic methods for latent TB infec-
tion (LTBI) is the tuberculin skin test (TST), administered by 
the Mantoux method. Because children with HIV infection 
are at high risk for TB, annual testing of this population is 
recommended to diagnose LTBI (AIII). Among persons with 
HIV infection, >5 mm of induration is considered a positive 
(diagnostic) reaction. However, among immunocompetent 
children with active TB disease, approximately 10% have a 
negative TST result, and HIV-infected children with TB are 
even more likely to have a negative result. Therefore, a nega-
tive TST result should never be relied on for excluding the 
possibility of TB. The use of control skin antigens at time 
of purified protein derivative testing to assess for cutaneous 
anergy is of uncertain value and no longer routinely recom-
mended (DII). 
Sensitivity to tuberculin is reduced by severe viral infec-
tions, such as wild-type measles. As a precaution, skin testing 
scheduled around the time of live-virus vaccination should 
be done at the same time as, or delayed until 6 weeks after 
vaccination to avoid any potentially suppressed sensitivity to 
the skin test (AIII).
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Two-step skin testing is used for detecting boosted sensitivity 
to tuberculin in health-care workers and others at the time of 
entry into a serial testing program for occupational TB expo-
sure. The utility and predictive value of two-step testing have 
not been assessed for children (with or without HIV infection), 
and its use is not recommended (DIII).
Recently, ex vivo assays that determine IFN-γ release from 
lymphocytes after stimulation by highly specific synthetic 
M. tuberculosis antigens have been developed to diagnose infec-
tion (175). QuantiFERON®-TB Gold and QuantiFERON-TB 
Gold In-Tube (Cellestis Limited, Valencia, California) and 
the T-SPOT®.TB assay (Oxford Immunotec, Marlborough, 
Massachusetts) are now Food and Drug Administration 
(FDA)-approved and available in the United States. These 
tests were more specific than the TST in studies among adults, 
especially among those who are BCG vaccinated. However, 
as with the TST, these tests are less sensitive in HIV-infected 
adults with advanced immune suppression (176). In addition, 
limited data suggest these tests, particularly QuantiFERON, 
might have less sensitivity for diagnosing infection in young 
children (177). Their routine use for finding LTBI or diagnos-
ing TB in HIV-infected children is not recommended because 
of uncertainty about test sensitivity (DIII) (175).
Patients with a positive test for LTBI should undergo 
chest radiography and clinical evaluation to rule out active 
disease. Diagnostic microbiologic methods for TB consist 
of microscopic visualization of acid-fast bacilli from clinical 
specimens, nucleic-acid amplification for direct detection in 
clinical specimens, the isolation in culture of the organism, and 
drug-susceptibility testing, and genotyping. Although acid-fast 
stained sputum smears are positive in 50%–70% of adults with 
pulmonary TB, young children with TB rarely produce sputum 
voluntarily and typically have a low bacterial load (178). Smear 
results frequently are negative, even among older children who 
can expectorate and provide a sample (158). Nevertheless, a 
positive smear result usually indicates mycobacteria, although it 
does not differentiate M. tuberculosis from other mycobacterial 
species. Mycobacterial culture improves sensitivity and permits 
species identification, drug-susceptibility testing, and genotyp-
ing. Confirming M. tuberculosis infection with a culture can 
have greater significance for HIV-infected children because 
of the difficulties of the differential diagnosis. Therefore, all 
samples sent for microscopy should be cultured for mycobac-
teria. Bronchoscopy will increase the likelihood of obtaining 
a positive smear and culture. Obtaining early-morning gastric 
aspirates for acid-fast–bacilli stain and culture is the diagnostic 
method of choice for children unable to produce sputum. A 
standardized protocol that includes testing of three samples 
obtained separately may improve the yield from gastric aspi-
rates to 50% (179). Others have shown the potential utility 
of induced sputum (180,181) and nasopharyngeal aspirates 
(182) of obtaining diagnostic specimens from children in the 
outpatient setting.
Two commercial nucleic acid amplification kits are FDA 
approved for direct detection of M. tuberculosis in sputum 
samples with positive smear-microscopy results. One of the 
methods also is approved for sputa with negative microscopy. 
A positive result from these methods immediately confirms the 
diagnosis. However, when these tests are used for other speci-
mens, such as gastric aspirates or CSF, sensitivity and specific-
ity have been disappointing (183–185). These assays provide 
adjunctive, but not primary, diagnostic evaluation of children 
with TB because a negative result does not rule out TB as a 
diagnostic possibility and a positive result, unlike culture, does 
not allow for drug-susceptibility testing. However, it might be 
useful in establishing the diagnosis of TB among HIV-infected 
children who have unexplained pulmonary disease when both 
culture and TSTs may be falsely negative.
Because of the difficulty in obtaining a specimen for bac-
teriologic diagnosis of TB among children, evidence for the 
diagnosis often involves linking the child to an adult with 
confirmed TB with a positive TST and an abnormal radiograph 
or physical examination in the child (178). A high index of 
suspicion is important. Suspicion for and diagnosis of TB in 
HIV-infected children is further complicated by the frequent 
presence of preexisting or coincidental fever, pulmonary symp-
toms, and radiographic abnormalities (e.g., chronic lymphoid 
interstitial pneumonitis or coincident pulmonary bacterial 
infection) and the decreased sensitivity of TST in this popula-
tion. Strenuous efforts should be made to obtain diagnostic 
specimens (three each of sputum or gastric aspirate specimens 
or induced sputum) whenever TB is presumptively diagnosed 
or when it is suspected.
Because many children do not have culture-proven TB, 
and the diagnosis of drug resistance may be delayed in source 
cases, MDR TB should be suspected in children with TB in 
the following situations (90,186–188):
A child who is a close contact of an MDR TB patient.•	
A child who is a contact with a TB patient who died while •	
undergoing treatment when reasons exist to suspect the 
disease was MDR TB (i.e., the deceased patient was a 
contact of another person with MDR TB, had poor adher-
ence to treatment, or had received more than two courses 
of antituberculosis treatment).
A child with bacteriologically proven TB who is not •	
responding to first-line drugs administered with direct 
observation.
A child exposed to a source case that remains smear- or •	
culture-positive after 2 months of directly observed first-
line antituberculosis therapy.
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A child born in or exposed to residents of countries or •	
regions with a high prevalence of drug-resistant TB.
Antimycobacterial drug-susceptibility testing should be 
performed on the initial M. tuberculosis isolate and on subse-
quent isolates if treatment failure or relapse is suspected; the 
radiometric culture system has been adapted to perform rapid 
sensitivity testing. Before obtaining results of susceptibility 
testing or if an organism has not been isolated from specimens 
from the child, the antimycobacterial drug susceptibility of the 
M. tuberculosis isolate from and treatment history of the source 
case can be used to define the probable drug susceptibility of 
the child’s organism and to design the empiric therapeutic 
regimen for the child.
Prevention Recommendations
Preventing Exposure
Children most commonly are infected with M. tuberculosis 
from exposure in their immediate environment, usually the 
household. HIV-infected children may have family members 
dually infected with HIV and TB. Homeless children and 
children exposed to institutional settings (including prolonged 
hospitalization) may be at increased risk. Risk factors (e.g., 
homelessness, incarceration, exposure to institutional set-
tings) of close contacts of HIV-infected children also should 
be considered. BCG vaccine, which is not routinely admin-
istered in the United States and should not be administered 
to HIV-infected infants and children, has potential to cause 
disseminated disease (EII) (189).
Preventing First Episode of Disease
In the United States, where TB exposure is uncommon and 
BCG is not routinely administered, HIV-infected infants and 
children should have a TST (5-TU purified protein derivitive) 
at 3 months of age, and children should be tested at HIV 
diagnosis. HIV-infected children should be retested at least 
once per year (AIII).
HIV-infected infants and children should be treated for LTBI 
if they have a positive TST (AI) or exposure to a person who has 
contagious TB (after exclusion of active TB disease in the infant 
or child and regardless of the child’s TST results) (AII). Duration 
of preventive therapy for children should be 9 months, and 
the preferred regimen is isoniazid (10–15 mg/kg/day [AII] or 
20–30 mg/kg twice weekly) [BII]). Liver function tests should 
be performed before start of isoniazid (AII) for HIV-infected 
children. The child should be further monitored if baseline tests 
are abnormal; the child has chronic liver disease; or medications 
include other potentially hepatotoxic drugs, such as acetamino-
phen and some antiretroviral drugs. If isoniazid resistance is 
known or suspected in the source case, rifampin for 4–6 months 
is recommended (BII). A 2-month regimen of rifampin and 
pyrazinamide was never recommended for children and now 
is not recommended for any age group because of an increased 
risk for severe and fatal hepatotoxicity (EII). Children exposed 
to drug-resistant strains should be managed by an experienced 
clinician, and the regimen should be individualized on the basis 
of knowledge about the source-case susceptibility pattern and 
treatment history.
A randomized, double-blind, controlled trial of isoniazid 
in HIV-infected children in South Africa was halted when 
isoniazid administered daily or twice weekly (according to 
the cotrimoxazole schedule) helped reduce overall mortality 
(hazard ratio: 0.46; 95% confidence interval [CI]: 0.22–0.95; 
p = 0.015) (190). These findings were found across all ages 
and CDC HIV disease classification categories and were inde-
pendent of TST result; however, the study may not have been 
adequately powered to detect these differences. These results 
suggest that HIV-infected children in areas of extremely high 
burden of TB may benefit from isoniazid preventive therapy 
irrespective of any known exposure to TB, but this approach 
is not recommended in the United States because of the low 
prevalence of TB (DII).
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
Empiric TB therapy should be started in HIV-infected 
infants and children in whom the diagnosis is suspected and 
continued until the diagnosis is definitively ruled out (AII). 
The use of directly observed therapy (i.e., a trained worker, 
and not a family member, watches the patient ingest each dose 
of medication) decreases rates of relapse, treatment failures, 
and drug resistance and is recommended for treatment of all 
children and adolescents with TB in the United States (AII). 
The principles for treating TB in the HIV-infected child are 
the same as for the HIV-uninfected child. However, treating 
TB in an HIV-infected child is complicated by antiretroviral 
drug interactions with the rifamycins and overlapping tox-
icities caused by antiretroviral drugs and TB medications. 
Rifampin is a potent inducer of the CYP3A family of enzymes. 
Rifabutin is a less potent inducer but is a substrate of this 
enzyme system.
Tables 4 and 5 provide doses and side effects of TB medica-
tions. In the absence of concurrent HAART, initial empiric 
treatment of TB disease usually should consist of a four-drug 
regimen (isoniazid, rifampin, pyrazinamide, and either etham-
butol or streptomycin) (AI). For the first 2 months of treat-
ment, directly observed therapy should be administered daily 
(intensive phase). Modifications of therapy should be based 
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on susceptibility testing, if possible. The drug-susceptibility 
pattern from the isolate of the adult source case can guide 
treatment when an isolate is not available from the child. 
If the organism is susceptible to isoniazid, rifampin, and 
pyrazinamide during the 2-month intensive phase of therapy, 
ethambutol (or streptomycin) can be discontinued and the 
intensive phase completed using three drugs (AI).
After the 2-month intensive phase, treatment of M. tuberculosis 
known to be sensitive to isoniazid and rifampin is continued 
with isoniazid and rifampin as directly observed therapy two 
to three times weekly (continuation phase) (AI); daily therapy 
during the continuation phase also is acceptable (AI). Children 
with severe immunosuppression should receive only daily or 
thrice-weekly treatment during the continuation phase because 
TB treatment regimens with once- or twice-weekly dosing have 
been associated with an increased rate of rifamycin resistance 
among HIV-infected adults with low CD4 cell counts; thus 
twice-weekly dosing should be considered only for children 
without immune suppression (e.g., CDC Immunologic 
Category I: CD4 >25% or >500 cells/mm3 if aged >6 years) 
(CIII) (98). Ethionamide can be used as an alternative to 
ethambutol in cases of TB meningitis (CIII) because ethion-
amide has better CNS penetration than does ethambutol.
For HIV-infected children with active pulmonary TB dis-
ease, the minimum recommended duration of antituberculous 
drug treatment is 6 months, but some experts recommend up 
to 9 months (AIII) (191). For children with extrapulmonary 
disease involving the bones or joints, CNS, or miliary disease, 
the minimum recommended duration of treatment is 12 
months (AIII) (90,192). These recommendations assume that 
the organism is susceptible to the medications, adherence to 
the regimen has been ensured by directly observed therapy, 
and the child has responded clinically and microbiologically 
to therapy.
For HIV-infected children diagnosed with TB disease, anti-
TB treatment must be started immediately (AIII). However, 
treatment of TB during HAART is complicated by unfavorable 
pharmacokinetic interactions and overlapping toxicities and 
should be managed by a specialist with expertise in treating 
both conditions (AIII). Issues to consider when treating both 
conditions include 1) the critical role of rifampin because of 
its potent bactericidal properties; 2) rifampin’s potent induc-
tion of the CYP3A enzyme system that precludes treatment 
with all protease inhibitors (PIs) but may allow treatment with 
non-nucleoside reverse transcriptase inhibitors (NNRTIs); 
3) the CYP3A induction by rifabutin is less potent but dose 
adjustments of both rifabutin and possibly the PIs still may 
be needed, although minimal data are available for children; 
4) overlapping toxicities; and 5) the challenges of adhering to 
a medication regimen that may include seven or more drugs.
Given these challenges, some experts have argued that the 
role of rifamycins in treating TB is so important that deferral of 
HAART should be considered until completion of TB therapy 
(CIII). Others recommend that, to improve adherence and 
better differentiate potential side effects, treatment of TB in an 
antiretroviral naïve HIV-infected child should be initiated 2–8 
weeks before antiretroviral medications are initiated (CIII). 
Consideration of which option to take must account for clini-
cal factors, such as clinical stage of HIV, immune status of the 
child, age, ability to adhere to complicated drug regimens, and 
other comorbid conditions. For severely immuno compromised 
children (Immunologic Category 3) (98), earlier initiation of 
HAART (e.g., 2 weeks after start of antimycobacterial therapy) 
may be advisable (despite risk for IRIS), whereas delayed initia-
tion of HAART might be considered for children with higher 
CD4 counts (BII).
The choice of antiretroviral regimen in an HIV-infected child 
being treated for TB disease is complex, and advice should be 
obtained from an expert in the treatment of these two diseases. 
Starting antiretroviral therapy with a NNRTI-based rather 
than a PI-based regimen is preferred because NNRTI regi-
mens have fewer interactions with rifampin-based TB therapy 
(BII). However, NNRTIs also are metabolized through the 
CYP3A enzyme system, and efavirenz and nevirapine are both 
CYP3A4 enzyme inducers. Efavirenz is the preferred NNRTI 
in HIV-infected children aged >3 years; and nevirapine is the 
preferred NNRTI for children aged <3 years, as the dosing 
for efavirenz in younger children has not been defined and 
no pediatric formulation exists. No data exist for children 
on the pharmacokinetics of either drug in combination with 
rifampin to make specific recommendations about potential 
need for an increase in dose of the NNRTI. If a PI is used, a 
ritonavir-boosted PI such as lopinavir/ritonavir is required. 
No pharmacokinetic data are available to address whether 
additional ritonavir boosting is needed in children receiving 
rifampin and lopinavir/ritonavir-based regimens.
For children already receiving antiretroviral therapy in 
whom TB has been diagnosed, the issues are equally compli-
cated, and require similar considerations. Treatment for TB 
must be started immediately (AIII), and the child’s antiret-
roviral regimen should be reviewed and altered, if needed, 
to ensure optimal treatment for both TB and HIV and to 
minimize potential toxicities and drug-drug interactions. 
These recommendations are limited because of the paucity 
of data on the optimal dosing of medications to treat TB in 
children, especially in HIV-infected children. Guidelines and 
recommendations exist for dose adjustments necessary in 
adults treated with rifabutin and PIs, but the absence of data 
preclude extrapolating these to HIV-infected children being 
treated for TB. Consultation with an expert in pediatric HIV 
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and TB infection is recommended. More data are needed on 
the pharmacokinetics of anti-TB medications in both HIV-
infected and HIV-uninfected children.
For treatment of drug-resistant TB, a minimum of three 
drugs should be administered, including two or more bacteri-
cidal drugs to which the isolate is susceptible (AII). Regimens 
can include three to six drugs with varying levels of activity. 
Children infected with MDR TB (e.g., resistance to at least 
isoniazid and rifampin) should be managed in consultation 
with an expert in this condition (AIII). If the strain is resistant 
only to isoniazid, isoniazid should be discontinued and the 
patient treated with 9–12 months of a rifampin- or rifabutin-
containing regimen (e.g., rifampin, pyrazinamide, and etham-
butol) (BII). If the strain is resistant only to rifampin, risk for 
relapse and treatment failure increases. Rifampin should be 
discontinued, and a 2-month induction phase of isoniazid, 
pyrazinamide, ethambutol, and streptomycin should be 
administered, followed by an additional continuation phase 
of isoniazid, pyrazinamide, and ethambutol to complete a 
minimum of 12–18 months of therapy, with the exact length 
of therapy based on clinical and radiologic improvement 
(BIII). Among older adolescents with rifampin-monoresistant 
strains, isoniazid, ethambutol, and a fluoroquinolone can 
be administered, with pyrazinamide added for the first 2 
months (BIII); an injectable agent (e.g., aminoglycoside such 
as streptomycin or amikacin) also can be included in the first 
2–3 months for patients with severe disease (BIII). When the 
strain is resistant to isoniazid and rifampin (i.e., MDR TB), 
therapeutic regimens must be individualized on the basis of 
the resistance pattern, treatment history of the patient or the 
source case, relative activities of the drugs, extent of disease, 
and any comorbid conditions. The duration of therapy should 
be at least 12 months—usually longer. In children who are 
smear- or culture-positive at treatment initiation, therapy 
usually should continue for 18–24 months after smear and 
culture conversion. Among children with paucibacillary disease 
(e.g., smear- and culture-negative), duration of therapy may be 
shorter but should be >12 months (BIII) (90,193).
Extensively drug-resistant TB (XDR TB) has emerged 
globally as an important new threat, particularly in persons 
infected with HIV (194). XDR TB is a strain of TB resistant 
to isoniazid and rifampin (which defined MDR TB) with 
additional resistance to any fluoroquinolone and at least 
one of three injectable drugs: capreomycin, kanamycin, and 
amikacin (195). Of the 49 cases of XDR TB identified in the 
United States from 1993 to 2006, one (2%) occurred in a 
child aged <15 years (195). However, this number possibly 
underestimates the burden in children because many TB cases 
in children are not culture-positive; thus, a definitive diagnosis 
of drug resistance (including MDR or XDR) is not possible. 
Children with suspected or confirmed XDR TB should be 
managed in consultation with an expert because such cases 
are associated with rapid disease progression in the prescence 
of HIV coinfection and a high death rate.
Adjunctive treatment with corticosteroids is indicated for 
children who have TB meningitis; dexamethasone lowers mor-
tality and long-term neurologic impairment (AII). These drugs 
might be considered for children with pleural or pericardial 
effusions, severe miliary disease, and substantial endobronchial 
disease (BIII). Antituberculous therapy must be administered 
concomitantly. Most experts use 1–2 mg/kg/day of prednisone 
or its equivalent for 6–8 weeks.
Monitoring and Adverse Events, Including IRIS
Monthly monitoring of clinical and bacteriologic response 
to therapy is important (AII). For children with pulmonary 
TB, chest radiographs should be obtained after 2–3 months of 
therapy to evaluate response (AIII). Hilar adenopathy might 
persist for as long as 2–3 years despite successful antituber-
culous therapy, and a normal radiograph is not a criterion to 
discontinue therapy. Follow-up radiographs after completion 
of therapy are not necessary unless clinical symptoms recur.
Common side effects associated with TB medications are 
listed in Table 5. Isoniazid is available as syrup, but some 
specialists advise against using it because the syrup is unstable 
and frequently causes diarrhea (DIII). Gastric upset during 
the initial weeks of isoniazid treatment occurs frequently and 
often can be avoided by having some food in the stomach 
when isoniazid is administered. Hepatotoxicity is the most 
common serious adverse effect. It includes subclinical hepatic 
enzyme elevation, which usually resolves spontaneously during 
continuation of treatment, and clinical hepatitis that usually 
resolves when the drug is discontinued. It rarely progresses 
to hepatic failure, but the likelihood of life-threatening liver 
damage increases when isoniazid is continued despite hepatitis 
symptoms. Hepatotoxicity is less frequent in children than in 
adults, but no age group is risk-free. Transient asymptomatic 
serum transaminase elevations have been noted in 3%–10% 
and clinical hepatitis in <1% of children receiving isoniazid; 
<1% of children required treatment discontinuation (192,196). 
However, the rate of hepatotoxicity might be greater in 
children who take multiple hepatotoxic medications and in 
children who have HIV infection. Pyridoxine (150 mg/day) 
is recommended for all symptomatic HIV-infected children 
treated with isoniazid (AII). HIV-infected children on anti-TB 
medications should have liver enzymes obtained at baseline 
and monthly thereafter (AIII). If symptoms of drug toxicity 
develop, a physical examination and liver enzyme measurement 
should be repeated (AIII). Mild elevations in serum transami-
nases (e.g., two to three times the upper limit of normal) do not 
Vol. 58 / RR-11 Recommendations and Reports 25
require discontinuation of drugs if other findings are normal 
(AII), but they do require more frequent rechecks—as often 
as weekly—until they resolve.
The most ominous toxicity associated with ethambutol 
is optic neuritis, with symptoms of blurry vision, central 
scotomata, and red-green color blindness, which is usually 
reversible and rare at doses of 15–25 mg/kg among children 
with normal renal function (193). Assessments of renal func-
tion, ophthalmoscopy, and (if possible) visual acuity and color 
vision, should be performed before starting ethambutol and 
monitored regularly during treatment with the agent (AIII). 
Hypothyroidism has been associated with ethionamide and 
periodic (e.g., monthly) monitoring of thyroid hormone serum 
concentrations is recommended with its use (AIII).
Major adverse effects of aminoglycoside drugs are ototoxic-
ity and nephrotoxicity. Periodic audiometry, monitoring of 
vestibular function (as possible), and blood urea nitrogen and 
creatinine are recommended (AIII).
Secondary drugs used to treat resistant TB have not been 
well studied in children. These medications should be used in 
consultation with a TB specialist (AIII). Coadministration of 
pyridoxine (150 mg/day) with cycloserine is recommended 
(AII). Thiacetazone can cause severe and often fatal reactions 
among HIV-infected children, including severe rash and aplas-
tic anemia, and should not be used (EIII).
IRIS in patients receiving anti-TB therapy during HAART 
has been reported in HIV-infected adults (197–199). New 
onset of systemic symptoms, especially high fever; expand-
ing CNS lesions; and worsening adenopathy, pulmonary 
infiltrates, or pleural effusions have been reported in HIV-
infected adults during HAART up to several months after 
the start of TB therapy. Such cases also have been reported in 
children (22,192,200) and should be suspected in children 
with advanced immune suppression who initiate HAART and 
subsequently develop new symptoms.
IRIS occurs in two common clinical scenarios. First, in 
patients who have occult TB before initiation of HAART, TB 
may have been unmasked by immune recovery after antiretrovi-
ral drug initiation. This “unmasking IRIS” or incident TB-IRIS 
usually occurs within the first 3–6 months after initiation of 
HAART, and the infectious pathogen typically is detectable. 
Secondly, IRIS can occur as paradoxical exacerbation of TB 
after initiation of HAART in a patient already receiving anti-
TB treatment through a clinical recrudescence of a successfully 
treated infection or symptomatic relapse despite initial clinical 
improvement and continued microbiologic treatment success 
(i.e., “paradoxical IRIS”); treatment failure associated with 
microbial resistance or poor adherence must be ruled out.
The literature on IRIS in children consists largely of case 
reports and small series, so whether IRIS occurs more often 
in children than in adults is not clear. Persons with mild-to-
moderate symptoms of IRIS have been treated symptomatically 
with nonsteroidal anti-inflammatory drugs while continuing 
anti-TB and HIV therapies. In certain cases, use of systemic 
corticosteroids steroids for 1–2 weeks results in improvement 
during continuation of TB/HIV therapies (CIII) (197–199). 
However, no controlled trials of the use of corticosteroids have 
been published. Despite the development of IRIS, TB therapy 
should not be discontinued.
Management of Treatment Failure
Most children with TB respond well to medical therapy. If 
response is not good, then adherence to therapy, drug absorp-
tion, and drug resistance should be assessed. Mycobacterial 
culture, drug-susceptibility testing, and antimycobacterial drug 
levels should be performed whenever possible. Drug resistance 
should be suspected in any child whose smear or culture fails 
to convert after 2 months of directly observed anti-TB therapy. 
In the absence of initial bacteriologic confirmation of disease, 
failure should be suspected in children whose clinical symp-
toms (including failure to gain weight) fail to respond and who 
have radiographic evidence of disease progression on therapy. 
As described above, drug-resistant TB should be managed in 
consultation with an expert.
Prevention of Recurrence
Risk for recurrence is rare in children with drug-susceptible 
TB who are treated under direct observation. If TB recurs, the 
child is at high risk for drug resistance and should be managed 
accordingly.
Chronic suppressive therapy is unnecessary for a patient 
who has successfully completed a recommended regimen of 
treatment for TB (DII). Secondary prophylaxis is not recom-
mended for children who have had a prior episode of TB. 
However, HIV-infected children who were treated for LTBI or 
TB and who again contact contagious TB should be treated for 
presumed latent infection, after diagnostic evalution excludes 
current disease.
Discontinuing Secondary Prophylaxis
Not applicable.
Mycobacterium avium Complex 
Disease
Epidemiology 
Mycobacterium avium complex (MAC) refers to multiple 
related species of nontuberculous mycobacteria (e.g., M. avium, 
M. intracellulare, M. paratuberculosis) that are widely dis-
tributed in the environment. Comprehensive guidelines on 
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the diagnosis, prevention, and treatment of nontuberculous 
mycobacterial diseases were recently published (201). These 
guidelines highlight the tremendous advances in laboratory 
methods in mycobacteriology that have expanded the number 
of known nontuberculous mycobacterial species from 50 in 
1997 to 125 in 2006. 
MAC was the second most common OI among children 
with HIV infection in the United States after PCP during the 
pre-HAART era, but its incidence has greatly decreased from 
1.3–1.8 episodes per 100 person-years during the pre-HAART 
era to 0.14–0.2 episodes per 100 person-years during the 
HAART era (3,4). MAC is ubiquitous in the environment and 
presumably is acquired by routine exposures through inhala-
tion, ingestion, or inoculation (202). A recent population-
based study in Florida of adults and children associated soil 
exposure, along with black race and birth outside the United 
States, with MAC infection (203). Respiratory and GI coloni-
zation can act as portals of entry that can lead to disseminated 
infection (204).
MAC can appear as isolated lymphadenitis among HIV-
infected children. Disseminated infection with MAC in pedi-
atric HIV infection rarely occurs during the first year of life; 
its frequency increases with age and declining CD4 count, and 
it is a complication of advanced immunologic deterioration 
among HIV-infected children (202,205,206). Disseminated 
MAC can occur at higher CD4 cell counts among younger 
HIV-infected children than among older children or adults, 
especially among HIV-infected children aged <2 years.
Clinical Manifestations 
Respiratory symptoms are uncommon among HIV-infected 
children who have disseminated MAC, and isolated pulmonary 
disease is rare. Early symptoms can be minimal and may pre-
cede mycobacteremia by several weeks. Symptoms commonly 
associated with disseminated MAC infection among children 
include persistent or recurrent fever, weight loss or failure to 
gain weight, sweats, fatigue, persistent diarrhea, and persistent 
or recurrent abdominal pain. Lymphadenopathy, hepato-
megaly, and splenomegaly can occur. Laboratory abnormalities 
include anemia, leukopenia, and thrombocytopenia. Although 
serum chemistries are usually normal, some children may 
have elevated alkaline phosphatase or lactate dehydrogenase. 
These signs and symptoms also are relatively common in the 
absence of disseminated MAC among HIV-infected children 
with advanced immunosuppression.
Diagnosis
Procedures used to diagnose MAC in children are the same 
as those used for HIV-infected adults (16). MAC is definitively 
diagnosed by isolation of the organism from blood or from 
biopsy specimens from normally sterile sites (e.g., bone marrow, 
lymph node). Multiple mycobacterial blood cultures over time 
may be required to yield a positive result. Use of a radiometric 
broth medium or lysis-centrifugation culture technique can 
enhance recovery of organisms from blood.
Histology demonstrating macrophage-containing acid-fast 
bacilli strongly indicates MAC in a patient with typical signs 
and symptoms, but culture is essential to differentiate non-
tuberculous mycobacteria from M. tuberculosis, determine 
which nontuberculous mycobacterium is causing infection, 
and perform drug-susceptibility testing. Testing of MAC 
isolates for susceptibility to clarithromycin or azithromycin is 
recommended (BIII). The BACTEC™ method for radiometric 
susceptibility testing can be used. Susceptibility thresholds 
for clarithromycin are minimal inhibitory concentrations 
of >32 µg/mL and a minimal inhibitory concentration of 
>256 µg/mL for azithromycin (207).
Prevention Recommendations
Preventing Exposure
MAC is ubiquitous in the environment. Available infor-
mation does not support specific recommendations regarding 
exposure avoidance. Person-to-person transmission is not believed 
to be common.
Preventing First Episode of Disease
The most effective way to prevent disseminated MAC among 
HIV-infected children is to preserve immune function through 
use of effective antiretroviral therapy. HIV-infected children 
who have advanced immunosuppression should be offered 
prophylaxis against disseminated MAC disease according to 
the following CD4 count thresholds (AII) (208,209):
Children aged •	 >6 years: <50 cells/mm3
Children aged 2–5 years: <75 cells/mm•	 3
Children aged 1–2 years: <500 cells/mm•	 3
Children aged <1 year: <750 cells/mm•	 3
For the same reasons that clarithromycin and azithromycin 
are the preferred prophylactic agents for adults, either one 
should be considered for prophylaxis in children (AII); oral suspen-
sions of both agents are commercially available in the United 
States. Before prophylaxis is initiated, the child should be 
evaluated for disseminated MAC disease, which should usually 
include obtaining a blood culture for MAC (AIII).
Although detecting MAC in stool or respiratory tract may 
precede disseminated disease, no data support initiating pro-
phylaxis in patients with detectable organisms at these sites in 
the absence of a blood culture positive for MAC. Therefore, 
routine screening of respiratory or GI specimens for MAC is 
not recommended (DIII).
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Discontinuing Primary Prophylaxis 
On the basis of both randomized controlled trials and 
observational data, primary prophylaxis for MAC can be safely 
discontinued in HIV-infected adults who respond to antiret-
roviral therapy with an increase in CD4 count. In a study of 
discontinuing OI prophylaxis among HIV-infected children 
whose CD4 percentages were >20% for those aged >6 years 
and >25% for those aged 2–6 years, 63 HIV-infected children 
discontinued MAC prophylaxis, and no MAC events were 
observed during >2 years of follow up (46). On the basis of 
both these findings and data from studies in adults, primary 
prophylaxis can be discontinued in HIV-infected children 
aged >2 years receiving stable HAART for >6 months and 
experiencing sustained (>3 months) CD4 cell recovery well 
above the age-specific target for initiation of prophylaxis (e.g., 
similar to adults, >100 cells/mm3, for children aged >6 years; 
and >200 cells/mm3 for children aged 2–5 years) (BII). No 
specific recommendations exist for discontinuing MAC pro-
phylaxis in HIV-infected children aged <2 years.
Treatment Recommendations
Treatment of Disease
Disseminated MAC infection should be treated in consulta-
tion with a pediatric infectious disease specialist who has exper-
tise in pediatric HIV infection (AIII). Combination therapy 
with a minimum of two drugs is recommended to prevent or 
delay the emergence of resistance (AI). Monotherapy with a 
macrolide results in emergence of high-level drug resistance 
within weeks.
Improved immunologic status is important for controling 
disseminated MAC disease; potent antiretroviral therapy 
should be initiated among children with MAC disease who 
are antiretroviral naïve. However, the optimal time to start 
HAART in this situation is unknown; many experts treat MAC 
with antimycobacterial therapy for 2 weeks before starting 
HAART to try to minimize IRIS, although whether this makes 
a difference is unknown (CIII). For children already receiving 
HAART, HAART should be continued and optimized unless 
drug interactions preclude the safe concomitant use of anti-
retroviral and antimycobacterial drugs.
Doses and side effects of MAC medications are included in 
tables 4 and 5. Initial empiric therapy should include two or 
more drugs (AI): clarithromycin or azithromycin plus etham-
butol. Some experts use clarithromycin as the preferred first 
agent (AI), reserving azithromycin for patients with substantial 
intolerance to clarithromycin or when drug interactions with 
clarithromycin are a concern (AII). Clarithromycin levels can 
be increased by PIs and decreased by efavirenz, but no data 
are available to recommend dose adjustments for children. 
Azithromycin is not metabolized by the cytochrome P450 
(CYP450) system; therefore, it can be used without concern 
for significant drug interactions with PIs and NNRTIs.
Because a study in adults demonstrated a survival benefit 
with the addition of rifabutin to clarithromycin plus etham-
butol, some experts would add rifabutin as a third drug to 
the clarithromycin/ethambutol regimen (CI); however, drug 
interactions should be checked carefully, and more intensive 
toxicity monitoring might be warranted if such drugs are 
administered concomitantly (AIII). Because rifabutin increases 
CYP450 activity that leads to increased clearance of other drugs 
(e.g., PIs and NNRTIs), and toxicity might increase with con-
comitant administration of drugs, other experts recommend 
against using this third agent in children (CIII). Guidelines 
and recommendations exist for dose adjustments necessary in 
adults treated with rifabutin and PIs, but the absence of data 
in children precludes extrapolating these to HIV-infected 
children undergoing treatment for disseminated MAC. No 
pediatric formulation of rifabutin exists, but the drug can be 
administered mixed with foods such as applesauce. Safety data 
are limited from use in 22 HIV-infected children (median age: 
9 years) who received rifabutin in combination with two or 
more other antimycobacterial drugs for treatment of MAC for 
1–183 weeks; doses ranged from 4 mg/kg/dose to 18.5 mg/kg/
dose, and reported adverse effects were similar to those reported 
in adults (210).
Monitoring and Adverse Events, Including IRIS
Clinically, most patients improve substantially during the 
first 4–6 weeks of therapy. A repeat blood culture for MAC 
should be obtained 4–8 weeks after initiation of antimyco-
bacterial therapy in patients who fail to respond clinically 
to their initial treatment regimen. Improvement in fever can 
be expected within 2–4 weeks after initiation of appropriate 
therapy. However, for those with more extensive disease or 
advanced immunosuppression, clinical response might be 
delayed, and elimination of the organism from the blood might 
require up to 12 weeks of effective therapy.
IRIS in patients receiving MAC therapy during HAART 
has been reported among HIV-infected adults and children 
(211–213). New onset of systemic symptoms, especially fever 
or abdominal pain, leukocytosis, and focal lymphadenitis 
(cervical, thoracic, or abdominal) associated with preexisting 
but relatively asymptomatic MAC infection has occurred 
after start of HAART. Before initiation of HAART among 
HIV-infected children with low CD4 counts, an assessment 
for MAC should be considered and treatment provided if 
MAC is identified. However, recent data indicate that MAC 
prophylaxis with azithromycin did not prevent IRIS (212). 
Children with moderate symptoms of IRIS can be treated 
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symptomatically with nonsteroidal anti-inflammatory drugs 
or, if unresponsive to nonsteroidals, a short course (e.g., 4 
weeks) of systemic corticosteroid therapy while continuing to 
receive HAART (CIII).
Adverse effects from clarithromycin and azithromycin 
include nausea, vomiting, abdominal pain, abnormal taste, and 
elevations of liver transaminase levels or hypersensitivity reac-
tions. The major toxicity associated with ethambutol is optic 
neuritis, with symptoms of blurry vision, central scotomata, 
and red-green color blindness, which usually is reversible and 
rare at doses of 15–25 mg/kg among children with normal renal 
function. Assessments of renal function, ophthalmoscopy, and 
(if possible) visual acuity and color vision should be performed 
before starting ethambutol and monitored regularly during 
treatment with the agent (AIII).
Patients receiving clarithromycin plus rifabutin should be 
observed for the rifabutin-related development of leukopenia, 
uveitis, polyarthralgias, and pseudojaundice. Tiny, almost 
transparent, asymptomatic peripheral and central corneal 
deposits that do not impair vision have been observed in some 
HIV-infected children receiving rifabutin as part of a multidrug 
regimen for MAC (210).
Management of Treatment Failure
Treatment failure is defined as the absence of clinical response 
and the persistence of mycobacteremia after 8–12 weeks of 
treatment. Repeat susceptibility testing of MAC isolates is rec-
ommended in this situation, and a new multidrug regimen of 
two or more drugs not previously used and to which the isolate 
is susceptible should be administered (AIII). Drugs that should 
be considered for this scenario include rifabutin, amikacin, and 
a quinolone. In HIV-infected adults, data from treating MAC 
in HIV-uninfected patients indicate an injectable agent such as 
amikacin or streptomycin should be considered (CIII) (201). 
Because dosing of these agents in children can be problematic, 
drug-resistant disseminated MAC should be treated with input 
from an expert in this disease (AIII). Optimization of antiret-
roviral therapy is especially important adjunct to treatment for 
patients in whom initial MAC therapy has failed.
Prevention of Recurrence
Children with a history of disseminated MAC should be 
administered lifelong prophylaxis to prevent recurrence (AII).
Discontinuing Secondary Prophylaxis
On the basis of immune reconstitution data in adults and 
data in children discontinuing primary prophylaxis, some 
experts recommend discontinuation of secondary prophylaxis 
in HIV-infected children aged >2 years who have completed 
>12 months of treatment for MAC, who remain asymptomatic 
for MAC, and who are receiving stable HAART (i.e., HAART 
not requiring change for viral or immune failure) and have 
sustained (>6 months) CD4 cell recovery well above the age-
specific target for initiation of primary prophylaxis (e.g., similar 
to adults, >100 cells/mm3, for children aged >6 years and >200 
cells/mm3 for children aged 2–6 years) (CIII). Secondary pro-
phylaxis should be reintroduced if the CD4 count falls below 
the age-related threshold.
Fungal Infections
Aspergillosis
Epidemiology
Aspergillus spp. are ubiquitous molds that are widespread in 
soil and grow on plants and decomposing organic materials 
(214); they are infrequent pathogens in HIV-infected children. 
The most common species causing aspergillosis is A. fumigatus, 
followed by A. flavus (215,216). Aspergillosis is rare but often 
lethal in pediatric AIDS patients; the estimated incidence of 
invasive aspergillosis in pediatric AIDS patients was 1.5%–3% 
before widespread use of HAART (217–219), and invasive 
aspergillosis is believed to be much less prevalent during the 
post-HAART era. Specific risk factors include low CD4 count, 
neutropenia, corticosteroid use, concurrent malignancy with 
chemotherapy, broad-spectrum antibiotic exposure, previous 
pneumonia and respiratory OIs, and HIV-related phagocytic 
impairment (217,220–224).
Clinical Manifestations
Invasive pulmonary aspergillosis is the most common 
presentation among HIV-infected children (223,225,226). 
Other manifestations include necrotizing tracheobronchitis; 
pseudomembranous tracheobronchitis; and involvement of 
CNS, skin, sinuses, middle ear, and mastoid bones (217–
221,227). Disseminated aspergillosis has been described rarely 
(217,228). Invasive pulmonary aspergillosis commonly asso-
ciated with fever, cough, dyspnea, and pleuritic pain. Acute 
respiratory distress and wheezing or fungal cast production can 
occur with necrotizing tracheobronchitis, and stridor can occur 
with laryngotracheitis (214,217,225). Aspergillus infections 
of the CNS manifest as single or multiple cerebral abscesses, 
meningitis, epidural abscess, or subarachnoid hemorrhage 
(214). Cutaneous aspergillosis typically is associated with 
contaminated adhesive tapes and arm boards used to secure 
IV devices (214,217).
Diagnosis
The organism usually is not recoverable from blood (except 
A. terreus) but is isolated readily from lung, sinus, brain, and 
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skin biopsy specimens (217,222,229). A definitive diagnosis 
requires relevant clinical signs and symptoms and the histo-
pathologic demonstration of organisms in biopsy specimens 
obtained from involved sites (e.g., liver or brain). Respiratory 
tract disease can be presumptively diagnosed in the absence of 
a tissue biopsy if Aspergillus spp. are recovered from a respira-
tory sample, compatible signs and symptoms are present, and 
no alternative diagnosis is identified (90). A serologic assay to 
detect galactomannan, a molecule in the cell wall of Aspergillus 
spp., is available commercially but has not been evaluated 
widely in infants and children. In addition, the assay has higher 
false-positive results in children (230,231). Therefore, use of 
galactomannan assays for early detection of aspergillosis is not 
recommended (DIII).
Radiologic examination plays an important role in diagnosis 
and follow-up of invasive pulmonary aspergillosis. Chest radio-
graph demonstrates either a diffuse interstitial pneumonitis or a 
localized wedge-shaped dense infiltrate representing pulmonary 
infarction (214,217). Computed tomography (CT) of the chest 
can be used to identify the halo sign, a macronodule surrounded 
by a perimeter of ground-glass opacity, which is an early sign 
of invasive pulmonary aspergillosis (232). Cavitation and air 
crescent formation shown in chest CT with an aspergilloma 
appear more frequently in older children and adults than in 
younger children (233–236).
Prevention Recommendations
Preventing Exposutre
In HIV-infected children who are severely immunosup-
pressed or neutropenic, considerations for preventing exposure 
to Aspergillus might include excluding plants and flowers from 
rooms, avoiding food items such as nuts and spices that often 
are contaminated, and minimizing application of nonsterile 
biomedical devices and adhesive tape (214,237–239). Other 
hospital environmental measures that can help prevent asper-
gillosis outbreaks include placing suitable barriers between 
patient-care areas and construction sites; routinely cleaning 
showerheads, hot water faucets, and air-handling systems; 
repairing faulty air flow; confining patients to hospital rooms 
supplied with sterile laminar airflow; and installing high-
efficiency particulate air filters (90,240–242).
Preventing First Episode of Disease
The use of chemoprophylaxis for aspergillosis is not recom-
mended in HIV-infected children because of the low incidence 
of invasive disease and the unknown efficacy of prophylaxis 
in children, combined with the toxicities of likely agents 
(DIII) (243–245). Low-dose amphotericin B, itraconazole, 
or voriconazole prophylaxis has been employed to prevent 
aspergillosis, with unknown efficacy.
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
The recommended treatment for invasive aspergillosis 
is voriconazole, a second-generation triazole and synthetic 
derivative of fluconazole (246–249). Data in adults have shown 
voriconazole to be superior to conventional amphotericin B in 
treating aspergillosis and to be associated with superior survival 
(AI) (246). However, data regarding fluconazole for children 
are limited (BII).
In a compassionate-use program of voriconazole that 
included 42 immuno compromised children with invasive 
aspergillosis, voriconazole treatment elicited a complete (43%) 
or partial (45%) response (250,251). The optimal pediatric 
dose of voriconazole is not yet known. Children require higher 
doses (on a mg/kg body weight basis) of voriconazole than 
do adults to attain similar serum concentrations. The recom-
mended dosage of voriconazole for children is 6–8 mg/kg 
intravenously or 8 mg/kg orally every 12 hours for two doses, 
followed by 7 mg/kg intravenously or orally twice daily (AII) 
(252). For critically ill patients, parenteral administration is 
recommended (AIII). Therapy is continued for >12 weeks, but 
treatment duration should be individualized for each patient 
according to clinical response (90). Voriconazole has not been 
studied in HIV-infected children.
Voriconazole is cleared primarily through three key hepatic 
microsomal CYP450 enzymes—CYP2C19, CYP2C9, 
and CYP3A4—with most metabolism mediated through 
CYP2C19 (253). As a result of a point mutation in the gene 
encoding CYP2C19, some persons poorly metabolize voricon-
azole, and others metabolize it extensively; about 3%–5% of 
whites and blacks are poor metabolizers, whereas 15%–20% of 
Asians are poor metabolizers (248,253). Drug levels can be as 
much as fourfold greater in persons who are poor metabolizers 
than in persons who are homozygous extensive metabolizers. 
Coadministration of voriconazole with drugs that are potent 
CYP450 enzyme inducers can significantly reduce voriconazole 
levels. Voriconazole should be used cautiously with HIV PIs 
and efavirenz because of potential interactions, and consider-
ation should be given to therapeutic drug monitoring if used 
concomitantly (CIII).
Amphotericin B, either conventional or a lipid formulation 
has recommendation level BIII in children (90,254). The stan-
dard amphotericin B deoxycholate dosage is 1.0–1.5 mg/kg/day. 
Lipid formulations of amphotericin B allow administration of 
higher dosage, deliver higher tissue concentrations of drug to 
reticuloendothelial organs (e.g., lungs, liver, spleen), have fewer 
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infusion-related side effects and less renal toxicity, but are more 
expensive; dosing of 5 mg/kg/day is recommended.
Surgical excision of a localized invasive lesion may be 
warranted, especially in sinus aspergillosis, certain cases of 
pulmonary aspergillosis with impingement on great vessels or 
pericardium, hemoptysis from a single focus, and erosion into 
the pleural space or ribs (BIII).
Monitoring and Adverse Events, Including IRIS
The main side effects of voriconazole are reversible dose-
dependent visual disturbances that include a perception of 
increased brightness and blurred vision that occurs in about 
one third of patients, elevated hepatic transaminases with 
higher doses, and occasional skin rash (248); as noted earlier, 
adverse side effects can result from interactions with PIs. The 
primary toxicities of amphotericin B include infusion-related 
fever and chills and nephrotoxicity.
Patients should be monitored for adverse effects related to 
antifungal agents, especially to amphotericin B. Only one case 
of aspergillosis-associated IRIS has been described (255).
Management of Treatment Failure
The efficacy of antifungal therapy in invasive aspergillosis is 
extremely poor. No data are available to guide recommenda-
tions for managing treatment failure. For patients in whom 
treatment failed or who were unable to tolerate voriconazole, 
amphotericin B should be considered (BIII). Itraconazole for 
aspergillosis refractory to primary therapy with voriconazole 
is not recommended because of similar mechanisms of action 
and possible cross-resistance (DIII).
Caspofungin is approved for adults with invasive aspergil-
losis who do not improve or do not tolerate standard therapy, 
and it can be considered for treatment failure in children, 
although data on this drug are limited in children (CIII). 
In a pharmacokinetic study in 39 children aged 2–12 years, 
dosing on a body surface area basis was recommended over a 
weight-based dosing scheme; 50 mg/m2 body surface area once 
daily resulted in area-under-the-curve concentrations similar 
to exposure in adults receiving the standard dosage of 50 mg/
day (256). Because of limited bioavailability, caspofungin is 
available only for IV use.
Combination therapy with caspofungin and voriconazole 
has been studied in a small number of adults and children 
with invasive aspergillosis (257–259). For salvage therapy, an 
additional antifungal agent might be added to current therapy, 
or combination antifungal drugs from different classes other 
than the initial regimen can be used (BIII) (257,259–264).
Prevention of Recurrence
For patients with acute leukemia and immunosuppression 
unrelated to HIV, continuation of antifungal therapy through-
out immunosuppression seems to be associated with a more 
favorable outcome (265). However, no data are available on 
HIV-infected populations, and hence no recommendations can 
be made for or against secondary prophylaxis (CIII).
Discontinuing Secondary Prophylaxis
Not applicable.
Candida Infections
Epidemiology 
The most common fungal infections among HIV-infected 
children are caused by Candida spp. Oral thrush and diaper 
dermatitis occur among 50%–85% of HIV-infected children. 
Candida albicans is the most common cause of mucosal and 
esophageal candidiasis. Localized disease caused by Candida is 
characterized by limited tissue invasion to the skin or mucosa. 
Examples of localized candidiasis include oropharyngeal and 
esophageal disease, vulvovaginitis, and diaper dermatitis. Once 
the organism penetrates the mucosal surface and widespread 
hematogenous dissemination occurs, invasive candidiasis 
ensues. This can result in candidemia, meningitis, endocarditis, 
renal disease, endophthalmitis, and hepatosplenic disease.
Oropharyngeal candidiasis (OPC) continues to be one of 
the most frequent OIs in HIV-infected children during the 
HAART era (28% of children), with an incidence rate of 
0.93 per 100 child-years (3). The incidence of esophageal 
or tracheobronchial candidiasis also has decreased from 1.2 
per 100 child-years during the pre-HAART era to 0.08 per 
100 child-years during the HAART era (2001–2004) (1). 
Candida esophagitis continues to be seen in children who are 
not responding to antiretroviral therapy (266,267). Children 
who develop esophageal candidiasis despite HAART may be 
less likely to have typical symptoms (e.g., odynophagia and 
retrosternal pain) or have concomitant OPC (268); during 
the pre-HAART era, concomitant OPC occurred in 94% 
of children with candida esophagitis (266). Risk factors for 
esophageal candidiasis include low CD4 count (<100 cells/
mm3), high viral load, and neutropenia (<500 cells/mm3) 
(1,3,266,267).
Disseminated candidiasis is infrequent among HIV-infected 
children, but Candida can disseminate from the esophagus 
particularly when coinfection with herpes simplex virus (HSV) 
or CMV is present (228,266). Candidemia occurs in up to 
12% of HIV-infected children with chronically indwelling 
central venous catheters for total parental nutrition or IV 
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antibiotics (267,269). Approximately 50% of reported cases of 
Candida bloodstream infections in HIV-infected children are 
caused by non-albicans Candida spp., including C. tropicalis, 
C. pseudotropicalis, C. parapsilosis, C. glabrata, C. kruse, and 
C. dubliniensis. In one study of Cambodian HIV-infected 
children on HAART who had candidiasis, seven (75%) of nine 
isolated C. glabrata were resistant to fluconazole, and three 
(40%) of seven C. parapsilosis isolated were resistant to more 
than three azole agents (270). Species-specific epidemiology 
varies widely by geographic location and hospital. A substantial 
number of children who develop candidemia have received 
systemically absorbed oral antifungal azole compounds (e.g., 
ketoconazole or fluconazole) for control of oral and esophageal 
candidiasis (267). Early detection and treatment of candidemia 
can decrease mortality. Overall mortality was 90% in one 
study in children who had >14 days of fever and symptoms 
before diagnosis of disseminated infection with Candida spp. 
(228).
Clinical Manifestations
Clinical manifestations of OPC vary and include pseudomem-
branous (thrush) and erythematous (atrophic), hyperplastic 
(hypertrophic), and angular cheilitis. Thrush appears as creamy 
white curdlike patches with inflamed underlying mucosa that 
is exposed after removal of the exudate. It can be found on 
the oropharyngeal mucosa, palate, and tonsils. Erythematous 
OPC is characterized by flat erythematous lesions on the 
mucosal surface. Hyperplastic candidiasis comprises raised 
white plaques on the lower surface of the tongue, palate, and 
buccal mucosa and cannot be removed. Angular cheilitis occurs 
as red fissured lesions in the corners of the mouth.
Esophageal candidiasis often presents with odynophagia, 
dysphagia, or retrosternal pain, and unlike adults, a substantial 
number of children experience nausea and vomiting. Therefore, 
children with esophageal candidiasis might present with 
dehydration and weight loss. Evidence of OPC can be absent 
among children with esophageal candidiasis, particularly those 
receiving HAART.
New-onset fever in an HIV-infected child with advanced dis-
ease and a central venous catheter is the most common clinical 
manifestation of candidemia. Renal candidiasis presents with 
candiduria and ultrasonographically demonstrated renal paren-
chymal lesions, often without symptoms related to renal disease 
(267). Candidemia can lead to endogenous endophthalmitis, 
and ocular examination by an ophthalmologist is warranted 
in children with bloodstream Candida infection.
Diagnosis 
Oral candidiasis can be diagnosed by a potassium hydroxide 
preparation and culture with microscopic demonstration of 
budding yeast cells in wet mounts or biopsy specimens. For 
recurrent or refractory OPC, cultures with in vitro susceptibil-
ity testing can be used to guide antifungal treatment (271).
Esophageal candidiasis has a classic cobblestoning appear-
ance on barium swallow. In refractory symptomatic cases, 
endoscopy should be performed to rule out other causes of 
refractory esophagitis (e.g., HSV, CMV, MAC, and azole-
resistant Candida spp.). Endoscopy might show few small white 
raised plaques to elevated confluent plaques with hyperemia 
and extensive ulceration.
Candidemia is best diagnosed with blood cultures using 
lysis-centrifugation techniques (267) or automated broth-based 
systems (272). When candidemia is present, depending on 
clinical suspicions, retinal examination for endophthalmitis, 
abdominal CT or ultrasound for hepatic or renal involvement, 
and bone scans for osteomyelitis can be considered.
New diagnostic techniques such as the urine D-arabinitol/ 
L-arabinitol ratio (273), serum D-arabinitol/creatinine ratio 
(274), Candida antigen mannan (275), (1,3)-beta-D-gulcan 
assay (276), and real time PCR (277) are promising diagnostic 
alternatives under development for early diagnosis of invasive 
candidiasis in children, but none of these assays have been 
validated for use in children.
Prevention Recommendations
Prevention of Exposure
Candida organisms are common commensals on mucosal 
surfaces in healthy persons, and no measures are available to 
reduce exposure to these fungi.
Preventing First Episode of Disease
Routine primary prophylaxis of candidiasis among HIV-
infected infants and children is not indicated, given the low 
prevalence of serious Candida infections (e.g., esophageal, 
tracheobronchial, disseminated) during the HAART era and 
the availability of effective treatment (DIII). Concerns exist 
about the potential for resistant Candida strains, drug interac-
tions between antifungal and antiretroviral agents, and lack of 
randomized controlled trials in children (278).
Discontinuing Primary Prophylaxi
Not applicable.
Treatment Recommendations
Treatment of Disease
Oropharyngeal candidiasis
Early, uncomplicated infection can be effectively treated with 
topical therapy using clotrimazole troches or oral polyenes 
(such as nystatin or amphotericin B suspension) (BII) (279). 
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Troches should not be used in infants (DIII). Resistance to 
clotrimazole can develop as a consequence of previous exposure 
to clotrimazole itself or to other azole drugs; resistance cor-
relates with refractory mucosal candidiasis (280).
Systemic therapy with one of the oral azoles (e.g., flucon-
azole, ketoconazole, or itraconazole) also is effective for initial 
treatment of OPC (281,282). Oral fluconazole is more effec-
tive than nystatin suspension for initial treatment of OPC 
in infants; is easier to administer to children than the topical 
therapies; and is the recommended treatment if systemic 
therapy is used (AI) (281,283).
Itraconazole solution has comparable efficacy to fluconazole 
and can be used to treat OPC, although it is less well tolerated 
than fluconazole (AI) (284). Gastric acid enhances absorp-
tion of itraconazole solution; itraconazole solution should be 
taken without food when possible. Itraconazole capsules and 
oral solution should not be used interchangeably because, at 
the same dose, drug exposure is greater with the oral solution 
than with capsules and absorption of the capsule formulation 
varies. Ketoconazole absorption also varies, and therefore nei-
ther itraconazole capsules nor ketoconazole are recommended 
for treating OPC if fluconazole or itraconazole solutions are 
available (DII).
Esophageal disease
Systemic therapy is essential for esophageal disease (AI) and 
should be initiated empirically among HIV-infected children 
who have OPC and esophageal symptoms. In most patients, 
symptoms should resolve within days after the start of effective 
therapy. Oral or IV fluconazole or oral itraconazole solutions, 
administered for 14–21 days, are highly effective for treatment 
of Candida esophagitis (AI) (285). For treatment of OPC, 
ketoconazole and itraconazole capsules are not recommended 
because of variable absorption and lower efficacy (DII).
Voriconazole, a newer azole antifungal, or caspofungin, 
an echinocandin inhibitor of fungal (1,3)-beta-D-glucan 
synthetase that must be administered intravenously because 
of limited bioavailability, also are effective in treating esopha-
geal candidiasis in HIV-infected adults (BI) (286–288), but 
there is little experience with use of these drugs in children. 
Voriconazole has been used in a limited number of children 
without HIV infection to treat invasive fungal infections, 
including esophageal candidiasis or candidemia (251,268). 
Usually children have been initiated on voriconazole intrave-
nously and then switched to oral administration to complete 
therapy after stabilization. The optimal pediatric dose of vori-
conazole is not yet known; children require higher doses (on 
a mg/kg body weight basis) than do adults to attain similar 
serum concentrations of voriconazole. The recommended 
voriconazole dosage for children is 6–8 mg/kg intravenously 
or 8 mg/kg orally every 12 hours (AII) (252,253). A phar-
macokinetic study of caspofungin in immuno compromised 
children aged 2–17 years without HIV infection demonstrated 
that 50 mg/m2 body surface area/day (70 mg/day maximum) 
provides comparable exposure to that obtained in adults 
receiving a standard 50-mg daily regimen (256). Because of 
limited experience with both of these drugs in children, data 
are insufficient to recommend use of voriconazole or caspo-
fungin for esophageal or disseminated candidiasis as first-line 
therapy (CIII).
Invasive disease
Central venous catheters should be removed when feasible in 
HIV-infected children with candidemia (AII) (267,271).
Conventional amphotericin B (sodium deoxycholate com-
plex) is the drug of choice for most invasive Candida infections 
in children, administered once daily intravenously over 1–2 
hours (AI). In children who have azotemia or hyperkalemia 
or are receiving high doses (>1 mg/kg), a longer infusion time 
of 3–6 hours is recommended (BIII) (289). In children with 
life-threatening disease, the target daily dose of amphotericin B 
should be administered from the beginning of therapy (BIII). 
Duration of therapy in treating candidemia should be deter-
mined by the presence of deep tissue foci, clinical response, and 
presence of neutropenia. Children at high risk for morbidity 
and mortality should be treated until 2–3 weeks after the last 
positive blood culture and until signs and symptoms of infec-
tion have resolved (AIII) (279). Among children with per-
sistent candidemia despite appropriate therapy, investigation 
for a deep tissue focus of infection should be conducted (e.g., 
echocardiogram, renal or abdominal ultrasound). Flucytosine 
has been used in combination with amphotericin B in some 
children with severe invasive candidiasis, particularly in those 
with CNS disease (CIII), but it has a narrow therapeutic 
index.
Fluconazole has been used as an alternative to amphotericin 
B to treat invasive disease in children who have not recently 
received azole therapy (AI) (279). Treatment of invasive can-
didiasis requires higher doses of fluconazole than are used 
for mucocutaneous disease. Alternatively, an initial course 
of amphotericin B therapy can be administered and then 
carefully followed by completion of a course of fluconazole 
therapy (BIII). Species identification is necessary when using 
fluconazole because of intrinsic drug resistance among certain 
Candida spp. (e.g., C. krusei and C. glabrata). Fluconazole 
administered to children at 12 mg/kg/day provides exposure 
similar to standard 400 mg daily dosing in adults. Clearance 
in older adolescents can be similar to adults, so dosing above 
600 mg/day should be employed with caution (290).
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Antifungal agents in the echinocandin class, including 
caspofungin, micafungin, and anidulafungin, have been 
studied in adults with HIV infection, neutropenic children 
at risk for fungal infections, and children with documented 
candidiasis (258,291–296). Because of limited experience 
in children and no data in HIV-infected children, data are 
insufficient to recommend these drugs as first-line agents for 
invasive candidiasis in children (CIII). Data are limited on 
the use of caspofungin in children with systemic candidiasis. 
A retrospective report in which caspofungin was administered 
to 20 children aged <16 years who had invasive fungal infec-
tions (seven had invasive candidiasis) but not HIV infection, 
the drug was efficacious and well tolerated (258). In a study 
of 10 neonates with persistent and progressive candidiasis and 
unknown HIV status, caspofungin was reported to be an effec-
tive alternative therapy (294). Micafungin has been studied 
in HIV-uninfected, neutropenic children at risk for invasive 
fungal infections. This drug demonstrates dose-proportional 
pharmacokinetics and an inverse relation between age and 
clearance suggesting a need for increased dosage in the young 
child (295). A study of 19 Japanese HIV-uninfected children 
aged <15 years who had confirmed invasive fungal infections, 
such as candidiasis, showed that plasma concentration of 
micafungin dosed at 3 mg/kg body weight was similar to that 
in adults administered 150 mg per dose (297). Micafungin was 
administered to premature infants receiving antifungal therapy 
for a suspected invasive fungal infection. Clearance of the drug 
in neonates was more than double that in older children and 
adults (296). Dosages of 10–15 mg/kg/day have been studied 
in premature neonates, resulting in area-under-the-curve val-
ues consistent with an adult dosage of 100–150 mg/day. One 
pharmacokinetic study of anidulafungin in HIV-uninfected 
neutropenic children aged 2–17 years showed drug concen-
trations at 0.75 mg/kg per dose and 1.5 mg/kg per dose were 
similar to drug concentrations in adults with 50 mg per dose 
and 100 mg per dose, respectively (298).
Data in adults are limited on use of combination antifungal 
therapy for invasive candidal infections; combination ampho-
tericin B and fluconazole resulted in more frequent clearance 
of Candida from the bloodstream but no difference in mor-
tality (299). Data are insufficient to support the routine use 
of combination therapy in children with invasive candidiasis 
(DIII) (249).
Monitoring and Adverse Events, Including IRIS
No adverse effects have been reported with the use of oral 
nystatin for treatment of oral candidiasis, but bitter taste might 
contribute to poor adherence.
The azole drugs have relatively low rates of toxicity, but 
because of their ability to inhibit the CYP450-dependent 
hepatic enzymes (ketoconazole has the strongest inhibi-
tory effect) they can interact substantially with other drugs 
undergoing hepatic metabolism. These interactions can result 
in decreased plasma concentration of the azole because of 
increased metabolism induced by the coadministered drug or 
development of unexpected toxicity from the coadministered 
drug because of increased plasma concentrations secondary to 
azole-induced alterations in hepatic metabolism. The potential 
for drug interactions, particularly with antiretroviral drugs 
such as PIs, should be carefully evaluated before initiation of 
therapy (AIII).
The most frequent adverse effects of the azole drugs are GI, 
including nausea and vomiting (10%–40% of patients). Skin 
rash and pruritus might occur with all drugs; rare cases of 
Stevens-Johnson syndrome and alopecia have been reported 
with fluconazole therapy. All drugs are associated with asymp-
tomatic increases in transaminases (1%–13% of patients) and, 
less frequently, hepatitis. Hematologic abnormalities have been 
reported with itraconazole, including thrombocytopenia and 
leukopenia. Of the azoles, ketoconazole is associated with 
the highest frequency of side effects. Its use has been associ-
ated with endocrinologic abnormalities related to steroid 
metabolism, including adrenal insufficiency and gynecomastia, 
hemolytic anemia, and transaminitis. Dose-related, reversible 
visual changes (e.g., photophobia and blurry vision) have been 
reported in approximately 30% of patients receiving vori-
conazole (300). Cardiac arrhythmias and renal abnormalities 
including nephritis and acute tubular necrosis also have been 
reported with voriconazole use.
Amphotericin B deoxycolate undergoes renal excretion as 
inactive drug. Adverse effects of amphotericin B are primarily 
nephrotoxicity, defined by substantial azotemia from glom-
erular damage, and can be accompanied by hypokalemia 
from tubular damage. Nephrotoxicity is exacerbated by use of 
concomitant nephrotoxic drugs. Permanent nephrotoxicity is 
related to cumulative dose. Nephrotoxicity can be ameliorated 
by hydration before amphotericin B infusion. Infusion-related 
fevers, chills, nausea, and vomiting occur less frequently in 
children than in adults. Onset occurs usually within 1–3 
hours after the infusion is started, typical duration is <1 hour, 
and the febrile reactions tend to decrease in frequency over 
time. Pretreatment with acetaminophen or diphenhydramine 
might alleviate febrile reactions. Idiosyncratic reactions, such 
as hypotension, arrhythmias, and allergic reactions, including 
anaphylaxis, occur less frequently. Hepatic toxicity, throm-
bophlebitis, anemia, and rarely neurotoxicity (manifested as 
confusion or delirium, hearing loss, blurred vision, or seizures) 
also can occur.
In approximately 20% of children, lipid formulations of 
amphotericin B can cause acute, infusion-related reactions, 
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including chest pain; dyspnea; hypoxia; severe pain in the 
abdomen, flank, or leg; or flushing and urticaria. Compared 
with infusion reactions with conventional amphotericin B, 
most (85%) of the reactions to the lipid formulations occur 
within the first 5 minutes after infusion and rapidly resolve 
with temporary interruption of the amphotericin B infusion 
and administration of IV diphenhydramine. Premedication 
with diphenhydramine can reduce the incidence of these 
reactions.
Flucytosine has considerable toxicity: adverse effects on the 
bone marrow (e.g., anemia, leukopenia, thrombocytopenia), 
liver, GI tract, kidney, and skin warrant monitoring of drug 
levels and dose adjustment to keep the level at 40–60 µg/mL. 
Drug levels should be monitored, especially in patients with 
renal impairment. High levels can result in bone marrow sup-
pression. The drug should be avoided in children who have 
severe renal impairment (EIII).
The echinocandins have an excellent safety profile. In a 
retrospective evaluation of 25 immuno compromised chil-
dren who received caspofungin, the drug was well tolerated, 
although three patients had adverse events potentially related 
to the drug (hypokalemia in all three children, elevated 
bilirubin in two, and decreased hemoglobin and elevated 
alanine aminotransferase in one) (256). In this study, children 
weighing <50 kg received 0.8–1.6 mg/kg body weight daily, 
and those weighing >50 kg received the adult dosage. In the 
pharmacokinetic study of 39 children who received caspo-
fungin at 50 mg/m2 body surface area/day, five (13%) patients 
experienced one or more drug-related clinical adverse events, 
including one patient each with fever, diarrhea, phlebitis, pro-
teinuria, and transient extremity rash. Two patients reported 
one or more drug-related laboratory adverse events, including 
one patient each with hypokalemia and increased serum aspar-
tate transaminase. None of the drug-related adverse events in 
this study were considered serious or led to discontinuation 
of caspofungin (256).
IRIS associated with Candida infection has not been 
described in children. However, evidence suggests that can-
didiasis occurs with increased frequency in adults during the 
first 2 months after initiation of HAART, except for candidal 
eosophagitis (301).
Management of Treatment Failure
Oropharyngeal and esophageal candidiasis
If OPC initially is treated topically, failure or relapse should 
be treated with oral fluconazole or itraconazole cyclodextrin 
oral solution (AI) (284,302).
Approximately 50%–60% of patients with fluconazole-
refractory OPC and 80% of patients with fluconazole-
refractory esophageal candidiasis will respond to itraconazole 
solution (AII) (303,304). Posaconazole is a second-generation 
orally bioavailable triazole that has been effective in HIV-
infected adults with azole-refractory OPC or esophageal 
candidiasis (305). However, experience in children is limited, 
and an appropriate pediatric dosage has not been defined; 
thus data in children are insufficient to recommend its use in 
HIV-infected children (CIII) (306,307).
Amphotericin B oral suspension at 1 mL four times daily of 
a 100-mg/mL suspension sometimes has been effective among 
patients with OPC who do not respond to itraconazole solution; 
however, this product is not available in the United States (CIII) 
(304). Low-dose IV amphotericin B (0.3–0.5 mg/kg/day) has 
been effective in children with refractory OPC or esophageal 
candidiasis (BII) (279,304,308,309).
Experience is limited with the use of echinocandins in the 
treatment of azole-refractory OPC or esophageal candidiasis 
in children (with or without HIV infection); however, given 
their excellent safety profile, the echinocandins (306) could 
be considered for treatment of azole-refractory esophageal 
candidiasis (CIII).
Invasive disease
Amphotericin B lipid formulations have a role among 
children who are intolerant of amphotericin B, have dis-
seminated candidal infection that is refractory to conventional 
amphotericin B, or are at high risk for nephrotoxicity because 
of preexisting renal disease or use of other nephrotoxic drugs 
(BII). Although lipid formulations appear to be at least as 
effective as conventional amphotericin B for treating serious 
fungal infections (310,311), the drugs are considerably more 
expensive than conventional amphotericin B. Two lipid formu-
lations are used: amphotericin B lipid complex and liposomal 
amphotericin B lipid complex. Experience with these prepara-
tions among children is limited (254,312,313).
For invasive candidiasis, amphotericin B lipid complex is 
administered as 5 mg/kg body weight intravenously once 
daily over 2 hours (254,312,314). Amphotericin B liposome 
is administered intravenously as 3–5 mg/kg body weight once 
daily over 1–2 hours. Duration of therapy is based on clinical 
response; most patients are treated for at least 2–4 weeks.
The role of the echinocandins in invasive candidiasis has not 
been well studied in HIV-infected children. However, invasive 
candidiasis associated with neutropenia in patients undergoing 
bone marrow transplantation has been treated successfully with 
this class of antifungals. These agents should be considered in 
the treatment of invasive candidiasis but reserved as alternative, 
second-line therapy to currently available treatment modali-
ties (CIII).
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Prevention of Recurrence
Secondary prophylaxis of recurrent OPC usually is not 
recommended because 1) the treatment of recurrence is typi-
cally effective, 2) the potential exists for the development of 
resistance and drug interactions, and 3) additional rounds of 
prophylaxis are costly (DIII). Immune reconstitution with 
HAART in immuno compromised children should be a priority 
(AIII). However, if recurrences are severe, data on HIV-infected 
adults with advanced disease on HAART suggest that sup-
pressive therapy with systemic azoles, either with oral fluconazole 
(BI) or with itraconazole solution (CI), can be considered (315). 
Potential azole resistance should be considered when long-term 
prophylaxis with azoles is considered.
Data on HIV-infected adults suggest that, in children with 
fluconazole-refractory OPC or esophageal candidiasis who 
responded to voriconazole or posaconazole therapy or to 
echinocandins, continuing the effective drug as secondary 
prophylaxis can be considered because of high relapse rate until 
HAART produces immune reconstitution (CIII).
Discontinuing Secondary Prophylaxis
In situations where secondary prophylaxis is instituted, no 
data exist on which to base a recommendation regarding dis-
continuation. On the basis of experience with HIV-infected 
adults with other OIs, discontinuation of secondary prophy-
laxis can be considered when the CD4 count or percentage has 
risen to CDC Immunologic Category 2 or 1 (CIII) (98).
Coccidioidomycosis
Epidemiology
Coccidioidomycosis is caused by the endemic dimorphic 
fungus, Coccidioides spp. Two species, Coccidioides posadasii 
and C. immitis, have been identified using molecular and bio-
geographic characteristics. C. immitis appears to be confined 
mainly to California; C. posadasii is more widely distributed 
through the southwestern United States, northern Mexico, 
and Central and South America. Most reported infections in 
these areas represent new infections. Clinical illnesses caused by 
each are indistinguishable. Infection results from inhalation of 
spores produced by the fungal form in arid environments with 
hot summers preceded by rainy seasons (316,317). Infections 
in regions in which coccidioidomycosis is not endemic usually 
result from reactivation of a previous infection. Contaminated 
fomites, such as dusty clothing or agricultural products, also 
have been implicated as sources of infection (318).
Preexisting impairment of cellular immunity is a major risk 
factor for severe primary coccidioidomycosis or relapse of past 
infection. In HIV-infected adults, both localized pneumonia 
and disseminated infection usually are observed in persons 
with CD4 counts <250 cells/mm3 (319,320). The threshold 
for risk in HIV-infected children has not been determined; 
systemic fungal infection has occurred when CD4 counts 
were <100 cells/mm3 and with CD4 <15%, both indicative 
of severe immunosuppression (1,15). Although no cases of 
coccidioidomycosis OI were reported in HIV-infected children 
from the Perinatal AIDS Collaborative Transmission Study, 
the study sites are not representative of the areas endemic for 
coccidioidomycosis (4). Data are limited in children, but in 
adults, HAART appears to be responsible for the declining 
incidence of coccidioidomycosis (321).
Clinical Manifestations
Immuno compromised persons and previously healthy 
blacks, Hispanics, and Filipinos with coccidioidomycosis are 
at increased risk for dissemination, as are pregnant women 
who acquire coccidioidal infection during the second or 
third trimester. Clinical manifestations of coccidioidomyco-
sis in HIV-infected adults are well described. Among these 
are diffuse pulmonary disease; focal pneumonitis in less 
immuno compromised patients; extrathoracic dissemination 
to meninges, lymph nodes, or liver; fever and weight loss syn-
drome with positive serologies; and the asymptomatic person 
with positive serologic tests (320). If untreated, a coccidioidal 
antibody-seropositive, HIV-infected person is at risk for seri-
ous disease. Bone and joint involvement is rarely observed in 
HIV-infected patients (321,322).
Children with primary pulmonary infection may present 
with fever, malaise, and chest pain. The presence of cough 
varies, and hemoptysis is rare. Persistent fever may be a sign of 
dissemination to extrathoracic sites. Children with meningitis 
may present with headaches, altered sensorium, vomiting, 
and focal neurologic deficits. Fever is sometimes absent, and 
meningismus occurs in 50% of patients. Hydrocephalus is 
common and may occur early. Generalized lymphadenopathy, 
skin nodules or ulcers, peritonitis, and liver abnormalities also 
may accompany disseminated disease.
Diagnosis
Because signs and symptoms are nonspecific, coccidioidomyco-
sis should be considered strongly in regions where it is endemic. 
Coccidioidomycosis also has been reported in regions where it is 
not endemic, and diagnostic evaluations should be considered in 
those areas as well.
In patients with meningitis, the CSF shows moderate hypo-
glycorrhachia, elevated protein concentration, and pleocytosis 
with a predominance of mononuclear cells. CSF eosinophilia 
has been reported.
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The observation of distinctive spherules containing endospores 
in histopathologic tissue or clinical specimens is diagnostic. 
However, stains of CSF in patients with meningitis usually 
are negative. Pyogranulomatous inflammation with endospo-
rulating spherules is seen readily with hematoxylin and eosin. 
Spherules can be observed using cytologic staining methods, 
such as Papanicolau and Gomori methenamine silver nitrate 
stains. However, cytologic stains are less useful for diagnos-
ing pulmonary coccidioidomycosis than for diagnosing 
Pneumocystis jirovecii, and a negative cytologic stain on a clinical 
respiratory specimen does not rule out possible active pulmo-
nary coccidioidomycosis (322). Potassium hydroxide stains are 
less sensitive and should not be used (DIII) (322).
Growth of Coccidioides spp. is supported by many conven-
tional laboratory media used for fungal isolation at 30°C–37°C 
(86°F–99°F) with growth occurring within 5 days (322). 
However, blood cultures are positive in <15% of cases and 
<50% of CSF from children with meningitis will have a positive 
culture (322). In contrast, cultures of respiratory specimens are 
frequently positive in cases of pulmonary coccidioidomycosis 
in adults.
Although serologic assays that detect coccidioidal-specific 
antibody are valuable noninvasive aides in diagnosis, nega-
tive assays cannot be used to exclude the diagnosis in the 
immuno compromised host. In the latter instance, detection 
of coccidioidin or cross-reacting antigens are important 
diagnostic tests, especially in severe manifestations of disease. 
Assays for coccidioidal antibody in serum or body fluids such 
as CSF provide valuable diagnostic and prognostic informa-
tion. Cross-reactivity may occur with other endemic mycoses. 
The presence of IgM-specific coccidioidal antibody suggests 
active or recent infection. The complement fixation (CF) assay 
detects IgG-specific antibody. CF titers become undetectable 
in several months if the infection resolves. Standardized CF 
titers >1:16 directly correlate with the presence and severity of 
extrapulmonary dissemination. Serologic tests may be falsely 
negative in severely immunosuppressed HIV-infected children. 
CF antibody is present in the CSF of 95% of patients with 
coccidioidal meningitis, but serial testing may be needed to 
demonstrate this. Titers decline during effective therapy.
Prevention Recommendations
Preventing Exposure
Although HIV-infected persons residing in or visiting regions 
in which coccidioidomycosis is endemic cannot completely avoid 
exposure to Coccidioides spp., exposure risk can be reduced by 
avoiding activities that predispose to inhalation of spores. 
Such activities include disturbing contaminated soil, excavat-
ing archaeologic sites, and being outdoors during dust storms. 
If such activities are unavoidable, use of respiratory filtration 
devices should be considered.
Preventing First Episode of Disease
No prospective studies have been published that examine the 
role of primary prophylaxis to prevent development of active 
coccidioidomycosis. Although some experts would provide 
primary prophylaxis with an azole (e.g., fluconazole) to coc-
cidioidal antibody-positive HIV-infected patients living in 
regions with endemic coccidioidomycosis, others would not 
(322). Some experts would consider chemoprophylaxis for 
coccidioidal antibody-positive HIV-infected persons consid-
ered at higher risk for active disease, including blacks, persons 
with unreconstituted cellular immunity with CD4 counts 
<250 cells/mm3, and persons with a history of thrush (CII) 
(323). However, given the low incidence of coccidioidomycosis 
in pediatric HIV-infected patients, possibility of drug interac-
tions, potential antifungal drug resistance, and cost, routine 
use of antifungal medications for primary prophylaxis of coc-
cidioidial infections in children is not recommended (DIII).
Routine skin testing of HIV-infected patients with coc-
cidioidin (spherulin) does not predict infection and should 
not be performed (EIII).
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
All HIV-infected patients in whom clinically active coccid-
ioidomycosis is diagnosed should be offered antifungal therapy. 
Treatment protocols for HIV-infected children are based on 
experience with adults in nonrandomized open-label studies. 
Physicians who infrequently treat children with coccidioidomy-
cosis should consider consulting with experts.
Because the critical factor in controlling coccidioidomycosis 
is cellular immune function, effective antiretroviral therapy 
also is important in treating disease and should be instituted 
contemporaneously with the initiation of antifungal therapy, 
if possible.
Diffuse pulmonary or disseminated infection should be 
treated with amphotericin B deoxycholate at 0.5–1.0 mg/kg/day 
(AII). Amphotericin B treatment is continued until clinical 
improvement is observed. The dose and duration of amphot-
ericin B depend on the severity of the symptoms, toxicity, and 
rapidity of response. Total doses of amphotericin B deoxy-
cholate in adults have ranged from 10 mg/kg to 100 mg/kg. 
Thereafter, amphotericin B can be discontinued and treat-
ment with fluconazole or itraconazole begun (BIII). Some 
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experts initiate therapy with amphotericin B combined with 
a triazole, such as fluconazole, in patients with disseminated 
severe disease and continue the triazole after amphotericin B 
is stopped (BIII) (322,324). Total duration of therapy should 
be >1 year (322).
No clinical evidence supports greater efficacy of the lipid 
formulations of amphotericin B than of deoxycholate. However, 
they are preferred when nephrotoxicity is of concern (BI). A dos-
age of 5 mg/kg/day is recommended for amphotericin B lipid 
complex and 3–5 mg/kg/day for liposomal amphotericin B.
For patients with mild disease (such as focal pneumonia), 
monotherapy with fluconazole or itraconazole is appropriate 
given their safety, convenient oral dosing, and pharmacody-
namic parameters (BII). Thus, fluconazole (5–6 mg/kg/dose 
twice daily) or itraconazole (5–10 mg/kg/dose twice daily for 3 
days followed by 2–5 mg/kg/dose twice daily) are alternatives 
to amphotericin B for children who have mild, nonmeningitic 
disease (BIII). In a randomized, double-blind trial in adults, 
fluconazole and itraconazole were equivalent in treating non-
meningeal coccidioidomycosis. However, itraconazole tended 
to be superior for skeletal infections (AI) (325).
Treatment of coccidioidal meningitis requires an antifun-
gal agent that achieves high CSF concentrations; thus, IV 
amphotericin B should not be used (EII). The relative safety 
and comparatively superior ability of fluconazole to penetrate 
the blood-brain barrier have made it the azole of choice for 
coccidioidal meningitis (AII). An effective dose of fluconazole 
in adults is 400 mg/day (AII), but some experts begin therapy 
with 800–1000 mg/day (BIII) (324). Children usually receive 
5–6 mg/kg/dose twice daily (800 mg/day maximum) (AII) 
(9). Dosages as high as 12 mg/kg/day have been used (CII) 
(326). This dosage is required to achieve serum concentrations 
equivalent to the adult dosage of 400 mg/day (249).
Monitoring and Adverse Events, Including IRIS
In addition to monitoring the patient for clinical improve-
ment, monitoring coccidioidal IgG antibody titers by the com-
plement fixation methodology is useful in assessing response 
to therapy. Titers should be obtained every 12 weeks (AIII). If 
therapy is succeeding, titers should decrease progressively, and 
a rise in titers suggests recurrence of clinical disease. However, 
if serologic tests initially were negative, titers during effective 
therapy may increase briefly and then decrease (322). This lag 
in response during the first 1 or 2 months of therapy should 
not be construed as treatment failure.
Adverse effects of amphotericin B are primarily nephrotoxic-
ity. Infusion-related fevers, chills, nausea, and vomiting also 
can occur, although they are less frequent in children than 
in adults. Lipid formulations of amphotericin B have lower 
rates of nephrotoxicity. Hepatic toxicity, thrombophlebitis, 
anemia, and rarely neurotoxicity (manifested as confusion 
or delirium, hearing loss, blurred vision, or seizures) also can 
occur (see discussion on monitoring and adverse events in 
Candida infection).
Triazoles can interact with CYP450-dependent hepatic 
enzymes, and the potential for drug interactions should 
be evaluated carefully before initiation of therapy (AIII). 
Fluconazole and itraconazole appear to be safe in combination 
with antiretroviral therapy. Voriconazole should be avoided in 
patients receiving HIV PIs or NNRTIs (320). The most fre-
quent adverse effects of fluconazole are GI, including nausea 
and vomiting. Skin rash and pruritis might be observed, and 
rare cases of Stevens-Johnson syndrome have been reported. 
Asymptomatic increases in transaminases occur in 1%–13% 
of patients receiving azole drugs. In HIV-infected patients, flu-
conazole at high doses can cause adrenal insufficiency (327).
Coccidioidomycosis disease in response to IRIS has not been 
described in children.
Management of Treatment Failure
Clinical information is limited about new therapeutic agents. 
Posaconazole was effective in six patients with disease refrac-
tory to treatment with azoles and amphotericin B (328). 
Voriconazole was effective in treating coccidioidal meningitis 
and nonmeningeal disseminated disease in patients who did 
not respond to fluconazole or were intolerant of amphot-
ericin B (329,330). Caspofungin alone successfully treated 
disseminated coccidioidomycosis in a renal transplant patient 
intolerant of fluconazole and in persons in whom conventional 
therapy failed (331,332). Others have used caspofungin in 
combination with fluconazole (333).
Adjunctive interferon-gamma was successfully used in a criti-
cally ill adult with respiratory failure who did not respond to 
amphotericin B preparations and fluconazole (334). However, 
no controlled clinical studies or data exist for children; thus, it is 
not recommended for use in HIV-infected children (DIII).
Patients with coccidioidal meningitis who do not respond to 
treatment with the azoles might improve with both systemic 
amphotericin B and direct instillation of amphotericin B into 
the intrathecal, ventricular, or intracisternal spaces with or 
without concomitant azole treatment (CI) (325,326). The 
basilar inflammation characteristic of coccidioidal meningitis 
commonly results in obstructive hydrocephalus, necessitating 
placement of a CSF shunt. Development of hydrocephalus 
in coccidioidal meningitis does not necessarily indicate treat-
ment failure.
Prevention of Recurrence
Relapse can occur in as many as 33% of patients with dis-
seminated coccidioidomycosis, even in the absence of HIV 
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infection, so lifelong antifungal suppression with either flucon-
azole or itraconazole is recommended for HIV-infected chil-
dren who have coccidioidomycosis (AII) (322,324,335–337). 
In coccidioidal meningitis, response rates to the azoles can 
be excellent, but cures are infrequent, and relapse after cessa-
tion of therapy is common, occurring in as many as 80% of 
patients (338). Thus, indefinite continuation of fluconazole 
therapy is recommended in patients who have coccidioidal 
meningitis (AII).
Discontinuing Secondary Prophylaxis
As with other disseminated fungal infections, continued 
suppressive therapy with fluconazole or itraconazole is rec-
ommended after completion of initial therapy. Patients with 
diffuse pulmonary disease, disseminated disease, or meningitic 
disease should remain on lifelong prophylaxis—even if immune 
reconstitution is achieved with HAART (322)—because of 
high risk for relapse (AIII). In HIV-infected adults with focal 
coccidioidal pneumonia who have clinically responded to anti-
fungal therapy and have sustained CD4 count >250 cells/mm3 
on HAART, some experts would discontinue secondary pro-
phylaxis after 12 months of therapy with careful monitoring 
for recurrence with chest radiographs and coccidioidal serology 
(CIII). However, only a small number of patients have been 
evaluated, and the safety of discontinuing secondary prophylaxis 
after immune reconstitution with HAART among children has 
not been studied extensively. Therefore, for coccidioidomycosis 
among HIV-infected children, lifelong suppressive therapy is 
recommended after an acute episode of the disease, regardless of 
HAART and immune reconstitution (AIII).
Cryptococcosis
Epidemiology
Most cases of cryptococcosis in HIV-infected patients 
are caused by Cryptococcus neoformans; C. gatti (formerly 
C. neoformans variety gatti) infection occurs primarily in tropi-
cal and subtropical areas. Cryptococcal infections occur much 
less frequently among HIV-infected children than among 
adults (339–341). During the pre-HAART era, most cases of 
cryptococcosis in HIV-infected children (overall incidence, 
1%) occurred in those aged 6–12 years and in those with CD4 
counts indicating severe immunosuppression (341). Access to 
HAART has dramatically decreased the overall incidence of 
cryptococcal infection (342,343), and cryptococcosis in HIV-
infected children on HAART remains exceedingly uncommon. 
Data from various PACTG studies during the pre-HAART 
and post-HAART eras indicate that the rate of invasive fungal 
infection, including cryptococcosis, has remained <0.1 per 
100 child-years (1,3). In the Perinatal AIDS Collaborative 
Transmission Study, no cases of cryptococcosis were identified 
during the HAART era (4).
Clinical Manifestations
Cryptococcosis often presents with subtle and nonspecific 
findings such as fever and headache. Early diagnosis requires 
consideration of this infection in a symptomatic patient 
whose CD4 counts indicate severe immunosuppression. In 
both HIV-infected adults and children, meningoencephalitis 
is the most common initial manifestation of cryptococcosis. 
The disease typically evolves over days to weeks with fever 
and headache. Less frequent findings include nuchal rigidity, 
photophobia, and focal neurologic signs, as were seen among 
30 HIV-infected children with cryptococcosis reported from 
the United States (341). In contrast to this indolent presenta-
tion, children in Zimbabwe presented with an acute form of 
neurologic cryptococcosis (69% with nuchal rigidity, 38% with 
seizure activity, and 23% with focal neurologic signs) (344). 
CNS mass lesions (cryptococcomas) have not been reported 
among HIV-infected children.
Disseminated cryptococcosis can be associated with cutane-
ous lesions, including small, translucent umbilicated papules 
(indistinguishable from molluscum contagiosum), nodules, 
ulcers, and infiltrated plaques resembling cellulitis. Diagnosis 
of pulmonary cryptococcosis without dissemination is unusual 
among children. Presenting findings include unexplained 
recurrent fever, cough with scant sputum, intrathoracic 
lymphadenopathy, and focal or diffuse pulmonary infiltrates. 
Alternatively the infection may be asymptomatic, with pulmo-
nary nodules revealed on routine chest radiograph (340).
Diagnosis
Detection of cryptococcal antigen in serum, CSF or other 
body fluids is highly effective for rapid and accurate diagnosis 
of cryptococcal infection.
Microscopic examination of CSF on India ink-stained wet 
mounts should be performed to diagnose suspected CNS dis-
ease. CSF cell count, glucose, and protein can be virtually nor-
mal with CNS cryptococcosis, but the opening pressure usually 
is elevated. Cryptococcal antigen can be detected in CSF or 
serum by latex agglutination test (several manufacturers) from 
>90% of patients with cryptococcal meningitis. However, CSF 
antigen detection may be negative in culture-positive crypto-
coccal meningitis; high titers of antigen (prozone effect), low 
levels of antigen, and nonencapsulated strains contribute to 
this contradictory result (345,346).
Fungal cultures from CSF, sputum, and blood can identify 
the organism; the lysis-centrifugation method is the most 
sensitive for blood specimens. In some cases (e.g., refractory 
or relapsed disease), susceptibility testing of the C. neoformans 
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isolate can be beneficial. Overall in vitro resistance to antifungal 
agents remains uncommon (347).
Diffuse pulmonary disease can be diagnosed through 
bronchoalveolar lavage and direct examination of India 
ink-stained specimens, culture, and antigen detection. Focal 
pulmonary and skin lesions may require biopsy with culture 
and staining.
Prevention Recommendations
Preventing Exposure
No strategies have been proven to prevent exposure. C. neo-
formans infection is believed to be acquired through inhalation 
of aerosolized particles from the environment. Serologic studies 
of immunocompetent children in an urban setting indicate that 
most children are infected by C. neoformans after the second 
year of life (348).
Preventing the First Episode of Disease
Because the incidence of cryptococcal disease is so low 
in HIV-infected children (4,339–341), routine testing of 
asymptomatic children for serum cryptococcal antigen is not 
recommended (DIII). Additionally, given the low incidence 
of cryptococcosis in HIV-infected children, lack of survival 
benefits in primary prevention studies of adults (349), pos-
sibility of drug interaction, potential resistance to antifungal 
drugs, and cost, routine use of antifungal medications is not 
recommended for primary prophylaxis of cryptococcal infec-
tions in children (DIII).
A review of randomized controlled trials using antifungal 
interventions for the primary prevention of cryptococ-
cal diseases indicates that fluconazole and itraconazole can 
reduce cryptococcal disease among adults who have advanced 
HIV disease and severe immunosuppression (CD4 count 
<50 cells/mm3) (349). However, neither of these interventions 
clearly affected mortality.
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
Given the low incidence of cryptococcosis in HIV-infected 
children even during the pre-HAART era, management of this 
disease in these patients has not been prospectively studied. 
Treatment recommendations reflect information extrapolated 
from many well-designed studies involving HIV-infected adults 
with cryptococcal meningitis.
Unlike immunocompentent hosts, in whom recovery from 
pulmonary infection without antifungal treatment can occur, 
immuno compromised hosts with cryptococcosis require treat-
ment because the condition is often fatal in the absence of 
treatment. Although antifungal treatment is effective, immune 
reconstitution of the host with the use of antiretroviral medica-
tions is crucial to the long-term outcome in terms of avoiding 
episodes of recurrence and relapse. However, IRIS can be 
problematic in the short term, posing a diagnostic dilemma 
when it presents as clinical worsening in a host that was (or 
is being) treated appropriately for cryptococcal infection. 
Although data are limited on how best to prevent and man-
age IRIS, because of the close proximity of OI diagnosis and 
HAART initiation in patients who developed IRIS (350,351), 
some clinicians consider delaying HAART in treatment-naïve 
patients who have treatable OIs until after the acute phase of 
initial OI therapy has been completed (CIII). Factors other 
than IRIS, such as tolerability of OI treatments and HAART 
and overlapping toxicities if both are started concurrently, are 
also reasons to delay HAART (CIII). No clinical trials have 
assessed optimal timing of HAART initiation in patients with 
concurrent cryptococcosis. Overall in vitro resistance to anti-
fungal agents used to treat cryptococcosis remains uncommon 
(347). Newer azoles (e.g., voriconazole, posaconazole, ravucon-
azole) are all active in vitro against C. neoformans (347), but 
published clinical experience in using them for cryptococcosis 
is limited (352,353).
CNS disease
The most common and well-studied presentation of cryp-
tococcal infection in HIV-infected patients is CNS disease. In 
light of studies in adults (354–356), combination therapy with 
amphotericin B and flucytosine for 2 weeks (induction therapy) 
followed by fluconazole for a minimum of 8 weeks (consolida-
tion therapy) is recommended for children (AI). Cryptococci 
were cleared from CSF significantly more rapidly from adults 
with CNS disease who received initial therapy with amphoteri-
cin B (0.7 mg/kg/day) and flucytosine (100 mg/kg/day) than it 
was in those who received amphotericin B alone, amphotericin 
B plus fluconazole, or triple-antifungal therapy (357,358). In 
one study of adults, liposomal amphotericin B (AmBisome®) 
dosed at 4 mg/kg/day resulted in significantly earlier CSF 
culture conversion than did amphotericin B at 0.7 mg/kg/day 
(359). Although the cost of specific amphotericin B formula-
tions is an important factor in selection of a specific prepara-
tion, the indication for use of the drug is also important. For 
example, the liposomal preparation is preferred for patients 
with renal insufficiency (AII). Monitoring for and managing 
raised intracranial pressure is crucial to the optimal manage-
ment of CNS cryptococcosis (see below).
In patients who cannot tolerate flucytosine, amphotericin 
B (or its liposomal preparation) alone can be used for initial 
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therapy (BI). Fluconazole plus flucytosine is superior to 
fluconazole alone (360,361) and provides an alternative to 
amphotericin B for acute therapy of invasive disease (BII); 
however, few data are available regarding use of this combina-
tion in children, and it should be used only if amphotericin 
B-based therapy is not tolerated (BIII). Although fluconazole 
monotherapy was an effective alternative to amphotericin B 
in adults with AIDS-associated cryptococcal meningitis (362), 
concerns in this study about differences in early death, delayed 
CSF sterilization, and drug resistance (363,364) make flucon-
azole monotherapy less favorable for initial therapy of CNS 
disease. Because of rapidly developing resistance, flucytosine 
alone should never be used to treat cryptococcosis (EII).
After a minimum of 2 weeks of induction therapy with 
evidence of clinical improvement and a negative CSF culture 
after repeat lumbar puncture, amphotericin B and flucytosine 
can be discontinued and consolidation therapy initiated with 
fluconazole (AI). Consolidation therapy is continued for a 
minimum of 8 weeks (365). Itraconazole is an alternative 
to fluconazole for the consolidation phase of CNS therapy 
and for secondary prophylaxis (BI). Fluconazole is preferred 
because studies comparing the two agents demonstrate higher 
rates of CSF sterilization during consolidation therapy (355) 
and less frequent relapse (365) during maintenance therapy 
in fluconazole recipients.
Pulmonary and extrapulmonary cryptococcosis 
(CNS disease ruled out)
No controlled clinical studies describe the outcome of non-
CNS cryptococcosis in HIV-infected patients. CNS disease 
should be ruled out in all patients, after which the choice 
of antifungal medication and length of initial therapy can 
be decided in light of the clinical severity of illness. Patients 
with severe pulmonary disease or disseminated cryptococcosis 
should be treated with amphotericin B with or without the 
addition of flucytosine, as for CNS disease (AIII). Usually com-
bination therapy should be provided until symptoms resolve. 
Those with mild-to-moderate pulmonary illness or other local-
ized disease can be managed with fluconazole monotherapy 
(AIII). Regardless of the antifungal agent selected for initial 
therapy, secondary prophylaxis with fluconazole or itraconazole 
should be continued (AIII) until a decision about when to stop 
prophylaxis can be determined on a case-by-case basis (see note 
below on discontinuing secondary prophylaxis).
Monitoring and Adverse Events, Including IRIS
Monitoring for raised intracranial pressure
Whenever a lumbar puncture is performed, opening pressure 
should be measured (AII). Studies in adults clearly show the 
role of increased intracranial pressure in death associated with 
CNS cryptococcosis (355,366). Health-care providers should 
be vigilant about this condition. Its management includes 
repeated lumbar punctures. In rare cases, CSF shunting may 
need to be considered for patients who do not tolerate daily 
lumbar punctures or if standard management does not relieve 
signs and symptoms of cerebral edema. Corticosteroids and 
acetazolamide should not be used to reduce intracranial pres-
sure in cryptococcal meningitis (DIII); acetazolamide was 
associated with severe acidosis, hypokalemia, and other adverse 
effects in a clinical trial among adults (367).
Monitoring for treatment response
In addition to monitoring clinical response, mycologic 
response in patients with CNS cryptococcosis typically is 
assessed by a repeat lumbar puncture and CSF examination at 
2 weeks of treatment, with continuation of induction therapy 
if the culture is positive until negative cultures are obtained.
Monitoring serial serum cryptococcal antigen titers is not 
useful for following treatment efficacy because changes in 
serum cryptococcal antigen titers do not correlate well with 
outcome during treatment for acute meningitis or during 
suppressive therapy (368,369). Serial measurement of CSF 
cryptococcal antigen is more useful; in one study, an unchanged 
or increased titer of antigen in CSF correlated with clinical and 
microbiologic failure to respond to treatment, and a rise in CSF 
antigen titer during suppressive therapy was associated with 
relapse of cryptococcal meningitis (368). However, monitoring 
of CSF cryptococcal antigen levels requires repeated lumbar 
punctures and is not routinely recommended for monitoring 
response (CIII).
Monitoring for adverse events
Adverse effects of amphotericin B (Table 5) are primarily 
nephrotoxicity; permanent nephrotoxicity is related to cumula-
tive dose. Infusion-related fevers, chills, nausea, and vomiting 
can occur, but they are less frequent in children than in adults. 
Close monitoring for drug toxicities is needed especially when 
amphotericin B is used with flucytosine.
Flucytosine has the potential for marked toxicity, espe-
cially affecting the bone marrow (e.g., anemia, leukopenia, 
and thrombocytopenia), liver, GI tract, kidney, and skin. In 
patients receiving flucytosine, flucytosine blood levels should be 
monitored to prevent bone marrow suppression and GI toxic-
ity; peak serum levels, which occur 2 hours after an oral dose, 
should not exceed 75 µg/mL. Flucytosine should be avoided 
in children with severe renal impairment (EIII).
Fluconazole and the other azoles have relatively low rates 
of toxicity, but their potential drug interactions can limit 
their use. Because of their ability to inhibit the CYP450-
dependent hepatic enzymes, the potential for drug interactions, 
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particularly with antiretroviral drugs, should be carefully evalu-
ated before initiation of therapy (AIII).
IRIS
Patients who develop IRIS related to cryptococcosis are more 
likely than those who do not develop cyrptococcal IRIS to be 
severely immuno compromised with disseminated infection 
and to have initiated potent antiretroviral therapy soon after 
diagnosis of cryptococcal disease (370); in antiretroviral-naïve 
patients newly diagnosed with cryptococcal meningitis, delay 
in potent antiretroviral therapy may be prudent until the end 
of the first 2 weeks of induction therapy (CIII).
IRIS related to cryptococcosis can present within weeks 
(e.g., meningitis) or months (e.g., lymphadenitis) after start of 
HAART. Symptoms of meningitis are similar to those described 
for meningitis presenting as the initial manifestation of 
cryptococcosis. In one study, about 30% of all HIV-infected 
adults hospitalized for infection with C. neoformans who 
received HAART were readmitted with symptoms attrib-
uted to an inflammatory response (350). Of the 18 patients 
with C. neoformans-related IRIS in the cited study, 17 had 
culture-negative meningitis, and most cases occurred during 
the first 30 days after initiation of HAART. The most com-
mon presentation of late cryptococcal IRIS is lymphadenitis, 
particularly mediastinal lymphadenitis (371).
The optimal management of cryptococcal IRIS has not been 
defined. Antifungal therapy should be initiated in patients 
not already receiving it, and antiretroviral therapy should be 
continued (AII). Although many cases resolve spontaneously, 
some experts also have used anti-inflammatory therapy (e.g., 
short-course corticosteroids) in patients with severely symp-
tomatic IRIS (BIII) (371,372).
Management of Treatment Failure
Treatment failure is defined as clinical deterioration despite 
appropriate therapy, including management of intracranial 
pressure; lack of improvement in signs and symptoms after 
2 weeks of appropriate therapy; or relapse after an initial 
clinical response. Differentiating IRIS from treatment failure is 
important because treatment approaches and outcomes differ. 
Optimal management of patients with treatment failure is not 
known. If cultures are positive at treatment failure, evaluation 
of antifungal susceptibilities might be considered, although 
fluconazole resistance with C. neoformans is rare in the United 
States (but more common in some international settings) 
(363). Patients in whom initial azole-based therapy fails should 
be switched to amphotericin B-based therapy (363), ideally in 
combination with flucytosine (BIII); the possibility of drug 
interactions resulting in subtherapeutic azole levels (e.g., con-
current rifampin use or other drugs metabolized by the liver) 
should be explored (363). Use of liposomal amphotericin B 
should be considered, as one study suggests improved efficacy 
in CSF sterilization with liposomal preparations than with 
standard amphotericin B (AII) (359). Some data from HIV-
infected adults indicate higher dosages (e.g., 400–800 mg/
day) of fluconazole in combination with flucytosine also can 
be considered for salvage therapy (BII) (356,373). Clinical 
experience with new antifungal agents in managing cryptococ-
cosis is limited. A few patients with cryptococcal infections 
refractory or intolerant to standard antifungal therapy have 
been treated with posaconazole or voriconazole with variable 
success (352,353). Echinocandins do not have clinical activity 
against cryptococcal infections and should not be used.
Prevention of Recurrence
Patients who have completed initial therapy for cryptococ-
cosis should receive suppressive treatment (i.e., secondary 
prophylaxis or chronic maintenance therapy) (AI). Fluconazole 
(AI) is superior and preferable to itraconazole (BI) for prevent-
ing relapse of cryptococcal disease (365,374,375). Suppressive 
therapy typically is continued long term.
Discontinuing Secondary Prophylaxis
Until recently, lifelong secondary prophylaxis typically was 
recommended. The safety of discontinuing secondary pro-
phylaxis for cryptococcosis after immune reconstitution with 
HAART has not been studied in children, and decisions in this 
regard should be made on a case-by-case basis. Adults at appar-
ent low risk for recurrence of cryptococcosis have successfully 
completed a course of initial therapy, remain asymptomatic 
with regard to signs and symptoms of cryptococcosis, and 
have a sustained (>6 months) increase in their CD4 counts 
to >200 cells/mm3 after HAART (376–378). In light of these 
observations and inference from data regarding discontinuing 
secondary prophylaxis for other OIs in adults with advanced 
HIV infection, discontinuing chronic suppressive therapy for 
cryptococcosis (after being on it for >6 months) can be con-
sidered for asymptomatic children aged >6 years, on HAART, 
and with sustained (>6 months) increase in their CD4 counts 
to >200 cells/mm3 (BII). Suppressive therapy should be reiniti-
ated if the CD4 count decreases to <200 cells/mm3 (AIII).
Histoplasmosis
Epidemiology
Histoplasmosis is caused by inhalation of microconidia 
produced by the mycelial form of Histoplasma capsulatum, an 
endemic dimorphic fungus, and cases have been reported from 
all continents except Antarctica. It is most highly endemic in 
the Ohio and Mississippi river valleys. Infections in regions in 
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which histoplasmosis is not endemic often result from travel 
to these regions. Risk factors predisposing to infection are a 
CD4 count <150 cells/mm3 and exposure to activities that dis-
turb contaminated sites and result in aerosolization of spores. 
Because yeast forms of the fungus may remain viable within 
granulomas formed after successful treatment or spontaneous 
resolution of infection, late relapse can occur if cellular immune 
function wanes. Infection can occur during pregnancy, and 
transplacental infection has rarely been reported (379).
During the pre-HAART era, histoplasmosis was reported 
in 2%–5% of HIV-infected adults in regions with endemic 
disease; rates of 25% have been reported in some cities (380). 
In a highly endemic region, histoplasmosis was the AIDS-
defining illness in 25% of adults and 8% of children (381). 
Progressive disseminated histoplasmosis (PDH) occurred in 
5% of HIV-infected children in another highly endemic region 
(M. Kleiman, unpublished data, November 28, 2007). The 
overall incidence of histoplasmosis in children has not been 
examined systematically but appeared to be low, even during 
the pre-HAART era (1).
Few epidemiologic data have been reported on disseminated 
histoplasmosis in HIV-infected children and adolescents 
treated with HAART. In several combined PACTG cohorts, 
the incidence rate of all non-Candida invasive fungal infection 
was 0.10 infections per 100 child-years (95% CI 0.05–0.20) 
during the pre-HAART era, and 0.08 infections per 100 child-
years (95% CI 0.03–0.17) during the HAART era (1,3). These 
data were contributed from centers that underrepresented 
the geographic regions of maximal histoplasmosis prevalence; 
so the statistical power to detect decreases in incidence rates 
associated with HAART may have been limited. However, 
none of the rates of domestic endemic fungal infections (e.g., 
histoplasmosis, coccidioidomycosis, and blastomycosis) are 
likely to exceed these estimates in HIV-infected children and 
adolescents.
Clinical Manifestations
In children without HIV infection, acute pulmonary mani-
festations are common, but chronic pulmonary infection has 
not been described. Because of greater airway pliability in chil-
dren, airway obstruction from mediastinal lymphadenopathy 
is more common in children (382). Although meningitis is 
common with progressive disseminated infection in infancy, 
subacute meningitis and parenchymal lesions characteristic of 
CNS disease in adults are unusual in children (383). Isolated 
pulmonary granulomas resulting from past infections are com-
mon incidental findings in chest radiographs of asymptomatic 
persons residing in histoplasmosis-endemic regions.
The most frequent clinical manifestation of histoplasmosis 
in HIV-infected children with AIDS is PDH; PDH is fatal if 
untreated. Prolonged fever and failure to thrive are uniform 
presenting complaints. Few reports have been published of pre-
senting signs and symptoms in children with PDH complicat-
ing AIDS (381,384–386). However, most are similar to those 
seen in PDH in otherwise normal infants and in infections 
in patients with other primary or acquired immunodeficien-
cies. These include splenomegaly, cough, respiratory distress, 
hepatomegaly, “septic” appearance, generalized lymphade-
nopathy, interstitial pneumonitis, cytopenia, coagulopathy, 
oropharyngeal/GI ulcerations, and erythematous nodular/
ulcerative cutaneous lesions (387–389).
Diagnosis
Culture and histopathologic, serologic, antigen-detection, 
and molecular diagnostic techniques have been developed to aid 
in diagnosing histoplasmosis (390,391). Understanding their 
uses and limitations is essential to interpretating results.
Histoplasmin skin tests are not available and were not useful 
in diagnosing disseminated disease (388,389). Although isola-
tion of the fungus using culture is diagnostic, it often requires 
invasive procedures, is insensitive, and may take 10–30 days 
to grow. Lysis-centrifugation methodology facilitates growth of 
H. capsulatum, and a DNA probe permits prompt identifica-
tion of isolates (392). Histopathologic demonstration of typical 
yeast forms in tissue specimens, bone marrow, or peripheral 
blood can be performed rapidly and, when positive, is highly 
suggestive of active infection. However, results are positive in 
12%–43% of adults with PDH (390). PCR and DNA probes 
have been developed to detect H. capsulatum DNA in tissues 
(393) and body fluids (394) but are neither sufficiently sensi-
tive nor specific (390,391).
Interpretation of serologic testing using CF and immunodif-
fusion methods is problematic in immuno compromised hosts 
with PDH. CF titers of >1:32 to the yeast and/or mycelial 
antigens or detection of H and/or M bands with the immu-
nodiffusion test are considered strongly suggestive of active or 
recent infection. However, only 41% of HIV-infected adults 
are seropositive, compared with 82% of adults with PDH and 
no underlying immunocompromise (395). Thus, seronegativity 
cannot be used to exclude active infection, especially PDH. 
Although a fourfold increase in CF antibody is diagnostic of 
active infection, 2–4 weeks is needed to determine this. CF 
antibody titers of CSF may be useful for diagnosing meningi-
tis. In these instances, the assay should begin with undiluted 
specimens. Concurrent serum titers should be evaluated to 
exclude false positivity caused by blood contamination of the 
CSF (383).
Development and refinement of an EIA that rapidly identi-
fies and quantifies histoplasmal antigen in body fluids fills most 
of the gaps left by other diagnostic methods. EIA is especially 
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suited for evaluating patients with large fungal burdens, a 
feature of infection in immuno compromised hosts. EIA can 
detect antigen in serum, bronchoalveolar lavage, and CSF. 
The reported sensitivity of antigen detection is 91%–92% in 
adults with PDH, and 95% in adults with AIDS (390,391); 
sensitivity in children with underlying immunocompromise 
and in otherwise normal infants is 100% (388; M Kleiman, 
unpublished data, November 28, 2007) (396).
EIA has necessitated changes in recommendations for 
specimen submission and interpretation. In contrast to earlier, 
semiquantitative assays, the third generation EIA is standard-
ized by extrapolating antigen concentrations from a calibration 
curve that is linear to a value of 39 ng/mL. However, urine 
antigen concentrations in serious infections frequently exceed 
this value. In these instances, serum specimens should be fol-
lowed because maximum serum concentrations are lower than 
those of urine and thus more likely to be in a range in which 
differences can be accurately measured. After resolution of the 
antigenemia, urine concentrations can be followed to monitor 
the effectiveness of treatment and, thereafter, to identify relapse. 
Antigenuria is identified in 90% of patients whose histoplasmo-
sis relapses (382). The histoplasmal antigen assay demonstrates 
cross-reactions with blastomycosis, paracoccidioidomycosis, 
and Penicillium marneffei infections (390,391).
Antigen is detectable in 75%–81% of immunocompetent 
hosts with acute, primary pulmonary infection. This occurs 
early in infection, reflecting the primary fungemia that is 
aborted by an effective cellular immune response. Thus, anti-
genuria in a patient with HIV who retains normal cellular 
immunity may not presage development of disseminated 
infection.
Diagnosis of CNS infection is difficult, particularly if the 
patient has isolated meningitis without disseminated disease 
(383). Highest sensitivity is achieved by testing CSF for 
histoplasmal antigen, antibody, and large-volume culture. In 
adults, CSF culture is positive in 20%–60% of patients, CSF 
antigen is positive in 40%–70%, and CSF antibody is positive 
in 70%–90% (390,391); Meningitis frequently accompanies 
PDH of infancy (387).
Prevention Recommendations
Preventing Exposure
Most infections occur without a recognized history of 
exposure to a high-risk site or activity. Therefore, complete 
avoidance of exposure in histoplasmosis-endemic regions is 
not possible. Sites and conditions commonly implicated in 
high-risk exposure and point-source outbreaks include soil 
contaminated with bird or bat droppings, older urban and 
rural structures, decaying vegetation or trees, and caves. Dry 
and windy conditions, excavation, demolition, and garden-
ing and agricultural activities predispose to aerosolization of 
spores. If avoidance of these activities is not feasible, reducing 
the release of spores by wetting soil, renovation sites, and other 
likely areas of aerosolization and using protective respiratory 
devices (397) may reduce the likelihood of infection.
Preventing First Episode of Disease
Prophylaxis with itraconazole is recommended for HIV-
infected adults whose CD4 count is <150 cells/mm3 and who 
reside in areas where histoplasmosis is highly endemic (i.e., 
incidence is >10 cases per 100 patient-years) and in instances 
in which risk for occupational exposure is high. Prophylaxis 
had no effect on survival (382). Given the low incidence of 
histoplasmosis in pediatric HIV-infected patients, possibil-
ity of drug interaction, potential antifungal drug resistance, 
and cost, routine use of antifungal medications for primary 
prophylaxis of histoplasma infections in children is not recom-
mended (DIII).
Discontinuing Primary Prophylaxis
Although studies have not been done to support the safety 
of discontinuing primary prophylaxis, the safety of discon-
tinuing suppressive therapy (secondary prophylaxis) for HIV-
infected adults with CD4 counts >150 cells/mm3 has been 
demonstrated; treatment should be resumed if CD4 count falls 
below this threshold and the patient continues to reside in an 
area in which the threshold of >10 cases per 100 patient-years 
is exceeded (382,398). Prophylaxis is not recommended for 
HIV-infected children (DIII).
Treatment Recommendations
Treatment of Disease
PDH is fatal without treatment. Therapy with either ampho-
tericin B deoxycholate or itraconazole (399,400) is highly 
effective. The clinical response to amphotericin B is faster 
and is preferred for initial treatment of severe infections (AI). 
Although amphotericin B may be used as monotherapy for 
an extended time, it is now more commonly used as induc-
tion therapy and is followed by long-term treatment with 
itraconazole. Itraconazole is the azole preferred for treatment 
of histoplasmosis (AIII). Trials of therapy and the effectiveness 
of primary and secondary prophylaxis have been evaluated 
in HIV-infected adults. Recommendations for HIV-infected 
children are derived from these data and from anecdotal 
experience in children (382). However, because of important 
differences in managing PDH in children, consultation with 
experts should be considered.
The dosage of liposomal amphotericin B for children is 
3–5 mg/kg/day. Other less costly or better tolerated lipid 
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formulations may be substituted for the liposomal product. 
Amphotericin B deoxycholate, at 1 mg/kg/day, is better toler-
ated by children than it is by adults, is effective, and may be 
used when cost of the lipid preparations is a consideration.
Itraconazole is usually well tolerated in children. Itraconazole 
has a long half-life and does not reach steady-state levels for 2 
weeks. The interval needed to achieve desired serum concen-
trations can be shortened if the recommended dose is admin-
istered three times daily for the initial 3 days of therapy (i.e., 
loading dose); the recommended dose administered twice daily 
should be started thereafter. Itraconazole solution is preferred 
to the capsule formulation because it is better absorbed and 
serum concentrations are 30% higher than those achieved 
with the capsules. Because absorption of itraconazole varies 
considerably from patient to patient, serum concentrations 
should be measured to ensure effective levels of drug, monitor 
changes in dosage, and assess compliance (BIII). The minimal 
inhibitory concentration of H. capsulatum is 0.01 µg/mL, 
and although minimally effective serum concentrations have 
not been determined, a serum concentration of 1.0 µg/mL is 
recommended; dosage should be reduced if concentrations 
exceed 10 µg/mL (382).
Fluconazole is an alternative for patients with mild his-
toplasmosis who are intolerant of itraconazole or in whom 
desired serum levels of itraconazole cannot be attained. 
However, fluconazole is less effective than itraconazole and 
has been associated with development of drug resistance (401). 
Ketoconazole is used infrequently because of its adverse reac-
tions; it is effective in mild infections, excluding disseminated 
infection, and may be considered because it is much less costly 
than the other azoles.
Acute primary pulmonary histoplasmosis
Acute primary pulmonary histoplasmosis can present with 
a wide spectrum of symptoms ranging from dyspnea with 
high fever and diffuse pulmonary infiltrates to only mild 
respiratory symptoms, variable fever, and a chest radiograph 
showing mediastinal adenopathy with or without focal pul-
monary infiltrate. For severe or moderately severe symptoms, 
amphotericin B should be administered for 1–2 weeks; ampho-
tericin B deoxycholate is preferred because it is well tolerated 
in children (AIII) (382). After clinical improvement, patients 
with intact immunity should receive itraconazole, beginning 
with a loading dose (see above) for the first 3 days, followed 
by the recommended doses administered twice daily for at 
least 12 weeks (AIII); adults with CD4 counts of <150 cells/
mm3, and by extrapolation, HIV-infected children with severe 
immunosuppression (e.g., CD4 <15% or <150 cells/mm3 
in children aged <6 years), should receive itraconazole for 
12 months (AIII). Urine antigen usually is elevated in these 
situations and should be monitored to gauge clinical response 
and, after treatment, identify relapse (AIII).
HIV-infected children, particularly those with functional cel-
lular immunity, occasionally will present with fever associated 
with mild primary pulmonary infection and histoplasma antigen 
in the urine. Although an effective cellular immune response may 
limit such illnesses, treatment with itraconazole for 12 weeks 
while following histoplasmal urine antigen concentrations may 
be prudent to ensure concentrations decrease (BIII).
Moderately severe to severe PDH
Data from HIV-infected adults suggest that HIV-infected 
children with moderately severe to severe disseminated his-
toplasmosis should be treated with an IV amphotericin B 
formulation for >2 weeks or until they clinically improve, 
followed by itraconazole for 12 months (AI). HIV-infected 
adults with moderately severe to severe PDH have a higher 
response rate to treatment with liposomal amphotericin B than 
with the deoxycholate formulation (88% vs 64%) and a lower 
death rate (2% vs 13%) (AI) (382). After a favorable clinical 
response, amphotericin B should be discontinued and followed 
by “step-down” therapy with itraconazole for 12 months (AII). 
A loading dose (see above) of itraconazole should be used for 
the initial 3 days. If itraconazole is not well tolerated, a 4- to 
6-week course of amphotericin B should be used and histo-
plasma urine antigen levels followed (AIII).
Although therapeutic trials of amphotericin B deoxycholate 
used to treat PDH in HIV-infected children have not been 
performed, this formulation is effective for treating severe 
PDH in infants (387,402), including those with CNS infec-
tion (387), and in children with other primary or acquired 
immuno deficiency states. Amphotericin B deoxycholate is 
better tolerated by children than by adults, and it is less costly 
than other formulations. It may be used if cost or availability 
of lipid formulations precludes their use (AIII).
Mild to moderate PDH
Mild to moderate PDH in adults without signs of CNS infec-
tion responds favorably in 80%–100% of patients treated with 
itraconazole monotherapy for 12 months (AII) (382,399). This 
regimen also is recommended for HIV-infected children with 
mild to moderate PDH (AII). A loading dose of itraconazole 
(see above) should be administered at the onset of treatment 
and serum concentrations monitored.
CNS infection
CNS infection that accompanies PDH is expected to respond 
to the regimen recommended for moderately severe to severe 
PDH. Isolated CNS infection is unusual in children. In adults, 
frequent failure and relapse are common, and aggressive therapy 
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is recommended. Liposomal amphotericin B is preferred for 
CNS disease in children and adults because it achieves higher 
concentrations in the brain (AII); penetration into the CSF is 
poor with all formulations. The deoxycholate formulation is 
an alternative. Amphotericin should be administered for 4–6 
weeks. Thereafter, the child should receive a loading dose of 
itraconazole and continuation of itraconazole for 12 months 
and until CSF abnormalities, including histoplasmal antigen, 
have resolved (AII). Itraconazole levels should be followed and 
dose adjusted to ensure optimal serum concentrations (AIII).
Asymptomatic Histoplasma granuloma
In asymptomatic HIV-infected children who have intact 
cellular immunity and have resided in an area with endemic 
histoplasmosis, the presence of a typical granuloma in a chest 
radiograph should prompt evaluation of both histoplasmal urine 
antigen and CF and immunodiffusion antibody. If any of these 
tests are positive, treatment with itraconazole for 12 weeks is 
prudent (BIII). If these tests are negative, therapy need not be 
used, and clinical follow-up is recommended. In either instance, 
histoplasmal urine antigen testing should be considered if unex-
plained fever or other systemic symptoms occur.
Monitoring and Adverse Events, Including IRIS
In manifestations of histoplasmosis in which antigenuria 
is demonstrated, antigen levels should be monitored during 
therapy and for a year thereafter to identify relapse (AIII) 
(403). After a recommended course of therapy and, in the 
absence of symptoms, low-level, stable antigenuria may not 
constitute a basis for prolonging the recommended course of 
therapy. Serum levels of itraconazole should be monitored in 
patients receiving treatment (AIII).
Adverse effects of amphotericin B are primarily nephrotoxic-
ity; permanent nephrotoxicity is related to cumulative dose. 
Infusion-related fevers, chills, nausea, and vomiting can occur, 
although they are less frequent in children than in adults. Renal 
dysfunction and electrolyte imbalances are its primary toxici-
ties; these parameters should be monitored during therapy.
Itraconazole, like other azoles, has relatively low rates of 
toxicity. GI upset is seen occasionally and its principal toxicity 
is hepatic. The azole drugs inhibit CYP450-dependent hepatic 
enzymes so that drug interactions, particularly with antiret-
roviral drugs, should be carefully evaluated before initiation 
of therapy.
IRIS caused by an inflammatory response to histoplasmo-
sis unmasked by HAART-induced improvement in cellular 
immunity is unusual, and symptoms are often mild (404). In 
the event of IRIS, antiretroviral therapy should be continued 
along with antifungal therapy (AIII).
Management of Treatment Failure
Both voriconazole and posaconazole have been used suc-
cessfully in a small number of refractory cases in adults (382). 
Because little experience has been reported using the newer 
azoles and data are limited on use of these agents in children, 
expert consultation is recommended for cases refractory to 
first-line agents.
Prevention of Recurrence
Children responding well after completion of initial ampho-
tericin B treatment should be continued on oral itraconazole 
maintenance therapy for at least 1 year (AII). Longer-term 
suppressive therapy with itraconazole may be required in HIV-
infected children who are severely immunosuppressed (i.e., 
CD4 <15% or <150 cells/mm3 in children aged >6 years) and 
patients who experience relapse despite receipt of appropriate 
therapy (AII) (382,398). Fluconazole is less effective than 
itraconazole (CII), and experience is limited in children with 
voriconazole.
Discontinuing Secondary Prophylaxis
Discontinuation of treatment has not been examined in 
children. Data from a clinical trial evaluating discontinua-
tion in adults with immune restoration on HAART suggest 
discontinuation of itraconazole is recommended in adults 
if itraconazole has been received for >1 year, blood cultures 
are negative, histoplasmal serum antigen is <2 ng/mL, CD4 
counts are >150 cells/mm3, and the patient is compliant with 
HAART (AI) (398). Extrapolating these recommendations to 
HIV-infected children on HAART with immune restoration 
(i.e., CD4 >150 cells/mm3 in children aged >6 years) seems 
reasonable (CIII). Treatment should resume if these parameters 
are not met. Chronic suppressive therapy is recommended for 
relapse that occurs despite appropriate treatment (BIII).
Pneumocystis Pneumonia
Epidemiology
Pneumocystis spp. are found worldwide in the lungs of 
humans and lower animals. The organisms are host specific, and 
cross-infection between humans and other animals does not 
occur. Pneumocystis spp. from all sources are morphologically, 
tinctorially, and biologically similar, but surface antigens and 
gene sequencing have demonstrated host-specific differences. 
Since the original designation of Pneumocystis carinii a century 
ago, several changes in terminology have been suggested. The 
most recent proposal to change P. carinii to P. jirovecii for 
isolates from human lungs has gained some popularity but 
remains controversial.
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Pneumocystis has been designated a fungus on the basis of 
DNA analysis, but it has several biologic features of protozoa. 
It is one of the most frequent causes of infection in humans. 
By age 2–4 years, more than 80% of children in most coun-
tries have acquired antibodies to Pneumocystis (405–407). 
Immunocompetent infants with the infection are either 
asymptomatic or have mild respiratory symptoms. Pneumocystis 
pneumonia (PCP) occurs almost exclusively in the immuno-
compromised host.
PCP remains a common AIDS-indicator disease among 
HIV-infected children. The highest incidence of PCP in 
HIV-infected children is in the first year of life, with cases 
peaking at age 3–6 months (408–410). Data from the CDC 
Pediatric Spectrum of Disease Project (1994–2001) indicate 
a decline in PCP infection rates (cases per 1000 HIV-infected 
children) from 25 in 1994 to 18 in 1996 to six in 2001 
(1,411). Similarly, analyses of data from the Perinatal AIDS 
Collaborative Transmission Study revealed a 95% decline in 
PCP (cases per 100 child-years) from 5.8 (pre-HAART era) 
to 0.3 (HAART era) (4). Finally, the incidence rate of PCP 
(cases per 100 child-years) was 1.3 during the pre-HAART era 
(1981–1988) and <0.5 during the HAART era (2001–2004) 
(3). This decline probably resulted from implementation of 
interventions to prevent mother-to-child transmission of HIV, 
introduction of HAART in HIV-infected children in 1995, 
and chemoprophylaxis for PCP.
PCP is a major cause of death among HIV-infected infants 
and children in Africa. Autopsies revealed PCP in 16% of 
children dying with HIV/AIDS during 1992 and 1993 (412), 
in 29% of those dying during 1997 and 2000 (413), and in 
44% of those dying during 2000 and 2001 (414).
The mode of transmission of Pneumocystis among HIV-
infected infants, children, and adults is not firmly established, 
but airborne human-to-human transmission is likely. Animal 
studies show Pneumocystis is transmitted by air from infected 
to susceptible rats (415,416). Human-to-human transmission 
has been suggested by molecular epidemiology and global clus-
tering of PCP cases in recent studies (417–419). Intrauterine 
transmission is considered rare. However, in one report, one of 
eight infants born to women who had AIDS and PCP during 
pregnancy had evidence of Pneumocystis infection (420).
The single most important factor in susceptibility of 
HIV-infected patients of all ages to PCP is the status of cell-
mediated immunity of the host. Severe compromise, reflected 
by a marked decrease in CD4 count and percentage, is the 
hallmark of high risk for PCP and is discussed further in the 
prevention section.
Clinical Manifestations
Prominent clinical features of PCP among HIV-infected 
children are fever, tachypnea, dyspnea, and cough. The severity 
of these signs and symptoms varies from child to child. Onset 
can be abrupt or insidious with nonspecific symptoms (e.g., 
mild cough, dyspnea, poor feeding, diarrhea, and weight loss). 
Some patients may not be febrile, but almost all will have tac-
hypnea by the time pneumonitis is evident on chest radiograph. 
Physical examination sometimes shows bilateral basilar rales 
with evidence of respiratory distress and hypoxia.
In HIV-infected children with pneumonia, four clinical vari-
ables are independently associated with PCP: age <6 months, 
respiratory rate >59 breaths per minute, arterial percentage 
hemoglobin saturation <92%, and the absence of vomiting 
(421). A high plasma HIV RNA concentration strongly pre-
dicts PCP and other OIs (422).
Extrapulmonary Pneumocystis organisms are found in 
<2.5% of HIV-infected adults and children (423,424). This 
can occur without concurrent PCP and can be located at 
multiple noncontiguous sites. Involved sites have included 
ear, eye, thyroid, spleen, GI tract, peritoneum, stomach, duo-
denum, small intestine, transverse colon, liver, and pancreas. 
Less frequently involved sites include adrenal glands, muscle, 
bone marrow, heart, kidney, ureter, lymph nodes, meninges, 
and cerebral cortex.
Diagnosis
Most children with PCP have substantial hypoxia with 
low arterial oxygen pressure and a PaO2 >30 mm Hg. The 
CD4 count is often <200 cells/mm3 and the CD4 percentage 
<15% in children aged >5 years. Lactic dehydrogenase is often 
increased, but this is not specific for PCP. Serum albumin may 
be depressed. Chest radiographs most commonly indicate 
bilateral diffuse parenchymal infiltrates with “ground-glass” or 
reticulogranular appearance, but they also can be normal or 
have only mild parenchymal infiltrates. The earliest infiltrates 
are perihilar, progressing peripherally before reaching the api-
cal portions of the lung. Rarely, lobar, cavitary, nodular, or 
miliary lesions; pneumothorax; or pneumomediastinum are 
observed.
A definitive diagnosis of PCP requires demonstration of 
the organism in pulmonary tissues or fluids in the presence of 
pneumonitis. Diagnostic procedures are the same as for adults 
suspected to have PCP (see Guidelines for the Prevention and 
Treatment of Opportunistic Infections in HIV-Infected Adults) 
(16), but some procedures may be more difficult to perform 
in children. Several procedures for collecting and staining 
specimens are available.
Induced sputum analysis, during which the patient produces 
sputum after inhalation of nebulized 3% hypertonic saline, 
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may be difficult among children aged <2 years because of small 
airways and poor ability to produce sputum. Complications 
from the procedure include nausea, vomiting, and bronchos-
pasm. Sensitivity of sputum analysis in adults ranges from 25% 
to 90%. After a negative induced sputum sample, a broncho-
alveolar lavage for definitive diagnosis may be necessary.
Nasogastric aspirates, if positive, are of diagnostic value. 
Pneumocystis organisms were found in 48.6% of HIV-infected 
children with respiratory illnesses in whom gastric aspirates 
were obtained on three consecutive mornings (425). Other 
studies have shown the organism is not found in gastric con-
tents without PCP (426).
Bronchoscopy with bronchoalveolar lavage is the diagnostic 
procedure of choice for most infants and children. Sensitivity 
ranges from 55% to 97% and may be positive for >72 hours 
after initiation of PCP treatment; treatment should not 
be delayed while awaiting results. Complications include 
hemoptysis, pneumothorax, transient increase in hypoxemia, 
a transient increase in pulmonary infiltrates at the lavage site, 
and postbronchoscopy fever.
Fiberoptic bronchoscopy with transbronchial biopsy is 
recommended only when bronchoalveolar lavage is negative 
or nondiagnostic despite a clinical picture consistent with 
PCP. Sensitivity is 87%–95%, and cysts can be identified up 
to 10 days after initiation of treatment (up to 4–6 weeks in 
certain patients). Complications include pneumothorax and 
hemorrhage; this procedure is contraindicated in children with 
thrombocytopenia.
Open-lung biopsy is the most sensitive and specific diag-
nostic technique, but because it requires thoracotomy and 
often chest tube drainage, is not recommended routinely. It 
has the advantage of revealing the type and extent of disease 
as well as the organism. Histopathology shows alveoli filled 
with eosinophilic, acellular, proteinaceous material that 
contains cysts and trophozoites but few inflammatory cells. 
Complications include pneumothorax, pneumomediastinum, 
and hemorrhage.
Three types of stains can be used to identify Pneumocystis 
organisms in specimens. Gomori methenamine-silver method 
stains the cyst wall brown or black. Toluidine blue stains the 
cyst wall blue or lavender. Both methods stain fungal elements. 
Giemsa, Diff-Quick®, and Wright stains depict the trophozo-
ites and intracystic sporozoites pale blue with a punctate red 
nucleus, but unlike other stains, these do not stain the cyst 
wall. Monoclonal immunofluorescent antibodies (Merifluor®, 
Meridian Bioscience, Inc., Cincinnati, OH) that stain the cyst 
wall also can be used for diagnosis and have enhanced specific-
ity compared with the other methods. A cyst wall, trophozoite, 
and immunofluorescent antibody stain is recommended for 
each specimen studied.
PCR assays to amplify the human Pneumocystis MSG 
gene, mitochondrial large subunit (mtlsu) rRNA, the dihy-
dropteroate synthase gene, and the internal transcribed spacer 
region genes have been developed for diagnostic evaluation. 
These tests are usually more sensitive but less specific than 
microscopic methods and are not standardized or available in 
most centers (427,428). Pneumocystis-specific DNA is found in 
18% of bronchoalveolar lavage samples from patients without 
clinical PCP, HIV, and other infections (429).
Coinfection with other organisms (e.g., CMV or pneu-
mococcus) has been reported in HIV-infected children 
(410,430,431). Children with dual infections may have more 
severe disease. Although CMV in lung secretions of children 
with PCP indicates colonization, it usually does not require 
therapy. The presence of Pneumocystis is always an indication 
for treatment.
Prevention Recommendations
Preventing Exposure
The need for isolation of hospitalized persons who have PCP 
has been neither demonstrated nor discounted. PCP patients 
clearly do not need to be isolated from persons with normal 
immune responses and from immuno compromised high-risk 
patients who are receiving PCP prophylaxis. Under unusual 
circumstances where prophylaxis cannot be administered, 
avoid placement in the same room with an immucompromised 
patient (CIII).
Preventing First Episode of Disease
Chemoprophylaxis is highly effective in preventing PCP. 
Criteria for its use are based on the patient’s age and CD4 
count or percentage (AII). Prophylaxis is recommended for all 
HIV-infected children aged >6 years who have CD4 counts 
<200 cells/mm3 or CD4 <15%, for children aged 1–5 years 
with CD4 counts of <500 cells/mm3 or CD4 <15%, and for 
all HIV-infected infants aged <12 months regardless of CD4 
count or percentage (432).
Infants born to HIV-infected mothers should be considered 
for prophylaxis beginning at 4–6 weeks of age. HIV-infected 
infants should be administered prophylaxis until 1 year of age, 
at which time they should be reassessed on the basis of the 
age-specific CD4 count or percentage thresholds mentioned 
above (AII). Infants with indeterminate HIV infection sta-
tus should receive prophylaxis until they are determined to 
be HIV-uninfected or presumptively uninfected with HIV 
(AIII). Prophylaxis is not recommended for infants who meet 
criteria for definitively or presumptively HIV-uninfected. In 
nonbreast-feeding infants with no positive HIV virologic test 
results, presumptive exclusion of HIV infection can be based 
on two negative virologic test results: one obtained at >2 weeks 
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and one obtained at >4 weeks of age, one negative virologic 
test result obtained at >8 weeks of age, or one negative HIV-
antibody test result obtained at >6 months of age. Definitive 
exclusion of HIV infection is based on two negative virologic 
test results: one obtained at >1 month of age and one obtained 
at >4 months of age, or on two negative HIV-antibody test 
results from separate specimens obtained at >6 months of age. 
For both presumptive and definitive exclusion of infection, 
the child should have no other laboratory (e.g., no positive 
virologic test results) or clinical (e.g., no AIDS-defining condi-
tions) evidence of HIV infection.
Four drug regimens have been found effective and relatively 
safe for preventing PCP in high-risk HIV-infected children 
and adults.
Trimethoprim–sulfamethoxazole (TMP–SMX) (Cotrimox-
azole) is the drug of choice for prophylaxis because of its high 
efficacy, relative safety, low cost, and broad antimicrobial 
spectrum (AI). TMP alone has little, if any, anti-Pneumocystis 
activity, but it enhances the activity of the sulfonamide. The 
prophylactic dosage is 150 mg/m2 body surface area/day TMP 
and 750 mg/m2 body surface area/day SMX (approximately 
5.0 mg/kg/day TMP and 25 mg/kg/day SMX) administered 
orally in equally divided doses twice a day on 3 consecutive 
days per week (433). The total daily dose should not exceed 
320 mg TMP and 1600 mg SMX. For patients with impaired 
renal function, a reduced dose may be necessary.
Alternatively, TMP–SMX can be administered daily 7 days 
a week (AI) (434). TMP–SMX also is effective in prevent-
ing toxoplasmosis (435) and some bacterial infections (e.g., 
Salmonella, Haemophilus, Staphylococcus) (434,436–438).
Dihydropteroate synthase gene mutations in Pneumocystis 
from humans have been observed with TMP–SMX and dap-
sone prophylaxis, suggestive of possible drug resistance, but 
studies for clinical correlates have not provided conclusive 
results (427). More apparent is the association of prolonged 
TMP–SMX prophylaxis for PCP with the emergence of selec-
tive pressure resistance of clinically important bacterial species 
to TMP-SMX, a point to be considered in managing bacterial 
infections in patients receiving prophylaxis (439,440).
Other effective and safe prophylaxis regimens are available 
for patients unable to take TMP-SMX. A second choice would 
be either atovaquone or dapsone (BI) (441). Atovaquone 
is effective and safe but expensive. Dapsone is effective and 
inexpensive but associated with more serious adverse effects 
than atovaquone.
Atovaquone is administered with a meal as an oral yellow 
suspension in single dosage of 30 mg/kg/day for patients 1–3 
months and >24 months of age, and 45 mg/kg/day for infants 
aged 4–24 months (442). Unlike TMP-SMX, atovaquone has 
no antibacterial activity but is effective against Toxoplasma 
gondii. Azithromycin, in a single dosage of 5.0 mg/kg/day 
has been used to supplement atovaquone for greater broad-
spectrum prophylaxis. The randomized, double-blind, placebo-
controlled study PACTG 254 compared TMP-SMX and 
atovaquone plus azithromycin for 3 years (median) in 366 
HIV-infected children qualifying for PCP prophylaxis (95). 
Results showed atovaquone-azithromycin to be as effective 
as TMP-SMX for preventing serious bacterial infections, as 
well as PCP.
Dapsone can be administered on a daily or weekly schedule 
as 2.0 mg/kg/day (maximum total dosage of 100 mg/day) or 
4.0 mg/kg/week (maximum total dosage of 200 mg/week) 
orally. Approximately two thirds of patients intolerant to TMP-
SMX can take dapsone successfully. Studies in adults show dap-
sone is as effective as atovaquone or aerosolized pentamidine 
but slightly less effective than TMP-SMX (441,442).
Aerosolized pentamidine is recommended for children who 
cannot take TMP-SMX, atovaquone, or dapsone and are old 
enough to use nebulization with a Respirgard II® nebulizer 
(Marquest, Englewood, CO) (BI). The dosage for all ages is 
300 mg once a month (437). Adverse reactions among HIV-
infected children include cough, sneezing, and bronchospasm 
(443).
Pyrimethamine-sulfadoxine (Fansidar®) also is recognized 
as an effective prophylaxis regimen in adults (CIII). Although 
this drug was effective in preventing PCP in Iranian orphan-
ages in the 1960s, it has not been evaluated adequately among 
HIV-infected children.
The use of IV pentamidine is not recommended for pro-
phylaxis (EIII) (444).
Discontinuing Primary Prophylaxis
Studies of HIV-infected adults and children following 
immune reconstitution after receipt of HAART demonstrate 
acceptable low risks for PCP after discontinuation of pro-
phylaxis (46,445–449). Data from the PACTG 1008 study 
evaluated 235 HIV-infected children and adolescents on anti-
retroviral therapy who received PCP prophylaxis >6 months 
and achieved CD4 percentages of >20% for patients 
aged >6 years and >25% for patients aged 2–6 years, after 
which the prophylaxis was stopped (46). During the median 
follow-up of 2.5 years (547 person-years), no cases of PCP 
occurred; 9.4% of patients enrolled required reinstitution of 
PCP prophylaxis during observation. These data, along with 
data from studies in adults, support the expectation for very 
low risk for PCP after prophylaxis is discontinued in children 
who have achieved immune reconstitution.
Discontinuation of PCP prophylaxis should be considered 
for HIV-infected children when, after receiving HAART 
for >6 months, CD4 percentage is >15% or CD4 count is >200 
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cells/mm3 for patients aged >6 years (BII) and CD4 percentage 
is >15% or CD4 count is >500 cells/mm3 for patients aged 
1–5 years (BII) for >3 consecutive months. Subsequently, the 
CD4 percentage and count should be reevaluated at least every 
3 months and prophylaxis reinstituted if the original criteria 
for prophylaxis are reached (BIII). PCP prophylaxis is not to 
be discontinued in HIV-infected infants aged <1 year.
Treatment Recommendations
Treatment of Disease
TMP-SMX is the recommended treatment for PCP (AI). 
The dose for HIV-infected children aged >2 months is 
15–20 mg/kg/day of the TMP component and 75–100 mg/kg/day 
of the SMX component administered intravenously in 3 or 4 
divided doses, with the dose infused over 1 hour for 21 days 
(AI). As the acute pneumonitis subsides, children with mild 
to moderate disease who do not have malabsorption or diar-
rhea can be administered oral treatment with the same dose 
of TMP-SMX in 3 or 4 divided doses to complete a 21-day 
course (AII). Effective therapeutic serum concentrations of 
5–10 µg/mL TMP can be reached with the recommended dose 
administered orally in HIV-infected children (450).
IV pentamidine isethionate once daily is recommended for 
patients who cannot tolerate TMP-SMX or who demonstrate 
clinical treatment failure after 5–7 days of TMP-SMX therapy 
(AI). No evidence exists for synergistic or additive effects on 
efficacy of these agents; therefore, because of potential increased 
toxicity, their combined use is not recommended (DIII). 
Among patients with clinical improvement after 7–10 days 
of IV therapy with pentamidine, an oral regimen (e.g., atova-
quone or TMP/dapsone) might be considered to complete a 
21-day course (BIII).
Atovaquone is an alternative for treatment of mild to mod-
erately severe PCP in adults (BI) (95). Therapeutic data are 
limited for children, but the dosage of 30–40 mg/kg/day in 
two divided doses administered orally is established for chil-
dren <3 months and >24 months of age. Children aged 3–24 
months require a higher dosage of 45 mg/kg/day (AII) (442). 
The dosage for adolescents and adults is 750 mg twice daily. 
Food increases the bioavailability of atovaquone approximately 
threefold compared with that achieved with the fasting state. 
Atovaquone concentration increases with coadministration of 
fluconazole and prednisone and decreased by coadministra-
tion with acyclovir, opiates, cephalosporins, rifampin, and 
benzodiazepines.
Dapsone/TMP is effective in treating mild to moderate PCP 
among adults (BI) (451); data on toxicity and efficacy among 
children are limited. The dosage of dapsone for adolescents 
and adults is 100 mg (total dose) orally once daily and TMP 
15 mg/kg/day divided into three daily doses administered for 
21 days. Among children aged <13 years, a dapsone dosage of 
2 mg/kg/day is required to achieve therapeutic levels in chil-
dren (AII) (452). The pediatric dose of TMP is 15 mg/kg/day 
divided into three daily doses. Dapsone is less effective than 
the combination (453).
Clindamycin/primaquine has been used to treat mild to 
moderate PCP among adults (BI); data for children are not 
available (CIII). Primaquine is contraindicated for patients 
with glucose-6-dehydrogenase deficiency because of the pos-
sibility of inducing hemolytic anemia. Dose information for 
treating PCP is available only for adults. For patients weighing 
>60 kg, clindamycin 600 mg intravenously every 6 hours for 
10 days, then 300–450 mg orally every 6 hours to complete 
21 days of treatment is recommended. Primaquine is adminis-
tered as 30 mg of base orally for 21 days. Dosing for children 
is based on use of these drugs for treating other infections: 
the usual pediatric dose of clindamycin for treating bacterial 
infection is 10 mg/kg/dose every 6 hours, and the pediatric 
dose of primaquine equivalent to an adult dose of 20 mg base 
(when used for malaria) is 0.3 mg/kg/day of the base.
On the basis of studies in adults, a short course of corticos-
teroids is recommended in cases of moderate or severe PCP, 
starting within 72 hours of diagnosis (AI). Pediatric studies 
have indicated reduced acute respiratory failure, decreased 
need for ventilation, and decreased mortality with early use 
of corticosteroids in HIV-infected children who have PCP 
(454–456). Indications for corticosteroid treatment include a 
PaO2 value of <70 mm Hg or an alveolar-arterial gradient of 
>35 mm Hg. Doses for children vary between studies. A com-
monly used scheme is prednisone on days 1–5, 1 mg/kg/dose 
twice daily; days 6–10, 0.5 mg/kg/dose twice daily; and days 
11–21, 0.5 mg/kg once daily. Alternative regimens include 
1) adult dosage prednisone on days 1–5, 40 mg twice daily; days 
6–10, 40 mg once daily; days 11–21, 20 mg once daily; and 
2) methylprednisolone (IV) on days 1–7, 1 mg/kg/dose every 
6 hours; days 8–9, 1 mg/kg/dose twice daily; days 10 and 11, 
0.5 mg/kg/dose twice daily; days 12–16, 1 mg/kg once daily.
Some case reports have documented improved pulmonary 
function with use of surfactant in cases of severe disease (e.g., 
respiratory distress syndrome with established respiratory 
failure requiring ventilation) (457–459). Alterations in sur-
factant function and composition have been demonstrated in 
HIV-infected adults with PCP (460). Data are insufficient to 
recommend surfactant administration for PCP.
Monitoring and Adverse Events, Including IRIS
Clinical parameters to monitor the status of disease include 
temperature, respiratory rate, arterial oxygen saturation, and 
chest radiograph (461). Clinical improvement can be expected 
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at a mean of approximately 4.5 + 2.5 days and radiographic 
improvement at approximately 7.7 + 4.5 days (461).
IRIS has been less frequently associated with Pneumocystis 
infection (2% of 44 adults with IRIS) than with several other 
OIs in HIV-infected adults and children (462). Whether this 
low rate is related to PCP prophylaxis is not known.
In children, adverse reactions to TMP-SMX include rash 
(mild maculopapular in most cases but rarely erythema mul-
tiforme and Stevens-Johnson syndrome), hematologic abnor-
malities (e.g., neutropenia, thrombocytopenia, megaloblastic 
or aplastic anemia), GI complaints (usually mild), hepatitis, 
and renal disorders (e.g., interstitial nephritis) (463,464). Data 
from a PACTG study of HIV-infected children at high risk 
for PCP receiving TMP-SMX for a median of 3 years showed 
28% had a rash, 9.3% had neutropenia, 8.8% had throm-
bocytopenia, and 2.2% had anemia (95). None were fatal or 
nonreversible reactions. Some very mild reactions will resolve 
while the drug is continued. With any significant adverse effect, 
TMP-SMX should be withheld until the reaction has subsided. 
Unless the reaction has been life-threatening, TMP-SMX 
prophylaxis can be resumed, preferably by beginning with low 
desensitizing daily doses and gradually increasing to full doses 
(BII) (465,466). In adults, 75% of patients affected tolerate 
rechallenge with TMP-SMX (466). The overall frequency of 
adverse reactions appears to be lower among HIV-infected 
children than among adults; approximately 15% of children 
have substantial adverse reactions to TMP-SMX (446). If an 
urticarial rash or Stevens-Johnson syndrome occurs, TMP-
SMX should be discontinued and not readministered (EIII).
The most common adverse drug reaction to pentamidine 
isethionate is renal toxicity, which usually occurs after 2 weeks 
of therapy and can be averted by adequate hydration and 
careful monitoring of renal function and electrolytes. Severe 
hypotension (particularly if infused rapidly), prolonged QT 
interval (torsades de pointes), and cardiac arrhythmias can 
occur. Hypoglycemia (usually after 5–7 days of therapy) or 
hyperglycemia, hypercalcemia, hyperkalemia, pancreatitis, 
and insulin-dependent diabetes mellitus also have been 
reported. The patient may experience a metallic or bitter taste. 
Serious adverse reactions to pentamidine have been reported 
in approximately 17% of children receiving the drug (467). 
This drug should not be administered with other nephrotoxic 
drugs (e.g., aminoglycosides, amphotericin B, cisplatin, or 
vancomycin) and with agents associated with pancreatitis 
(e.g., didanosine).
With dapsone and TMP, the primary adverse reaction is 
reversible neutropenia; other reactions include skin rashes, 
elevated serum transaminases, methemaglobinemia, anemia, 
and thrombocytopenia (451,453). Dapsone is the problematic 
component of the combination and accounts for most of the 
adverse reactions (442).
Skin rashes (10%–15%), nausea, and diarrhea can occur 
with atovaquone administration. Liver enzymes may increase 
briefly. No serious toxicity or fatality has been demonstrated 
from the use of atovaquone in adults or children.
Adverse reactions to clindamycin/primaquine include skin 
rash, nausea, and diarrhea.
Management of Treatment Failure
An inflammatory reaction to antibiotic-induced killing of 
the organism in the lungs can result in an initial early and 
reversible deterioration during the first 3–5 days of therapy, so 
an adequate trial of therapy is needed before switching drugs 
because of lack of clinical improvement. Clinical failure is 
defined by lack of improvement or worsening of respiratory 
function documented by arterial blood gases after at least 4–8 
days of anti-PCP treatment. Other concomitant infections 
need to be excluded as causees of clinical failure. With evidence 
of treatment failure after the use of TMP-SMX, drugs can be 
changed. If tolerated, pentamidine isethionate is the drug of 
next choice (BII). No evidence exists for synergistic or additive 
therapeutic effects; therefore, because of potential increased 
toxicity, their combination is not recommended.
Prevention of Recurrence
None of the drugs administered to treat and prevent PCP 
completely eliminates Pneumocystis, and prophylaxis is effective 
only while the selected drug is administered. Patients who have 
experienced an episode of PCP should have prophylaxis admin-
istered continuously after completion of treatment (AI).
Discontinuing Secondary Prophylaxis
In most patients, secondary prophylaxis can be discontinued 
using the same criteria as for discontinuing primary prophy-
laxis. PCP prophylaxis is not to be discontinued in HIV-
infected infants <1 year. Children who present with clinical 
signs and symptoms compatible with PCP after discontinu-
ation of prophylaxis should be evaluated thoroughly despite 
normal or high CD4 counts or percentages (BII) (468).
Parasitic Infections
Cryptosporidiosis/Microsporidiosis
Epidemiology
Cryptosporidium spp. are protozoal parasites that mainly 
cause enteric illness (e.g., chronic diarrhea) in humans and ani-
mals; the parasites have worldwide distribution. The three most 
common species infecting humans are C. hominis, C. parvus, 
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and C. meleagridis. In addition, infections with C. canis, 
C. felis, C. muris, and Cryptosporidium pig genotype have been 
reported in immuno compromised patients. Cryptosporidium 
parasites usually invade the small bowel, but in immuno-
compromised hosts, the large bowel and extraintestinal sites 
also are involved.
The parasite is transmitted by ingestion of oocysts excreted 
in the feces of infected animals and humans. The parasite is 
highly infectious, with an ID50 ranging from nine to 1042 
oocysts, depending on the isolate (469). Infection occurs when 
the ingested oocyst releases sporozoites, which attach to and 
invade the intestinal epithelial cells. The parasite has a predilec-
tion for the jejunum and terminal ileum (469).
Person-to-person transmission is common in child care 
centers; infants with cryptosporidiosis-associated diarrhea can 
infect adults during diapering (470). Oocysts can contami-
nate recreational water sources (e.g., swimming pools, lakes) 
and public water supplies and may persist despite standard 
chlorination. Physical steps—flocculation, sedimentation, or 
filtration—are necessary to remove the parasite from the water. 
Outbreaks have been associated with ingestion of contaminated 
drinking water in large metropolitan areas that have chlori-
nation but not filtration systems and with public swimming 
pools (471). Foodborne and person-to-person spread have 
been documented (469).
Cryptosporidiosis also occurs among international travelers. 
Although fewer than 4000 such cases were reported each year 
in the United States during 1995–2002, an estimated 300,000 
persons are infected each year; underuse of diagnostic tests 
and poor sensitivity of the older tests combined with under-
reporting are the main reasons for this difference (472). In 
industrialized countries, the prevalence of cryptosporidiosis 
among children is usually considered to range from 3.0% to 
3.6% (473); it is reported more frequently among children in 
developing countries (474–476).
Before the advent of effective antiretroviral therapy, cryp-
tosporidiosis was diagnosed primarily in patients with advanced 
HIV disease and AIDS. However, the incidence has declined 
dramatically in areas where HAART became widely available 
(476,477).
Microspora spp. are obligate, intracellular, spore-forming 
protozoa that primarily cause moderate to severe diarrhea 
among children. They are related to fungi but defined by their 
unique single polar tube that coils around the interior of the 
spore (478). Many microsporidia were reported as pathogens 
in humans, but Enterocytozoon bieneusi and Encephalitozoon 
intestinalis are the most common microsporidia that cause 
infection among patients with HIV infection. Other microspo-
ridia such as Encephalitozoon cuniculi, Encephalitozoon hellem, 
Trachipleistophora hominis, T. anthropophthera, Pleistophora spp., 
P. ronneeafiei, Vittaforma (Nosema) corneae, Microsporidium 
spp., Nosema ocularum, Anncaliia (syns Brachiola/Nosema) 
connori, A. (syn Brachiola) vesicularum, and A. (syns Brachiola/
Nosema) algerae also have been implicated in human infec-
tions. The Microspora parasites develop in enterocytes and are 
excreted with feces and, like C. parvum, are transmitted by the 
fecal-oral route, including through ingestion of contaminated 
food or water (479). They cause infection in HIV-uninfected 
children, elderly persons, travelers, and organ transplant recipi-
ents. Although the incidence of microsporidiosis has declined 
dramatically in areas where HAART is used, it continues to 
affect HIV-infected patients who are unable to receive or 
continue HAART.
Clinical Manifestations
Symptoms of cryptosporidiosis develop after an incubation 
period of 1 week. Frequent, usually nonbloody, persistent 
watery diarrhea is the most common manifestation of both 
cryptosporidial and microsporidial infection, with abdominal 
cramps, fatigue, vomiting, anorexia, weight loss, and poor 
weight gain. Fever and vomiting are relatively common in 
children, mimicking viral gastroenteritis (474). In almost half 
of the cases, the diarrhea persists for >2 weeks (480). Longer 
episodes of diarrhea have been associated with increased risk 
for recurrent episodes and weight loss (481). Among immuno-
compromised children, chronic severe diarrhea can result in 
malnutrition, failure to thrive, and substantial intestinal fluid 
losses, resulting in severe dehydration and even death. Clinical 
history or physical examination does not allow differentiation 
of cryptosporidial or microsporidial disease from those caused 
by other pathogens.
Cryptosporidium can migrate into the bile duct and result 
in inflammation of the biliary epithelium, causing acalculous 
cholecystitis, and sclerosing cholangitis (482). Symptoms and 
signs include fever, right upper abdominal pain, and elevated 
alkaline phosphatase. Pancreatitis occurs rarely. Although 
infection usually is limited to the GI tract, pulmonary or dis-
seminated infection can occur among immuno compromised 
children.
The most common manifestation of microsporidiosis is GI 
tract infection. In addition to the more common acute and 
chronic diarrhea, microsporidia species have been described 
as causing hepatitis, peritonitis, keratoconjunctivitis, myositis, 
cholangitis, respiratory disease, sinusitis, encephalitis, and 
disseminated disease (483). Different infecting species may 
result in different clinical syndromes. Enterocytozoon bieneusi 
is associated with malabsorption, diarrhea, and cholangitis. 
Encephalitozoon cuniculi is associated with hepatitis, encepha-
litis, and disseminated disease. Encephalitozoon (syn Septata) 
intestinalis is associated with diarrhea, disseminated infection, 
52 MMWR September 4, 2009
and superficial keratoconjuctivitis. Encephalitozoon hellem is 
associated with superficial keratoconjunctivitis, sinusitis, respi-
ratory disease, prostatic abscesses, and disseminated infection. 
Nosema, Vittaforma, and Microsporidium are associated with 
stromal keratitis following trauma in immunocompetent hosts. 
Pleistophora, Anncaliia, and Trachipleistophora are associated 
with myositis. Trachipleistophora is associated with encephalitis 
and disseminated disease.
Diagnosis
Because Cryptosporidium cannot be grown on laboratory 
media, cryptosporidiosis usually is diagnosed by microscopic 
identification of the oocysts in stool or tissue. Stool samples 
are concentrated using the sucrose flotation or formalin-ethyl 
acetate methods. Monoclonal antibody-based fluorescein-
conjugated stain for oocysts and an EIA to detect antigen in 
stool are preferred to staining methods (e.g., with a modified 
Kinyoun acid-fast stain) because of enhanced sensitivity and 
specificity (484,485). Antigen-detection assays (e.g., enzyme-
linked immunosorbent assay, immunochromatography) are 
available commercially that have good sensitivity and excellent 
specificity (485,486). Molecular methods such as PCR hold 
promise to further enhance sensitivity (487). Among persons 
with profuse diarrheal illness, one stool specimen is usually 
adequate for diagnosis. However, oocyst excretion can be 
intermittent; therefore, the parasite might not be detected in 
every stool, and among persons with milder disease, repeat stool 
sampling is recommended. Organisms also can be identified 
on small intestinal biopsy or intestinal fluid samples.
To diagnose microsporidia infection, thin smears of uncon-
centrated stool-formalin suspension or duodenal aspirates can 
be stained with modified trichrome stain. Chemofluorescent 
agents such as chromotrope 2R and calcofluor white (a fluores-
cent brightener) are useful as selective stains for microsporidia 
in stool and other body fluids. Microsporidia spores are small 
(1–5 µm diameter), ovoid, stain pink to red with modified 
trichrome stain, and contain a distinctive equatorial-belt-like 
stripe.
Urine sediment examination by light microscopy can be used 
to identify microsporidia spores causing disseminated disease 
(e.g., Encephalitozoonidae, Trachipleistophora). Transmission 
electron microscopy or PCR (using specific primers) is needed 
for speciation.
Endoscopic biopsy should be considered for all patients 
with chronic diarrhea of >2 months’ duration and negative 
stool examinations. Touch preparations are useful for rapid 
diagnosis (i.e., within 24 hours). Sensitive assays using PCR 
amplification of parasite DNA sequences extracted from stool 
or biopsy specimens have been developed for Cryptosporidium 
and for Enterocytozoon bieneusi (487,488) but are research tools 
and not commercially available.
Prevention Recommendations
Preventing Exposure
Caregivers and HIV-infected children should be educated 
and counseled about the different ways Cryptosporidium 
can be transmitted. Modes of transmission include directly 
contacting fecal material from adults, diaper-aged children, 
and infected animals; contacting contaminated water during 
recreational activities; drinking contaminated water; and eating 
contaminated food.
Hand washing after exposure to potentially fecally contami-
nated material, including diapers, is important in reducing 
the risk for Cryptosporidium infection. HIV-infected children 
should not be allowed contact with ill pets or stool from pets, 
particularly dogs and cats <6 months of age; stray pets; or 
surfaces contaminated with human or animal stool. HIV-
infected children should avoid direct contact with calves and 
lambs at farms or petting zoos.
HIV-infected children should not be allowed to drink water 
directly from lakes or rivers, including swallowing water while 
swimming or playing in recreational water. Caregivers and 
HIV-infected children should be aware that lakes, rivers, salt-
water beaches, certain swimming pools, recreational water parks, 
and ornamental water fountains might be contaminated with 
human or animal waste that contains Cryptosporidium.
Some outbreaks of cryptosporidiosis have been linked to inges-
tion of water from municipal water supplies. During outbreaks 
or in other situations in which a community advisory to boil 
water is issued, water used in preparing infant formula and for 
drinking should be boiled for >3 minutes to eliminate risk for 
cryptosporidiosis.
Nationally distributed brands of bottled or canned carbonated 
soft drinks are safe to drink. Commercially packaged noncarbon-
ated soft drinks and fruit juices that do not require refrigeration 
until after they are opened (i.e., can be stored unrefrigerated 
on grocery shelves) also are safe. Nationally distributed brands of 
frozen fruit juice concentrate are safe if they are reconstituted 
by the user with water from a safe water source. Fruit juices that 
must be kept refrigerated from the time they are processed to the 
time of consumption might be either fresh (i.e., unpasteurized) or 
heat-treated (i.e., pasteurized); only juices labeled as pasteurized 
should be considered free of risk from Cryptosporidium. Other 
pasteurized beverages also are considered safe to drink.
Cryptosporidium-infected patients should not work as food 
handlers, especially if the food to be handled is intended to be 
eaten without cooking.
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In a hospital, standard precautions (i.e., use of gloves and 
hand washing after removal of gloves) should be sufficient to 
prevent transmission of cryptosporidiosis from an infected 
patient to a susceptible HIV-infected person. However, because of 
the potential for fomite transmission, some experts recommend 
that severely immuno compromised HIV-infected patients not share 
a room with a patient with cryptosporidiosis (CIII).
Similar to precautions for preventing cryptosporidiosis, 
attention to hand washing and other personal hygiene measures 
will reduce exposure to microsporidia.
Preventing First Episode of Disease
Because chronic Cryptosporidium infection occurs most 
frequently in HIV-infected persons with advanced immune 
deficiency, antiretroviral treatment of HIV-infected children 
before development of severe immune deficiency is a primary 
modality of prevention (AII).
Some observational studies from the pre-HAART era sug-
gested that rifabutin or clarithromycin prophylaxis for MAC 
may be associated with decreased rates of cryptosporidiosis 
(489,490). However, data are conflicting and insufficient to 
recommend using these drugs solely for prophylaxis of cryp-
tosporidiosis. No chemoprophylactic regimens are known to 
be effective in preventing microsporidiosis.
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
Immune reconstitution resulting from HAART frequently 
will result in clearance of Cryptosporidium and Microsporidium 
infections. Effective HAART is the primary initial treatment 
for these infections in HIV-infected children and adults (AII) 
(477,491). Supportive care with hydration, correction of elec-
trolyte abnormalities, and nutritional supplementation should 
be provided (AIII). Antimotility agents should be used with 
caution among young children (CIII).
Cryptosporidium
No consistently effective therapy is available for cryptospori-
diosis, and duration of treatment among HIV-infected persons 
is uncertain (492). Multiple agents have been investigated in 
small randomized controlled clinical trials of HIV-infected 
adults, including nitazoxanide, paromomycin, spiramycin, 
bovine hyperimmune colostrum, and bovine dialyzable leu-
kocyte extract. No pharmacologic or immunologic therapy 
directed specifically against C. parvum has yet been shown 
consistently effective and durable when used alone without 
concomitant antiretroviral therapy (492).
A review of clinical trials of treatment for Cryptosporidia in 
immuno compromised patients, including those with HIV 
infection, found that no agent has proven efficacy for treating 
cryptosporidiosis in immuno compromised patients; however, 
in immunocompetent persons, nitazoxanide reduces the load 
of parasites. Given the seriousness of this infection among 
immuno compromised persons, use of nitazoxanide can be 
considered in immuno compromised HIV-infected children 
in conjunction with HAART for immune restoration (CIII) 
(492).
Nitazoxanide is approved in the United States to treat diar-
rhea caused by Cryptosporidium and Giardia lamblia among 
children and is available in liquid and tablet formulations (BI 
for HIV-uninfected and CIII for HIV-infected children). An 
Egyptian clinical trial among 100 HIV-uninfected adults and 
children randomized patients to a 3-day course of nitazoxanide 
or placebo (493). Nitazoxanide therapy reduced the dura-
tion of both diarrhea and oocyst shedding; among children, 
clinical response was 88% with nitazoxanide and 38% with 
placebo. No severe adverse events were reported, and adverse 
events that were reported were similar in the treatment and 
placebo groups in this study. A study in Zambia among 100 
malnourished children (half of whom were HIV-infected) 
aged 12–35 months reported a clinical response in 56% 
of HIV-uninfected children treated with nitazoxanide 
compared with 23% receiving placebo (494). However, 
among the children with HIV infection, no benefit was 
observed from nitazoxinide (clinical response in 8% treated 
with nitazoxanide compared with 25% receiving placebo). 
These results may be due to the short course (3 days) of therapy 
as retreatment for additional 3 days increased the number of 
responders. In a study in HIV-infected adults who had CD4 
counts >50 cells/mm3, 14 days of nitazoxanide resulted in 
71% (10 of 14) response using 500 mg twice daily and 90% 
(9 of 10) using 1000 mg twice daily, compared with 25% with 
placebo (495). The recommended dose for children is 100 mg 
orally twice daily for children aged 1–3 years and 200 mg 
twice daily for children aged 4–11 years. A tablet preparation 
(500 mg twice daily) is available for children aged >12 years. 
All medications should be administered with food.
Paromomycin, a nonabsorbable aminoglycoside indicated 
for the treatment of intestinal amebiasis, is effective for treat-
ing cryptosporidiosis in animal models but is not specifically 
approved for treatment of cryptosporidiosis in humans. A 
review and a meta-analysis of the two randomized controlled 
trials comparing paromomycin with placebo among adults with 
AIDS found the drug was no more effective than placebo in 
reducing diarrheal frequency or parasite burden (492,496,497), 
and a clinical response to paromomycin is rare in patients with 
CD4 count <100 cells/mm3. Therefore, data do not support a 
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recommendation for the use of paromomycin for cryptospo-
ridiosis (DII).
Azithromycin has demonstrated some activity against 
C. parvum infection in a limited number of HIV-infected 
children (498). An azithromycin regimen of 10 mg/kg/day 
on day 1, and 5 mg/kg/day on days 2–10 rapidly resolved 
enteric symptoms in three of four HIV-infected children 
with cryptosporidiosis (498). However, data are insufficient 
to recommend use of this drug to treat cryptosporidial infec-
tion (CIII).
Microsporidium
Albendazole has activity against many species of microspo-
ridia, but it is not effective against Enterocytozoon infections 
or V. corneae (499,500). Albendazole decreased diarrhea and 
sometimes eliminated the organism (498,500). Albendazole 
is recommended for initial therapy of intestinal and dissemi-
nated microsporidiosis caused by microsporidia other than 
Enterocytozoon bieneusi and V. corneae (AII).
Although two drugs, fumagillin and nitazoxanide, have been 
studied in small numbers of patients for treatment of 
Enterocytozoon bieneusi infection, neither has definitive 
evidence for efficacy in adequate and controlled trials. 
Fumagillin (Sanofi-Synthelabo Laboratories, Gentilly, France), 
a water-insoluble antibiotic made by Aspergillus fumigatus, and 
its synthetic analog TNP-470 (501) have each been used to 
treat microsporidiosis in animals and humans. In a placebo-
controlled study of immuno compromised adults (including 
HIV-infected adults) with Enterocytozoon bieneusi microsporidi-
osis, fumagillin (20 mg/dose orally three times daily for 2 weeks) 
was associated with decreased diarrhea and clearance of 
microsporidial spores, which was not observed in placebo 
patients (501). No data are available on use of fumagillin or 
TNP-470 among HIV-infected children, and neither drug is 
available in the United States. Data are insufficient to make 
recommendations on the use of these drugs in children (CIII). 
One report indicated that treatment with nitazoxanide for 
60 days might resolve chronic diarrhea caused by Enterocytozoon 
bieneusi in the absence of antiretroviral therapy (502), but this 
effect was minimal among patients with low CD4 counts and 
therefore may be of limited utility (CIII).
Keratoconjunctivitis caused by microsporidia among HIV-
infected adults responds to topical therapy with investigational 
fumagillin eye drops prepared from Fumidil-B® (fumagillin 
bicylohexylammonium, a commercial product used to control 
a microsporidial disease of honeybees) in saline (to achieve a 
concentration of 70 µg/mL of fumagillin) (BII) (503). The 
combination of albendazole and fumagillin has demonstrated 
consistent activity against microsporidia in vitro and is recom-
mended for ocular infections, in addition to topical therapy, 
because microsporidia may remain systemically despite clear-
ance from the eye with topical therapy alone (BIII) (504).
Metronidazole and atovaquone are not active in vitro or in 
animal models and should not be used to treat microsporidi-
osis (EII).
Monitoring and Adverse Events, Including IRIS
Patients should be closely monitored for signs and symptoms 
of volume depletion, electrolyte and weight loss, and malnutri-
tion. In severely ill patients, total parenteral nutrition may be 
indicated (BIII).
Nitazoxanide has not been associated with substantial side 
effects. Albendazole side effects are rare but hypersensitivity 
(e.g., rash, pruritis, fever), neutropenia (reversible), CNS effects 
(e.g., dizziness, headache), GI disturbances (e.g., abdominal 
pain, diarrhea, nausea, vomiting), hair loss (reversible), and 
elevated hepatic enzymes (reversible) have been reported. Dose-
related bone marrow toxicity is the principal adverse effect of 
fumagillin, with reversible thrombocytopenia and neutropenia 
being the most frequent adverse events; topical fumagillin has 
not been associated with substantial side effects.
IRIS has not been described in association with treatment of 
cryptosporidiosis or with treatment for Enterocytozoon bieneusi 
or non-Enterocytozoon bieneusi microsporidiosis.
Management of Treatment Failure
The only feasible approaches to managing treatment failure 
are supportive treatment and optimization of ART to achieve 
full virologic suppression (AIII).
Prevention of Recurrence
No pharmacologic interventions are known to be effective 
in preventing recurrence of cryptosporidiosis or microsporidi-
osis. However, treatment for ocular microsporidiosis should 
be continued indefinitely because recurrence or relapse might 
follow treatment discontinuation (BIII).
Discontinuing Secondary Prophylaxis
Not applicable.
Malaria
Epidemiology
Malaria is an acute and chronic disease caused by obligate, 
intracellular protozoa of the genus Plasmodium. In 2005, CDC 
received reports of 1528 cases of malaria in the United States; 
of these, patient age was known for 1460, and 276 (18.9%) 
occurred in persons aged <18 years (505). For 220 pediatric 
patients aged <18 years for whom malarial species was known, 
most infections were caused by P. falciparum (70.9%) and P. 
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vivax (19.5%) (505). Of 231 children for whom country of 
exposure was known, 76% of malarial infections were acquired 
in Africa, 16% in Asia and the Middle East, and 6.1% in the 
Americas (505).
Most (82%) malaria becomes symptomatic within 30 
days after arrival in the United States; 99% of malaria cases 
become symptomatic within 1 year. Typically, 75% of U.S. 
travel-associated malaria occurs in persons who have not taken 
appropriate malaria chemoprophylaxis. Approximately 50% 
of infections among U.S. citizens are acquired during visits to 
friends and relatives in malaria-endemic regions (505). U.S.-
born children of immigrants returning to visit family are at 
highest risk for malaria-associated death. In 2005, refugees or 
immigrants accounted for 28.3% of U.S. pediatric malaria 
cases, and the proportion of malaria among refugees and immi-
grants has not changed in the past decade (505–508).
No reliable data exist on the prevalence of HIV infection 
among immigrant and refugee children resettling in the United 
States because children aged <15 years are exempt from manda-
tory screening. Underlying HIV prevalence rates in children 
relocating to the United States are assumed to reflect the 
overall rates of HIV in the migrating population. For example, 
Somali refugees have very low rates of HIV, whereas rates in 
Central and West Africa are substantially higher. Presumably, 
children at risk for coinfection with HIV and malaria, par-
ticularly asymptomatic children or those with unrecognized 
disease, would be highest in populations where the underlying 
prevalence of both HIV and malaria are excessive (i.e., West, 
Central, and portions of East Africa).
Clinical Manifestations
In contrast to data suggesting increased frequency of both 
parasitemia and clinical malaria in HIV-infected adults 
(509,510), studies in young HIV-infected children in malaria-
endemic areas usually have not found increased frequency or 
density of parasitemia with HIV coinfection (511–517), with 
one exception. Parasite density in children aged <5 years was 
higher in those with HIV infection than in those without 
HIV infection in Uganda (518). Additionally, most studies 
have not found malarial episodes to be more frequent or to 
present differently in HIV-infected than uninfected children 
(511,513). However, one study found that HIV-infected 
children aged >1 year may be more likely to have severe 
or complicated malaria (516). A study in Kenya suggested 
that HIV-exposed children aged <2 years (regardless of their 
infection status) were more likely than children without HIV 
exposure to have severe anemia with malarial episodes (517). 
Published studies on HIV/malaria coinfection have focused on 
adults and younger HIV-infected children; whether data from 
such studies applies to older HIV-infected children is uncertain. 
In a study in Uganda, HIV-infected persons aged >5 years 
with lower CD4 counts (<200 cells/mm3) had higher parasite 
counts during clinical malaria (518).
Signs and symptoms of malaria vary and depend on previ-
ous exposure (partial immunity), age of onset, and species of 
infecting organism but do not differ by HIV infection status 
in children. Fever is the most common symptom. In children, 
nonspecific symptoms predominate and may include chills, 
sweating, headache, myalgia, malaise, nausea, vomiting, diar-
rhea, and cough (519,520). These symptoms might increase 
the potential for misdiagnosis as a viral syndrome, upper 
respiratory tract infection, or gastroenteritis. Two thirds of all 
malaria in children in an area where malaria is nonendemic 
was misdiagnosed; children had two to four clinical visits 
before malaria was diagnosed (508).
Non-P. falciparum will be responsible for 75% of malaria 
diagnoses in nonimmune persons >30 days after they return 
to or travel to the United States from regions with malaria.
In contrast, the epidemiology in partially immune children 
may vary considerably. In one study, 60% of children migrat-
ing from malaria-holoendemic regions were smear-positive 
for P. falciparum 1 month after arrival in the United States 
(521). Since these data were collected, CDC has issued guid-
ance to organizations resettling refugees to the United States 
to presumptively treat all refugees from sub-Saharan Africa, 
except under special circumstances, before they depart for 
the United States. This treatment should decrease malaria 
rates among refugees but does not completely eliminate risk 
because predeparture treatment with drugs effective against 
blood-stage parasites do not eliminate liver-stage parasites. 
However, nonrefugee immigrants from similar areas do not 
receive this presumptive therapy and are at greater risk for 
clinical manifestations of malaria after arrival in the United 
States. Therefore, children who have recently migrated from 
regions where malaria is highly endemic should be either pre-
sumptively treated for malaria or tested postarrival for malaria 
infection. CDC guidance can be found at http://www.cdc.
gov/ncidod/dq/health.htm.
Chronic symptoms of splenomegaly, fever, and thrombocy-
topenia are highly specific for malaria in immigrant children 
and need appropriate evaluation (519,522). Congenital malaria 
is rare but should be considered in febrile neonates whose 
mothers migrated from areas where malaria is endemic; how-
ever, empiric therapy should not be administered without a 
diagnosis to febrile neonates of recent immigrants (519).
Diagnosis
Malaria is diagnosed by microscopic examination of a 
patient’s blood. A Giemsa-stained thick blood smear is the 
most sensitive smear technique for detecting infection, with 
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a thin blood smear used for accurate parasite speciation. In 
nonimmune persons, because symptoms may develop before 
parasitemia is detectable, several blood-smear examinations 
taken at 12- to 24-hour intervals may be needed to positively 
rule out malaria in symptomatic patients. The sensitivity and 
specificity of blood smear depends substantially on the labora-
torian’s skills. Assistance with microscopic diagnosis of malaria 
is available through state public health departments and the 
CDC Division of Parasitic Diseases diagnostic service (http://
www.dpd.cdc.gov/dpdx).
Although blood smear examination remains the gold stan-
dard for laboratory confirmation of malaria, FDA has approved 
the Binax Now® Malaria Test, a rapid malaria antigen-capture 
assay, for use in clinical diagnosis of symptomatic malaria in 
children and adults. This test, which uses a monoclonal anti-
body to histidine-rich protein 2 to detect P. falciparum, and 
a monocloncal antibody aldolase to detect all malaria species, 
can be performed within 15 minutes. The studies presented 
to FDA show specificity approaching 100% for all malaria 
and a sensitivity of >95% for P. falciparum and 85%–95% for 
P. vivax. However, sensitivity for P. ovale, a less common form 
of human malaria, probably does not exceed 70%. Although 
this test performs well in symptomatic persons, preliminary 
data suggest poor performance of rapid diagnostic tests, includ-
ing the Binax Now® Malaria Test for screening asymptomatic 
persons for malaria (523,524). Similarly, among asymptomatic 
immigrants, the sensitivity of a single blood smear is relatively 
poor (<50%) (523,524). Specific guidelines for laboratory 
diagnosis are summarized elsewhere and are available at the 
CDC malaria website (http://www.cdc.gov/malaria).
Prevention Recommendations
Preventing Exposure
HIV-infected children, particularly immunosuppressed 
children, should be advised to use personal protective measures 
to prevent mosquito bites when traveling to malaria-endemic 
areas (525). Specifically, clothing can be impregnated with 
permethrin, effective for weeks, even through 10 washings 
(AI). Long-acting DEET mosquito repellents (30% concen-
tration) are practical and 99% effective when combined with 
permethrin-treated clothing (AI). DEET should be applied 
onto young children by caregivers and usually should not be 
applied to young children’s hands (AIII). Specific instructions 
by providers on product purchasing and use are invaluable. 
Insecticide-treated bed nets are inexpensive and readily avail-
able in countries with endemic malaria. All children, regardless 
of their HIV infection status, should sleep under an insecticide-
treated bed net when traveling in malaria-endemic areas. 
Primary Prophylaxis
U.S.-born children of immigrant parents traveling to 
malaria-endemic regions are at especially high risk for malaria 
(525). Child immigrants, or second-generation immigrant 
children whose caregivers are from malaria-endemic areas, are 
likely to travel to high-risk destinations and be more suscep-
tible than their caregivers because of lack of previous malaria 
exposure. These children and their caregivers are at especially 
high risk for acquiring malaria. Children who will be traveling 
to malaria-endemic regions should receive pretravel counseling 
on avoiding insects and appropriate chemoprophylaxis (AII) 
(526,527). Recommendations for chemoprophylaxis are the 
same for HIV-infected persons as for noninfected persons 
and are available at the CDC website (http://www.cdc.gov/
malaria).
Potential exists for antiretroviral and antimalarial drug-drug 
interactions. Specifically, mefloquine significantly decreases 
steady-state ritonavir area-under-the-curve plasma levels by 
31%. In children receiving a boosted PI regimen with preex-
isting moderate resistance, this decrease may be significant. In 
addition, antimalarial medications may need special prepara-
tion, and some are not easily delivered to children. Therefore, 
patients planning to travel to malaria-endemic areas are advised 
to visit a travel medicine specialist with training and experience 
in pediatrics at least 2 weeks before departure (AII).
Although TMP-SMX prophylaxis, in combination with use 
of bed nets, resulted in >90% reduction of clinical malaria 
in nonholoendmic areas in one study (528), CDC does not 
recommend TMP-SMX as an antimalarial prophylactic regi-
men. HIV-infected travelers must not rely on TMP-SMX for 
chemoprophylaxis against malaria because TMP–SMX has 
not been studied in areas of high malaria transmission, and 
TMP–SMX most likely will not provide adequate protection 
(DIII).
Discontinuing Primary Prophylaxis
Travel-related chemoprophylaxis with chloroquine, meflo-
quine, and doxycycline usually should be discontinued 4 weeks 
after departure from a malaria-endemic area because these 
drugs are not effective against malarial parasites developing in 
the liver and kill the parasite only once it has emerged to infect 
the red blood cells. Atovaquone-proguanil should be discon-
tinued 1 week after departure from malaria-endemic areas. 
Chemoprophylaxis is not 100% effective, and malaria should 
be included in the differential diagnosis of fever or other signs 
or symptoms consistent with malaria in anyone who traveled 
to malaria-endemic areas during the previous 12 months.
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Treatment Recommendations
Treatment of Disease
Treatment of malaria is based on the severity of disease, 
patient’s age at onset, parasite species, and known resistance 
patterns (AI). HIV infection status does not affect choice of 
therapy (AII), and no recommendations exist for alterna-
tive dosing of antimalarial drugs in HIV-infected persons. 
Whether response to antimalarial treatment differs in regard 
to HIV infection status is unclear, but it does not appear 
to be appreciably different in young children (BIII). HIV-
infected or HIV-exposed children frequently are excluded 
from drug efficacy trials because the children are receiving 
TMP–SMX prophylaxis. Published studies have reported 
conflicting results, have used older antimalarials, or were 
not adequately powered to answer this question (529–531). 
Treatment dosing for adolescents and children is provided 
in Table 4.
P. falciparum
Uncomplicated chloroquine-sensitive P. falciparum malaria 
should be treated with chloroquine. The recommended treatment 
options for uncomplicated chloroquine-resistant P. falciparum 
in the United States are atovaquone-proguanil (Malarone®), 
quinine with clindamycin or doxycycline (in children 
aged >8 years), or mefloquine (Lariam®) (AI). For dosages, refer 
to the CDC website above. It is imperative that the clinician 
choose a medication according to known sensitivity patterns 
from the area where the malaria was acquired.
The current drug of choice for uncomplicated chloroquine-
resistant P. falciparum malaria is atovaquone-proguanil, which is 
FDA-approved for use in children weighing >5 kg, is well toler-
ated, has a wide therapeutic window, and provides simple dosing 
(pediatric tablets are available) (AIII). Although mefloquine is 
FDA-approved for persons aged >6 months, pediatric tablets are 
not available. However, mefloquine is the only treatment choice 
for uncomplicated chloroquine-resistant P. falciparum malaria 
in children weighing <5 kg.
Severe P. falciparum should be treated with IV quinidine 
gluconate (or IV quinine when available). Duration of qui-
nine/quinidine therapy is typically 3 days with clindamycin, 
or doxycycline, continued for 7 days (AI). IV quinidine can 
cause hypoglycemia, ventricular arrhythmia, and QT prolonga-
tion; close monitoring, including telemetry, is required during 
infusion. Increasingly, hospital pharmacies do not always stock 
quinidine. Ritonavir inhibits quinidine metabolism and is 
therefore contraindicated in patients being treated with quini-
dine. An alternative is artesunate, which is available from CDC 
as an investigational new drug protocol (532). When signs or 
symptoms exist of severe disease, especially with indicators of a 
poor prognosis (including clinical features of impaired level of 
consciousness, respiratory distress, jaundice, seizures, or shock 
or laboratory features of hypoglycemia, elevated bilirubin, 
acidosis, elevated liver aminotransferase levels, or renal insuf-
ficiency), a tropical medicine specialist should be consulted. For 
artesunate release or additional assistance, contact the 24-hour 
CDC malaria hotline at 770-488-7788 during the day and 
770-488-7100 after hours and on weekends and holidays.
P. vivax, P. ovale, P. malariae
The medication of choice for non-P. falciparum malaria 
is chloroquine; the parasite usually is sensitive to this drug 
(AI). Chloroquine usually is well tolerated. The most com-
mon reaction is self-limited itching (2%). However, among 
persons of African descent, the rate of this reaction is sub-
stantially higher (50%). In certain areas—most notably in 
New Guinea—P. vivax has known high rates of chloroquine 
resistance. A patient infected with known or suspected chlo-
roquine-resistant P. vivax malaria should receive an alternative 
first-line agent (i.e., quinine plus clindamycin or doxycycline, 
atovaquone-proguanil, mefloquine). Both P. vivax and P. ovale 
have an intrahepatic stage (hypnozoite) that is not treated 
with the medications mentioned for the acute blood stage. To 
prevent relapse of P. vivax or P. ovale infection, patients should 
receive presumptive antirelapse therapy with primaquine after 
the primary treatment for the blood stage (AI). Glucose-6-
phosphate dehydrogenase deficiency must be excluded before 
any use of primaquine because of the risk for severe hemolytic 
anemia.
Unknown species
When reliable identification of the malaria species is not pos-
sible or in a severely ill person, clinicians always should treat for 
the worst-case scenario of chloroquine-resistant P. falciparum 
malaria (AIII). PCR assays are now commercially available to 
speciate when microscopy is not sufficient. Assistance with 
speciation also is available from state public health depart-
ments and the CDC Division of Parasitic Diseases diagnostic 
service (http://www.dpd.cdc.gov/dpdx). After completion 
of initial therapy, knowing the malaria species is important 
because presumptive antirelapse therapy is necessary for P. ovale 
and P. vivax.
Monitoring and Adverse Events, Including IRIS
Severe malaria commonly induces hypoglycemia in children, 
especially when treated with IV quinine/quinidine because of 
the inhibition of gluconeogenesis and induction of endogenous 
insulin production. Therefore, use of a crystalloid solution 
containing glucose for fluid maintenance is prudent while 
closely monitoring glucose levels until IV quinine/quinidine 
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therapy has been completed. Monitoring glucose is especially 
important for infants and for persons with altered mental sta-
tus. Cardiac and intensive-care monitoring is recommended 
because quinine/quinidine can cause hypotension and may 
widen the QRS interval. Another common (50%–75%) 
adverse reaction to quinine is tinnitus, although this usually 
resolves after treatment. HIV-infected children may have more 
hematologic side effects, particularly neutropenia and anemia, 
following antimalarial therapy. IRIS caused by malaria has not 
been reported.
Management of Treatment Failure
Treatment failure with P. falciparum among children receiving 
a full course of appropriate antimalarial therapy occurs uncom-
monly. Patients should be monitored for clinical response and 
for signs of recrudescence after therapy completion. Published 
studies do not have the power to detect a difference in treat-
ment outcomes between HIV-infected and HIV-uninfected 
children (529,530). Relapse of P. vivax and P. ovale can occur 
from the dormant (hypnozoite) liver form but is less common 
with primaquine treatment. Malaria medications purchased in 
sub-Saharan Africa or Southeast Asia may be counterfeit (533). 
When treatment failure occurs, malaria speciation should be 
confirmed, as should the geography of where the malaria was 
acquired. Retreatment with an appropriate first-line regimen 
should be given. Discussion with a tropical medicine expert or 
a call to the CDC malaria hotline is appropriate when complex 
situations arise.
Prevention of Recurrence
Except for reactivation of P. vivax and P. ovale hypnozoites, 
malaria, once successfully treated, does not recur. Malaria 
infection does not infer protective immunity and continued 
exposure to malaria parasites can result in repeated infection.
Discontinuing Secondary Prophylaxis
Not applicable.
Toxoplasmosis
Epidemiology
The major mode of transmission of Toxoplasma gondii 
infection among infants and young children is congenital, 
occurring almost exclusively among neonates born to women 
who sustain primary Toxoplasma infection during pregnancy. 
The estimated incidence of congenital toxoplasmosis in the 
United States is one case per 1,000–12,000 live-born infants 
(534,535). The seroprevalence of T. gondii in U.S.-born per-
sons aged 12–49 years declined from 14.1% in the National 
Health and Nutrition Examination Survey 1988–1994 to 9.0% 
in 1999–2004 (536). Older children, adolescents, and adults 
typically acquire Toxoplasma infection by eating poorly cooked 
meat that contains parasitic cysts or by unintentionally ingest-
ing sporulated oocysts in soil or contaminated food or water 
(537). Cats are the only definitive host for T. gondii. However, 
cats excrete sporulated oocysts in their feces only transiently 
after initial infection, and studies have failed to show a cor-
relation between cat ownership and Toxoplasma infection in 
humans. Indeed, Toxoplasma infection in humans in the United 
States has declined despite increased cat ownership (537).
The overall risk for maternal-fetal transmission in HIV-
uninfected women who acquire primary Toxoplasma infection 
during pregnancy is 29% (95% confidence interval [CI]: 
25%–33%) (538). The risk for congenital infection is low 
among infants born to women who become infected dur-
ing the first trimester (range: 2%–6%) but increases sharply 
thereafter, with a risk as high as 81% for women acquiring 
infection during the last few weeks of pregnancy (538,539). 
Infection of the fetus in early gestation usually results in more 
severe disease than does infection late in gestation.
The prevalence of latent Toxoplasma infection among women 
with and without HIV infection in the United States was 
assessed in a cross-sectional study of 2525 nonpregnant women 
enrolled in the Women’s Interagency Health Study (540). The 
prevalence of Toxoplasma seropositivity was 15% and did not 
differ by HIV infection status. A few cases of mother-to-infant 
transmission of Toxoplasma in HIV-infected women have been 
reported (541–545). Prenatal transmission of T. gondii from 
women without HIV infection who have chronic Toxoplasma 
infection acquired before pregnancy is rare (546). However, 
with HIV coinfection, perinatal transmission of Toxoplasma 
has been observed among women with chronic Toxoplasma 
infection (transmission rate: <4%), presumably because of 
reactivation of replication of the organism among women with 
severe immune suppression (541–544).
CNS infection with T. gondii was reported as an AIDS-
indicator condition in <1% of pediatric AIDS cases before 
the advent of HAART (547). During the HAART era, this 
condition is rarely encountered in U.S. children with HIV 
infection. Development of CNS toxoplasmosis in HIV-infected 
children during the HAART era occurred in 0.2% (five of 
2767) of those enrolled in the long-term follow-up study 
PACTG 219c (3). In most cases of Toxoplasma encephalitis 
(TE) among HIV-infected children, infection is considered 
to have occurred in utero. More rarely, it has been reported 
among older HIV-infected children, who presumably had 
primary acquired toxoplasmosis (548–550). As in adults, the 
greatest risk is among severely immunosuppressed children 
(e.g., CD4 count <50 cells/mm3).
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Clinical Manifestations
In studies of nonimmuno compromised infants with congeni-
tal toxoplasmosis, most infants (70%–90%) are asymptomatic 
at birth. However, most asymptomatic children develop late 
sequelae (e.g., retinitis, visual impairment, and intellectual 
or neurologic impairment), with onset of symptoms ranging 
from several months to years after birth. Symptoms in new-
borns take either of two presentations: generalized disease or 
predominantly neurologic disease. Symptoms might include 
maculopapular rash; generalized lymphadenopathy; hepatos-
plenomegaly; jaundice; hematologic abnormalities, including 
anemia, thrombocytopenia, and neutropenia; and substantial 
CNS disease, including hydrocephalus, intracerebral calcifica-
tion, microcephaly, chorioretinitis, and seizures (551).
Similarly, toxoplasmosis acquired after birth is most often 
initially asymptomatic. When symptoms occur, they are 
frequently nonspecific and can include malaise, fever, sore 
throat, myalgia, lymphadenopathy (cervical), and a mono-
nucleosis-like syndrome featuring a maculopapular rash and 
hepatosplenomegaly.
TE should be considered among all HIV-infected children 
with new neurologic findings. Although focal findings are 
more typical, the initial presentation can vary and reflect dif-
fuse CNS disease. Other symptoms include fever, reduced 
alertness, and seizures.
Isolated ocular toxoplasmosis is rare and usually occurs 
in association with CNS infection. As a result, a neurologic 
examination is indicated for children in whom Toxoplasma 
chorioretinitis is diagnosed. Ocular toxoplasmosis appears as 
white retinal lesions with little associated hemorrhage; visual 
loss might occur initially.
Less frequent presentations among HIV-infected children 
with reactivated chronic toxoplasmosis include systemic 
toxoplasmosis, pneumonitis, hepatitis, and cardiomyopathy/
myocarditis (544,552).
Diagnosis
HIV-infected women might be at increased risk for trans-
mitting T. gondii to their fetuses, and serologic testing for 
Toxoplasma should be performed for all HIV-infected pregnant 
women. All infants whose mothers are both HIV-infected 
and seropositive for Toxoplasma should be evaluated for con-
genital toxoplasmosis (90). Congenital toxoplasmosis can 
be diagnosed by EIA or an immunosorbent assay to detect 
Toxoplasma-specific IgM, IgA, or IgE in neonatal serum within 
the first 6 months of life or persistence of specific IgG antibody 
beyond age 12 months (553–556). IgA might be more sensi-
tive for detecting congenital infection than IgM or IgE (554). 
However, approximately 20%–30% of infants with congenital 
toxoplasmosis will not be identified during the neonatal period 
with IgA or IgM assays (555).
Serologic testing is the major method of diagnosis, but inter-
pretation of assays often is confusing and difficult. Using the 
services of a specialized reference laboratory that can perform 
serology, isolation of organisms, and PCR and offers assistance 
in interpreting results, especially when attempting to diagnose 
congenital toxoplasmosis, can be helpful (554).
Additional methods that can be used to diagnose infection 
in the newborn include isolation of the Toxoplasma parasite 
by mouse inoculation or inoculation in tissue cultures of CSF, 
urine, placental tissue, amniotic fluid, or infant blood. T. gondii 
DNA can be detected by PCR performed on clinical speci-
mens (e.g., white blood cells, CSF, amniotic fluid, or tissue) 
in a reference laboratory (554,555). If a possible diagnosis of 
congenital toxoplasmosis at delivery is uncertain, the neonate 
should be evaluated, including ophthalmologic, auditory, and 
neurologic examinations; lumbar puncture; and imaging of 
the head (either CT or magnetic resonance imaging [MRI] 
scans) to determine whether hydrocephalus or calcifications 
are present.
In the United States, routine Toxoplasma serologic screen-
ing of HIV-infected children whose mothers do not have 
toxoplasmosis is not recommended because of its low preva-
lence. However, in regions with high incidence of Toxoplasma 
infection (>1% per year), serologic testing might be selectively 
considered for HIV-infected children aged >12 months. HIV-
infected adolescents without previous Toxoplasma infection 
should undergo serologic testing.
CNS toxoplasmosis is presumptively diagnosed on the basis 
of clinical symptoms, serologic evidence of infection, and 
presence of a space-occupying lesion on imaging studies of the 
brain (557). TE rarely has been reported in persons without 
Toxoplasma-specific IgG antibodies; therefore, negative serology 
does not definitively exclude that diagnosis. CT of the brain 
might indicate multiple, bilateral, ring-enhancing lesions in 
CNS toxoplasmosis, especially in the basal ganglia and cerebral 
corticomedullary junction. MRI is more sensitive and will 
confirm basal ganglia lesions in most patients (558). F-fluoro-
2-deoxyglucose–positive emission tomography reportedly is 
helpful in adults in distinguishing Toxoplasma abscesses from 
primary CNS lymphoma, but the accuracy is not high, and 
this test is not widely available.
Definitive diagnosis of TE requires histologic or cytologic 
confirmation by brain biopsy, which might demonstrate lep-
tomeningeal inflammation, microglial nodules, gliosis, and 
Toxoplasma cysts. Brain biopsy is reserved by some experts for 
patients who do not respond to specific therapy.
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Prevention Recommendations
Preventing Exposure
All HIV-infected children and adolescents and their care-
givers should be counseled about sources of T. gondii infection. 
They should be advised not to eat raw or undercooked meat, 
including undercooked lamb, beef, pork, or venison (BIII). All 
meat (lamb, beef, pork, and chicken) should be cooked to an 
internal temperature of 165°F–170°F (559) until it is no longer 
pink inside. Hands should be washed after contact with raw meat 
and after gardening or other contact with soil; in addition, fruits 
and vegetables should be washed well before being eaten 
raw (BIII). Stray cats should not be handled or adopted; a cat 
already in the household should be kept inside and the litter box 
changed daily, preferably by an HIV-negative, nonpregnant 
person (BIII). Cats should be fed only canned or dried com-
mercial food or well-cooked table food, not raw or undercooked 
meats (BIII). Patients need not be advised to part with their cats 
or to have their cats tested for toxoplasmosis (EII).
Preventing First Episode of Disease
Toxoplasma-seropositive adolescents and adults who have 
a CD4 count of <100 cells/mm3 should be administered 
prophylaxis against TE (AII) (435). Specific levels of immu-
nosuppression that increase the risk for TE in children are less 
well defined. Toxoplasma-seropositive children with CD4 <15% 
should be administered prophylaxis against TE (AIII). For chil-
dren aged >6 years, the same absolute CD4 cell count level used 
for HIV-infected adults can be used (AIII).
In HIV-infected adolescents and adults, the double-strength 
tablet daily dose of TMP-SMX recommended as the preferred 
regimen for PCP prophylaxis is effective TE prophylaxis (AII) 
(435). TMP–SMX, one double-strength tablet three times 
weekly (or 3 consecutive days a week), is an alternative (BIII). 
Data are limited on the efficacy of TMP–SMX as a primary 
preventive agent for TE in children. However, data on adults 
suggest it also is the regimen of choice in children (BIII) 
(Table 1). If patients cannot tolerate TMP–SMX, the recom-
mended alternative is dapsone-pyrimethamine, which also is 
effective against PCP (BI) (560,561). Atovaquone with or 
without pyrimethamine also can be considered (CIII). Single-
drug prophylaxis with dapsone, pyrimethamine, azithro-
mycin, or clarithromycin cannot be recommended (DII). 
Aerosolized pentamidine does not protect against TE and is 
not recommended (EI) (435,436). Toxoplasma-seronegative 
adults and adolescents who are not taking a PCP-prophylactic 
regimen known to be active against TE should be retested for 
IgG antibody to Toxoplasma when their CD4 count declines to 
<100 cells/mm3 to determine whether they have seroconverted and 
are therefore at risk for TE (CIII). Severely immunosuppressed 
children who are not receiving TMP–SMX or atovaquone 
who are seropositive for Toxoplasma should be administered 
prophylaxis for both PCP and toxoplasmosis (i.e., dapsone plus 
pyrimethamine) (BIII).
Discontinuing Primary Prophylaxis
Prophylaxis against TE should be discontinued among HIV-
infected adults and adolescents who have responded to HAART 
with an increase in CD4 count to >200 cells/mm3 for >3 months 
(AI). Multiple observational studies (447,562,563) and two 
randomized trials (564,565) have reported that primary pro-
phylaxis can be discontinued with minimal risk for TE recrudes-
cence among patients who have responded to HAART with an 
increase in CD4 count from <200 cells/mm3 to >200 cells/mm3 
for >3 months. Although patients with CD4 counts of <100 cells/
mm3 are at greatest risk for TE, the risk for TE when CD4 
count increases to 100–200 cells/mm3 has not been studied 
as rigorously as an increase to >200 cells/mm3. Thus, the recom-
mendation specifies discontinuing prophylaxis after an increase 
to >200 cells/mm3. Discontinuing primary TE prophylaxis is 
recommended because prophylaxis adds limited disease preven-
tion for toxoplasmosis and because discontinuing drugs reduces 
pill burden, the potential for drug toxicity, drug interactions, 
selection of drug-resistant pathogens, and cost. Data do not exist 
on the safety of discontinuing primary TE prophylaxis for HIV-
infected children whose CD4 percentage rises above 15%. Data 
on adults suggest discontinuation of TMP-SMX may be safe 
once a child responds to HAART with a sustained rise in CD4 
percentage above 15%; for children aged >6 years, the same CD4 
count used for HIV-infected adults can be used (CIII).
Prophylaxis should be reintroduced in HIV-infected adults 
and adolescents if the CD4 count decreases to <100–200 cells/
mm3 (AIII) or the CD4 percentage falls below 15% for HIV-
infected children (BIII).
Treatment Recommendations
Treatment of Disease
Pregnant women with suspected or confirmed primary 
toxoplasmosis and newborns with possible or documented 
congenital toxoplasmosis should be managed in consultation 
with an appropriate specialist. Although controversy exists 
about the efficacy of treating pregnant women who have acute 
toxoplasmosis in an attempt to prevent infection of the fetus 
(566), most experts would recommend such therapy (BII) (90). 
For an HIV-infected woman with a symptomatic Toxoplasma 
infection during pregnancy, empiric therapy of the newborn 
should be strongly considered, regardless of whether the mother 
was treated during pregnancy (BIII).
The preferred treatment for congenital toxoplasmosis is 
pyrimethamine combined with sulfadiazine, with supplementary 
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leucovorin (folinic acid) to minimize pyrimethamine-associated 
hematologic toxicity (AII) (551,567). Although the optimal 
duration of therapy is undefined, the recommended duration 
of treatment of congenital toxoplasmosis for infants without 
HIV infection is 12 months (AII) (567).
For HIV-uninfected children who have mild congenital 
toxoplasmosis, certain experts alternate pyrimethamine/sulfa-
diazine/folinic acid monthly with spiramycin during months 
7–12 of treatment (CIII). However, for children with moder-
ate to severe disease and children with HIV infection, the full 
12-month regimen of pyrimethamine/sulfadiazine should be 
administered (AII).
HIV-infected children with acquired CNS, ocular, or sys-
temic toxoplasmosis should be treated with pyrimethamine 
and leucovorin plus sulfadiazine (AI). Acute therapy should 
be continued for 6 weeks, assuming clinical and radiologic 
improvement (BII). Longer courses of treatment might be 
required for extensive disease or poor response after 6 weeks. 
The primary alternative for sulfadiazine in patients who develop 
sulfonamide hypersensitivity is clindamycin, administered with 
pyrimethamine and leucovorin (AI). Azithromycin instead 
of clindamycin also has been used with pyrimethamine and 
leucovorin among sulfa-allergic adults, but this regimen has 
not been studied among children (CIII).
Another alternative in adults is atovaquone plus pyrimethamine 
and leucovorin, or atovaquone with sulfadiazine alone, or 
atovaquone as a single agent among patients intolerant to both 
pyrimethamine and sulfadiazine (BII); however, these regimens 
have not been studied in children (CIII). TMP-SMX alone 
has been used as an alternative to pyrimethamine-sulfadiazine 
in adults but not in children (CIII).
For isolated ocular toxoplasmosis in nonimmuno-
compromised hosts, TMP-SMX alone is as effective as 
pyrimethamine-sulfadiazine (568). However, these data have 
not been duplicated in HIV-infected persons; therefore, this 
regimen cannot be recommended for this group of patients 
(DIII).
Corticosteroids (e.g., dexamethasone or prednisone) are 
recommended for children with CNS disease when CSF 
protein is highly elevated (i.e., >1000 mg/dL) or with focal 
lesions with substantial mass effects (BIII). Because of the 
potential immunosuppressive effects of steroids, they should 
be discontinued as soon as possible.
Anticonvulsants should be administered to children with 
TE who have a history of seizures (AIII) but should not be 
administered prophylactically to children without a history of 
seizures (DIII). Anticonvulsants, if administered, should be 
continued at least through acute therapy.
Monitoring and Adverse Events, Including IRIS
Children with TE should be routinely monitored for clinical 
and radiologic improvement and for adverse effects of treat-
ment; changes in antibody titers are not useful for monitoring 
responses to therapy.
Toxoplasmosis-associated IRIS has been described rarely 
in HIV-infected adults and has not been described in HIV-
infected children (569).
Pyrimethamine can be associated with rash (including 
Stevens-Johnson syndrome) and nausea. The primary toxicity 
of pyrimethamine is reversible bone marrow suppression (i.e., 
neutropenia, anemia, and thrombocytopenia). A complete 
blood count should be performed at least weekly while the 
child is on daily pyrimethamine and at least monthly while 
on less-than-daily dosing (AIII). Leucovorin (folinic acid) 
always should be administered with pyrimethamine; increased 
doses of leucovorin might be required in the event of marrow 
suppression. Because of the long half-life of pyrimethamine, 
leucovorin should be continued 1 week after pyrimethamine 
has been discontinued.
Adverse effects of sulfadiazine include rash, fever, leukopenia, 
hepatitis, GI symptoms (e.g., nausea, vomiting, and diarrhea), 
and crystalluria. Clindamycin can be associated with fever, 
rash, and GI symptoms (e.g., nausea; vomiting; and diarrhea, 
including pseudomembranous colitis) and hepatotoxicity.
Drug interactions between anticonvulsants and antiretro-
virals should be evaluated. Patients receiving corticosteroids 
should be closely monitored for development of other OIs.
Management of Treatment Failure
Brain biopsy should be considered in the event of early 
clinical or radiologic neurologic deterioration despite adequate 
empiric treatment or in children who do not clinically respond 
to anti-Toxoplasma therapy after 10–14 days. For children who 
undergo brain biopsy and have confirmed histopathologic 
evidence of TE despite treatment, a switch to an alternative 
regimen as previously described should be considered (BIII).
Prevention of Recurrence
Patients who have completed initial therapy for acquired 
TE should be administered lifelong suppressive therapy (i.e., 
secondary prophylaxis or chronic maintenance therapy) (AI) 
(570,571) unless immune reconstitution occurs with antiret-
roviral therapy (Table 3). The combination of pyrimethamine 
plus sulfadiazine plus leucovorin is highly effective for this 
purpose (AI). A commonly used regimen for patients who 
cannot tolerate sulfa drugs is pyrimethamine plus clindamycin 
(BI); however, only the combination of pyrimethamine plus 
sulfadiazine provides protection against PCP as well (AII). Data 
on adults indicate atovaquone with or without pyrimethamine 
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also can be considered for children (CIII). Limited data sup-
port the use of TMP-SMX for secondary prophylaxis (572); 
this regimen should be used only for persons who do not 
tolerate pyrimethamine plus sulfadiazine or pyrimethamine 
plus clindamycin (CII).
Discontinuing Secondary Prophylaxis
Adults and adolescents receiving secondary prophylaxis for 
acquired TE are at low risk for recurrence of TE when they have 
successfully completed their initial therapy, continue to have 
no signs or symptoms of TE, and have a sustained increase in 
CD4 count of >200 cells/mm3 after HAART (e.g., >6 months) 
(562,563,565,573,574). Discontinuing chronic maintenance 
therapy in HIV-infected adolescents and adults who meet 
these criteria is a reasonable consideration (BI). Highest risk 
for relapse appears to occur within the first 6 months after 
stopping secondary prophylaxis. Certain specialists would 
obtain an MRI of the brain as part of their evaluation to 
determine whether discontinuing therapy is appropriate. The 
safety of discontinuing secondary prophylaxis after immune 
reconstitution with HAART among children has not been 
studied extensively. However, given the data in adults, clinicians 
caring for HIV-infected children aged 1–5 years can consider 
discontinuing secondary prophylaxis against T. gondii after they 
have completed TE therapy and >6 months of stable HAART 
and are asymptomatic and once the CD4 percentage has risen 
to >15% for >3 consecutive months. For children aged >6 years, 
the same CD4 count used in adults (CD4 >200 cells/mm3) 
also can be used (BIII). Prophylaxis should be reinstituted if 
these parameters are not met.
Viral Infections
Cytomegalovirus
Epidemiology
Infection with human cytomegalovirus (CMV) is common 
and usually inapparent; CMV can be acquired during infancy, 
early childhood, or adolescence. Transmission can occur verti-
cally from an infected woman to her offspring or horizontally 
by contact with virus-containing breast milk, saliva, urine, 
or sexual fluid or through transfusion of infected blood or 
transplantation of infected organs. During infancy and early 
childhood, infection usually occurs secondary to ingestion of 
infected breast milk or exposure to infected saliva or urine. 
Infection occurs at younger ages in locations where sanitation 
is less than optimal. Among adolescents, sexual transmission 
is the major mode of CMV acquisition.
Age-related prevalence of infection varies widely, depending 
on living circumstances and social customs. Breast-feeding, 
child-rearing practices, crowding, sanitation, and sexual 
behavior most likely influence age-related variations in CMV 
prevalence. Where rates of maternal seropositivity are high 
and breast-feeding is common, more than half of infants 
acquire CMV during the first year of life (575). Group care 
of children facilitates spread of CMV, especially in toddlers, 
and leads to higher prevalence of infection in children who 
attend child care centers and in their caregivers (576,577). In 
Africa, Asia, and Latin America, most children are infected by 
CMV before adolescence. In the United States and western 
Europe, the prevalence of antibody to CMV in adults from 
middle and upper socioeconomic strata is 40%–60%, whereas 
the prevalence in low-income adults is >80% (578). Overall, 
among U.S. women of childbearing age, the prevalence of 
CMV infection is 50%–80%, with the highest prevalence in 
women in lower socioeconomic strata (579,580). The preva-
lence of CMV infection among HIV-infected pregnant women 
is higher than in the general population, with approximately 
90% of HIV-infected pregnant women coinfected with CMV 
(581,582).
CMV is the most common congenitally transmitted infec-
tion, occurring in 0.2%–2.2% of live-born infants in the 
United States (583). Congenital (in utero) CMV infection 
occurs most commonly among infants born to women who 
have primary CMV infection during pregnancy. Following 
primary infection during pregnancy, the rate of transmis-
sion to the fetus is approximately 30%–40% (579,584). In 
comparison, the rate of congenital infection after nonprimary 
CMV infection usually is believed to be significantly lower 
(range: 0.15%–1.0%) (583,585,586). More recent studies 
demonstrate that in utero transmission of nonprimary maternal 
infection can occur because of reactivation of infection among 
women infected before pregnancy or reinfection with a differ-
ent CMV strain among CMV-seropositive women (587,588); 
these studies challenge the traditional understanding of trans-
mission risk and clinical outcomes following nonprimary 
maternal CMV infection.
CMV also can be transmitted during the intrapartum or 
postpartum periods from mother to infant. Up to 57% of 
infants whose mothers shed CMV at or around delivery 
become infected with CMV, and up to 53% of children who 
are breast-fed milk containing infectious virus can become 
CMV infected. Symptomatic CMV disease in the infant is 
much less common when CMV is acquired intrapartum or 
through breast-feeding than when acquired antenatally and 
occurs primarily in premature neonates.
HIV-infected women with CMV infection have a higher rate 
of CMV shedding from the cervix than do women without 
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HIV infection (52%–59% and 14%–35%, respectively) (589). 
The risk for mother-to-infant transmission of CMV may be 
higher among infants born to women dually infected with 
CMV and HIV. In one study of 440 infants born to HIV-
infected U.S. women, the overall rate of in utero infection was 
4.5% (11), higher than the <2% rate of in utero infection in 
the general U.S. population.
HIV-infected children appear to be at higher risk for CMV 
infection during early childhood than do HIV-uninfected 
children (11). The rate of CMV acquisition in HIV-infected 
children appears to be particularly high during the first 12 
months of life but remains higher among HIV-infected than 
HIV-uninfected children through age 4 years when they are 
exposed to CMV infection in other children in child care or 
school.
CMV disease occurs less frequently among HIV-infected 
children than HIV-infected adults but contributes substantially 
to morbidity and mortality. In the pre-antiretroviral era, CMV 
caused 8%–10% of pediatric AIDS-defining illness (590). Data 
in HIV-infected adults have shown a 75%–80% decrease in 
the incidence of new cases of CMV end-organ disease with the 
advent of antiretroviral therapy, with an incidence now esti-
mated to be <6 cases per 100 person-years (591). In a study of 
OIs in approximately 3000 children followed in PACTG stud-
ies during the pre-HAART era, the frequency of CMV retinitis 
was 0.5 cases per 100 child-years and, of other CMV disease, 
0.2 cases per 100 child-years (1). The rate varied significantly 
by CD4 percentage; the incidence of CMV retinitis was 1.1 
cases per 100 child-years in children with CD4 <15%, com-
pared with 0.1 case per 100 child-years in children with CD4 
>25%. In data from the same cohort during the HAART era, 
the overall rate of CMV retinitis was <0.5 per 100 child-years 
(3). In the Perinatal AIDS Collaborative Transmission Study, 
the incidence of nonocular CMV before and after January 
1997 (pre- and post-HAART eras) was 1.4 per 100 child-years 
and 0.1 per 100 child-years, respectively (4). Similarly, CMV 
retinitis declined from 0.7 to 0.0 per 100 child-years during 
the same period.
Symptomatic HIV-infected children coinfected with CMV 
have a higher rate of CMV viruria than do asymptomatic 
HIV-infected or HIV-exposed children. Overall, up to 60% of 
children with AIDS shed CMV. This compares with one third 
of HIV-infected children shedding CMV; 15%–20% of CMV-
infected, HIV-exposed but uninfected children; and <15% of 
CMV-infected infants not exposed to HIV (592).
Clinical Manifestations
Approximately 10% of infants with in utero CMV infec-
tion are symptomatic at birth with congenital CMV syn-
drome (CMV inclusion disease); mortality of children with 
symptomatic disease is as high as 30%. About half of neonates 
with symptomatic congenital CMV disease are small for gesta-
tional age; additional findings may include petechiae (76%), 
jaundice (67%), hepatosplenomegaly (60%), chorioretinitis 
(20%), microcephaly (53%), intracranial calcifications (55%), 
and hearing impairment (<65%) (593,594). Approximately 
90% of infants with symptomatic disease at birth who survive 
have late complications, including substantial hearing loss, 
mental retardation, chorioretinitis, optic atrophy, seizures, 
or learning disabilities (579). Although most children with 
in utero CMV infection do not have symptoms at birth, 
10%–15% are at risk for later developmental abnormali-
ties, sensorineural hearing loss, chorioretinitis, or neurologic 
defects.
HIV-infected children coinfected with CMV appear to have 
faster progression of HIV disease than do those without CMV 
infection (11,590,595). In one study from the pre-HAART 
era, 53% of infants coinfected with HIV and CMV had pro-
gression to AIDS or had died by age 18 months, compared 
with 22% of HIV-infected children without CMV infection; 
those with HIV/CMV coinfection also were more likely to 
have CNS manifestations (36% versus 9%). The relative risk 
for HIV disease progression in children coinfected with CMV 
compared with children without CMV was 2.6 (95% CI: 
1.1–6.0) (11).
CMV retinitis is the most frequent severe manifestation of 
CMV disease among HIV-infected children, accounting for 
approximately 25% of CMV AIDS-defining illnesses. CMV 
retinitis among young HIV-infected children is frequently 
asymptomatic and discovered on routine examination. Older 
children with CMV retinitis present similarly to adults, with 
floaters, loss of peripheral vision, or reduction in central vision. 
Diagnosis of CMV retinitis is based on clinical appearance 
with white and yellow retinal infiltrates and associated retinal 
hemorrhages. A more indolent, granular retinitis also can occur. 
HIV-infected children with CD4 counts <100 cells/mm3 are 
more likely than those with higher CD4 counts to develop 
CMV retinitis; however, CD4 count is less predictive of risk 
for CMV disease in young infants, and systemic and localized 
CMV disease can occur in HIV-infected infants with higher, 
age-adjusted CD4 counts (592,596).
End-organ CMV disease has been reported in the lung, 
liver, GI tract, pancreas, kidney, sinuses, and CNS (596–599). 
In children with extraocular CMV disease, predominantly 
nonspecific symptoms (e.g., fever, poor weight gain, and loss 
of developmental milestones with laboratory abnormalities of 
anemia, thrombocytopenia, and elevated lactic dehydrogenase) 
are initially observed, although the extent to which CMV or 
HIV infection themselves contribute to these findings is unclear 
(592). GI manifestations among HIV-infected children include 
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CMV colitis (the most common GI manifestation), oral and 
esophageal ulcers, hepatic involvement, ascending cholang-
iopathy, or gastritis. Odynophagia is a common presentation of 
CMV esophagitis, whereas abdominal pain and hematochezia 
frequently occur with CMV colitis. Sigmoidoscopy in CMV 
colitis is nonspecific, demonstrating diffuse erythema, submu-
cosal hemorrhage, and diffuse mucosal ulcerations. Esophageal 
or colonic ulcerations may cause perforation or hemorrhage.
The role of CMV in pulmonary disease among HIV-infected 
children is difficult to assess because it often is isolated with 
other organisms (e.g., P. jirovecii). Histologic evidence of CMV 
disease is needed to determine whether active disease is pres-
ent. CMV pneumonia is an interstitial process with gradual 
onset of shortness of breath and dry, nonproductive cough; 
auscultatory findings may be minimal.
CNS manifestations of CMV include subacute encephal-
opathy, myelitis, and polyradiculopathy (primarily observed 
in adults but rarely reported in children). The subacute or 
chronic encephalopathy of CMV can be difficult to differenti-
ate clinically from HIV dementia, with symptoms of confusion 
and disorientation attributable to cortical involvement. Focal 
signs can be attributed to lesions in the brainstem. CSF find-
ings are nonspecific and might indicate a polymorphonuclear 
predominance (>50% of patients), elevated protein (75%), 
and low glucose (30%). However, up to 20% of children with 
CMV CNS involvement have completely normal CSF indices. 
CMV also can cause a rapidly progressive, often fatal, CNS 
disease with defects in cranial nerves, nystagmus, and increas-
ing ventricular size (600).
Diagnosis
CMV infection (versus disease) can be difficult to differenti-
ate in HIV-infected children. Because of transplacental transfer 
of antibody from mother to child, a positive CMV antibody 
assay in an infant aged <12 months can indicate maternal infec-
tion but not necessarily infection of the infant. In an infant 
aged >12 months, a positive CMV antibody assay indicates 
previous infection with CMV but not necessarily active dis-
ease. In children of any age, a positive CMV culture or PCR 
indicates infection but not necessarily disease.
CMV can be isolated in cell culture from peripheral blood 
leukocytes, body fluids (e.g., urine), or tissues. Using centrif-
ugation-assisted shell vial culture amplification techniques, 
CMV can be detected within 16–40 hours of culture inocu-
lation. A positive blood buffy-coat culture establishes CMV 
infection and increases the likelihood that disease or symptoms 
were caused by CMV because children with positive blood 
cultures are at higher risk for end-organ disease.
Different methods have been used to detect viral antigen 
or DNA directly and to identify patients at risk for CMV 
disease, including detection of pp65 antigenemia, qualitative 
and quantitative PCR, and DNA hybridization. The DNA 
assays are more sensitive than buffy-coat or urine cultures for 
detecting CMV and can be used to identify patients at higher 
risk for clinically recognizable disease. CMV DNA detection in 
CSF by DNA PCR is highly sensitive for CMV CNS disease. 
Quantitative DNA PCR can be used as a marker of risk for 
disease and to monitor response to therapy (601).
Recovery of virus from tissues (e.g., endoscopically guided 
biopsies of GI or pulmonary tissue) provides evidence of disease 
in symptomatic patients. The limitation of this method is that 
detection of visible cytopathic effects in cell culture takes 1–6 
weeks. Staining of shell vial culture with CMV monoclonal 
antibodies or immunostaining for CMV antigens can allow 
earlier diagnosis of infection. Histopathology demonstrates 
characteristic “owl’s eye” intranuclear and smaller intracyto-
plasmic inclusion bodies in biopsy specimens; staining with 
CMV monoclonal antibodies or immunostaining for CMV 
antigens also can be done. The same procedures can be used 
on cells obtained from bronchoalveolar lavage.
Prevention Recommendations
Preventing Exposure
HIV-exposed infants and HIV-infected children, adolescents, 
and adults who are seronegative for CMV and require blood trans-
fusion should be administered only CMV antibody-negative or 
leukocyte-reduced cellular blood products in nonemergency 
situations (BIII).
Annual CMV antibody testing is recommended beginning 
at 1 year of age for CMV-seronegative HIV-infected infants 
and children who are severely immunosuppressed (e.g., CD4 
count <100 cells/mm3 or CD4 percentage <10%) (BII). 
Annual testing allows identification of children who have 
acquired CMV infection and might benefit from screening 
for retinitis.
HIV-infected adults and adolescents who are child care 
providers or parents of children in child care facilities should 
be informed that they are at increased risk for CMV infection 
(BI). Risk for CMV infection can be diminished by optimal 
hygienic practices (e.g., hand-washing) (AII).
Preventing First Episode of Disease
The primary method for preventing severe CMV disease is rec-
ognition of the early manifestations of the disease and preven-
tion of severe immunosuppression by treating with HAART. 
HIV-infected children aged <5 years who are CMV-infected 
and severely immunosuppressed (e.g., CD4 count <50 cells/
mm3 or CD4 percentage <5%) should have a dilated retinal 
examination performed by an ophthalmologist every 6 
months (AIII). Older children should be counseled to be 
Vol. 58 / RR-11 Recommendations and Reports 65
aware of floaters in the eye and visual changes, similar to the 
recommendation for adults (BIII). During the HAART era, 
CMV end-organ disease has diminished to such an extent that 
primary prophylaxis with antiviral agents in CMV and HIV 
coinfected people usually is not recommended (DIII). CMV 
end-organ disease is best prevented by antiretroviral therapy to 
maintain CD4 count >100 cells/mm3. If this is not possible, 
prophylaxis with valganciclovir can be considered for HIV-
infected adolescents who are CMV-seropositive, have a CD4 
count of <50 cells/mm3, and weigh enough to receive adult 
doses of valganciclovir (CIII).
Discontinuing Primary Prophylaxis
Because primary prophylaxis with antiviral agents in per-
sons coinfected with CMV and HIV is not recommended (as 
discussed above), no consideration of discontinuing primary 
prophylaxis is necessary.
Treatment Recommendations
Treatment of Disease
Treatment of newborns who have symptomatic congenital 
CMV disease involving the CNS with IV ganciclovir for 6 
weeks has been evaluated in a series of clinical trials conducted 
by the National Institute of Allergy and Infectious Diseases 
Collaborative Antiviral Study Group (602,603); all infants in 
these studies were HIV-uninfected. Infants receiving therapy 
cleared their urine of CMV by culture by the end of the 6-week 
treatment period, although all experienced a rebound in their 
viruria after antiviral discontinuation (602). In a phase III, 
randomized, controlled trial, infants receiving IV ganciclovir 
for 6 weeks were less likely to have hearing deterioration over 
the first 2 years of life than were infants receiving no antiviral 
therapy (603). Treated infants also had more rapid resolution 
of liver enzyme abnormalities and a greater degree of growth 
during the course of therapy. They also experienced fewer 
neurodevelopmental delays at 1 year of life than did non-
treated infants (604). However, approximately two thirds of 
the infants developed substantial neutropenia during therapy 
(603). Among patients developing neutropenia, 48% required 
dose modification, but most were able to complete the 6 weeks 
of therapy. On the basis of these results, IV ganciclovir therapy 
(6 mg/kg/dose administered every 12 hours) for 6 weeks should 
be offered to HIV-exposed or HIV-infected infants who have 
symptomatic congenital CMV disease involving the CNS (BI). 
If during the 6 weeks of therapy an infant is confirmed as HIV-
infected, some experts would recommend longer duration of 
treatment (>6 weeks) (BIII).
CMV retinitis should be managed in concert with an expe-
rienced ophthalmologist. IV ganciclovir, oral valganciclovir, 
IV foscarnet, IV cidofovir, and the ganciclovir intraocular 
implant coupled with valganciclovir are all effective treatments 
for CMV retinitis in HIV-infected adults (AI) (605–609). For 
HIV-infected children, the drug of choice for initial treatment 
for CMV retinitis—and for other end-organ disseminated 
CMV disease (e.g., colitis, esophagitis, and CNS disease)—is 
IV ganciclovir (AI). Oral valganciclovir, a prodrug of ganciclo-
vir, is one of the first-line treatments for HIV-infected adults 
with CMV retinitis (AI) (607). The drug is well absorbed 
from the GI tract and rapidly metabolized to ganciclovir in 
the intestine and liver. However, data on appropriate dosage 
of this drug for children are limited (610). Additionally, a val-
ganciclovir liquid formulation is not commercially available. 
Even though extemporaneously compounded valganciclovir 
“recipes” are available, the pharmacokinetics, bioavailability, 
safety, and shelf-life of such formulations are unknown, and 
they should not be used in children. Thus, oral valganciclovir 
is an option primarily for older children who weigh enough to 
receive the adult dose and tablet formulation of valganciclovir 
(CIII).
An alternative drug for treating CMV disease or for use in 
ganciclovir-resistant CMV infections in HIV-infected children 
is foscarnet (AI). Foscarnet used as suppressive therapy has 
been associated with increased length of survival relative to 
ganciclovir in HIV-infected adults. Doses should be modified 
among patients with renal insufficiency.
Combination therapy with ganciclovir and foscarnet delays 
progression of retinitis in certain patients in whom mono-
therapy fails (596,607,611,612) and can be used as initial 
therapy among children with sight-threatening disease (BIII). 
Combination therapy also has been used for adults with 
retinitis that has relapsed on single-agent therapy. Combination 
therapy with IV ganciclovir and foscarnet also can be consid-
ered in initial therapy of CMV CNS disease (BII). However, 
substantial rates of adverse effects are associated with combi-
nation therapy.
Before the availability of valganciclovir, oral ganciclovir in 
combination with an intraocular ganciclovir implant had been 
used for maintenance treatment of CMV retinitis in adults. 
Given the lack of commercial availability of oral ganciclovir, 
its use in children can no longer even be considered.
In adults, the combination of oral valganciclovir with a 
ganciclovir sustained-release intraocular implant, replaced 
every 6–9 months, was superior to daily IV ganciclovir in 
preventing relapse of retinitis and is preferred by some adult 
HIV specialists for patients who have CMV lesions adjacent 
to the optic nerve or fovea (AI) (605–609). This regimen can 
be considered for treatment and chronic suppression of CMV 
retinitis in older children who weigh enough to receive the 
adult dose and tablet formulation of valganciclovir.
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Cidofovir is effective in treating CMV retinitis among adults 
who are intolerant of other therapies. However, cidofovir has 
not been studied in children with CMV disease (CIII).
Intravitreous injections of ganciclovir, foscarnet, or cidofovir 
have been used to control retinitis but require biweekly intraoc-
ular injections. Data are limited in children, and biweekly 
injection is impractical for use in most children (DIII). 
Implantation of an intravitreous ganciclovir medication-release 
device in the posterior chamber of the eye also has been used 
in HIV-infected adults and adolescents. In HIV-infected adults 
with CMV retinitis, ganciclovir intraocular implant plus oral 
valganciclovir is superior to once daily IV ganciclovir for 
preventing relapse of CMV retinitis (605–607). Intraocular 
implant plus IV ganciclovir or oral valganciclovir may be the 
preferred initial treatment for patients with immediate sight-
threatening infections (e.g., adjacent to the optic nerve or 
fovea). Small peripheral lesions can be treated with systemic 
therapy without local treatment (BII). Intraocular implants 
should not be used in children aged <3 years because of the 
small size of their eyes (EIII). Intraocular cidofovir is not 
recommended in children because of lack of data and the risk 
for hypotonia in adults (EIII).
For CMV neurologic disease, prompt initiation of therapy 
is critical for an optimal clinical response. However, levels of 
ganciclovir in the CNS are 24%–70% of plasma levels, and 
levels in the brain are approximately 38% of plasma levels 
(613); hence, combination treatment with ganciclovir and 
foscarnet might be preferred as initial therapy to stabilize dis-
ease and maximize response (BII). However, this approach is 
associated with substantial rates of adverse effects, and optimal 
treatment for neurologic disease in children receiving optimized 
HAART is unknown.
Monitoring and Adverse Events, Including IRIS
CMV retinitis should be managed in concert with an expe-
rienced ophthalmologist. Recommendations for HIV-infected 
adults include indirect ophthalmoscopy through a dilated pupil 
performed at diagnosis of CMV retinitis, after completion of 
induction therapy, 1 month after initiation of therapy, and 
monthly thereafter while the patient is on anti-CMV treat-
ment; recommendations should be similar for HIV-infected 
children with CMV retinitis (AIII). Monthly fundus pho-
tographs, using a standardized photographic technique that 
documents the appearance of the retina, provide the optimum 
method for following patients and detecting early relapse 
(AIII). For patients who have experienced immune recovery 
(Table 3), the frequency of ophthalmologic follow-up can be 
decreased to every 3 months. However, because relapse of the 
retinitis occurs among patients with immune recovery, regular 
ophthalmologic follow-up still is needed.
The major side effects of ganciclovir and valganciclovir are 
myelosuppression (i.e., anemia, neutropenia, and thrombo-
cytopenia) and renal toxicity. Dose reduction or interrup-
tion because of hematologic toxicity might be necessary in 
up to 40% of patients receiving IV ganciclovir; granulocyte 
colony-stimulating factor can be used to ameliorate marrow 
suppression. The main toxicities of foscarnet are decreased 
renal function and metabolic derangements. Renal toxicity 
and foscarnet binding to divalent metal ions, such as calcium, 
lead to metabolic abnormalities in approximately one third of 
patients, and serious electrolyte imbalances (including abnor-
malities in calcium, phosphorus, magnesium, and potassium 
levels) and secondary seizures, cardiac dysrhythmias, abnormal 
liver transaminases, and CNS symptoms can occur. Metabolic 
disturbances can be minimized if foscarnet is administered 
by slow infusion, with rates not exceeding 1 mg/kg/minute. 
Concomitant use of other nephrotoxic drugs increases the like-
lihood of renal dysfunction associated with foscarnet therapy. 
For patients receiving ganciclovir or foscarnet, complete blood 
counts and serum electrolytes and renal function should be 
monitored twice weekly during induction therapy and once 
weekly thereafter (AIII).
The major side effect of cidofovir is potentially irreversible 
nephrotoxicity; the drug produces proximal tubular dysfunc-
tion including Fanconi syndrome and acute renal failure. 
Renal toxicity manifests as proteinuria and glycosuria. To 
minimize nephrotoxicity, probenicid should be administered 
before each infusion, and IV hydration with normal saline 
should be administered before and after each cidofovir infu-
sion. For patients receiving IV cidofovir, blood urea nitrogen, 
creatinine, and urinalysis should be performed before each 
infusion; administration of the drug is contraindicated if 
renal dysfunction or proteinuria is detected. Other reported 
adverse events include anterior uveitis and ocular hypotony; 
serial ophthalmologic monitoring for anterior segment inflam-
mation and intraocular pressure is needed while receiving the 
drug systemically. Cidofovir should not be administered con-
comitantly with other nephrotoxic agents. Cidofovir therapy 
must be discontinued if serum creatinine increases >0.5 mg/dL 
above baseline.
Immune recovery uveitis after initiation of effective HAART 
is an immunologic reaction to CMV associated with inflam-
mation in the anterior chamber and/or the vitreous (614). 
Ocular complications of uveitis include macular edema and 
development of epiretinal membranes, which can cause loss 
of vision. Immune recovery uveitis may respond to periocular 
corticosteroids or a short course of systemic steroids. Oral 
valganciclovir was beneficial in one small uncontrolled study 
(615).
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Management of Treatment Failure
Resistant strains of CMV should be suspected when progres-
sive disease and continued recovery of virus occurs despite 
ganciclovir therapy. Foscarnet is the drug of choice when 
ganciclovir resistance is suspected (AI).
In patients with CMV retinitis, although drug resistance 
occurs among patients receiving long-term therapy, early 
relapse might be caused by the limited intraocular penetration 
of systemically administered drugs; in HIV-infected adults, the 
placement of a ganciclovir implant in a patient whose retini-
tis has relapsed during systemic treatment is recommended 
because it achieves greater drug levels in the eye and often will 
control the retinitis for 6–8 months until the implant requires 
replacement (BIII). Because of the size requirements of the 
implants, this option would be limited to older children with 
CMV retinitis. Many experts would initially treat early first 
relapse of retinitis with reinduction with the same drug, fol-
lowed by reinstitution of maintenance therapy (AII). However, 
if drug resistance is suspected or if side effects or toxicities 
interfere with optimal courses of the initial agent, change to 
an alternative drug is reasonable (AIII). Combination ganci-
clovir and foscarnet can be considered but is accompanied by 
greater toxicity.
Prevention of Recurrence
Courses of antiviral agents (e.g., ganciclovir, foscarnet, or 
cidofovir) do not cure CMV disease. After induction therapy, 
the standard recommendation has been to provide secondary 
prophylaxis (chronic maintenance therapy) for the remainder 
of the patient’s life (AI). Regimens that can be considered for 
chronic suppression in adults and adolescents include IV ganci-
clovir, oral valganciclovir, IV foscarnet, combined IV ganci-
clovir and foscarnet, parenteral cidofovir, and (for retinitis 
only) ganciclovir administration by intraocular implant (AI) 
(616–623). Because of limited data on drug pharmacokinetics and 
dosing in children, IV ganciclovir or foscarnet are the preferred 
secondary prophylaxis regimens for children; oral valganciclovir 
can be considered for older children able to receive adult dosing. 
Repetitive intravitreous injections of ganciclovir, foscarnet, 
and cidofovir reportedly are effective for secondary prophylaxis 
of CMV retinitis (624,625), although intraocular therapy alone 
does not protect the contralateral eye or other organ systems and 
therefore typically is combined with systemic treatment (616). 
Additionally, frequent intravitreous injections are impractical 
for use in most children (DIII).
A chronic maintenance regimen for patients treated for 
CMV disease should be chosen in consultation with a specialist. 
Chronic maintenance therapy is not routinely recommended 
for GI disease but should be considered if relapses occur (BII). 
A role for maintenance therapy for CMV pneumonitis has not 
been established (CIII). For patients with retinitis, decisions 
should be made in consultation with an ophthalmologist and 
should take into consideration the anatomic location of the 
retinal lesion, vision in the contralateral eye, and the immu-
nologic and virologic status of the patient (BIII). Intraocular 
implants should not be used in children aged <3 years because 
of the small size of their eyes (EIII).
Discontinuing Secondary Prophylaxis
Multiple case series have reported that maintenance therapy 
can be discontinued safely in adults and adolescents with CMV 
retinitis whose CD4 counts have increased substantially in 
response to HAART (626–631). These patients have remained 
disease free for >30 to 95 weeks, whereas during the pre-HAART 
era, retinitis typically reactivated in <6 to 8 weeks after stopping 
CMV therapy. Plasma HIV RNA levels varied among these 
patients, supporting the hypothesis that the CD4 count is the 
primary determinant of immune recovery to CMV. CMV 
retinitis can occur in HAART-treated adults with high CD4 
counts, however (632), suggesting that CMV-specific cellular 
immunity may be important in controlling CMV in immune-
reconstituted HIV-infected adults (633,634). In HIV-infected 
adults with CMV retinitis, discontinuing secondary prophy-
laxis is considered for patients with a sustained increase in CD4 
count to >100 cells/mm3 in response to treatment.
The safety of discontinuing secondary prophylaxis after 
immune reconstitution with HAART in HIV-infected children 
has not been as well studied. Low or undetectable HIV replica-
tion in children is the strongest correlate with CMV immune 
reconstitution, being associated with a higher frequency of 
CMV-specific CD4 cells (635). Early institution of HAART 
may help control CMV infection by maintaining normal CD4 
count and cytotoxic T-lymphocyte responses in HIV-infected 
children (636). In deciding whether to discontinue secondary 
prophylaxis, the significant toxicities associated with antiviral 
drugs active against CMV, including those in in vitro and 
animal models, need to be considered.
Recognizing the limitations of the data in children but 
drawing on the growing experience in adults, discontinuing 
prophylaxis may be considered for children aged 1–5 years who 
are receiving HAART and have a sustained (e.g., >6 months) 
increase in CD4 count to >500 cells/mm3 or CD4 percent-
age to >15%, and for children aged >6 years, an increase 
in CD4 count to >100 cells/mm3 as for adults (CIII). Such 
decisions should be made in close consultation with an oph-
thalmologist and should account for such factors as magnitude 
and duration of CD4 cell increase, anatomic location of the 
retinal lesion, vision in the contralateral eye, and the feasibility 
of regular ophthalmologic monitoring (CIII).
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All patients in whom anti-CMV maintenance therapy has 
been discontinued should continue to undergo regular ophthal-
mologic monitoring at at least 3- to 6-month intervals for early 
detection of CMV relapse and for immune reconstitution uveitis 
(AII). CMV viral load or other markers of CMV infection (e.g., 
antigenemia or viral DNA tests) are not well standardized; their 
role in predicting relapse remains to be defined, and they are not 
recommended for routine monitoring (DIII) (637,638).
Reinitiating Secondary Prophylaxis
CMV retinitis relapses among adults whose anti-CMV 
maintenance therapies have been discontinued and whose 
CD4 counts have decreased to <50 cells/mm3 (624); reinsti-
tution of secondary prophylaxis is recommended for HIV-
infected adults when CD4 count falls to <100 cells/mm3. 
For HIV-infected children in whom secondary prophylaxis 
has been discontinued because of immune reconstitution, 
secondary prophylaxis should be reinstituted in children aged 1–5 
years when the CD4 count decreases to <500 cells/mm3 or 
CD4 percentage to <15%, and for children aged >6 years 
when the CD4 count decreases to <100 cells/mm3 or CD4 
percentage to <15% (BIII).
Hepatitis B Virus
Epidemiology
Chronic hepatitis B infection is defined as persistence of 
hepatitis B surface antigen (HbsAg) for >6 months. Risk of 
developing chronic hepatitis B infection after acute infection 
correlates with age at time of hepatitis B virus (HBV) infection. 
Among HBV-infected persons, chronic hepatitis B infection 
develops in <90% of infants, 25%–50% of children aged 
1–5 years, and 6%–10% of older children and adolescents 
(639–641).
Childhood HBV infection can be acquired parenterally, 
perinatally, or through sexual transmission. Horizontal trans-
mission of HBV can occur secondary to frequent interpersonal 
contact of nonintact skin or mucus membranes with blood or 
body fluids that contain blood (e.g., saliva) or from sharing 
household objects, such as toothbrushes or razors. Universal 
hepatitis B vaccination of newborns has dramatically lowered 
chronic HBV infection among children and reduced the 
rates of HBV-related morbidity and mortality in the United 
States.
Adolescents are at risk for HBV infection through sexual 
activity or injection-drug use. In a study of HIV-infected 
adolescents at 43 PACTG centers, 19% had evidence of cur-
rent or resolved HBV infection; the rate of current or resolved 
HBV infection in HIV-infected adolescent girls was twice the 
U.S. population-based rates for HIV-uninfected adolescent 
girls and, for adolescent boys, nearly seven times higher (642). 
Substance abuse and sexual activity increase the risk for HIV/
HBV coinfection in adolescents, particularly among males who 
have sex with other males (643).
Most children who acquire HBV perinatally are immuno-
tolerant to HBV. Although they have high HBV DNA levels, 
serum transaminase levels are usually normal, and necroinflam-
matory liver disease is minimal. Childhood-acquired HBV 
infection is characterized by lower HBV DNA levels, greater 
serum transaminase elevation, and higher necroinflamma-
tory liver disease than in perinatally acquired HBV infection 
(644).
Data from the National Health and Nutrition Examination 
Survey, 1999–2004, indicate that 0.51% (95% CI: 0.3%–
0.9%) of children aged 6–19 years had ever been infected with 
HBV (645). Data are limited on the prevalence of chronic HBV 
infection in HIV-infected children in the United States. In a 
study of 228 HIV-infected children at an inner-city hospital, 
six HIV-infected children had chronic HBV infection (2.6% 
[95% CI: 1.1%–5.9%]) (646). The mean age of HIV/HBV-
coinfected children was 17 years; 33% had acquired both HIV 
and HBV infection through blood transfusion; and 84% were 
HBV early antigen-positive (HBeAg), indicating infectious-
ness. Half of coinfected children had normal serum transami-
nase levels, and half had mild elevations of up to twofold above 
upper limit of normal.
Clinical Manifestations
Most acute HBV infections in children are asymptomatic. 
Prodromal symptoms of lethargy, malaise, fatigue, nausea, and 
anorexia can occur. Jaundice and right upper quadrant pain 
can follow and, less commonly, hepatomegaly and spleno-
megaly. Gianotti-Crosti syndrome (papular acrodermatitis), 
urticaria, macular rash, or purpuric lesions may be seen in 
acute HBV infection. Extrahepatic manifestations associated 
with circulating immune complexes that have been reported 
in HBV-infected children include arthralgias, arthritis, pol-
yarteritis nodosa, thrombocytopenia, and glomerulonephritis. 
Most children with chronic HBV infection are asymptomatic. 
However, rare cases of fulminant hepatic failure have occurred 
during childhood HBV infection (647).
Most children with chronic HBV infection are asymptom-
atic. One quarter of infants and children with chronic HBV 
eventually will develop cirrhosis or hepatocellular carcinoma 
(HCC) (648,649). However, these sequelae usually develop 
over 2–3 decades and rarely occur during childhood (650). 
Development of HCC correlates with HBV DNA levels and 
duration of HBV infection, with the highest risk in persons 
infected in early life (651). HIV/HBV-coinfected adults are at 
Vol. 58 / RR-11 Recommendations and Reports 69
increased risk for cirrhosis, end-stage liver disease, and liver-
related mortality (652).
Diagnosis
Testing for HBV infection should be performed in any child 
whose mother is known to be infected with HBV. Adolescents 
and young adults with histories of injection-drug use or 
high-risk sexual contact also should undergo testing for HBV 
infection.
HBsAg is the first marker detectable in serum, appear-
ing 30 days after infection; it precedes the elevation of 
serum aminotransferase levels and the onset of symptoms. 
Necroinflammatory liver disease then can occur, during which 
serum transaminase levels increase, along with high HBV DNA 
levels and HBeAg positivity. HBeAg correlates with viral rep-
lication, DNA polymerase activity, infectivity, and increased 
severity of liver disease. Antibody to hepatitis B core antigen 
(anti-HBc) appears 2 weeks after HBsAg and persists for life. 
Passively transferred maternal anti-HBc can be detectable in the 
infant up to age 12 months. In self-limited infections, HBsAg 
is usually eliminated in 1–2 months, and hepatitis B surface 
antibody (anti-HBs) develops during convalescence. Anti-
HBs indicates immunity from HBV infection. After recovery 
from natural infection, both anti-HBs and anti-HBc usually 
are present. In persons who become chronically infected (i.e., 
persistently positive for HBsAg beyond 24 weeks), anti-HBs 
is not detectable. Persons who have been vaccinated may have 
detectable anti-HBs but not anti-HBc.
HBeAg seroconversion, defined as loss of HBeAg, followed 
by the production of antibodies to HBeAg (e.g., anti-HBe), 
heralds transition of the HBV-infected person to the inactive 
carrier state. HBeAg seroconversion is infrequent in children 
aged <3 years and may not occur until the third or fourth 
decade of HBV infection (653). Less than 10% of children 
infected perinatally with HBV undergo HBeAg seroconver-
sion. In contrast, higher rates of HBeAg seroconversion occur 
in childhood-acquired HBV infection, with 70%–80% of 
children acquiring anti-HBe by the second decade of life 
(650). HBeAg seroconversion usually is followed by reduc-
tion of serum HBV DNA levels, an initial increase and then 
subsequent normalization of serum transaminase levels, fol-
lowed by resolution of necroinflammatory liver disease (650). 
Development of cirrhosis and HCC occur more commonly in 
patients with delayed HBeAg seroconversion (654). HBeAg-
negative infection (precore mutant) occurs uncommonly in 
children (641).
HBV DNA is a marker for HBV replication. In the 
active phase of chronic hepatitis B, high HBV DNA levels 
have been associated with necroinflammatory liver disease. 
Children infected perinatally, however, may remain in an 
immunotolerant phase with high levels of HBV DNA without 
evidence of liver damage. Quantitative DNA assays may help 
determine the need for treatment and for evaluating treatment 
response. Although not necessary for diagnostic purposes, liver 
biopsy may be useful to assess the degree of liver damage and 
determine the need for treatment.
Prevention Recommendations
Prevention of Exposure
All pregnant women should be tested for HBsAg during an 
early prenatal visit in each pregnancy (AI). Testing should be 
repeated in late pregnancy for HBsAg-negative women at high 
risk for HBV infection (e.g., injection-drug users, women with 
intercurrent sexually transmitted infections, and women with 
multiple sex partners). Pregnancy is not a contraindication to 
hepatitis B vaccination for women who have not previously 
been vaccinated; current hepatitis B vaccines contain noninfec-
tious HBsAg and should cause no risk to the fetus.
Preventing First Episode of Disease
All infants born to HBV-infected women, including HIV-
coinfected women, should receive hepatitis B vaccine and 
hepatitis B immune globulin (HBIG) within 12 hours after 
birth, a second dose of hepatitis B vaccine at age 1–2 months, 
and a third dose at age 6 months (A1) (Figures 1 and 2) (38). 
For preterm infants weighing <2000 g, the initial vaccine dose 
(birth dose) should not be counted as part of the vaccine series 
because of the potentially reduced immunogenicity of hepatitis 
B vaccine in these infants; three additional doses of vaccine 
(for a total of four doses) should be administered beginning 
when the infant reaches age 1 month (AI) (38). A three-dose 
hepatitis B vaccine regimen is 95% effective in preventing 
HBV infection in HBV-exposed infants. Postvaccination 
testing for anti-HBs and HBsAg should be performed at age 
9–18 months in infants born to HBsAg positive women. The 
level of anti-HBs that is considered protective is >10 mIU/
mL. Infants who are HBsAg negative and have anti-HBs levels 
<10 mIU/mL should be revaccinated with a second three-dose 
series of hepatitis B vaccine and retested 1–2 months after the 
final vaccine dose (38).
The three-dose series of hepatitis B vaccine also is recom-
mended for all children and adolescents aged <19 years who 
were not previously vaccinated. However, antibody responses 
to hepatitis B vaccination may be diminished in HIV-infected 
children, especially in older children or children with CD4 
counts <200 cells/mm3 (655,656). For this reason, HIV-
infected infants, children, and adolescents should be tested for 
anti-HBs 1–2 months after completing the vaccination series 
and, if anti-HBs levels are <10 mIU/mL, revaccinated with a 
second three-dose series of hepatitis B vaccine (AIII). Modified 
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hepatitis B vaccine dosing regimens, including a doubling 
of the standard antigen dose, might increase response rates. 
However, although a current randomized trial is evaluating 
use of various hepatitis B vaccine preparations and doses in 
HIV-infected youth, no data are available yet.
The need for booster doses of hepatitis B vaccine in HIV-
infected persons has not been determined. Annual anti-HBs 
testing and booster doses when the anti-HBs levels decline to 
<10 mIU/mL should be considered in persons with ongoing 
risk for hepatitis B exposure (CIII) (38).
In addition to hepatitis B vaccine, hepatitis A vaccine can 
prevent hepatitis infection and its potential devastating long-
term sequelae and thus all children should receive hepatitis A 
vaccination at age 12–23 months with the two doses in the 
series administered >6 months apart (39). Children who are 
not fully vaccinated by age 2 years can be vaccinated at sub-
sequent visits. Hepatitis A vaccine is also recommended for 
children aged >24 months who live in areas where vaccination 
programs target older children or those who are at increased 
risk for infection (Figures 1 and 2).
HBV-infected children should be advised not to share 
toothbrushes or other personal-care articles that might be 
contaminated with blood. Although efficiency of sexual trans-
mission of HBV is relatively low, safe-sex practices should be 
encouraged for all HIV-infected adolescents and young adults; 
barrier precautions (e.g., latex condoms) are recommended to 
reduce the risk for exposure to sexually transmitted pathogens, 
including HBV.
Treatment Recommendations
Treatment of Disease
General issues
Individualization of therapy is essential for any HBV-infected 
child and should be based on the child’s age, age at acquisi-
tion of infection, HBV DNA levels, and serum transaminase 
levels. Antiviral therapy regimens for chronic hepatitis B are 
approved only for children aged >2 years who have compen-
sated liver disease.
HIV-infected children who are not receiving anti-HBV 
therapy should be closely monitored with determination 
of serum aminotransferase levels every 6 months. If serum 
transaminase levels are persistently elevated (more than two-
fold the upper limit of normal for >6 months), HBeAg, anti-
HBe, and HBV DNA levels should be obtained. Monitoring 
of serum transaminases and HBV DNA levels over time is 
important before the initiation of antiviral therapy to identify 
patients who may be in the process of spontaneous HBeAg 
seroconversion who would not require treatment. Liver biopsy 
is not required before treatment but may help to determine the 
severity of hepatic inflammation and fibrosis and to exclude 
other causes of liver disease.
No clear recommendations exist for treating chronic child-
hood HBV infection. HBV-infected children often have milder 
disease than adults and may show spontaneous HBeAg sero-
conversion. Few large randomized controlled trials exist of anti-
viral therapies for chronic hepatitis B infection in childhood. 
Moreover, the long-term safety of many of the agents used to 
treat chronic hepatitis B infection in adults is not known in 
children. However, a 2004 consensus meeting of pediatric liver 
experts recommended that antiviral treatment be considered 
in children with chronic HBV infection and a duration of 
necroinflammatory liver disease >6 months (657).
Indications for treatment of chronic HBV infection in 
HIV-coinfected children are the same as in HBV-infected 
children without HIV infection: 1) evidence of ongoing 
HBV viral replication, as indicated by detectable serum HBV 
DNA, with or without HBeAg positivity, for >6 months and 
persistent elevation of serum transaminase levels (at least twice 
the upper limit of normal for >6 months); or 2) evidence of 
chronic hepatitis on liver biopsy (BII) (641,657). Children 
without necroinflammatory liver disease usually do not warrant 
antiviral therapy (DIII). Treatment is not recommended for 
children with immunotolerant chronic HBV infection (i.e., 
normal serum transaminase levels despite detectable HBV 
DNA) (DIII). The goals of treatment for children with chronic 
hepatitis B infection are identical to those for adults: suppres-
sion of HBV replication; normalization of serum transaminase 
levels; acceleration of HBeAg seroconversion; preservation of 
liver architecture; and prevention of long-term sequelae, such 
as cirrhosis and HCC.
The optimal agent and duration of therapy for childhood 
hepatitis B infection remain unclear. Treatment of chronic 
hepatitis B infection is evolving; consultation with provid-
ers with expertise in treating chronic hepatitis B infection in 
children is recommended.
Treatment of chronic hepatitis B infection 
in adults and adolescents
Seven medications have been approved to treat chronic 
hepatitis B infection in adults: interferons (both standard and 
pegylated); nucleoside analogues (i.e., lamivudine; telbivudine; 
and entecavir); and the nucleotide analogues, adefovir and 
tenofovir. The FDA-approved HIV antiretroviral medica-
tion emtricitabine also has significant activity against HBV, 
although it is not approved for this indication. Preferred initial 
therapies for adults who have chronic hepatitis B without HIV 
infection include pegylated interferon-alfa, entecavir, or adefo-
vir monotherapy. In adults who have chronic hepatitis B infec-
tion with or without HIV infection, treatment for hepatitis 
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B is considered in HBeAg-positive persons with HBV DNA 
>20,000 IU/mL (>105 copies/mL), HBeAg-negative persons 
with HBV DNA >2000 IU/mL (>104 copies/mL), patients 
with persistent serum transaminase elevation, or patients with 
evidence of cirrhosis or fibrosis (652).
Treatment options for HBV in HIV-infected persons must 
account for the goals of therapy and the impact treatment 
might have on both HIV and HBV replication. In coinfected 
patients who require treatment for chronic hepatitis B, HIV, 
or both, many experts would initiate a fully suppressive regi-
men to treat HIV infection that includes a dual nucleoside 
analogue backbone with drugs active against both HIV and 
HBV plus a third agent active against HIV; this approach 
might reduce the risk for IRIS, particularly in patients with 
advanced immune deficiency. Tenofovir plus lamivudine or 
emtricitabine would be the first choice for the nucleoside 
backbone; the combination of tenofovir with lamivudine was 
demonstrated to be more effective in suppressing HBV than 
either drug alone and prevents development of lamivudine 
resistance (658). In instances in which HIV treatment is not 
an option but treatment of hepatitis B infection is needed, 
pegylated interferon-alfa can be used alone because it does not 
lead to development of drug-resistant HIV or HBV mutants. 
Use of tenofovir, lamivudine, or emtricitabine without a fully 
suppressive HAART regimen should be avoided because of the 
rapid development of drug-resistant HIV mutations.
Treatment of chronic hepatitis B infection 
in children without HIV infection
Only two drugs (monotherapy with interferon-alfa [stan-
dard] or lamivudine) are FDA-approved to treat chronic 
hepatitis B in children (AI). The limited pediatric trials of these 
agents show that although they are well-tolerated by children, 
response rates are low, and treatment does not fully eliminate 
HBV infection (659,660). In HIV-uninfected children, HBeAg 
seroconversion rates after 1 year of treatment are similar (641). 
Interferon-alfa treatment is administered for only 6 months but 
requires subcutaneous administration and has more frequent 
side effects, including growth impairment. Although lamivu-
dine is administered orally and has a lower rate of side effects, 
it requires a longer duration of therapy and has a high rate of 
resistance if taken for an extended time (641).
Although various combination regimens involving sequen-
tial or concurrent lamivudine and standard or pegylated 
interferon-alfa have been studied in children or adults with 
chronic hepatitis B, the superiority of combination therapy 
over monotherapy with standard or pegylated interferon-alfa 
or lamivudine has not been demonstrated; however, lamivu-
dine resistance rates may be lower (661–670). A recent study 
of children with immunotolerant HBV infection suggested 
possible benefit from sequential lamivudine and interferon-alfa 
therapy, with 78% of patients clearing HBV DNA by the end 
of treatment (664). However, combination therapy cannot be 
recommended for pediatric HBV infection until more data 
are available (DII).
Treatment of HBV/HIV-coinfected children
None of the clinical studies of treatment of chronic hepatitis 
B infection have specifically studied children with HIV/HBV 
coinfection. As in coinfected adults, choice of antiviral therapy 
for the HIV/HBV-coinfected child involves consideration of 
whether concurrent HIV treatment is warranted.
If treatment of chronic hepatitis B but not HIV infection •	
is indicated, standard interferon-alfa is the preferred agent 
(BIII). Adefovir also could be considered in older children 
able to receive adult dosing (BIII). Antiviral drugs with 
activity against HIV (e.g., lamivudine, emtricitabine, teno-
fovir, and possibly entecavir) should be avoided to prevent 
future development of drug-resistant HIV mutations.
If treatment of HIV infection but not chronic hepatitis B •	
is indicated, use of a HAART regimen that avoids drugs 
with activity against HBV (e.g., lamivudine, emtricitabine, 
or tenofovir) is recommended to prevent future develop-
ment of HBV drug resistance (BIII). Alternatively, in 
older coinfected children who can receive tenofovir, use of 
a HAART regimen with a nucleoside analogue backbone 
that contains two drugs effective against HBV (tenofovir 
plus lamivudine or emtricitabine) can be considered 
(BIII).
If treatment for both HIV and chronic hepatitis B is indi-•	
cated and the child is lamivudine-naïve, an antiretroviral 
regimen that includes lamivudine (or emtricitabine) is 
recommended (BIII). A regimen containing tenofovir and 
a nucleoside analogue (either lamivudine or emtricitabine) 
is preferred for HIV/HBV-coinfected adults, and should 
be considered for use in older HIV-infected children 
or adolescents who can receive adult dosage. However, 
tenofovir is not approved for use in HIV-infected children 
<18 years, and no pediatric formulations are available. 
Although pediatric studies with an investigational pedi-
atric formulation of tenofovir are under way, data are not 
yet available.
 If treatment for HIV and chronic hepatitis B is indicated •	
and the child is receiving antiretroviral therapy including 
lamivudine or emtricitabine with HIV suppression but 
detectable plasma HBV DNA, HBV lamivudine resistance 
can be assumed. However, HBV drug-resistant isolates 
may have lower replicative capacity, and some experts 
recommend continued use of lamivudine or emtricitabine, 
although this recommendation is controversial (CIII). 
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Treatment options for such children who require HBV 
therapy include the addition of interferon therapy to 
the antiretroviral regimen (BIII), or tenofovir (BIII), or 
adefovir if the child can receive adult dosing (BIII). Data 
are insufficient on other anti-HBV drugs in children to 
make recommendations.
Interferons
Standard interferon-alfa-2a or -2b has received the most 
study in children who have chronic hepatitis B (without HIV 
infection) and is recommended for treating chronic hepatitis 
B infection with compensated liver disease in HIV-uninfected 
children aged >2 years who warrant treatment (BII). In a review 
of six randomized clinical trials in 240 HBV-infected children 
aged >1.5 years, interferon-alfa therapy resulted in HBV DNA 
clearance in 35% of treated children, HBeAg clearance in 10%, 
and normalization of serum transaminase levels in 39% at 
treatment completion (671). Six to 18 months after therapy 
discontinuation, 29% of children had persistent HBV DNA, 
and 23% demonstrated HBeAg clearance. Children most likely 
to respond to interferon treatment are of younger age, higher 
baseline serum transaminase levels, and lower baseline HBV 
DNA levels (659,672–674). Response is less likely (10%) in 
those with normal serum transaminase levels, high HBV DNA 
levels, HBV genotypes C or D, or HBeAg-negative chronic 
HBV infection. Interferon-alfa therapy might be considered 
to treat chronic hepatitis B in HIV-coinfected children who 
do not require antiretroviral therapy for their HIV infection 
(BIII).
The standard course of interferon-alfa therapy for children 
without HIV infection is 24 weeks. Pegylated interferon-alfa, 
which results in more sustained plasma interferon concentra-
tions and can be administered by injection once weekly for 
48 weeks, has proven superior to standard interferon-alfa in 
treating HBV-infected adults (667,675). However, the limited 
data on use of pegylated interferon-alfa in children come from 
treatment of hepatitis C infection, and appropriate dosing 
information is not available for use of pegylated interferon-alfa 
to treat chronic hepatitis B in children (DIII) (676–678).
Lamivudine
Lamivudine (3TC) is an oral nucleoside analogue that inhib-
its HBV replication. It is approved for use in children aged 
2–17 years who have compensated liver disease from chronic 
hepatitis B. In a placebo-controlled trial in children who have 
chronic hepatitis B without HIV infection, lamivudine was well 
tolerated, with virologic response (clearance of HBV DNA and 
HBeAg) in 23% of children receiving 52 weeks of lamivudine 
therapy, compared with 13% in placebo recipients (679). 
Response rates were higher (35%) for children with baseline 
serum transaminases more than two times normal (679). 
In a 2-year, open-label extension of this study, 213 children 
who remained HBeAg-positive after 1 year of therapy were 
continued on lamivudine treatment; virologic response was 
seen in 21% of the original lamivudine recipients, compared 
with 30% of prior placebo recipients, indicating that addi-
tional clinical response could occur over time with prolonged 
treatment (680). However, longer duration of lamivudine 
therapy also was associated with progressive development of 
lamivudine-resistant HBV, with base pair substitutions at the 
tyrosine-methionine-aspartate-aspartate (YMDD) locus of 
HBV DNA polymerase.
Accordingly, lamivudine should not be used as a single 
agent for treatment of chronic hepatitis B in HIV-infected 
children because of the risk for HIV resistance to lamivudine 
(EIII); as discussed above, lamivudine should be used only 
in HIV/HBV-coinfected children in combination with other 
antiretroviral drugs in a HAART regimen (BIII). The dose of 
lamivudine required to treat HIV infection is higher than to 
treat pediatric chronic hepatitis B alone; therefore, the higher 
dose of lamivudine should be used in HIV/HBV-coinfected 
children to avoid development of lamivudine-resistant HIV 
(AIII). Lamivudine resistance should be suspected if HBV 
DNA levels increase during antiviral therapy. Such increases 
may precede increases in serum transaminase levels (hepatic 
flare) and liver decompensation (674).
Emtricitabine
Emtricitabine is structurally similar to lamivudine and is 
active against HBV and HIV, although not approved for treat-
ment of chronic hepatitis B. Like lamivudine, emtricitabine 
also is associated with relatively rapid onset of HBV and HIV 
drug resistance, and patients with suspected lamivudine resis-
tance should be assumed to have cross-resistance to emtricit-
abine. Lamivudine and emtricitabine should be considered 
interchangeable for treatment of chronic hepatitis B and not 
additive (BIII). As with lamivudine, emtricitabine should not 
be used to treat chronic hepatitis B in coinfected children who 
are not being treated with combination antiretroviral therapy 
for their HIV infection because of the risk for HIV-associated 
resistance mutations (EIII).
Adefovir
Adefovir dipivoxil is an oral nucleotide analogue active 
against HBV. Although active against HBV, adefovir has 
minimal anti-HIV activity, and HIV resistance has not been 
observed in patients receiving a 10-mg daily dose of adefovir for 
48 weeks (681). HBV resistance to adefovir is much lower than 
in lamivudine, being reported as 2% after 2 years, 4% after 3 
years, and 18% after 4 years of therapy in adults (682). These 
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adefovir-associated mutations in HBV Pol gene result in only a 
modest (threefold to eightfold) increase in the 50% inhibitory 
concentration and are partially cross-resistant with tenofovir. 
Adefovir is now FDA-approved for adults who require treat-
ment for chronic hepatitis B but do not yet require treatment 
for their HIV infection. Adefovir has been studied in HIV/
HBV-coinfected adults with lamivudine-resistant HBV infec-
tion, and HBV suppression was demonstrated (681). Safety and 
effectiveness of adefovir for treating chronic hepatitis B in chil-
dren has not yet been established, but an ongoing randomized 
clinical trial is evaluating its use in HIV-uninfected children 
aged 2–17 years who have chronic hepatitis B (659).
Tenofovir
Tenofovir is a nucleotide analog structurally similar to adefo-
vir that reduces HBV DNA levels in adults with lamivudine-
resistant and wild-type HBV infection. A study in HIV/
HBV-coinfected adults receiving stable antiretroviral therapy 
comparing treatment with tenofovir or adefovir found similar 
efficacy in suppression of HBV DNA without differences in 
toxicity (683). Another study of HIV/HBV-coinfected adults 
receiving tenofovir in addition to lamivudine as part of their 
antiretroviral regimen found that HBV DNA became undetect-
able in 30% of HBeAg-positive and 82% of HBeAg-negative 
patients, most of whom had lamivudine-resistant HBV infec-
tion (681). As noted earlier, tenofovir is not approved for use 
in HIV-infected children aged <18 years, and no pediatric 
formulation is available. However, for HIV/HBV-coinfected 
adolescents who require treatment of both infections and who 
can receive adult doses, tenofovir in combination with an anti-
HBV nucleoside (either lamivudine or emtricitabine) can be 
considered for treatment (BIII); a combined formulation of 
emtricitabine and tenofovir (Truvada) is available for adults. 
As with lamivudine and emtricitabine, tenofovir should not 
be used for treatment of chronic hepatitis B in HIV-coinfected 
patients who are not receiving combination antiretroviral 
therapy for their HIV infection because of the risk for HIV-
associated resistance mutations (EIII).
Entecavir
Entecavir is an oral nucleoside analogue that inhibits HBV 
DNA polymerase. Compared with lamivudine, entecavir 
therapy results in greater HBV viral suppression, increased 
normalization of serum transaminase levels, improved liver his-
tology, and lower HBV resistance rates (684). HBV viral sup-
pression also has been demonstrated in HIV/HBV-coinfected 
adults. Entecavir treatment is approved for treatment of chronic 
hepatitis B in adults and is preferred for lamivudine-resistant 
HBV infections. However, it recently was demonstrated to 
have suppressive activity against HIV (685). Entecavir should 
not be used in HIV/HBV-coinfected patients who are not 
receiving combination antiretroviral therapy for their HIV 
infection. No data are available on safety and efficacy of ente-
cavir in children.
Telbivudine
Telbivudine is a thymidine nucleoside analogue that was 
approved to treat chronic hepatitis B in adults. It is well toler-
ated, but like lamivudine, resistance emerges over time, and 
telbivudine is not active against lamivudine-resistant HBV. 
No data are available on telbivudine in HIV/HBV-coinfected 
adults. No data on children exist on safety and efficacy of 
telbivudine.
Duration of therapy
The optimal duration of therapy in HIV/HBV-coinfected 
children is not known. The duration of interferon-alfa treat-
ment in HIV-uninfected children with chronic hepatitis B is 6 
months. At least 1 year of lamivudine therapy is recommended 
for HIV-uninfected children who have chronic hepatitis B, 
with continuation of medication for >6 months after docu-
mented HBeAg seroconversion (659). However, because lami-
vudine would be administered only to HIV/HBV-coinfected 
children who need HIV treatment and as part of a suppressive 
antiretroviral regimen, treatment with lamivudine (or other 
anti-HBV drugs with anti-HIV activity) should be continued 
indefinitely in children with HIV/HBV coinfection, even in 
the instance of HBeAg seroconversion (CIII).
Monitoring and Adverse Events, Including IRIS
The parameters of successful therapy for chronic hepatitis 
B are not well defined, but markers of improvement include 
decreased hepatic necroinflammatory disease, normalization 
of serum transaminase levels, reduction of HBV DNA levels, 
and HBeAg seroconversion. In children starting treatment 
for chronic hepatitis B, serum transaminase levels should be 
measured every 3–6 months. If the child also is beginning 
HAART, some experts would monitor transaminase levels 
more frequently during the first few months of therapy (e.g., 
monthly for 3 months) because of the risk for IRIS (see below). 
Monitoring of response to treatment for chronic hepatitis 
B is based on testing for HBV DNA and HBeAg and anti-
HBe antibody on the same schedule as transaminase evalua-
tions (every 3–6 months). Among HBeAg-positive persons, 
treatment for chronic hepatitis B should be continued until 
HBeAg seroconversion has been achieved and >6 months of 
additional treatment has been completed after the appearance 
of anti-HBe (BIII). Close monitoring for relapse is needed 
after withdrawal of therapy. Among persons who are HBeAg 
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negative, treatment should be continued until HBsAg clear-
ance has been achieved.
In HIV/HBV-coinfected persons starting HAART, serum 
transaminase elevations (“flares”) can occur as part of IRIS 
or secondary to HAART-associated hepatotoxicity. HBV-
associated liver injury is thought to be immune-mediated, 
and restoration of immunocompetence with antiretroviral 
treatment may reactivate liver inflammation and damage. 
Initiation of HAART without anti-HBV therapy can lead 
to reactivation of HBV. This does not represent a failure of 
HAART but rather a sign of immune reconstitution. IRIS 
manifests by an increase in serum transaminase levels as the 
CD4 count increases during the first 6–12 weeks of HAART. 
Thus, serum transaminase levels should be monitored closely 
after introduction of HAART. In such situtations, HAART 
should be continued and treatment for HBV initiated. The 
prognosis for most IRIS cases is favorable because a robust 
inflammatory response may predict an excellent response to 
HAART in terms of immune reconstitution and, perhaps, 
improved survival. In a patient experiencing a hepatic flare, 
differentiating between IRIS and drug-induced liver toxicity 
may be difficult, and no reliable clinical or laboratory predictor 
exists to distinguish between the two. Close collaboration of 
the HIV specialist with a specialist in hepatic disease is recom-
mended for such patients; a hepatologist should be consulted 
promptly if elevated aminotransferases levels are associated 
with clinical jaundice or other evidence of liver dysfunction 
(e.g., low serum albumin).
Clinical and laboratory exacerbations of hepatitis and hepatic 
flare can occur in children receiving HAART if agents with 
anti-HBV activity are discontinued. Some experts recom-
mend that once antiretroviral drugs with anti-HBV activity 
are begun, they should be continued unless contraindicated 
or until the child has been treated for >6 months after HBeAg 
seroconversion and can be closely monitored after discontinua-
tion (BIII). If discontinuation of therapy for chronic hepatitis 
B results in hepatic flare, therapy for chronic hepatitis B should 
be reinstituted (BIII).
Some clinicians recommend monitoring HBV-infected 
children or adolescents for HCC with baseline screening and 
then yearly determinations of serum alpha fetoprotein levels 
and abdominal ultrasonography; however, no data support the 
benefit of such surveillance (641,657,659,660).
Adverse effects of interferon-alfa use in children, although 
frequent, usually are not severe or permanent; however, 
approximately 5% of children require treatment discontinua-
tion. The most common side effects include an influenza-like 
syndrome, cytopenias, and neuropsychiatric effects. Influenza-
like symptoms comprising fever, chills, headache, myalgia, 
arthralgia, abdominal pain, nausea, and vomiting are seen in 
80% of patients during the first month of treatment. These 
side effects decrease substantially during the first 4 months 
of therapy; premedication with acetaminophen or ibuprofen 
might reduce side effects. Subtle personality changes, which 
resolve when therapy is discontinued, have been reported 
in 42% of children (686). Depression and suicidal ideation 
have also been reported in clinical trials of children treated 
with interferon-alfa (687). Neutropenia, which resolves after 
discontinuation of therapy, is the most common laboratory 
abnormality; anemia and thrombocytopenia are less com-
mon. Abnormalities in thyroid function (hypothyroidism 
or hyperthyroidism) have been reported with interferon-alfa 
therapy (688). Loss of appetite with transient weight loss and 
impaired height growth might occur but usually resolves after 
completion of therapy (689). Less commonly observed side 
effects of interferon-alfa include epistaxis and transient mild 
alopecia. Antinuclear autoantibodies have been detected in 
some children treated with interferon-alfa. Interferon-alfa 
therapy is contraindicated for children with decompensated 
liver disease; severe cytopenia; severe renal, cardiac, or neu-
ropsychiatric disorders; and autoimmune disease (EII) (690). 
Elevation of serum transaminase levels has been reported dur-
ing interferon-alfa therapy in children and adults but usually 
is not an indication to stop therapy; these flares may herald 
impending HBeAg seroconversion (659). Children receiving 
interferon-alfa therapy should be monitored with a complete 
blood count and serum level of thyroid stimulating hormone 
at baseline and periodically (e.g., at least every 3 months) for 
the duration of treatment.
Lamivudine usually is well-tolerated in children; rare cases 
of lactic acidosis and pancreatitis have been reported in HIV/
HBV-coinfected adults. Tenofovir and adefovir can cause 
renal tubular disease. Patients receiving either drug should 
have baseline urinalysis and periodic serum creatinine and 
phosphate monitoring. Administration of other nephrotoxic 
agents increases the risk for renal toxicity.
Management of Treatment Failure
Treatment failure is defined as ongoing HBV replication, per-
sistent serum transaminase elevations, and the failure of HBeAg 
seroconversion in HBeAg-positive persons. Flares of liver 
disease with increasing HBV DNA levels can be seen with the 
development of resistance to lamivudine or emtricitabine.
In some children who have received initial treatment for 
chronic hepatitis B with standard-dose interferon-alfa mono-
therapy, use of higher-dose interferon-alfa for retreatment 
improves response (665,691,692). Lamivudine has also been 
used as secondary therapy for children without HIV infection 
who have not responded to standard interferon-alfa therapy 
(CII) (693–695); in HIV-infected children, initiation of 
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a lamivudine-based HAART regimen could be considered 
(CIII).
For HIV/HBV-coinfected children developing lamivudine 
resistance during therapy, treatment options are more limited 
because of the lack of data on use of adefovir, entecavir, and 
tenofovir in children. Because these HBV drug-resistant isolates 
may have lower replicative capacity than wild-type HBV, some 
experts recommend continuing lamivudine or emtricitabine 
therapy in such cases. Alternatively, the addition of interferon-
alfa therapy could be considered or, in children old enough to 
receive adult doses of tenofovir or adefovir, addition of tenofo-
vir or adefovir to the regimen could be considered (CIII).
Prevention of Recurrence
Not applicable.
Discontinuing Secondary Prophylaxis
Not applicable.
Hepatitis C Virus
Epidemiology 
In the United States, the prevalence of hepatitis C virus 
(HCV) infection is 0.2% among children aged 1–11 years 
and 0.4% among adolescents aged 12–19 years (696,697). The 
prevalence of HCV infection among HIV-infected children 
may be higher. In a serostudy of 535 HIV-infected children 
followed in pediatric HIV clinical trials, the prevalence of HCV 
infection by HCV antibody and RNA testing was 1.5% (698). 
In a more recent study of 228 HIV-infected children at an 
inner-city hospital in the Bronx, seven HIV-infected children 
had chronic HCV infection (3.1% [95% CI: 1.4%–6.5%]), 
defined as a reactive HCV antibody and positive HCV real-
time PCR (646). The mean age of HIV/HCV-coinfected chil-
dren was 16 years, and 57% had mild elevation (up to twofold 
above upper limit of normal) in serum transaminase levels.
Mother-to-child transmission is the predominant mode 
of HCV acquisition in children (699,700). Other potential 
sources of HCV infection in older children include injection-
drug use, body piercing, tattoos, unintentional needlestick 
injury, household contact, and sexual exposure (701,702). 
Before 1992, blood transfusion was a source of HCV infec-
tion in children; a recent retrospective study found that 3% 
of infants who had received blood transfusions in a neonatal 
intensive-care unit during 1975–1992 were anti-HCV-positive 
(703). However, the incidence of HCV infection from trans-
fusion has dramatically declined since 1992, when second-
generation HCV EIA screening was implemented. With the 
current additional use of nucleic acid amplification testing, the 
risk for HCV infection through transfusion is approximately 
1 per 2 million (704).
The overall risk for mother-to-infant transmission of HCV 
from a woman infected with HCV alone ranges from 4% to 
10% (699,705–712). The primary risk factor for perinatal 
HCV transmission is maternal HCV viremia at delivery, 
although an absolute threshold for HCV transmission has 
not been identified (706,713–717). Data do not indicate that 
HCV genotype is related to risk for perinatal HCV trans-
mission (706,712). Although a few studies have suggested 
that vaginal delivery increases risk for HCV transmission 
(705,707,709,713) and that HCV can be transmitted during 
the intrapartum period (718), most studies have found mode of 
delivery does not appear to influence perinatal HCV transmis-
sion (700,707,708,710,719–722). Additionally, even though 
HCV can be detected in breast milk, studies of infants born to 
HCV-infected women have not demonstrated a higher HCV 
transmission risk for breast-fed infants than for formula-fed 
infants (700,705–708,710,716,718,719,723).
Maternal HIV coinfection increases the risk for perinatal 
transmission, with perinatal HCV transmission rates of 
6%–23% reported for infants born to women coinfected 
with HCV and HIV (699,705–707,711,717,720–722,724–
729). Furthermore, a few studies suggest that children who 
acquire perinatal HIV infection may be more likely than 
children who did not acquire HIV to acquire HCV infection 
from HIV/HCV-coinfected mothers (720,721,727,729). 
Reported dual virus transmission has been reported in 
4%–10% of children born to HIV/HCV-coinfected mothers 
(705,720,725,727,728). HCV RNA levels are hypothesized 
to be higher among women coinfected with HIV than women 
infected with HCV alone, which could account in part for the 
increased risk for mother-to-child HCV transmission from 
HIV/HCV-coinfected women; however, not all studies have 
found higher levels of HCV viremia among HIV-infected 
mothers (715,721,724). One European study suggested that 
HCV perinatal transmission may be reduced among HIV-
infected women receiving HAART (722).
Chronic HCV infection, defined as the presence of HCV 
RNA for >6 months, appears to spontaneously resolve in 
15%–40% of adults (730). Findings from a limited number 
of longitudinal studies suggest that HCV infection resolves 
spontaneously in 17%–59% of children with perinatal HCV 
infection (731–736). Viral clearance occurs by age 3 years in 
most children and may be more frequent in children infected 
with HCV genotype 3 (735,737).
Clinical Manifestations
Children with perinatal HCV infection appear to have 
a more benign clinical course than do adults with newly 
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acquired HCV infection (701,738,739). Most HCV-infected 
children are asymptomatic, with minor abnormalities, such as 
hepatomegaly, or mild nonspecific symptoms, such as fatigue, 
myalgias, and poor weight gain (701,739,740); however, 
intermittent asymptomatic elevations in transaminase levels 
are common during the first 2 years of life (734,740,741). 
In a large European cohort of HCV-infected children, about 
20% of children had apparent clearance of HCV viremia; 50% 
had chronic asymptomatic infection, characterized by inter-
mittent viremia, rare hepatomegaly, and usually normal liver 
transaminase levels; and 30% had chronic active infection with 
persistent viremia and abnormal transaminase levels (735).
Histopathologic inflammatory changes of chronic hepatitis 
may be present in persons with chronic HCV infection despite 
lack of symptoms, normal serum transaminase levels, and low 
HCV RNA levels (740). However, most children with chronic 
HCV infection who have undergone liver biopsy and are 
included in published studies typically have mild-to-moderate 
liver disease as determined by signs of structural alterations, 
inflammatory activity, and necrosis (701,715,739,741). A small 
subset of children may develop more severe liver disease. In a 
study of 60 children with perinatally acquired or transfusion-
acquired HCV infection who were infected for a mean dura-
tion of 13 years, 12% had significant fibrosis on liver biopsy 
(739). Older age at time of infection and elevated serum 
gamma-glutamyltranspeptidase correlated with fibrosis; serum 
transaminase levels correlated with inflammation (739).
In HIV/HCV-coinfected adults, the natural history of 
HCV infection appears to be accelerated, with more rapid 
progression to cirrhosis, decompensated liver disease, HCC, 
and death (742,743). Data are minimal on the effect of HIV/
HCV coinfection on the natural history of HCV infection in 
children and are insufficient to draw conclusions about HCV 
disease progression in coinfected children (699).
Data on the impact of HCV infection on HIV disease 
progression in adults conflict; some studies suggest higher 
rates of HIV progression, and others do not (699). The effect 
of pediatric coinfection on HIV disease progression also is 
unclear because the number of coinfected children is small, and 
few studies have evaluated this. Two studies of children with 
perinatal HIV/HCV coinfection found no increase in HIV 
progression, but a study of older HIV/HCV-coinfected chil-
dren with thalassemia infected through transfusion observed 
more rapid disease progression and higher mortality than in 
children infected only with HIV (720,728,744).
Diagnosis
Testing for HCV infection should be considered for any 
child whose mother is known to have HCV infection. All 
HIV-infected adults or adolescents should be tested for HCV 
infection.
Serologic and nucleic acid tests are used to diagnose HCV 
infection. HCV RNA first becomes detectable 1–3 weeks after 
HCV infection and precedes serologic response to HCV (730). 
A third-generation EIA is available for detecting antibody to 
HCV (anti-HCV). Passively transferred maternal anti-HCV 
can be detected for up to 18 months in infants born to HCV-
infected mothers. In a large cohort of HCV-exposed but HCV-
uninfected children, anti-HCV was present in 15% of children 
at 12 months, 5% at 15 months, and 2% at 18 months (715). 
Therefore, only the presence of persistent HCV viremia can be 
used to reliably verify HCV infection in at-risk infants aged 
<18 months (745). HCV infection can be diagnosed in such 
infants using a nucleic acid test to detect HCV RNA after 
1 month of age; the sensitivity of the HCV RNA testing is 
low at birth (22%), but increases to 85% at 6 months (746). 
Most children with perinatal HCV infection will have a posi-
tive HCV RNA test by age 12 months. However, because of 
intermittent viremia, a single negative HCV RNA test is not 
conclusive evidence of lack of infection, and HCV RNA should 
be tested on at least two occasions between age 2 months and 
6 months to definitively exclude HCV infection in an HCV-
exposed infant (746).
A positive anti-HCV test in a child aged >18 months indi-
cates HCV infection. Supplemental testing with a more specific 
assay, such as HCV RNA testing, is recommended to prevent 
the reporting of a false-positive result. A positive HCV RNA 
test confirms HCV infection and, if positive for >6 months, 
suggests chronic infection. HCV RNA can be measured quali-
tatively or quantitatively. Qualitative nucleic acid tests include 
qualitative PCR and transcription-mediated amplification. 
Quantitative tests include branched-chain DNA amplification, 
quantitative PCR, and real-time PCR and are most useful for 
monitoring response to anti-HCV therapy (730). Quantitative 
HCV RNA level (i.e., HCV viral load) does not correlate 
with degree of liver damage and does not serve as a surrogate 
for measuring disease severity, but it does provide important 
information about the response to antiviral therapy. Assays 
vary substantially, and if serial values are required to monitor 
antiviral therapy, continued use of the same quantitative assay 
for all assessments is strongly recommended.
Liver biopsy is the most accurate test to assess the severity of 
hepatic disease and quantitate the amount of hepatic fibrosis 
present. A liver biopsy may be useful for determining whether 
to initiate therapy for chronic HCV infection (652,657). 
However, liver biopsy is not required before the initiation of 
anti-HCV therapy, particularly in patients with a high prob-
ability of responding to therapy.
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At least six HCV genotypes are known, with genotype 1 
occurring most commonly in the United States (730). Persons 
with HCV genotypes 2 and 3 are more likely than those with 
genotype 1 to achieve sustained virologic response to anti-HCV 
therapy; thus, results from a liver biopsy may be less likely to 
affect decisions about the need for treatment in patients with 
genotypes 2 or 3 (657,687).
Prevention Recommendations
Prevention of Exposure
All HIV-infected persons should be screened for HCV. No 
reliable strategy exists to prevent perinatal HCV transmission. 
Cesarean delivery is not associated with reduced perinatal 
transmission of HCV infection and is not recommended for 
this purpose for women with chronic HCV infection who are 
HIV-uninfected. Scheduled cesarean delivery is recommended 
for HIV-infected women who have HIV RNA levels >1000 
copies/mL near delivery to prevent perinatal HIV transmis-
sion (AII). Limited data suggest that breast-feeding does not 
transmit HCV. However, to prevent HIV transmission in the 
United States, where safe infant formula is available, HIV-
infected women should not breast-feed (AII) (747).
No vaccines are available to prevent HCV infection. 
Adolescents considering tattooing or body-piercing should 
be informed about potential risks for acquiring HCV, which 
could be transmitted if equipment is not sterile or if proper 
infection-control procedures are not followed, and to avoid 
injection-drug use and unprotected sex (BIII) (748). HCV-
infected persons should be advised not to share toothbrushes, 
razors, and other personal-care articles that might be contami-
nated with blood to prevent transmission of HCV.
Preventing First Episode of Disease
Patients with chronic liver disease can develop fulminant 
hepatitis from hepatitis A or B infection; all children (regardless 
of HIV and HCV infection status) should receive standard vac-
cination with hepatitis A and B vaccines (AIII) (39,40,748).
Treatment Recommendations
Treatment of Disease
Published studies are limited on treatment recommendations 
for HCV-infected children. Current pediatric trials in the 
United States—including the PEDS-C study, a randomized, 
double-blind, placebo-controlled trial of pegylated interferon-
alfa with and without ribavirin—should provide additional 
data. Data on treating children coinfected with HCV and HIV 
are even more limited. Consultation with experts in treating 
chronic HCV infection in children is recommended.
HIV/HCV-coinfected adults and adolescents
Treatment should be considered in any nonpregnant HCV-
infected adult, regardless of HIV coinfection status, who has 
abnormal serum transaminase levels with a liver biopsy showing 
chronic hepatitis with significant fibrosis and compenstated 
liver disease (749). Treatment should be considered for HIV/
HCV-coinfected adults for whom potential benefits of treat-
ment are judged to outweigh potential risks, including those 
infected with HCV genotype 2 or 3, those with stable HIV 
infection not requiring antiretroviral therapy, and those with 
cryoglobulinemic vasculitis or glomerulonephritis (652,750). 
Baseline serum HCV RNA level and HCV genotype are the 
primary predictors of response to treatment; younger age, 
higher CD4 count, elevated transaminase levels, lack of liver 
fibrosis, low body mass index, lack of insulin resistance, and 
white race are other variables associated with better treatment 
response (750). The recommended treatment is combined 
pegylated-interferon-alfa-2a or-2b plus daily oral ribavirin 
for 48 weeks regardless of HCV genotype. In HIV/HCV-
coinfected adults, rates of sustained virologic response range 
from 44% to 73% for treatment of HCV genotype 2 and 3 
infection and from 14% to 29% for HCV genotype 1 infection 
(641,751,752). Although some preliminary data from clini-
cal treatment trials suggest better rates of sustained virologic 
response, these may result from better preselection of patients 
for therapy or improved adherence after dose adjustment(s). 
Response to anti-HCV treatment improves in HIV/HCV-
coinfected adults with CD4 count >200 cells/mm3; therefore, 
HAART should be considered before anti-HCV therapy is 
initiated in HIV/HCV-coinfected patients with CD4 count 
<200 cells/mm3. Anti-HCV treatment usually is not recom-
mended during pregnancy for HCV-infected women because 
ribavirin is teratogenic.
HCV-infected children without HIV infection
Treatment of HIV-uninfected children aged <3 years who 
have HCV infection usually is not recommended because 
spontaneous HCV clearance can occur in this age group (DIII). 
All decisions about treatment of HCV infection in children 
should be individualized because HCV usually causes mild 
disease in children, and few data exist to identify risk factors 
differentiating those at greater risk for progression of liver 
disease (641,753).
The only currently FDA-approved therapy for HCV-infected 
children aged 3–17 years with compensated liver disease is 
combined standard interferon-alfa-2b and ribavirin. Standard 
interferon-alfa is administered by subcutaneous injection three 
times per week. Ribavirin oral solution has been approved 
for treatment of chronic HCV infection among children 
aged >3 years. For HIV-uninfected children with HCV 
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infection, a 24-week course of therapy is recommended for 
genotypes 2 and 3; 48-week courses are administered for 
other HCV genotypes. Combination therapy with standard 
interferon-alfa and ribavirin results in overall rates of sustained 
virologic response of 46%–65% and is well-tolerated in chil-
dren (657,687,754–757). Similar to adults, children infected 
with genotype 1 were less likely to have a sustained virologic 
response (36%) than those infected with genotype 2 or 3 (84%) 
(687). Other factors associated with favorable response to anti-
HCV treatment in children include lower pretreatment HCV 
RNA levels, white race, and possibly younger age (657).
HIV/HCV-coinfected children
No specific treatment studies have been done of children with 
HIV/HCV-coinfection, and recommendations are based pri-
marily on data from adults. Because therapy for HCV infection 
is more likely to be effective in younger patients and in those 
without advanced disease or immunodeficiency, treatment 
should be considered for all HIV/HCV-coinfected individuals, 
including HIV-infected children aged >3 years who have no 
contraindications to treatment (BIII). Some specialists would 
treat children infected with HCV genotypes 2 or 3 without 
first obtaining a liver biopsy (BIII). Pegylated interferon-alfa, 
which is administered by injection once weekly for 48 weeks 
combined with ribavirin, is recommended for treatment of 
HCV infection in adults. However, pegylated interferon-alfa 
is not FDA-approved for use in HCV-infected children—
although it is under study. On the basis of the increased efficacy 
of combination therapy with ribavirin and either standard or 
pegylated interferon-alfa and on data from adults, treatment 
of HCV-infected children, regardless of HIV status, should 
include combination therapy with ribavirin and interferon-alfa 
(BIII). In HIV/HCV-coinfected adults, the recommended 
duration of treatment is 48 weeks for infections with all HCV 
genotypes, including 2 and 3, because coinfected adults may 
not respond as well as those without HIV infection and may 
have greater relapse rates. Moreover, the efficacy of shorter 
treatment duration has not been adequately evaluated in HIV-
infected persons (750). By extrapolation, 48 weeks of therapy 
also are recommended for HIV/HCV-coinfected children 
(BIII). Potential drug interactions complicate the concomitant 
use of antiretroviral therapy and anti-HCV therapy. Ribavirin 
enhances phosphorylation of didanosine, which could increase 
the risk for toxicity; therefore, these drugs should not be used 
together (EIII). Ribavirin and zidovudine both are associated 
with anemia and, when possible, should not be administered 
together (DII) (750).
Monitoring and Adverse Events, Including IRIS
Although no evidence-based long-term monitoring guide-
lines exist for children with perinatally acquired HCV, many 
experts monitor HCV RNA levels and serum transaminase 
levels every 6–12 months and hemogram and serum alpha 
fetoprotein levels annually (748). Serum transaminase levels 
can fluctuate and do not necessarily correlate with histologic 
liver damage because significant liver disease can be present 
in patients with normal serum transaminase levels. In HCV-
infected persons without HIV, HCC rarely is seen in the 
absence of cirrhosis. The benefits of serum alpha fetoprotein 
and abdominal sonography as screening tools for HCC have 
not been studied in children. Some experts will perform peri-
odic sonographic screening at defined intervals (every 2–5 
years) in children with chronic HCV infection; others will 
do these tests only in those with advanced liver disease and/
or rising serum alpha fetoprotein concentrations (748). The 
risk for HCC in HCV-infected children, with or without HIV 
infection, is not known.
HCV RNA quantitation is used to monitor response to 
antiviral therapy. HCV RNA levels should be performed at 
baseline, after 12 and 24 weeks of antiviral therapy, at treatment 
completion (48 weeks), and 6 months after treatment cessation. 
Some experts continue to perform serial HCV RNA testing at 
6- to 12-month intervals for an additional 1–5 years to exclude 
late virologic relapse. Decreases in HCV RNA >2 logs below 
the baseline during the first 12 weeks of therapy constitute an 
early virologic response (730). A sustained virologic response 
is defined as absence of detectable HCV RNA using an HCV 
RNA assay with a lower limit of detection of >50 IU/mL at 
24 weeks after antiviral treatment ends. Relapse is defined 
as HCV RNA rebound at the end of therapy after an initial 
response to undetectable HCV RNA levels. Nonresponse is 
defined as failure to suppress HCV RNA below detection at 
any time during treatment; breakthrough is the reemergence 
of detectable HCV RNA after suppression below the limits of 
detection despite the continuation of therapy.
In the absence of data from HIV/HCV-coinfected children, 
the same criteria for determining response to therapy in HIV/
HCV-coinfected adults should be used. If an early virologic 
response is observed after the first 12 weeks of treatment, 
completion of additional HCV therapy is recommended. 
Adults who do not achieve an early virologic response by week 
12 have a limited chance (<3%) of achieving sustained virologic 
response, regardless of duration of therapy, and treatment can 
be discontinued after 12 weeks in such patients. Persons who 
achieve a >2 log10 reduction in HCV RNA level but who 
have detectable HCV RNA after 12 weeks of therapy should 
be retested after completion of 24 weeks of therapy. If HCV 
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RNA remains detectable after 24 weeks, anti-HCV treatment 
should be stopped, whereas an additional 24 weeks of therapy 
is indicated (total 48 weeks) if HCV RNA is not detected at 
that time. Persons who achieve an undetectable HCV RNA 
level after 12 weeks of therapy should complete an additional 
36 weeks of anti-HCV treatment (total 48 weeks).
In addition to HCV RNA quantitation, patients receiving 
antiviral therapy for HCV infection should be closely moni-
tored for medication side effects with complete blood count, 
serum transaminase levels, and tests of thyroid function. If the 
child also is initiating HAART, some experts would monitor 
transaminase levels more frequently during the first few months 
of therapy (e.g., monthly for 3 months) because of the risk for 
IRIS (see below).
Side effects of interferon-alfa in children, although frequent, 
usually are not severe; approximately 5% of children require 
treatment discontinuation because of side effects. The most 
common side effects include influenza-like symptoms (e.g., 
fever, chills, headache, myalgias, arthralgias, abdominal pain, 
nausea, and vomiting) in 80% of patients during the first 
month of treatment. However, these symptoms usually resolve 
over time and usually are not treatment-limiting; premedica-
tion with acetaminophen or ibuprofen might reduce the inci-
dence of side effects. Subtle personality changes that resolve 
when therapy is discontinued have been reported in 42% of 
children (686). Depression and suicidal ideation also have been 
reported in clinical trials of children treated with interferon-alfa 
(687). Neutropenia, which resolves after discontinuation of 
therapy, is the most common laboratory abnormality; anemia 
and thrombocytopenia are less common. Abnormalities in thy-
roid function (hypothyroidism or hyperthyroidism) have been 
reported with interferon-alfa therapy (688). Loss of appetite, 
with transient weight loss and impaired height growth, can 
occur but usually resolves after completion of therapy (689). 
Less commonly observed side effects of interferon-alfa include 
epistaxis and transient mild alopecia. Certain children have 
developed antinuclear autoantibodies. Interferon-alfa therapy is 
contraindicated for children with decompensated liver disease; 
substantial cytopenias; severe renal, cardiac, or neuropsychiatric 
disorders; and autoimmune disease (EII) (690).
Side effects of ribavirin include hemolytic anemia and 
lymphopenia. Ribavirin-induced hemolytic anemia is dose-
dependent and usually presents with a substantial decrease in 
hemoglobin within 1–2 weeks after ribavirin initiation, but 
the trend usually stabilizes. Significant anemia (hemoglobin 
<10 g/dL) occurs in about 10% of ribavirin-treated children 
(753). Use of erythropoietin for managing clinically signifi-
cant anemia during HCV treatment can be considered (BIII). 
Coadministration of didanosine is contraindicated in children 
receiving ribavirin because this combination can increase the 
risk for mitochondrial toxicity and hepatic decompensation 
(EIII). Children receiving concomitant zidovudine may be 
more likely to experience bone marrow suppression; if possible, 
zidovudine should be avoided in children receiving ribavirin 
(DIII). If zidovudine and ribavirin are administered together, 
the child should be monitored closely for neutropenia and 
anemia. Ribavirin is teratogenic and should not be used in 
pregnant women. Sexually active adolescent boys and girls 
or those likely to become sexually active who are receiving 
ribavirin should be counseled about the risks and need for 
consistent contraceptive use during, and for 6 months after 
completion of, ribavirin therapy.
As with HIV/HBV coinfection, the institution of HAART 
in HIV/HCV-coinfected patients can worsen hepatitis, with 
increases in serum transaminase levels and clinical signs of 
liver disease, including hepatomegaly and jaundice. This 
does not represent a failure of HAART but rather a sign of 
immune reconstitution. IRIS manifests by an increase in serum 
transaminase levels as the CD4 count increases during the first 
6–12 weeks of HAART. Thus, serum transaminase levels should 
be monitored closely after introduction of HAART in HIV/
HCV-coinfected children. The prognosis for most persons with 
IRIS is favorable because a robust inflammatory response may 
predict an excellent response to HAART in terms of immune 
reconstitution and, perhaps, improved survival. In a patient 
experiencing a hepatic flare, differentiating between IRIS and 
drug-induced liver toxicity may be difficult, and no reliable 
clinical or laboratory predictors exist to distinguish between the 
two. Close interaction of the HIV specialist with a specialist 
in hepatic disease is recommended for such patients; prompt 
consultation with a hepatologist should be sought if elevated 
aminotransferases are associated with clinical jaundice or other 
evidence of liver dysfunction (e.g., low serum albumin).
Management of Treatment Failure
No data exist on which to base recommendations for treat-
ment of HIV/HCV-coinfected children or adults in whom 
initial HCV treatment fails. In HIV/HCV-coinfected adults, 
a second course of treatment for nonresponders (those who 
do not achieve early virologic response by week 12 or unde-
tectable HCV load at week 24) or patients whose HCV 
relapses has limited chances of resulting in sustained virologic 
response. Therapeutic interventions for such patients need to 
be individualized according to prior response, tolerance, and 
adherence to therapy; severity of liver disease; viral genotype; 
and other underlying factors that might influence response. 
Some experts might extend the duration of treatment (e.g., to 
72 weeks) for adults who experience a virologic response fol-
lowed by relapse after adequate HCV therapy or for patients 
with advanced fibrosis, long-term administration of low-dose 
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pegylated interferon. No data exist for HIV/HCV-coinfected 
children on which to base a recommendation.
Prevention of Recurrence
Not applicable.
Discontinuing Secondary Prophylaxis
Not applicable.
Human Herpesvirus 6 and 7
Epidemiology
Human herpesvirus 6 (HHV-6) and herpesvirus 7 (HHV-7) 
are closely related members of the Roseolovirus genus of her-
pesviruses. Humans are the only known natural host for these 
two viruses. The cellular reservoir is believed to be peripheral 
blood mononuclear cells (PBMCs) and possibly epithelial cells 
of the salivary glands and the bronchial tree. The infection is 
believed to be transmitted primarily through saliva; sexual 
transmission may occur, and presumptive in utero infection 
has been described. Reactivation, with salivary shedding, 
occurs frequently among immunocompetent children and 
adults (758).
HHV-6 has two subtypes, A and B. HHV-6B is the etiologic 
agent of most primary infections; HHV-6A has been linked to 
neurologic syndromes. The vast majority of children become 
infected with HHV-6 early in childhood, with 70%–90% 
of children HHV-6 seropositive by age 2 years, and virtually 
100% by age 3 years (759,760). In a large prospective study 
of North American children, the peak age of acquisition of 
HHV-6 was 6–9 months (761). Such infection is associated 
with varied clinical manifestations, viremia, and the frequent 
persistence of the viral genome in PBMCs (762).
HHV-6 also can be transmitted from mother to child. In 
several recent studies, virtually 100% of pregnant women 
were HHV-6–seropositive. During pregnancy, 2%–9% of 
women shed virus in the genital tract (763,764). Congenital 
HHV-6 infection has been documented in <2% of newborns 
(760,761,765,766). In one large study of approximately 5000 
births, 1% of cord blood samples were positive for HHV-6 
DNA. None of the congenitally infected infants were symp-
tomatic (761). The virus does not appear to be transmitted 
by breast-feeding.
HHV-6 infects the same target cells as HIV, and HHV-6 
and HIV can simultaneously infect the same CD4 cells under 
experimental conditions. Some evidence exists for interactions 
between HHV-6 and HIV at the cellular or molecular levels. 
Some studies have suggested that HHV-6 upregulates HIV 
expression in coinfected cells in vitro (767,768).
In a study of HHV-6 infection in 227 children born to 
HIV-infected mothers, three (7%) of 41 HIV-uninfected 
infants were positive for HHV-6 DNA in the first month of life, 
suggesting possible intrauterine infection (759). The cumula-
tive infection rates of HHV-6 at ages 6 and 12 months were 
significantly lower in HIV-infected children (11% and 33%, 
respectively) than in HIV-uninfected children (28% and 78%, 
respectively), and high CD4 percentage (>15%) in the child 
before HHV-6 infection was associated with high HHV-6 
infection rate. However, HIV disease progressed longitudinally 
in all 10 infants with HIV/HHV-6 coinfection and in 58% 
of those without HHV-6 coinfection, suggesting that HHV-6 
coinfection might increase risk for HIV disease progression.
HHV-7 is acquired later in life than HHV-6. In contrast 
to HHV-6, seropositivity to HHV-7 is approximately 50% at 
age 2 years. Reactivation and/or persistent shedding also can 
occur. Salivary shedding is common, noted in up to 90% of 
seropositive adults, and HHV-7 DNA has been found in breast 
milk (unlike HHV-6) (769).
Clinical Manifestations
Many cases of primary infection with HHV-6, which usually 
occurs by age 2 years, are asymptomatic or accompanied by 
mild, nonspecific symptoms. The most common symptom is 
fever, which can be high and abrupt, associated with cranki-
ness and rhinitis. In several studies, primary HHV-6 infection 
was associated with infants presenting for care of acute febrile 
illness. Among children aged <3 years presenting for evalua-
tion of a febrile illness, 10% had primary HHV-6 infection; 
the incidence was 20% for febrile infants aged 6–8 months 
(770).
HHV-6 is the causative agent of most cases of exanthem 
subitum (also known as roseola infantum), a febrile illness of 
early childhood, associated with a distinctive exanthem. The 
incidence of HHV-6–related exanthem subitum peaks at age 
6–9 months and is associated with fever of 4–5 days, with 
rash developing as the fever subsides (771). Ten percent to 
20% of infants with primary HHV-6 infection will present 
with exanthem subitum. HHV-7 also has been associated with 
exanthem subitum.
Both primary infection with and reactivation of HHV-6 has 
been associated with several CNS syndromes in immunocom-
petent children and adults, including febrile and nonfebrile 
seizures, encephalitis/encephalopathy and acute necrotizing 
encephalopathy (770,772,773). Convulsions, a feature of 
severe HHV-6 infection, often can be prolonged and com-
plicated (774).
Reactivation of HHV-6 occurs in adults with immuno-
deficiency or in patients on immunosuppressive therapy after 
transplantation. Although the exact frequency of HHV-6 
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reactivation in transplant recipients (bone marrow and solid 
organ) is difficult to determine, it appears to be common and 
occurs within the first 12 weeks after transplantation (775). 
Most reactivation involves HHV-6B. Many episodes of reac-
tivation are asymptomatic, but when symptoms occur, they 
can include fever, skin rash, and leukopenia. Pneumonitis, 
encephalitis, bone marrow suppression, and graft versus host 
disease have been associated with reactivation of HHV-6 after 
bone marrow transplantation (775,776).
HIV-infected persons exhibit frequent reactivation of 
HHV-6 (775); whether this causes symptoms or progression of 
illness is controversial. Symptoms most likely to be associated 
with HHV-6 are pneumonitis and encephalitis.
Reactivation of HHV-7 also occurs in immunocompetent 
and immunodeficient persons. The relation of HHV-7 reacti-
vation to disease states is still poorly understood.
Diagnosis
Many primary infections result in a nonspecific febrile ill-
ness. The 10%–20% of primary infections that manifest as 
exanthem subitum can be clinically diagnosed on the basis of 
symptomatology and distinctive rash.
Diagnosing HHV-6–related illness can be difficult because 
of the frequent reactivation in immunocompetent healthy 
children and adults. Specific testing for HHV-6 or -7 infection 
may be performed using such laboratory methods as serology, 
culture, antigen detection, PCR, in situ hybridization, and 
immunohistochemistry. The latent nature of these herpesvi-
ruses must be considered, and the differing capability of these 
tests to distinguish nonreplicating latent virus from replicating 
active virus must be understood (777). Laboratory evaluations 
(e.g., serology and PCR) to diagnose HHV-7 infections are 
rarely used and typically limited to research.
Demonstration of an HHV-6–specific antibody seroconver-
sion or significant change in antibody titer between acute and 
convalescent paired serum samples can diagnose infection with 
HHV-6; delay can occur between initial infection and seroposi-
tivity, especially in immunodeficient patients. The sensitivity of 
serology varies and does not distinguish between HHV-6A and 
HHV-6B. Some cross reactivity may occur with HHV-7.
Identification of HHV-6 or -7 in PBMCs by virus culture 
firmly establishes the presence of active infection in immu-
nocompetent hosts, but association with specific disease is 
problematic in immuno compromised patients because of a 
low background rate of viremia. Virus culture requires cocul-
tivation with PBMCs or cord blood and requires 1–3 weeks 
(777). Therefore, it is available only in specialized research 
laboratories.
PCR can be used to detect HHV-6 DNA or RNA. A positive 
serum, plasma, or PBMC viral DNA or RNA PCR assay, in 
the absence of measurable antibody, indicates a primary infec-
tion. HHV-6 is found in cellular material such as PBMCs and 
tissue even during latency; therefore, after primary infection a 
positive DNA PCR cannot be used to establish reactivation, 
whereas detection of cell-free viral DNA or RNA in plasma, 
serum, or CSF by PCR (776) is considered evidence of active 
viral replication—and thus reactivation—in a seropositive 
patient. Evidence of reactivation and clinical disease must be 
correlated cautiously because of the frequent asymptomatic 
reactivation in most adults and children (775,776).
Prevention Recommendations
Preventing Exposure
Because HHV-6 and HHV-7 infections are ubiquitous, pre-
vention of primary infection is not possible. Among transplant 
recipients, prophylactic ganciclovir may decrease the number 
of episodes and severity of HHV-6 reactivation (778,779).
Preventing First Episode of Disease
Given the ubiquity of HHV-6 and -7 during early childhood 
and the lack of an effective vaccine, prevention of HHV-6 
disease is not feasible.
Discontinuing Primary Prophylaxis
Not applicable.
Treatment Recommendations
Treatment of Disease
Most HHV-6 primary infections result in a mild, self-limited 
febrile illness. For the immunodeficient adult or child with 
possible HHV-6–associated lung or CNS disease, care must 
be used to exclude other diagnostic possibilities. No clear 
indications exist for treating HHV-6 infection in HIV-infected 
children, although treatment might be considered for the rare 
instance of severe encephalitis proven to result from HHV-6 
(CIII). However, no clinical trials or proven therapies exist for 
HHV-6. On the basis of data in adults, drugs that might be 
considered for severe HHV-6 disease are ganciclovir, foscarnet, 
and cidofovir. However, even though in vitro data suggest 
ganciclovir and foscarnet are active against HHV-6, data are 
limited that support their use among HIV-infected patients 
with possible HHV-6 related illness (CIII) (776,780,781). 
Ganciclovir has been used to treat HHV-6 encephalitis in adult 
transplant patients (782). However, limited success of ganciclo-
vir therapy in preventing fatal outcome has been reported; in 
the patients who died, ganciclovir did not reduce HHV-6 load 
in CSF (783). Case reports have documented both successful 
and disappointing results of foscarnet treatment for HHV-6 
encephalitis in transplant recipients (783–785). Cidofovir 
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followed by foscarnet has been used in a stem cell transplant 
recipient who developed HHV-6 encephalitis with evidence of 
a significant reduction in HHV-6 load in CSF and in plasma 
after cidofovir administration (786). One case of successful 
use of high-dose ganciclovir to treat HHV-6 encephalitis was 
reported in a pediatric bone marrow transplant patient (787). 
Given the lack of data in children, no specific recommenda-
tions can be made.
HHV-7 has not been recognized as responsible for any 
specific disease in HIV-infected persons, and no treatment is 
indicated.
Monitoring and Adverse Events, Including IRIS
The major side effect of ganciclovir is myelosuppression (i.e., 
anemia, neutropenia, and thrombocytopenia). Dose reduction 
or interruption because of hematologic toxicity may be neces-
sary in <40% of patients receiving IV ganciclovir; granulocyte 
colony-stimulating factor can be used to ameliorate marrow 
suppression. The main toxicities of foscarnet are decreased renal 
function and metabolic derangements. For patients receiv-
ing ganciclovir or foscarnet, complete blood counts, serum 
electrolytes, and renal function should be monitored twice 
weekly during induction therapy and once weekly thereafter. 
The major side effect of cidofovir is potentially irreversible 
nephrotoxicity; the drug produces proximal tubular dysfunc-
tion, including Fanconi syndrome and acute renal failure. 
When present, renal toxicity manifests as proteinuria and 
glycosuria. To minimize nephrotoxicity, probenicid should 
be administered before each infusion, and IV hydration with 
normal saline should be administered before and after each 
cidofovir infusion. For patients receiving IV cidofovir, blood 
urea nitrogen, creatinine, and urinalysis should be performed 
before each infusion; administration of the drug is contra-
indicated if renal dysfunction or proteinuria is detected. Other 
reported adverse events include anterior uveitis and ocular 
hypotony; serial ophthalmologic monitoring for anterior seg-
ment inflammation and intraocular pressure is needed while 
the drug is being received systemically. Cidofovir should not 
be administered concomitantly with other nephrotoxic agents. 
Cidofovir therapy must be discontinued if serum creatinine 
increases >0.5 mg/dL above baseline.
HHV-6 and HHV-7 have not been associated with IRIS with 
HAART treatment in HIV-infected children or adults.
Management of Treatment Failure
Mutations conferring resistance of HHV-6 to ganciclovir, 
cidofovir, and foscarnet have been described (788). Whether 
a change from one drug to the other would be beneficial is 
unknown.
There are currently no recommendations for the manage-
ment of treatment failure.
Prevention of Recurrence
No data exist on preventing HHV-6 or HHV-7 reactivation 
from latency in HIV-infected patients.
Discontinuing Secondary Prophylaxis
Not applicable.
Human Herpesvirus 8 Disease
Epidemiology
Human herpesvirus 8 (HHV-8) is a transmissible DNA 
virus, with similarities in DNA structure to Epstein-Barr virus. 
HHV-8 has been causally linked to all forms of KS (HIV-
related and endemic KS) and with two rare neoplastic condi-
tions usually associated with HIV infection, body cavity-based 
lymphoma and multicentric Castleman disease. The exact 
mechanism by which HHV-8 infection leads to neoplastic 
disease has not been fully elucidated, but seroconversion to 
HHV-8 antibody positivity virtually always precedes develop-
ment of the tumors (789). Higher plasma HHV-8 DNA titers 
are associated with increased risk for KS (790).
The prevalence of antibodies to HHV-8 varies widely with 
age and geography. In the United States and Europe, 1%–3% 
of the general adult population is seropositive, with higher rates 
(8%) among men who have sex with men (791). Among other 
adult men in the general population, HHV-8–seropositivity 
was marginally associated with duration of heterosexual activ-
ity and positively associated with the number of lifetime sex 
partners and coinfection with HBV and HSV type 2 viruses; 
none of these were significantly associated with risk for women. 
In contrast, the seropositivity rate in some areas of Africa is 
>80% (792–795).
HHV-8 is transmitted through oral and genital secretions. 
Immunocompetent HHV-8–infected adults frequently shed 
HHV-8 in their oropharyngeal secretions, with virus detected 
in saliva on 22% of test days (796). In areas where HHV-8 
infection is endemic, the seroprevalence increases quickly 
during the first 5 years of life, especially when other family 
members are HHV-8–positive, then plateaus until adoles-
cence and young adult years. In a study in rural Tanzania, the 
rate of positivity for HHV-8 was 3.7% among infants, 58% 
among children aged 4–5 years, and 89% among adults aged 
>45 years (797). The incidence among infants and children 
increased with the number of HHV-8-positive parents and 
siblings in the home, indicating nonsexual transmission for 
prepubertal children, with a limited role for perinatal trans-
mission (797–803).
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In the United States, among a cohort of high-risk HIV-
infected and HIV-negative adolescents, with a median age 
of 19 years, 11.2% were HHV-8–positive (804). The highest 
rates were in adolescent HIV-infected males reporting sex with 
males (23%). Seropositivity was associated with HIV infec-
tion, men who have sex with men, a history of syphilis, and 
injection-drug use (804,805).
HHV-8 also may be transmitted through exposure to 
infected blood. Adult injection-drug users have an increased 
rate of HHV-8 positivity (804,805). In addition, recent evi-
dence suggests that HHV-8 may be transmitted through blood 
product transfusions. In one study in an area of Uganda with 
a high incidence of HHV-8–seropositivity, the excess risk for 
acquiring HHV-8 through transfusion was nearly 3%, recipi-
ents of HHV-8 antibody-positive blood were compared with 
those receiving HHV-8–negative blood (806).
A small study suggested that maternal HHV-8 infection 
might increase risk for perinatal transmission of HIV, although 
no evidence of HHV-8 infection was identified among HIV-
infected infants (801). Women coinfected with HHV-8 and 
HIV had increases in both HHV-8 and HIV viral load in serum 
and/or cervical fluid during pregnancy (807).
During the pre-HAART era, the overall incidence of KS 
among HIV-infected adults was as high as 20%. However, the 
rate among children was low. In the United States and England, 
KS represented <1% of pediatric AIDS-defining illnesses.
The incidence of KS appeared to decline even before the 
widespread use of HAART. The reason for this decline was 
unclear but may have been related to the use of other antiviral 
agents, such as those used to treat CMV (i.e., foscarnet, ganci-
clovir, and cidofovir), which may inhibit HHV-8 (808–814). 
KS, primary effusion lymphoma, and multicentric Castleman 
disease are described most frequently among HIV-infected 
persons with more advanced immunosuppression (CD4 count 
of <200 cells/mm3), but they can occur at any CD4 count. 
With the advent of earlier and more aggressive HAART, the 
incidence of KS in adults has continued to decrease (815).
Although KS occurs primarily in adults, the incidence in 
children has increased substantially as a result of the HIV 
pandemic, particularly in Africa, and the frequent use of 
immunosuppressive drugs. One series reported a 40-fold 
increase in incidence of childhood KS in Uganda in the era 
of AIDS (816).
Clinical Manifestations
A febrile illness with mild respiratory symptoms and a macu-
lopapular rash has been associated with primary infection in 
young immunocompetent children (817). A similar self-limited 
illness has been described in adults with primary infection. 
Evidence suggests more significant symptomatology among 
immunodeficient adults with primary infection, including 
reports of fever, arthralgia, splenomegaly, and bone marrow 
suppression (818,819).
KS presentation varies widely, but most persons have non-
tender, purplish, indurated skin lesions; intraoral lesions can 
be seen and visceral dissemination can occur, occasionally 
without skin lesions. Multicentric Castleman disease presents 
with generalized adenopathy and fever and may progress to 
multiorgan failure.
Diagnosis
The laboratory diagnosis of HHV-8 is most commonly based 
on serologic assays, such as immunofluorescence, enzyme-
linked immunosorbent assay, and Western blot. However, 
without a standard for diagnosing HHV-8 infection, these 
tests range in sensitivity from 80% to >90% and demonstrate 
poor interassay agreement (820). Combination assays contain-
ing both lytic and late-phase antigens may improve detection 
rates. Nucleic acid-based tests, such as in situ DNA hybrid-
ization and PCR, are important for pathologic diagnoses in 
biologic specimens. Although these tests have high levels of 
sensitivity, specificity and reproducibility are highly variable. 
Routine screening for HHV-8 by PCR or serologic testing is 
not indicated for HIV-infected persons.
Prevention Recommendations
Preventing Exposure
For HIV-infected persons, coinfection with HHV-8 places 
them at risk for KS. The risk is highest in adults (compared 
with children) and in persons with severe immunodeficiency. 
Routine testing of children and adults for HHV-8 is not 
recommended; therefore, the serostatus of newly identified 
HIV-infected persons usually is not known. For adolescents 
in whom KS is diagnosed, counseling should include the pos-
sibility of transmitting HHV-8 to their sexual contacts through 
intercourse and possibly kissing. Although efficacy of condom 
use for preventing HHV-8 exposure has not been established, 
HIV-infected persons should use latex condoms during every act 
of sexual intercourse to reduce exposure to sexually transmitted 
pathogens. HIV-infected injection-drug users should be coun-
seled not to share drug-injection equipment, even if both users 
are already HIV-infected, because of the risk of becoming 
infected with HHV-8 or other bloodborne pathogens.
In the future, HHV-8 testing of donated blood products, 
before use for immunodeficient patients, might be considered. 
In addition, the routine use of leukocyte reduction for red cell 
transfusions may lower the transmission risk.
Infants can acquire HHV-8 perinatally or through contact with 
infected family members and playmates. No effective interven-
tion is known to prevent childhood acquisition of HHV-8.
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Preventing First Episode of Disease
The use of HAART with suppression of HIV replication 
has markedly decreased the incidence of KS among HIV-
infected adults and should be the goal of treatment wherever 
possible (AII). Routine testing to identify HHV-8 seropositive 
HIV-infected persons is not recommended (DIII). Although 
several antiviral agents inhibit HHV-8 replication in vitro (e.g., 
ganciclovir, foscarnet, cidofovir), no data exist on their use to 
prevent KS in persons coinfected with HIV and HHV-8.
Treatment Recommendations
Treatment of Disease
Because the HIV-related clinical entities associated with 
HHV-8, such as KS and Castleman’s disease, are oncologic and 
traditionally have been treated with cytotoxic chemotherapy, 
specific treatment is not included in this report. However, 
effective suppression of HIV replication with HAART among 
HIV-infected patients with KS might prevent KS progres-
sion or occurrence of new lesions and should be considered 
for all persons with evidence of active KS and other HHV-
8–associated malignant lymphoproliferative disorders (AII).
In HIV-infected adults, HHV-8 cellular viremia and higher 
viral load have been associated with disease progression (821). 
Treatment with specific antiviral agents, such as ganciclovir, 
foscarnet, and cidofovir, which have in vitro activity against 
the lytic but not latent phase of HHV-8, has not been widely 
studied. Additionally, the vast majority of infected cells are not 
undergoing lytic replication, and antiherpes medications have 
had little or no effect on established KS or HHV-8 cellular 
viremia. Efforts to induce lytic replication or to attack the 
episomal (latent) HHV-8 genome are in progress (822,823).
In contrast to KS, many of the cells in Castleman disease sup-
port lytic replication of HHV-8, and treatment of Castleman 
disease with antiherpesvirus drugs has led to substantial clinical 
improvement in some studies (823). The use of IV ganciclovir 
or oral valganciclovir is recommended for treating multicentric 
Castleman disease (BII) (824) and may be a useful adjunct 
for treating primary effusion lymphoma (BII) (825,826). 
Appropriate chemotherapy, in combination with potent 
antiretroviral therapy, should be considered for patients with 
visceral KS or primary effusion lymphoma (BII).
Monitoring and Adverse Events, IRIS
Rapid progression of KS after initiation of HAART and after 
a change from a failing regimen to a more potent one have 
been reported. Progression of KS, representing IRIS, usually 
appeared within 8 weeks after start of a potent HAART regi-
men. Most patients experienced rapid progression of cutaneous 
lesions; however, sudden worsening of pulmonary KS, with 
resultant deaths, was reported in at least four patients. All 
reported fatalities were linked to pulmonary KS. In most cases, 
HAART was continued with stabilization and then regression 
of lesions. In more severe cases, especially those involving vis-
ceral lesions, chemotherapy was instituted and, in combination 
with HAART, led to regression of the KS (827,828).
Management of Treatment Failure
No recommendations exist for management of treatment 
failure.
Prevention of Recurrence
Effective suppression of HIV replication with HAART 
among HIV-infected patients with KS might prevent KS pro-
gression or occurrence of new lesions and should be considered 
for all persons with evidence of active KS (BII).
Discontinuing Secondary Prophylaxis
Not applicable.
Herpes Simplex Virus
Epidemiology
HSV-1 and HSV-2 affect all populations. HSV-1 is trans-
mitted primarily through contact with infected oral secretions; 
HSV-2 is acquired primarily through contact with infected 
genital secretions. In developed countries, urban poor popula-
tions acquire HSV-1 at a younger age (70%–80% seropositive 
by age 20 years) than do the rest of the population (30%–40%) 
(829). In a large U.S. study, HSV-1 seroprevalence in children 
aged 6–13 years was 31% and increased with age, from 26% 
in 6- to 7-year-olds to 36% in 12- to 13-year-olds, and varied 
by race/ethnicity, birthplace, and poverty levels (higher in 
non-Hispanic blacks, children born in Mexico, and children 
living below poverty level) (830). The seroprevalence of HSV-1 
approaches 60% among the general older adult population 
(831). HSV-2 seroprevalence in persons aged 14–49 years was 
17% and increased with age, from 2% in 14- to 19-year-olds 
to 26% in 40- to 49-year-olds. HSV-2 seroprevalence was 
higher in non-Hispanic blacks, persons with large numbers of 
sex partners, and females and varied by birthplace and poverty 
level (831,832).
An HSV-infected mother can transmit HSV to her infant, 
resulting in neonatal infection. In older children and adults, 
classic HSV transmission is person to person through direct 
contact with infected oral secretions or lesions. Neonatal HSV 
infection rate is 1 case per 2000–15,000 deliveries (833). 
Neonatal transmission occurs primarily through exposure of 
the infant to HSV-infected maternal genital fluids during pas-
sage through the birth canal; by ascending infection; or through 
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use of invasive procedures, such as fetal scalp monitoring, that 
disrupt fetal skin integrity during labor (834). Congenital (in 
utero) HSV acquisition is rare but can result in devastating 
cutaneous, ocular, and CNS damage.
Maternal HSV antibody status before delivery influences 
both the severity and likelihood of transmission to the infant 
(834). The risk for neonatal HSV infection is greatest in an 
infant born to a woman with primary HSV infection (range: 
30%–50%) (829). The risk is much lower (0%–5%) for infants 
born to women shedding HSV caused by reactivated infection 
(589). Genital shedding of HSV at delivery increases risk for 
transmission, and prolonged rupture of membranes (>6 hours) 
increases the risk, probably because of ascending HSV infection 
from the cervix. Cesarean delivery substantially lowers the risk 
for transmission (829,834,835). Importantly, many mothers 
of neonates with HSV-related illness will have pregnancy 
histories void of either past HSV infection or primary lesions 
(834). In the United States, 75% of neonatal infections are 
caused by genital herpes, HSV type 2, and the remainder by 
HSV type 1.
In a study of seroprevalence among pregnant U.S. women, 
overall HSV-1 seroprevalence was 63%; HSV-2 seroprevalence, 
22%; and infection with both HSV-1 and 2, 13% (836). HSV 
seroprevalence differed by race/ethnicity and number of life-
time sex partners. HSV-2 infection rates might be higher in 
HIV-infected than HIV-uninfected women. Women infected 
with HIV, particularly those with low CD4 count, shed HSV 
from the vulva and cervix more commonly than do HIV-
uninfected women; most of this shedding is asymptomatic 
(589,837). Among HIV-uninfected women, the rate of HSV 
reactivation is approximately 25% during the last month of 
pregnancy, but 2%–3% will be shedding on the day of delivery 
(838). In comparison, in women coinfected with HIV and 
HSV, an estimated 10% have cervical shedding of HSV on 
the day of delivery (839). The risk for genital HSV reactivation 
and shedding increases as HIV-related immunosuppression 
progresses (837,839). No evidence indicates that in utero HSV 
infection of the infant occurs more frequently in HIV-infected 
pregnant woman or whether infants born to women coin-
fected with HIV and HSV-2 are at increased risk for perinatal 
(intrapartum) HSV infection. However, HSV infection may 
increase the risk for mother-to-child HIV transmission. In a 
study in Kenya of women receiving zidovudine prophylaxis, 
the presence of HSV-2–related genital ulcers in late pregnancy 
was associated with increased plasma HIV RNA levels and 
increased risk for intrapartum HIV transmission, even after 
adjustment for plasma HIV RNA levels (840).
Recurrent or persistent HSV infection is the AIDS-indicator 
condition in approximately 6% of children with AIDS. In a 
study in HIV-infected children in the United States during 
the HAART era, the incidence of systemic HSV infection 
was 0.9 per 100 child-years and was most common among 
children with reduced CD4 percentage (<25%) (3). As in HIV-
infected adults, HIV-infected children have more frequent and 
severe episodes of HSV reactivation. Five percent to 10% of 
children with AIDS and primary gingivostomatitis develop 
frequent recurrences, which can be associated with severe 
ulcerative disease and symptoms similar to primary infection 
(841). HIV-infected children also can shed virus longer with 
both primary and reactivation HSV infection than can HIV-
uninfected children.
Clinical Manifestations
Neonatal HSV can appear as disseminated multiorgan dis-
ease (approximately 25% of neonates with HSV infection); 
localized disease of the CNS (approximately 35% of neonates); 
or CNS disease localized to the skin, eyes, and mouth (approxi-
mately 40% of neonates) (842). Infants with disseminated 
disease usually present at age 9–11 days; encephalitis occurs in 
60%–75% of these infants. Vesicular rash occurs in approxi-
mately 80% of children with localized disease of the skin, eyes, 
and mouth, but in only approximately 60% of children with 
CNS or disseminated disease (842,843). Localized disease 
usually presents by the 10th day of life, and even with treat-
ment, neonates with skin lesions commonly have cutaneous 
recurrences during the first 6 months after treatment (842). 
Infants with localized CNS disease, or CNS disease with skin, 
eyes, and mouth involvement, usually are ill by day 16–19 of 
life (843). Although treatment has reduced morbidity and 
mortality, infants with neonatal HSV infection remain at 
risk for neurologic sequelae, with the most severe neurologic 
sequelae seen in those with CNS disease. Two percent to 6% 
of infants with localized skin, eye, or mucus membrane dis-
ease have later neurologic sequelae after apparently successful 
treatment (844,845).
After the neonatal period, the most common appearance of 
HSV infection in children is orolabial disease. Fever; irritabil-
ity; tender submandibular lymphadenopathy; and superficial, 
painful ulcers in the gingival and oral mucosa and perioral area 
characterize primary HSV gingivostomatitis. HIV-infected 
children who experience primary infection when they are 
immuno compromised can have severe local lesions or, more 
rarely, disseminated HSV with visceral involvement and 
generalized skin lesions with primary infection. Other sites 
of involvement among HIV-infected children with severe 
immunocompromise include the esophagus, CNS, and genitals 
and disseminated disease involving the liver, adrenals, lung, 
kidney, spleen, and brain.
HSV genitalis is the more common manifestation of HSV-2 
infection. Painful, ulcerative lesions on the perineum and on 
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vaginal and urethral mucosal surfaces are common during 
primary infection. Local symptoms include pain and pruritis. 
Mucosal disease usually is accompanied by dysuria, or vaginal 
or urethral discharge; inguinal lymphadenopathy, particularly 
in primary infection, is common with perineal disease (846).
Among HIV-infected persons, HSV keratitis, neonatal HSV, 
HSV encephalitis, and herpetic whitlow are similar in presenta-
tion and treatment to diseases in HIV-uninfected persons but 
might be more severe. HSV retinitis occurs as acute retinal 
necrosis, occasionally in patients with HSV encephalitis. 
HSV encephalitis occurs among HIV-infected persons, but no 
evidence indicates it is more severe or common than among 
HIV-uninfected persons.
Diagnosis
Clinical diagnosis is based on the typical appearance of 
vesicles and ulcers. The virus can be isolated in culture and 
usually can be detected in tissue culture cells within 1–3 days. 
HSV DNA by PCR also can be used to establish the presence of 
HSV infection in skin lesions or infected mucosal sites of peri-
natally exposed newborns. To diagnose neonatal HSV infec-
tion, specimens for HSV culture or HSV DNA PCR should be 
obtained from blood and skin vesicles, mouth or nasopharynx, 
eyes, urine, and stool or rectum; positive cultures from any of 
the latter sites >48 hours after birth indicate viral replication 
rather than contamination after intrapartum exposure. CSF 
should be tested for HSV DNA by PCR amplification of an 
HSV DNA sequence common to both HSV-1 and HSV-2.
Direct immunofluorescence for HSV antigen can be con-
ducted on cells collected from skin, conjunctiva, or mucosal 
lesion scrapings. Giemsa staining (Tzanck preparation) of 
lesion cell scrapings might show multinucleated giant cells and 
eosinophilic intranuclear inclusions, but this test is insensitive, 
nonspecific, and not routinely recommended.
Among children with suspected HSV encephalitis, cul-
tures of the CSF for HSV usually are negative. Detection of 
HSV DNA by PCR in the CSF has replaced brain biopsy as 
the diagnostic test of choice for such patients. The reported 
sensitivity of the CSF PCR in neonatal CNS HSV disease is 
75%–100%, with the specificity 70%–100% (847). During 
therapy for HSV-proven encephalitis, the CSF HSV PCR 
remains positive for a mean of 10 days (848).
Definitive diagnosis of HSV esophagitis requires endoscopy 
with biopsy (histologic evidence of multinucleated giant cells 
with intranuclear viral inclusion) and culture.
Prevention Recommendations
Preventing Exposure
The rate of HSV transmission to the fetus and neonate 
among HIV-infected pregnant women coinfected with HSV 
is not known. Although isolated cases of in utero HSV trans-
mission with primary HSV infection during pregnancy among 
HIV-uninfected women have been reported, the predominant 
risk, regardless of HIV coinfection, is from maternal genital 
shedding at delivery. Effective HAART regimens may decrease, 
but not prevent, maternal genital HSV shedding and recur-
rence of genital lesions (849).
Use of acyclovir or valacyclovir near term suppresses genital 
herpes outbreaks and shedding in late pregnancy among HIV-
uninfected women with HSV infection and appears to reduce 
the need for cesarean delivery for recurrent HSV (850–852). 
However, the safety and efficacy of this strategy have not been 
evaluated among HIV-infected women who are more likely 
to have antibody to HSV-2 and to have both symptomatic 
and asymptomatic reactivation of genital HSV. Therefore, the 
use of acyclovir or valacyclovir specifically to reduce the need 
for cesarean delivery among HIV/HSV-coinfected women 
is not recommended (DIII) (853). In addition, cases have 
been reported of HSV-infected neonates born to women who 
received suppressive antiviral therapy near term (854).
For pregnant women who have active genital HSV at the 
onset of labor, delivery by elective cesarean delivery, preferably 
before rupture of membranes, is recommended (AI) (855).
For the HIV-infected child, exposure to HSV-1 is an inevi-
table part of childhood, and no proven ways exist to prevent 
exposure. Direct contact of children with secretions from 
active HSV lesions, such as herpes labialis, on the mother, 
household member, or other persons should be avoided.
Among sexually active HIV-infected adults, latex condoms 
should be used during every act of sexual intercourse to reduce 
the risk for exposure to HSV and other sexually transmitted 
pathogens (AII). They should specifically avoid sexual contact 
when herpetic lesions (genital or orolabial) are evident (AII). 
Data suggest that chronic suppressive therapy with valacyclovir 
in persons with genital herpes reduced HSV-2 transmission to 
susceptible heterosexual partners by 50%. HIV-infected adults 
receiving HAART had fewer symptomatic herpetic lesions than 
did HIV-infected adults not receiving HAART, but mucosal 
HSV-2 shedding was similar (856).
Preventing First Episode of Disease
Antiviral prophylaxis after exposure to HSV, or to prevent 
initial episodes of HSV disease among persons with latent 
infection, is not recommended (DIII).
Treatment Recommendations
Treatment of Disease
Acyclovir is the drug of choice for treatment of local and 
disseminated HSV among infants and children, regardless of 
HIV-infection status (AI). Both oral and IV preparations are 
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available. Neonatal HSV disease should be treated with high-
dose IV acyclovir (20 mg/kg/dose three times daily) adminis-
tered for 21 days for CNS and disseminated disease, and for 
14 days for disease of the skin, eyes, and mouth (AI) (857). 
Acyclovir therapy should not be discontinued in neonates 
with CNS disease unless a repeat CSF HSV DNA PCR assay 
is negative near the end of treatment (BIII). Orolabial lesions 
in HIV-infected children can be treated with oral acyclovir 
for 5–10 days (AI). Moderate-to-severe mucocutaneous HSV 
lesions are best treated initially with IV acyclovir (AI). Patients 
may be switched to oral therapy after the lesions have begun to 
regress, and therapy continued until lesions have completely 
healed. Acyclovir is the drug of choice for disseminated HSV 
and HSV encephalitis in children. Regardless of patient age, 
HSV encephalitis should be treated for 21 days (AII). Genital 
HSV should be treated with oral acyclovir for 5–14 days (AI). 
Trifluridine, a fluorinated pyrimidine nucleoside, is the treat-
ment of choice for herpes keratoconjunctivitis, one drop onto 
the cornea (858) every 2 hours, not to exceed nine drops/day; 
it is not recommended for longer than 21 days (AII).
Alternatives to acyclovir in older adolescents and adults 
include valacyclovir, famciclovir, and foscarnet (AI) (859-862). 
Valacyclovir is a prodrug of acyclovir with improved bioavail-
ability that is rapidly converted to acyclovir after absorption. 
Data are limited on valacyclovir use in children (863); bio-
availability is approximately 45% and independent of age in 
children. Limited data indicate pediatric blood levels of acy-
clovir (from the prodrug valacyclovir) similar to levels achieved 
with valacyclovir tablets in adults can be achieved by an oral 
dose of valacyclovir of 20−25 mg/kg/dose administered two to 
three times a day (864). However, no pediatric formulation is 
available; thus, this drug is an alternative only for children old 
enough to swallow the large valacyclovir tablets. The tablets 
can be crushed, but they have an unpleasant taste. No specific 
data exist on the pharmacokinetics and dosing of famciclovir 
in children, and no pediatric preparation is available (864). 
Intravenous foscarnet may be used in cases of acyclovir-resistant 
herpes infection (BIII).
Monitoring and Adverse Events, Including IRIS
Acyclovir is excreted primarily by the kidney; as a result, 
dose adjustment based on creatinine clearance is needed in 
patients with renal insufficiency or renal failure. Primary tox-
icities of acyclovir are phlebitis, renal toxicity, nausea, vomit-
ing, and rash. Toxicities are similar for valacyclovir. In infants 
receiving high-dose acyclovir for neonatal disease, the major 
side effect was neutropenia (e.g., absolute neutrophil count 
<1000/mm3) (857). Grade 3 or higher nephrotoxicity was 
observed in 6%. For infants and children receiving high-dose 
IV acyclovir, monitoring of complete blood counts and renal 
function is recommended at initiation of treatment and once 
or twice weekly for the duration of treatment, particularly for 
those with underlying renal dysfunction or those receiving 
prolonged therapy.
Management of acyclovir-resistant herpes with foscarnet is 
associated with decreased renal function; <30% of patients 
experience increases in serum creatinine levels. Renal toxicity 
and foscarnet binding to divalent metal ions such as calcium 
leads to metabolic abnormalities in approximately one third 
of patients, and serious electrolyte imbalances (including 
abnormalities in calcium, phosphorus, magnesium, and potas-
sium levels) and secondary seizures, or cardiac dysrhythmias 
can occur. Abnormal liver transaminases and CNS symptoms 
also can occur. For patients receiving foscarnet, complete 
blood counts, serum electrolytes, and renal function should 
be monitored twice weekly during induction therapy and once 
weekly thereafter.
Atypical lesions that may have a delayed response to therapy 
have been reported in adults initiating HAART and attributed 
to IRIS (856).
Management of Treatment Failure
Treatment failure related to resistance to antiviral drugs 
should be suspected if lesions do not indicate signs of resolu-
tion within 7–10 days after initiation of therapy. In immuno-
compromised patients with suspected acyclovir-resistant HSV, 
a lesion culture should be obtained and, if virus is isolated, 
susceptibility testing performed to confirm drug resistance 
(858).
The treatment of choice for acyclovir-resistant HSV is IV 
foscarnet (AI) (858,865). All acyclovir-resistant HSV strains are 
resistant to valacyclovir, and most are resistant to famciclovir. 
Topical trifluridine or cidofovir also have been used success-
fully for lesions on cutaneous surfaces, although prolonged 
application for 21–28 days or longer might be required (866). 
IV cidofovir has been used to treat a child with acyclovir and 
foscarnet resistant HSV (867).
Prevention of Recurrence
Administration of oral acyclovir prevented cutaneous recur-
rences of HSV after neonatal disease of the skin, eyes, and 
mouth. However, the effect of such therapy on neurologic 
outcome needs assessment, and additional investigation is 
necessary before routine use of suppressive therapy can be 
recommended for children (845).
Because episodes of HSV disease can be treated successfully, 
chronic therapy with acyclovir is not required after lesions 
resolve. However, children who have frequent or severe recurrences 
(e.g., four to six severe episodes a year) can be administered daily 
suppressive therapy with oral acyclovir (AI) (864). Valacyclovir 
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or famciclovir also are options for older children (AI). Effective 
HAART may decrease recurrences.
Discontinuing Secondary Prophylaxis
Not applicable, secondary prophylaxis not usually recom-
mended in children.
Human Papillomavirus 
Epidemiology
Human papillomavirus (HPV) infects cutaneous and 
mucosal squamous epithelium. More than 100 distinct types 
of HPV exist (868). They can be categorized on the basis of 
the site at which they occur (genital, cutaneous) and as high- 
or low-risk on the basis of their potential to induce malignant 
proliferation. Of the approximately 40 genital (i.e., muscosal) 
HPV types, 12 types are identified as established high risk 
(HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), and 
six, as probable high risk (HPV 26, 53, 66, 68, 73, 82) (868). 
Genital HPV types can infect the genitals, conjunctiva, mouth, 
throat, and respiratory tract. Nongenital (i.e., cutaneous) HPV 
types that cause skin warts (such as HPV 2) are distinct from 
those causing genital infections. Children with compromised 
cellular immunity might have intense and widespread appear-
ance of both cutaneous and mucosal warts.
HPV-associated cutaneous warts are transmitted by close 
person-to-person contact that is facilitated by minor trauma 
to the skin. HPV-associated anogenital warts are transmitted 
by sexual contact but also might be acquired at delivery. There 
is some evidence that transmission may occur from nongenital 
sites. Genital warts (condyloma accuminatum) in young chil-
dren might be a sign of sexual abuse (869,870).
Mother-to-child transmission of HPV is not surprising 
because pregnant women have high rates of HPV infection 
(871,872). HPV DNA has been identified in 5%–42% of 
pregnant women without HIV infection (873–875). Although 
a few studies have demonstrated an increased prevalence of 
detectable HPV DNA during pregnancy, this finding has 
not been consistent across studies (874,875). Among non-
pregnant women, HPV DNA is detected more frequently 
among HIV-infected than HIV-uninfected women, with 
reported prevalence rates of 12%–77% (876,877). Few data 
have been reported about HPV prevalence in HIV-infected 
pregnant women, with one study reporting a prevalence of 
35% (878).
HPV DNA has been detected in cord blood and amniotic 
fluid, indicating the potential for in utero infection (879,880). 
Duration of membrane rupture has been associated with 
mother-to-child HPV transmission, and reports of HPV trans-
mission to infants born by cesarean delivery suggest that HPV 
can cross the placental barrier (881,882). Most transmission 
studies report on the detection of HPV DNA because clinical 
disease (i.e., warts) is rare in infants. Reported rates of HPV 
DNA detection in nasopharyngeal aspirates, buccal brush 
swabs, or genital swabs from infants born to HPV-infected 
mothers have varied from 2% to 80% (871,872,881). Neonatal 
clinical abnormalities at birth are rare. Genital condylomata 
can occur within weeks to months after birth but are rare. 
Respiratory papillomatosis, a rare condition in which respi-
ratory papillomas develop and typically recur (i.e., juvenile 
onset recurrent respiratory papillomatosis), usually manifests 
within 2–5 years after birth. Respiratory papillomatosis in 
children is thought to be secondary to HPV transmitted from 
mother to child through aspiration of infectious maternal 
genital secretions during delivery; however, other methods of 
transmission are possible (871). A recent parent-child study 
found that the cumulative detection rate for high-risk HPV 
from the child’s genital samples was 53% over 3 years; 1.5% 
persisted with the same HPV type at the end of study. During 
the same period, HPV was detected more commonly from oral 
samples, with a cumulative rate of 63% with 10% persistence 
(871). Persistence in infant oral samples was associated with 
persistent oral HPV detection in the mothers. Persistent genital 
infections were associated with the mother’s history of genital 
warts. The prevalence of HPV DNA in the oropharynx in 
1235 children in Iowa was assessed in one study; a bimodal 
age distribution was found, with highest HPV prevalence in 
the youngest and oldest groups: 2.5% at age <1 year, 0.8% 
at 1–4 years, 1.2% at 5–11 years, 1.5% at 12–15 years, and 
3.3% at 16–20 years (883). These data support the high rate 
of HPV clearance in children, even if the infant is exposed to 
HPV during infancy.
Although perinatal transmission is possible, genital HPV 
is most commonly sexually transmitted. Young age at first 
intercourse and a higher number of recent sex partners are 
strong risk factors for HPV (884–888). Prevalence of HPV is 
common in sexually active adolescent girls, with prevalences 
of 12%–64% compared with 2%–7% in women aged >35 
years (885,889–891). Cervical HPV is acquired shortly after 
onset of sexual activity, with 50% cumulative exposure within 
3 years (884,886), even among young women with one sex 
partner (892).
Although the incidence of anogenital HPV infection in 
sexually active youth is high, longitudinal studies have dem-
onstrated that 80%–90% of infections among youth without 
HIV infection might be transient and spontaneously regress 
(890,893). Repeated infections with new types are common 
(889), but whether repeat detection of same HPV type infec-
tions result from new exposures or from reactivation of latent 
infection is not known (894). Even though the prevalence of 
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HPV consistently has been higher among HIV-infected men 
and women, acquisition rates of HPV appear similar among 
HIV-infected and HIV-uninfected persons (895). The higher 
prevalence results from the increased rate of HPV persistence 
in HIV-infected persons. In one study of adolescents with 
HIV, only 50% cleared their HPV infections (895). Other 
possible risk factors for persistence have included multiple 
types or high-risk types of HPV (e.g., 16 and 18), older age, 
smoking cigarettes, and duration of HPV detection for >12 
months (896). Detection of anal HPV also is higher among 
HIV-infected youth (897). Receptive anal sex is a risk for anal 
HPV among HIV-infected and HIV-uninfected men; the 
association between anal HPV infection and anal sex is not 
as clear for women (897,898). In one study of HIV-infected 
women, anal HPV infection was more prevalent than cervical 
infection (899).
Persistent infection with high-risk HPV is associated with 
increased risk for cervical intraepithelial neoplasia (CIN) 
and cervical and vulvovaginal carcinoma in women and for 
anal intraepithelial neoplasia and anal carcinoma in both 
women and men. Rates of all these HPV-associated cancers 
are higher among HIV-infected persons (900) and believed 
to result predominantly from the increased risk for persistent 
infection in this group. Interestingly, the risk for these HPV-
associated cancers is highest among young persons with HIV 
(900). Adolescent girls differ biologically from adult women 
(e.g., cervical squamous metaplasia) that might increase 
their susceptibility to either persistent infection or disease 
(877,901). The risk for HPV-associated cervical abnormali-
ties increases among HIV-infected youth. In one study, 33% 
of HPV-infected youth with HIV progressed to high-grade 
squamous intraepithelial lesions (HSIL) within 3 years of 
observation (902). CD4 immunosuppression correlated with 
HPV persistence but not with HSIL. Even though HAART 
has dramatically altered HIV’s natural history, its impact on 
HPV and HPV-associated neoplasia is less clear. Other risks 
associated with cervical cancers include lack of cervical can-
cer screening, prolonged hormonal contraceptive use, parity, 
smoking, and immunocompromising conditions (other than 
HIV) (888).
Clinical Manifestations
Genital HPV types cause hyperplastic, papillomatous, and 
verrucous squamous epithelial lesions on skin and mucus 
membranes, including anal, genital, oral, nasal, conjunctival, 
GI, bladder, and respiratory tract mucosa. Wart lesions can 
appear as papules, flat, smooth, or pedunculated lesions. 
Sometimes they can be soft, pink, or white “cauliflower-like” 
sessile growths on moist mucosal surfaces (condyloma accumi-
natum), or keratotic lesions on squamous epithelium of the 
skin with a thick, horny layer. Because HPV requires access 
to basal epithelial cells through disruption of the squamous 
epithelium, common sites for skin warts are the hand, elbows, 
knees, and feet.
Diagnosis
Most cutaneous and anogenital warts can be diagnosed 
by physical examination. Diagnosis of laryngeal papillomas 
requires laryngoscopy, and children with suspected respira-
tory tract papillomas need to be evaluated by a pediatric 
otolaryngologist.
Whether all cervical HPV infections result in microscopic 
abnormalities described as squamous intra-epithelial lesions 
(SIL) remains debatable. Most HPV DNA detected from cervi-
cal samples is associated with normal cervical cytology. These 
infections either have microscopic lesions not detected by the 
insensitive cytologic test or are truly latent. The Pap test (con-
ventional or liquid-based) is a screening test for HPV-associated 
disease, including cervical cancer. However, histology remains 
the gold standard for confirming HPV-associated cervical and 
anal precancerous lesions and invasive cancers.
Biopsies for histologic diagnosis usually are directed by col-
poscopy or high-resolution anoscopy. No screening tests are 
available for vaginal and vulvar disease; however, these lesions 
often are diagnosed in women referred to colposcopy for abnor-
mal cytology or because of abnormalities noted on macroscopic 
examination. Histology also should be confirmed for vulvar 
and vaginal squamous intraepithelial lesions and cancer.
HPV DNA can be detected using several platforms (903). The 
only FDA-approved test is HybridCapture, which detects any 
of 13 high-risk HPV types and is not type specific. Detection 
and typing of HPV is not recommended for diagnosing or 
managing anogenital or cutaneous warts or papillomas (870). 
HPV testing is not recommended in any circumstance for 
adolescent girls (aged <20 years) (904), regardless of whether 
they are HIV-infected or HIV-uninfected, because of the high 
rates of HPV infection. These recommendations may change 
once specific HPV testing has been studied in clinical trials.
Prevention Recommendations
Preventing Exposure
HIV-infected persons should use latex condoms during 
every act of sexual intercourse to reduce the risk for exposure to 
sexually transmitted pathogens (AII), including HPV (887).
HPV vaccine
In June 2006, FDA approved the first preventive vaccine for 
HPV types 16, 18, 6, and 11. HPV 16 and 18 cause almost 
70% of invasive cervical cancers, and HPV 6 and 11 cause 
90% of external genital warts. HPV exposure is extremely 
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common after sexual contact, not just sexual intercourse, 
is initiated. Administration of the vaccine is critical before 
onset of sexual activity for it to be fully effective. Data for 
HIV-uninfected women showed efficacy rates of 95% for 
preventing HPV infection and high-grade CIN related to 
vaccine-related HPV strains and 99% efficacy for genital 
warts (905,906). However, if previous exposure to the vac-
cine HPV types was documented, no efficacy was noted 
for that type, underscoring the fact that the vaccine is not 
therapeutic. A second vaccine targeting HPV 16 and 18 has 
had similar efficacy (Cervarix, Glaxo Smith Kline, Research 
Triangle Park, North Carolina) (907) and is expected to 
receive FDA approval in 2009.
Although the vaccines are considered safe, studies in HIV-
infected persons are not yet available, so immunogenicity and 
efficacy in this population has not been established. However, 
because quadrivalent HPV vaccine is noninfectious, it can be 
administered to females who are immunosuppressed by disease 
(including HIV) or medications (AI); immune response and 
vaccine efficacy might be less than in immunocompetent per-
sons (Figure 2) (30,908). Studies of the immunogenicity and 
safety of the HPV vaccine in HIV-infected children show that 
the vaccine is safe. Although seroconversion occurred in 100% 
of those HIV-infected seronegative children, titers for HPV 6 
and 18 were lower than those for healthy children (909). CDC 
recommendations for HPV vaccination of all children and 
adolescents should be followed for both HIV-infected and 
HIV-uninfected persons (908). The first dose of the HPV 
vaccine series should be administered to girls aged 11–12 years 
but can be administered as early as 9 years. The second dose 
should be administered 2 months after the first dose, and the 
third dose should be administered 6 months after the first dose. 
HIV-infected adolescent girls and young women aged 13–26 
years who have not been previously vaccinated also should be 
vaccinated with the three-dose HPV vaccine series.
The HPV vaccine does not have any therapeutic benefit 
for existing HPV-related lesions in either HIV-infected or 
HIV-uninfected women. No studies using the HPV vaccine 
to prevent HPV infection and associated lesions of the anus, 
penis, or oral cavity in men have been published, and the vac-
cine is not approved for use in men in the United States. As 
in HIV-infected women, no data exist on the safety or efficacy 
of the HPV vaccine in HIV-infected men.
Preventing First Episode of Disease
HPV-associated genital epithelial cancers 
among HIV-infected women
As part of a complete history and physical examination, 
HIV-infected sexually active women should have a pelvic 
examination and a cervical cancer screening test (Pap test, either 
conventional or liquid-based). In accordance with the recom-
mendation of the Agency for Health Care Policy and Research, a 
Pap smear should be obtained twice during the first year after 
diagnosis of HIV infection and, if the results are normal, annu-
ally thereafter (AII). If the results of the Pap smear are abnormal, 
care should be provided according to treatment guidelines 
described below for adolescents. Adult women (e.g., aged >20 
years) should be managed according to adult guidelines. No 
data are available that demonstrate these guidelines should be 
modified to prevent cervical disease for women on HAART.
HPV-associated anal intraepithelial neoplasia 
and anal cancer among HIV-infected women 
and HIV-infected men who have sex with men
Evidence from multiple studies demonstrates that HIV-
infected men who have sex with men and HIV-infected women 
are at increased risk for anal HSIL and might be at increased risk 
for anal cancer. In view of this evidence, and given a cost-effec-
tiveness analysis projecting that screening and treatment for anal 
HSILs provide clinical benefits comparable to other measures to 
prevent OIs among HIV-infected persons (910), anal cytology 
screening of HIV-infected men who have sex with men and of 
women might become a useful preventive measure (911). However, 
studies of screening and treatment programs for anal HSIL need 
to be implemented before recommendations for anal cytology 
screening can be made.
Treatment Recommendations
Treatment of Disease
Genital warts
Multiple treatments for HPV-associated skin and external 
genital lesions exist, but no one treatment is ideal for all 
patients or all lesions (CIII) (870). Standard topical therapy 
for HPV-associated lesions among HIV-infected children often 
is ineffective. Treatment can induce wart-free periods, but the 
underlying viral infection can persist and result in recurrence. 
No data suggest that treatment modalities for external genital 
warts should differ in HIV-infected persons. However, persons 
who are immunosuppressed because of HIV might have larger 
or more numerous warts, might not respond as well as immu-
nocompetent persons to therapy for genital warts, and might 
have more frequent recurrences after treatment (154,912,913). 
In addition, topical treatments are seldom effective in patients 
with large or extensive lesions. Topical treatments include 
podofilox (0.5%) solution or gel (antimitotic agent), imiqui-
mod (5%) cream (topical immune enhancer that stimulates 
production of interferon and other cytokines), trichloroacetic 
or bichloroacetic acid (80%–90% aqueous solution) (caustic 
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agents that destroy warts by chemical coagulation of proteins), 
and podophyllin resin (10%–25%) in a compound tincture 
of benzoin (contains antimitotic compounds and mutagens). 
Podofilox and imiquimod are patient-applied. Podofilox is 
applied to all lesions twice a day for 3 consecutive days, fol-
lowed by 4 days of no therapy. This cycle can be repeated weekly 
up to 4 weeks (BIII). Imiquimod is applied once daily at bed-
time for 3 nonconsecutive nights a week for up to 16 weeks. 
The treatment area should be washed with soap and water the 
following morning (BII). Acid cauterization (i.e., tricholo-
racetic or bichloroacetic acid) and podophyllin resin require 
application by a health-care provider. Acid cauterization should 
be discontinued if substantial improvement is not observed 
after three treatment sessions or complete clearance has not 
occurred after six consecutive treatments (BIII). Podophyllin 
resin is applied and removed by washing a few hours later; 
applications can be repeated weekly for up to 6 weeks (CIII). 
Podophyllin resin has lost favor because the resin can vary in 
potency and is not reliable.
Other treatments include Veregen® (based on the anti-
oxidative effect of green tea extract), intralesion interferon or 
5-fluorouracil/epinephrinegel implant, and cidofovir topical 
gel (1%). Veregen (sinecatechins) is a new FDA-approved 
topical product for external genital wart treatment that can be 
used three times daily for up to 16 weeks. No data are available 
on this treatment for HIV-infected persons (CIII). Cidofovir 
topical gel (1%) is a topical preparation that has been evaluated 
in a limited number of adults for treatment of anogenital HPV 
infection (CIII). Topical cidofovir can be absorbed systemi-
cally and be associated with renal toxicity (914). Injectable 
therapy (e.g., interferon or 5-fluoracil/epinephringel implant) 
should be offered in only severe recalcitrant cases because of 
inconvenient routes of administration, frequent office visits, 
and a high frequency of systemic adverse effects.
Lesions can be removed by cryotherapy or surgery (BIII). 
Cryotherapy (application of liquid nitrogen or dry ice) must be 
applied until each lesion is thoroughly frozen. Treatment can be 
repeated every 1–2 weeks up to four times. The major toxicity 
is local pain. Adequate local pain management is essential for 
all caustic treatments. Topical anesthetics are favored. Lesions 
can be removed surgically by tangential scissor, tangential shave 
excision, curettage, or electrosurgery.
Oral warts
Oral warts can be located on various surfaces in the mouth. 
In contrast to other oral manifestations of HIV, an increased 
prevalence of oral warts in patients on HAART has been 
reported from the United States and the United Kingdom 
(915,916). No randomized trials have been conducted on 
treatment of oral warts. Treatments include surgical excision 
and cryotherapy. Some topical modalities have had success 
(917). 
Respiratory papillomatosis
Respiratory papillomatosis should be managed by a specialist 
(918). Treatment is directed toward removing lesions obstruct-
ing the airway rather than at the elimination of disease. Lesions 
are removed by debridement or laser. Systemic interferon-alfa 
therapy or intralesional cidofovir has been used as an inves-
tigational treatment with limited success in children, with 
frequent recurrences or extension into the trachea, bronchi, 
or lung parenchyma (CIII).
Management of abnormal cytology
Management of anogenital HPV infection accompanied 
by cytologic changes indicating dysplasia/carcinoma among 
adolescents differs slightly from that for adults. Adolescents 
aged 13 –20 years and young women are considered a special 
population. The risk for invasive cervical cancer is low in this 
group, but CIN lesions are common. As noted earlier, CIN in 
HIV-uninfected adolescents also has a high rate of spontaneous 
regression of CIN lesions (919). HPV testing for follow-up is 
not recommended for adolescents, regardless of HIV infection 
status (904).
Because of the high rate of progression to HSIL, all HIV-
infected adolescents with any SIL, either low-grade (LSIL) or 
high-grade (HSIL), or atypical squamous cells of undetermined 
significance (ASCUS) suggestive of HSIL should be referred for 
colposcopy (BIII). In patients with ASCUS alone, Pap smear 
for cytology can be repeated in 6–12 months. If ASCUS or 
greater is found on repeat cytology, referral to colposcopy is 
warranted.
Treatment of histologic CIN
Follow-up with annual cytologic assessment is recommended 
for adolescents with CIN 1 (AII) (904). At the 12-month 
follow-up, only adolescents with HSIL or greater on the 
repeat cytology should be referred back to colposcopy. At the 
24-month follow-up, those with an ASCUS or greater result 
should be referred back to colposcopy (AII).
For adolescent girls and young women with a histologic diag-
nosis of CIN 2 or 3 not otherwise specified, either treatment 
or observation for up to 24 months using both colposcopy 
and cytology at 6-month intervals is acceptable, provided 
colposcopy is satisfactory (BIII) (904). When a histologic 
diagnosis of CIN 2 is specified, observation is preferred, 
but treatment is acceptable. When CIN 3 is histologically 
diagnosed or when colposcopy is unsatisfactory, treatment is 
recommended (BIII).
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If the colposcopic appearance of the lesion worsens or if 
HSIL cytology or a high-grade colposcopic lesion persists 
for 1 year, repeat biopsy is recommended (BIII). After two 
consecutive “negative for intraepithelial lesion or malignancy” 
results, adolescents and young women with normal colposcopy 
can return to routine cytologic screening (BII). Treatment is 
recommended if CIN 3 is subsequently identified or if CIN 
2 or 3 persists for 24 months (BII).
Persistent CIN 1, 2, and 3 lesions in HIV-infected women 
should be treated as in HIV-uninfected women (904). 
Conventional therapies used to treat CIN 2 or 3 include cryo-
therapy, laser therapy, cone biopsy, and a loop electrosurgical 
excision procedure (LEEP). LEEP usually is the preferred 
mode of treatment (BIII). Recurrence rates of 40%–60% after 
treatment have been reported among HIV-infected women 
undergoing these procedures. Pregnant HIV-infected adoles-
cents should be treated similarly to pregnant HIV-infected 
women.
Role of antiretroviral therapy
HAART has not been consistently associated with reduced 
risk for HPV-related cervical abnormalities in HIV-infected 
women. However, severe immunosuppression is associated 
with higher morbidity and mortality.
Monitoring of Adverse Events, Including IRIS
Monitoring is required during and after treatment of genital 
warts because each treatment has associated toxicity and recur-
rences are common after treatment. Patients can be monitored 
by physical examination for evidence of recurrence. The major 
toxicity of podophyllotoxin and topical podophyllin resin is 
local skin irritation. Also, if podophyllin is applied to a large 
treatment area, systemic absorption can cause nausea, vomiting, 
and CNS effects. The major toxicity of imiquimod is inflamma-
tion at the application site. The major toxicity of cryotherapy 
is local pain. The major side effects of surgical treatment for 
genital warts are local pain, bleeding, and secondary infection. 
The major adverse events associated with acid cauterization 
are local pain and irritation or ulceration of adjacent normal 
skin. Intralesional interferon can be associated with systemic 
toxicities of interferon, including fever, fatigue, myalgia, mal-
aise, depression, and other influenza-like symptoms. Infrared 
coagulation may lead to bleeding and abscess formation. 
Scarring can occur with any of the above treatment modali-
ties. Topical cidofovir may result in systemic absorption and 
be associated with renal toxicity (914). Secondary infections 
are not uncommon if ulcerations occur. Patients should be 
monitored regularly after each treatment.
Because risk for recurrence of CIN and cervical cancer 
after conventional therapy increases among HIV-seropositive 
persons, patients should be carefully followed after treatment 
with frequent cytologic screening and colposcopic examination 
according to published guidelines (AII) (920,921). Treatment 
of CIN with ablative and excisional modalities can be associ-
ated with several adverse events such as pain and discomfort, 
intraoperative hemorrhage, postoperative hemorrhage, infec-
tion and cervical stenosis.
The major toxicity of topical agents for treatment of external 
genital warts is local pain or irritation of adjacent normal skin. 
HIV-infected patients with immunosuppression might have a 
lower response rate to all of these modalities. Secondary infec-
tions are not uncommon if ulcerations occur. Patients should 
be monitored regularly after each treatment.
Because of the frequent recurrence of squamous intraepithe-
lial lesions after treatment, close surveillance with colposcopy 
and cytology are recommended.
An “immune reconstitution”-like syndrome related to HPV-
associated oral warts among HIV-infected adults has been 
observed in which the occurrence of oral warts was associated 
with decreased HIV RNA levels with HAART (915). Immune 
reconstitution in response to viral load reduction might result 
in a return of marked inflammatory responses against latent 
oral HPV infection. 
Management of Treatment Failure
Treatment failure is defined as the persistence or recurrence 
of lesions after appropriate therapy. For persistent or recurrent 
genital warts, retreatment with any of the modalities previously 
described should be considered, preferably with an alternative 
modality to the one that previously failed (AIII). Genital warts 
often require more than one course of treatment. Recalcitrant 
warts should be managed by experienced clinicians and referred 
for excisional therapy. Recurrence of CIN may require addi-
tional treatments (i.e., LEEP and laser).
Prevention of Recurrence
No recommendations exist for preventing recurrence of 
external genital warts. Patients should be monitored with cyto-
logic screening according to published guidelines and, when 
indicated, colposcopic examination for recurrent lesions (AI) 
(922,923). In one study, use of low-dose intravaginal flurouracil 
reduced recurrence of CIN after LEEP, but lack of additional 
studies do not warrant routine use (924). Efudex should not 
be used in pregnant women.
Discontinuing Secondary Prophylaxis
Not applicable.
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Progressive Multifocal 
Leukodystrophy
Epidemiology
First described in association with chronic lymphocytic 
leukemia and Hodgkin disease, progressive multifocal leuko-
encephalopathy (PML) is a rare demyelinating disease of the 
CNS that occurs in immuno compromised patients (925). It 
is caused by primary infection or reactivation of Jamestown 
Canyon virus (JCV), a ubiquitous polyoma virus. Most 
humans are infected with JCV early in life; 50% of children 
are seropositive by age 9–11 years, and seropositivity among 
adult women aged >25 years is 72% (926). Infection results in 
chronic asymptomatic carriage in the kidneys, lymphoid tissue, 
bone marrow, and lymphocytes (927,928); in a patient with a 
weakened immune system, the virus may reactivate and spread 
to the brain by lymphocytes causing neurologic dysfunction 
and serious and life-threatening disease.
PML is an AIDS-defining illness in HIV-infected persons. 
PML has been rare in reports from large series of HIV-infected 
children (1,4,929), but cases have been reported in children 
(930–935).
Clinical Manifestations
No symptoms are known to be associated with acute JCV 
infection. PML is the only disease caused by JCV. Cases in 
children are similar to those in adults.
Demyelination is at first patchy, involving subcortical 
regions, and then spreads to deep white matter in confluent 
pattern; thus, PML initially may present with focal neurologic 
deficits that can involve different brain regions. The established 
criteria for clinical diagnosis are focal signs and symptoms on 
neurologic examination, focal white matter lesions on MRI 
or CT without mass effect, and exclusion of other causes of 
the clinical and neuroradiologic findings (936). The disease 
has an insidious onset and produces a neurologic syndrome 
that steadily progresses over weeks or months, characterized 
by confusion, disorientation, lack of energy, loss of balance, 
cognitive dysfunction, dementia, seizures, ataxia, aphasia, 
cranial nerve deficits, visual abnormalities (e.g., blurred or 
double vision or loss of vision), hemiparesis or quadraparesis, 
and eventually coma. During the pre-HAART era, adults and 
children with PML had extremely poor survival (929). Survival 
among adults has improved during the HAART era (937–939). 
No comparable data exist for children.
Diagnosis
A confirmed diagnosis of PML requires a compatible clini-
cal syndrome and radiographic findings coupled with brain 
biopsy demonstrating a characteristic triad of pathologic foci 
of demyelination, enlarged hyperchromatic oligodendrocytes 
with enlarged nuclei and basophilic-staining intranuclear 
material, and enlarged astrocytes with bizarre hyperchromatic 
nuclei. When only two of these features are present, JCV 
can be demonstrated by in situ hybridization or by electron 
microscopy for definitive diagnosis.
Although brain biopsy remains the confirmative test for 
diagnosis of PML, brain scans such as MRI or CT can reveal 
lesions in the brain. The radiologic features of PML are typi-
cally noninflammatory (unless associated with HAART-related 
IRIS). Typical CT abnormalities include single or multiple 
hypodense, nonenhancing cerebral white matter lesions; 
cerebellum and brain stem occasionally are involved. MRI 
depicts white matter lesions of low T1 signal intensity and high 
proton density on T2 weighted images with absence of edema 
or mass effects, as might be seen with cerebral toxoplasmosis or 
lymphoma. Postcontrast enhancement is unusual and, when 
present, usually is sparse, with a thin or reticulated appearance 
adjacent to the edge of the lesions.
PML diagnosis is now facilitated by use of PCR to detect 
JCV DNA in CSF, which may obviate the need for brain 
biopsy in patients with a compatible clinical syndrome and 
radiographic findings. Nested JCV PCR on CSF is highly 
sensitive (90%–100%) and specific (92%–100%) for PML 
(940). Measurement of JCV DNA levels in CSF samples can 
be a useful virologic marker for managing PML in patients 
receiving HAART (941).
Prevention Recommendations
Preventing Exposure
There are no known means of preventing exposure to JCV.
Preventing First Episode of Disease
There are no means of preventing PML in severely immune-
suppressed persons. Use of HAART can prevent or reverse 
severe immunosuppression.
Discontinuing Primary Prophylaxis
No means of primary prophylaxis of JCV infection or devel-
opment of PML have been demonstrated.
Treatment Recommendations
Treatment of Disease
No effective therapy has been established for JCV infec-
tion or PML. Survival in HIV-infected adults with PML has 
substantially improved during the post-HAART era, with a 
median survival increase from 14 to 64 weeks (942). A CD4 
count of >100 cells/mm3 at PML diagnosis was associated with 
improved survival, and the use of HAART postdiagnosis of 
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PML also was strongly associated with improved survival (942). 
Thus, the main approach to treatment involves maximally opti-
mizing antiretroviral therapy to reverse the immunosuppression 
that interferes with normal host response to this virus (AII).
A number of agents have been proposed or reported anec-
dotally as more specific treatments for PML, but none have 
proven effective after greater scrutiny or more extensive study. 
In a randomized open-label trial of IV and intrathecal cytosine 
arabinoside (943) and a nonrandomized, open-label trial of 
cidofovir (944), neither drug was effective in producing clinical 
improvement of PML and neither is routinely recommended 
(DII). Immunomodulatory approaches, such as interferon-
alfa, also have been described in case reports in HIV-infected 
adults; however, none have been studied in a prospective, 
controlled clinical trial and, in one analysis, did not provide 
any benefit beyond that with HAART (945), and thus are also 
not routinely recommended (DIII).
Monitoring and Adverse Events, Including IRIS
Neurologic stability or improvement and prolonged sur-
vival are associated with reduced JCV DNA and appearance 
of JCV-specific antibody in CSF of HAART-treated PML 
patients (946).
When antiretroviral therapy is initiated and CD4 counts rise, 
certain patients will experience neurologic improvement and 
others might become neurologically stable; however, reports 
have documented worsening neurologic manifestations after 
initiation of HAART (939). In certain instances, this wors-
ening is caused by IRIS (939,947–949), examples of which 
have occurred in children (21). Other cases may represent the 
natural history of PML. The underlying etiology and trigger 
of HAART-associated PML is controversial. One hypothesis 
postulates a reduction in inhibitory cytokines (e.g., interferon-
alfa and interleukin-12) after HAART, thus promoting JCV 
reactivation within the brain or, by increasing trafficking of 
JCV-infected peripheral lymphocytes, into the brain (950). 
JCV infection occurring coincidental to HAART initiation 
resulting in a beneficial inflammatory response with lack of dis-
ease progression is another hypothesis (950), particularly given 
that JCV infection in children with perinatal HIV infection 
most often would be acquired during childhood. The overall 
prevalence of IRIS in children is not known. Inflammatory 
PML should be suspected in HAART-treated children with 
advanced HIV disease who show acute neurologic deterioration 
and contrast-enhancing demyelinating lesions on MRI.
Management of Treatment Failure
PML remission with HAART may take several weeks, and 
no criteria exist that define progression of disease. A working 
definition used for HIV-infected adults is continued clinical 
worsening and continued detection of CSF JCV at 3 months 
(see Guidelines for the Prevention and Treatment of Opportunistic 
Infections in HIV-Infected Adults) (16). Some patients’ PML 
worsens despite HAART, either because of IRIS or the natural 
history of PML. In both cases, HAART should be contin-
ued. If HAART fails to suppress HIV RNA or to boost the 
CD4 count, then attention should focus on modifying and 
optimizing the antiretroviral treatment (AII). However, in 
HIV-infected children responding well to HAART but with 
continued worsening PML, an expert in pediatric HIV infec-
tion should be consulted. 
Prevention of Recurrence
On the basis of its role in reversing the disease, the main 
preventive measure is an effective antiretroviral regimen that 
suppresses HIV viremia and maintains CD4 count (AII).
Discontinuing Secondary Prophylaxis
No means of secondary prophylaxis of JCV infection or 
PML have been demonstrated.
Varicella-Zoster Virus
Epidemiology
Varicella-zoster virus (VZV) infections occur worldwide. In 
the prevaccine era, approximately 4 million cases of varicella 
occurred annually in the United States. Since the institution 
of universal varicella vaccination for healthy children, the inci-
dence of varicella and its associated morbidity and mortality 
have decreased by approximately 74%–90% (951). Varicella 
can cause greater morbidity and mortality in HIV-infected 
persons than among the general population (952,953).
VZV causes both varicella (a primary infection) and zoster 
(a secondary infection caused by reactivation of latent VZV 
acquired during varicella) (954). The incubation period for 
varicella ranges from 10 to 21 days (average: 14 days). Before 
the widespread use of varicella vaccine in the United States, the 
annual rate of varicella infection in children aged <10 years was 
9%; by adulthood >95% of persons had antibodies to VZV, 
indicating a history of primary infection (955).
Once established, VZV latency persists for life. Reactivation, 
causing clinical zoster, occurs in roughly 25% of people. A 
decline in specific cellular immunity to VZV contributes 
significantly to development of zoster (954). HIV-infected 
persons are at higher risk for zoster, by a factor of 15–25 times, 
than the general population (956). The incidence of zoster also 
increased with age, particularly in persons aged >50 years.
VZV is transmitted mainly from skin lesions during illness 
but also can be transmitted through airborne spread (957). 
Varicella is highly contagious; clinical infection develops in 
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about 80% of susceptible persons exposed in a household 
(958). Second attacks of varicella are uncommon (954). Zoster 
is less contagious than varicella.
Mother-to-child transmission of VZV can occur; however, 
because most adults are immune, varicella complicating 
pregnancy is unusual. In one study, 13% of HIV-infected 
pregnant women lacked immunity to VZV (959). Whether 
mother-to-child VZV transmission increases among HIV-
infected pregnant women who have varicella is unknown. 
Congenital varicella syndrome occurs in approximately 0.4% 
(95% CI: 0.05%–1.5%) of infants born to women who have 
varicella during pregnancy before 13 weeks’ gestation and 
in approximately 2% (95% CI: 0%–5%) of infants born to 
women who have varicella at 13–20 weeks’ gestation (960). 
This syndrome is not seen among women who develop herpes 
zoster during pregnancy. Fewer than 100 cases of congenital 
VZV have been reported, none so far in HIV-infected mothers. 
However, congenital varicella syndrome may not be recognized. 
Before the availability of varicella vaccine in the United States, 
approximately 44 cases occurred each year. Congenital varicella 
syndrome is characterized by cicatricial skin scarring, limb hyp-
oplasia, and neurologic (e.g., microcephaly, cortical atrophy, 
seizures, and mental retardation), eye (e.g., chorioretinitis, 
microphthalmia, and cataracts), renal (e.g., hydroureter, and 
hydronephrosis) and autonomic nervous system abnormalities 
(neurogenic bladder, swallowing dysfunction, and aspiration 
pneumonia) (961–963).
VZV can be transmitted to the fetus in later gestation, result-
ing in acute neonatal varicella. When the mother develops 
varicella from 4 days before to 2 days after delivery without 
passive antibody prophylaxis, the attack rate for infants is 
approximately 20% and mortality, before the availability of 
antiviral therapy, was approximately 30% (961). In compari-
son, if maternal varicella precedes delivery long enough to allow 
transfer of VZV IgG antibodies across the placenta, infants can 
develop varicella in the first 5 days of life, but it is rarely severe 
and usually requires no medical intervention.
Zoster occurs only among persons previously infected with 
VZV. Zoster used to be common in HIV-infected children 
who had primary varicella infections when their CD4 counts 
were normal or mildly suppressed. Before PIs were commonly 
administered to children, among HIV-infected children with 
low CD4 percentage (i.e., CD4 <15%) at the time of primary 
varicella, the rate of subsequent zoster was approximately 
70% (952,953). The incidence of zoster among HIV-infected 
children who developed primary varicella when they were 
immuno compromised was 467 per 1000 child-years, sub-
stantially higher than the rates for immuno compromised 
HIV-infected adults (98 per 1000 person-years) and for chil-
dren with leukemia (25 per 1000 child-years). As in adults, 
the CD4 count in children correlates with the frequency of 
zoster recurrences (964). The incidence of zoster reportedly 
increases transiently after institution of PIs (22,965). The cause 
of this phenomenon is not known; one hypothesis is that it 
results from return of regulatory T-cell function with transient 
immune dysregulation. Overall, however, the incidence of 
herpes zoster in HIV-infected children is lower during the 
HAART era than it was during the pre-HAART era (3). One 
reason may be immunization of many HIV-infected children 
with the Oka vaccine strain. The Oka vaccine strain of VZV 
is the licensed live attenuated varicella vaccine (marketed by 
Merck in the United States and by GlaxoSmithKline in other 
countries).
Clinical Manifestations
Varicella in HIV-infected children may be associated with a 
prodrome of malaise and fever, followed by pruritic vesiculo-
papular lesions that are more numerous on the face and trunk 
than on the extremities. Lesions evolve over 5 days through 
macular, papular, vesicular, pustular, and crust stages. In pro-
foundly immuno compromised hosts, vesicles can persist for 
weeks and coalesce to form large lesions resembling a burn. 
Complications of varicella include superinfection of skin with 
bacterial pathogens, such as staphylococci and streptococci; 
neurologic manifestations, such as encephalitis, cerebellar 
ataxia, and transverse myelitis; and on occasion, vasculitic 
stroke, hepatitis, and pneumonia.
Initial reports of varicella among HIV-infected children 
suggested severe disease manifestations (966), but more recent 
studies support less complicated courses, particularly in chil-
dren receiving antiretroviral therapy or having higher CD4 
counts at the time of infection (952,953,967,968). However, 
the disease may last longer than normal, and the rate of com-
plications is higher than in otherwise healthy children with 
varicella (968).
Uncommonly, HIV-infected children can have persistent 
chronic infection, with continued appearance of new VZV 
lesions for >1 month after primary or recurrent infection (969). 
The lesions are characteristically varicelliform at onset but 
evolve into nonhealing ulcers that become necrotic, crusted, 
and hyperkeratotic. Persistent lesions may be atypical and lack 
a vesicular component. Chronic VZV was reported in 14% of 
HIV-infected children with VZV, usually in children with low 
CD4 counts (964). The virus may become resistant to acyclovir 
during prolonged therapy (970).
The classical presentation of zoster is a painful or pruritic 
unilateral vesicular eruption with a dermatomal distribution. 
Less typical rashes, however, including those that extend 
beyond dermatomal boundaries or are bilaterally distributed 
or generalized, also can represent zoster in HIV-infected 
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children. HIV-infected children can have recurrent episodes 
of reactivated VZV infection that present with a disseminated 
rash more similar to varicella than zoster but without visceral 
dissemination; they also can have multiple episodes of recurrent 
dermatomal disease (964). Encephalitis without rash resulting 
from zoster also has been reported (971). Diagnostic labora-
tory studies are useful if children or adolescents present with 
unusual clinical manifestations suspected to be caused by zoster. 
Ruling out HSV infection, which can be confused with VZV 
skin manifestations, also is important (972).
Retinitis is a complication of VZV infection among HIV-
infected patients that occurs in children and adolescents (973). 
VZV-associated retinitis may be confused with CMV retinitis 
(974). Progressive outer retinal necrosis is a VZV-associated 
entity that typically occurs among HIV-infected persons with 
CD4 counts <50 cells/mm3. This rapidly progressive necrotiz-
ing herpetic retinopathy often is associated with dermatomal 
zoster and is characterized by multifocal retinal opacifica-
tion with little or no ocular inflammation (975,976) and 
rapid visual loss. Acute retinal necrosis occurs as a peripheral 
necrotizing retinitis with yellowish thumbprint lesions, retinal 
vascular sheathing, and vitritis, with a high rate of visual loss 
often caused by retinal detachment. This latter syndrome can 
occur in both immunologically normal and deficient persons. 
Among patients with HIV infection, acute retinal necrosis 
can occur at any CD4 count, but more often occurs at higher 
CD4 counts, and progressive outer retinal necrosis more often 
occurs at lower CD4 counts.
VZV infection should be suspected in children with uni-
lateral vesicular rashes. Retinitis as a complication of VZV 
should be suspected when CMV cannot be implicated or 
with progressive and otherwise unexplained encephalitis and 
a history of varicella or varicella vaccination.
Diagnosis
Varicella and zoster are diagnosed clinically by the typical 
appearance of generalized pruritic vesicular rash and fever 
in the former and a frequently painful or pruritic unilateral 
vesicular rash in a dermatomal pattern in the latter. Direct 
immunofluorescence for VZV antigen can be performed on 
cells collected from skin, conjunctiva, or mucosal lesion scrap-
ings for diagnosis (972). The optimal sensitivity of this method 
requires obtaining cells from the base of a lesion after unroof-
ing a fresh vesicle. Direct and indirect immunofluorescence or 
immunoperoxidase methods also can be used to detect VZV-
infected cells in tissue sections of lung, liver, brain, or other 
organs. Giemsa-staining (Tzanck preparation) of scrapings 
from lesions is nonspecific; detection of multinucleated giant 
cells does not distinguish between VZV and HSV infection.
VZV can be isolated in cell culture from vesicular fluid or 
ulcer swabs, but the virus is labile. The specimen must be 
processed rapidly or kept on dry ice or frozen at -70°C (-94°F) 
if storage is required for more than a few hours (961). Typical 
cytopathic effects usually can be detected 5–7 days after inocu-
lation; confirmation by staining with virus-specific antiserum 
is then needed. Shell vial cultures combine centrifugation and 
staining with fluorescein-conjugated monoclonal antibodies to 
detect synthesis of VZV proteins in infected cells. This allows 
results 1–3 days after inoculation, before cytopathic effect is 
visible. Standard culture usually is necessary when testing the 
virus for antiviral susceptibility is anticipated, although PCR 
also can be used (972,977).
PCR can be used to detect VZV in samples, is extremely 
sensitive and specific, can differentiate between wild-type and 
vaccine VZV, and is becoming increasingly available and used. 
In some laboratories, PCR has replaced culture as the “gold 
standard” (972). Serologic tests can be used to diagnose VZV 
infection, noting a substantial increase in antibody titer dur-
ing convalescence (e.g., 2–3 weeks after illness onset) or VZV 
IgM antibody. VZV reactivation also can induce VZV-IgM 
antibodies so their presence does not differentiate primary 
from recurrent VZV infections (961,972).
Prevention Recommendations
Preventing Exposure
HIV-infected children and adults who have no evidence of 
immunity to VZV (with no history of varicella or zoster; or 
who are seronegative for VZV by a sensitive, specific antibody 
assay; or who lack evidence of age appropriate vaccination) 
should avoid exposure to persons with varicella or zoster (AII). 
Household contacts of HIV-infected persons should receive 
varicella vaccine if they lack evidence of immunity (i.e., have 
no history of varicella or zoster, are seronegative for HIV, were 
born in the United States after 1980, or lack evidence of age-
appropriate vaccination) so they will be less likely to transmit 
wild-type VZV to their HIV-infected contacts (AIII) (32).
Preventing Disease
HIV-infected children aged 1–8 years in CDC clinical cate-
gories N, A, and B (98) and whose CD4 levels are >15% should 
be considered for vaccination (two doses of monovalent single-
antigen varicella vaccine); first dose administered at age 12–15 
months and second dose 3 months later (BII) (32). Limited 
data from a clinical trial in HIV-infected children with these 
characteristics indicate that the vaccine was well-tolerated and 
that >80% of subjects had detectable VZV-specific immune 
response (either antibody or cell immune response or both) at 
1 year after vaccination (978,979). Data are not available on 
safety, immunogenicity, or efficacy of the combination measles-
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mumps-rubella-varicella vaccine in HIV-infected children, 
and the combination measles-mumps-rubella-varicella vaccine 
should not be administered as a substitute for the single-antigen 
varicella vaccine to HIV-infected children (EIII).
Data are lacking on use of varicella vaccine in older HIV-
infected children and adolescents. However, on the basis of 
expert opinion, the safety of varicella vaccine in HIV-infected 
persons aged >8 years who have similar levels of immune func-
tion (e.g., CD4 count >200 cells/mm3) is likely to be similar 
to that in children aged <8 years. Immunogenicity might be 
lower in older HIV-infected children, adolescents, and adults. 
However, weighing the risk for severe disease from wild VZV 
and potential benefit of vaccination, vaccination (two doses 
of single-antigen vaccine, administered 3 months apart) for 
persons with CD4 count >200 cells/mm3 in these age groups 
can be considered (BIII) (32).
HIV-infected children tolerate the vaccine well; as in healthy 
children, serious vaccine-related adverse events are rare. As 
with healthy children, vaccinated HIV-infected children who 
develop mild rashes >2 weeks after vaccination rarely require 
antiviral therapy for Oka VZV; these rashes usually clear in 
3–5 days without treatment. If vaccination of HIV-infected 
children results in more severe clinical disease, the use of acy-
clovir to treat the Oka vaccine strain of VZV (which is sensitive 
to acyclovir) might modify the severity of disease. VZV rashes 
developing <2 weeks after vaccination, however, usually result 
from wild-type VZV (32).
HIV-infected children with low CD4 levels (<15%) may 
develop pneumonia and neurologic manifestations from 
VZV and should not be vaccinated against varicella (EIII). 
Vaccination of such children after reconstitution of their 
immune system (CD4 percentage >15%) with antiretroviral 
therapy, however, can be considered (980). Zoster from the 
vaccine (Oka strain) has been reported in healthy children and 
in children with acute lymphocytic leukemia, but it has not 
been described in HIV-infected children (981,982).
Efficacy studies on preventing varicella in HIV-infected 
children are not available. In vaccinated healthy children 
(after one dose) and in children with underlying leukemia 
(after two doses), the effectiveness of varicella vaccine is about 
80%–85% for prevention of clinical infection. The majority 
of varicella cases in vaccinated children are modified, with 
fewer lesions (commonly <50), fever, and a shorter duration 
of illness (32,951).
Because Zostavax is licensed only for use in healthy people 
aged >60 years to prevent zoster, it should not be given to 
HIV-infected children. Being immuno compromised is a 
contraindication for its use. There are no data on safety or 
efficacy for HIV-infected children (EIII).
For postexposure prophylaxis against varicella, HIV-infected 
children and adolescents who lack evidence of immunity to 
VZV (i.e., have no history of varicella or zoster; are seronegative 
for VZV by a sensitive, specific antibody assay; or lack evidence 
of age-appropriate vaccination) should be passively immunized 
as soon as possible and within <96 hours after close contact 
with a person with varicella or zoster (AIII). Previously this was 
performed by administering varicella-zoster immune globu-
lin (VZIG), but because licensure of varicella vaccine in the 
United States resulted in dramatically fewer requests for VZIG, 
VZIG is no longer produced. A new product, human varicella 
immune globulin (VariZIG), manufactured in Canada, is the 
replacement. VariZIG is a lyophilized preparation which, when 
properly reconstituted, is approximately a 5% solution of IgG 
that can be administered intramuscularly. VariZIG is available 
under an investigational new drug application expanded access 
protocol (available at http://www.fda.gov/cber/infosheets/
mphvzig020806.htm) (983). VariZIG can be obtained in the 
United States, and it has received central institutional review 
board approval but local institutional review board approval 
also may be necessary. VariZIG can be obtained 24 hours a 
day from the sole authorized U.S. distributor (FFF Enterprises, 
Temecula, California) at 1-800-843-7477 or online at http://
www.fffenterprises.com. An alternative to VariZIG for passive 
immunization is IVIG, 400 mg/kg, administered once. IVIG 
should be administered within 96 hours after exposure.
Data are lacking about the effectiveness of acyclovir for 
preventing varicella among susceptible HIV-infected chil-
dren. Published information about this form of prophylaxis 
for healthy children is minimal (984–986). If VariZIG is 
not available or >96 hours have passed since exposure, some 
experts recommend prophylaxis with acyclovir (80 mg/kg/day, 
administered four times per day for 5–7 days; beginning day 
7–10 after exposure, maximum dose of 80 mg, four times per 
day) (90). However, the use of acyclovir for prophylaxis in 
HIV-infected VZV-exposed children has not been studied. For 
that reason, some experts would consider it prudent to wait 
until the first appearance of rash to start acyclovir therapy for 
the VZV-susceptible and VZV-exposed HIV-infected child for 
whom passive immunization was not administered (CIII).
Treatment Recommendations
Treatment of Disease
On the basis of controlled trials among children with 
malignancies, acyclovir is the drug of choice for treating VZV 
infection in HIV-infected children (AI). For varicella, acyclo-
vir should be initiated as soon as possible after initial lesions 
appear. New lesions can continue to appear for 72 hours after 
initiation of acyclovir and crusting of all lesions might take 
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5–7 days. IV acyclovir is recommended for treating primary 
varicella among HIV-infected children with severe immuno-
suppression (i.e., CD4 < 15%, CDC Immunologic Category 3) 
(98) or who have high fever or numerous or deep, necrotic, or 
hemorrhagic skin lesions (AIII). For children aged <1 year, the 
dose of acyclovir is 10 mg/kg/dose administered intravenously 
every 8 hours as a 1-hour infusion. Some health-care providers 
administer the same dose for children aged >1 year, and others 
base dosage of acyclovir on body surface area among children 
aged >1 year old (500 mg/m2 body surface area/dose intrave-
nously every 8 hours as a 1-hour infusion) (90). Administration 
is for 7–10 days or until no new lesions appear for 48 hours. 
Oral administration should be used only to treat primary 
varicella among HIV-infected children with normal or only 
slightly decreased CD4 counts (CDC Immunologic Category 
1 or 2) (98) and have mild varicella disease (BIII).
Acyclovir is the treatment of choice for zoster among HIV-
infected children, administered for 7–10 days, although longer 
durations of therapy should be considered if lesions are slow to 
resolve (AII). With zoster, oral acyclovir can be administered 
because the chance for disseminated, life-threatening disease 
is less with zoster than with varicella. Initial IV administration 
should be considered for HIV-infected children with severe 
immunosuppression (i.e., CD4 <15%, CDC Immunologic 
Category 3) (98), trigeminal nerve involvement, or extensive 
multidermatomal zoster (AII). If cutaneous lesions are exten-
sive or if clinical evidence of visceral involvement is observed, 
IV acyclovir should be initiated and continued until cutaneous 
lesions and visceral disease are clearly resolving (AII), then 
change to oral administration can be considered to complete 
the course of therapy (10–14 days in this situation) (AIII) 
(987). Doses of acyclovir for treating zoster are the same as 
those for treating varicella.
Progressive outer retinal necrosis is rapidly progressive and 
leads to profound loss of vision; prognosis for visual preserva-
tion is poor despite aggressive therapy, and optimal therapy 
is yet to be defined (988,989). Regardless of specific VZV 
antiviral therapy, optimization of antiretroviral therapy also is 
recommended. Some experts recommend anti-VZV therapy 
that includes a combination of IV ganciclovir (5 mg/kg/dose 
administered intravenously every 12 hours) and foscarnet 
(90 mg/kg/dose administered intravenously every 12 hours) 
plus twice weekly intravitreal injections of ganciclovir 
(2 mg/0.05 mL and/or foscarnet 1.2 mg/0.05 mL) (BIII) (990). 
In contrast, acute retinal necrosis appears more responsive to 
antiviral therapy, and one recommended treatment is high-
dose IV acyclovir (10–15 mg/kg intravenously every 8 hours 
for 10–14 days), followed by prolonged (i.e., 4–6 weeks) oral 
valacyclovir (AIII) (990). Involvement of an ophthalmologist 
experienced in managing patients with VZV retinitis is strongly 
recommended (AIII).
Alternatives to acyclovir in older adolescents and adults 
include valacyclovir and famciclovir. Valacyclovir is a prodrug 
of acyclovir with improved bioavailability that is rapidly con-
verted to acyclovir after absorption and is approved for treating 
zoster in adults. It is not active against acyclovir-resistant VZV 
strains. Data are limited for its use in children (863,991); bio-
availability is about 45% and independent of age in children. 
Limited data indicate that pediatric blood levels of acyclovir 
(from the prodrug valacyclovir) similar to that of valacyclovir 
tablets in adults can be achieved by administering an oral dose 
of valacyclovir of 20–25 mg/kg/dose administered two or three 
times a day (CIII) (864). However, valacyclovir is available only 
in a caplet formulation; hence this drug is an alternative only 
for children old enough to swallow the valacyclovir caplets. 
Although tablets can be crushed, they have a unpleasant taste. 
A liquid formulation that is stable for 21 days can be prepared 
in Ora-Sweet® and Syrpalta® syrups and stored in amber glass 
bottles (991).
Famciclovir is the oral prodrug of penciclovir. It is not active 
against acyclovir-resistant VZV strains. It is comparable in 
efficacy to oral acyclovir in treatment of immuno compromised 
adults with localized zoster but has not been approved for this 
indication. It is available only in tablet form. No specific data 
exist on the pharmacokinetics and dosing of famciclovir in chil-
dren, and no pediatric preparation is available (EIII) (864).
Monitoring and Adverse Events, Including IRIS
Acyclovir is excreted primarily by the kidney, and dose adjust-
ment (based on creatinine clearance) is needed for patients with 
renal insufficiency or renal failure. Primary toxicities of acy-
clovir are phlebitis, renal toxicity, nausea, vomiting, and rash. 
Toxicities are similar for valacyclovir. Among infants receiv-
ing high-dose acyclovir for neonatal HSV disease, the major 
toxicity was neutropenia (absolute neutrophil count <1000/
mm3), which was observed in 21% of children (857). Grade 
3 or higher nephrotoxicity was observed in 6% of children. 
For children receiving high-dose IV acyclovir, monitoring of 
renal function is recommended at initiation of treatment, and 
once or twice weekly for the duration of treatment, particularly 
for those with underlying renal dysfunction or those receiving 
prolonged therapy.
In HIV-infected adults, immune reconstitution after ini-
tiation of HAART may be associated with increased VZV 
reactivation (965,992). VZV-associated IRIS after HAART 
also has been described in HIV-infected children (20,24). In 
a study of 153 HAART-treated children in Thailand, 19% of 
children starting HAART experienced IRIS; 22% of IRIS cases 
were secondary to VZV. In the reported cases, manifestations 
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were typically mild and cutaneous, had a typical dermatomal 
distribution of vesicular lesions as seen in VZV reactivation, 
and responded well to treatment with oral acyclovir. Most cases 
presented in the first 4 months of HAART; the median time 
from initiation of HAART to onset of clinical symptoms was 
6 weeks (range: 2–21 weeks) (24).
Management of Treatment Failure
Children who continue to develop lesions or whose lesions 
fail to heal after 10 days of treatment may be infected with 
acyclovir-resistant VZV. If possible, a culture should be 
obtained to analyze the virus for drug resistance. HIV-infected 
children with acyclovir-resistant VZV can be treated with IV 
foscarnet for 7 days or until no new lesions have appeared for 
48 hours (AII) (990,993,994). The dose of foscarnet should be 
administered slowly over the course of 2 hours (i.e., no faster 
than 1 mg/kg/minute). Infusing foscarnet with saline fluid 
loading can minimize renal toxicity. Doses should be modified 
among patients with renal insufficiency.
The main toxicity of foscarnet is decreased renal function; in 
<30% of patients, serum creatinine levels increase. Renal toxic-
ity and foscarnet binding to divalent metal ions (e.g., calcium) 
leads to metabolic abnormalities in approximately one third of 
patients. In addition, serious electrolyte imbalances (including 
abnormalities in calcium, phosphorus, magnesium, and potas-
sium levels), secondary seizures, cardiac dysrhythmias, abnor-
mal liver transaminases, and CNS symptoms can occur.
Prevention of Recurrence
Preventing Recurrence
No preventive measures are available for zoster in HIV-
infected children and adolescents. A vaccine to prevent herpes 
zoster has been approved for use in immunocompetent adults 
aged >60 years. Data regarding safety and efficacy of this vac-
cine in HIV-infected persons of any age are lacking, and use 
of the vaccine in HIV-infected persons is not recommended 
(DIII). However, prospective clinical trials are planned to 
evaluate the safety and immunogenicity of herpes zoster vac-
cine in HIV-infected adults.
Discontinuing Secondary Prophylaxis
Not applicable.
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TABLE 1. Prophylaxis to prevent first episode of opportunistic infections among HIV-exposed and HIV-infected infants and 
children, United States*†
Preventive regimen
Pathogen Indication First choice Alternative
Strongly recommended as standard of care
Pneumocystis 
pneumonia§
HIV-infected or HIV- indeterminate infants 
aged 1–12 mos; HIV-infected children aged 
1–5 yrs with CD4 count of <500 cells/mm3 
or CD4 percentage of <15%; HIV-infected 
children aged 6–12 yrs with CD4 count of 
<200 cells/mm3 or CD4 percentage of <15%
TMP-SMX, 150/750 mg/m•	 2 body surface 
area per day (max: 320/1600 mg) orally 
divided into 2 doses daily and administered 
3 times weekly on consecutive days (AI)
Acceptable alternative dosage schedules •	
for same dose (Al): single dose orally 3 
times weekly on consecutive days; 2 divided 
doses orally daily; or 2 divided doses orally 
3 times weekly on alternate days
Dapsone: children aged •	 >1 mo, 2 mg/kg body 
weight (max 100 mg) orally daily; or 4 mg/kg body 
weight (max 200 mg) orally weekly (BI)
Atovaquone: children aged 1–3 mos and >24 mos, •	
30 mg/kg body weight orally daily; children aged 
4–24 mos, 45 mg/kg body weight orally daily (BI)
Aerosolized pentamidine: children aged •	 >5 yrs, 
300 mg every mo by Respirgard II™ (Marquest, 
Englewood, CO) nebulizer (BI)
Malaria  Travel to area in which malaria is endemic Recommendations are the same for HIV-•	
infected and HIV-uninfected children. Refer 
to http://www.cdc.gov/malaria/ for the most 
recent recommendations based on region 
and drug susceptibility.
Mefloquine, 5 mg/kg body weight orally •	
1 time weekly (max 250 mg)
Atovaquone/Proguanil (Malarone) 1 time •	
daily
11–20 kg = 1 pediatric tablet   —
(62.5 mg/25 mg)
21–30 kg = 2 pediatric tablets   —
(125 mg/50 mg)
31–40 kg = 3 pediatric tablets   —
(187.5 mg/75 mg)
>40 kg = 1 adult tablet   —
(250 mg/100 mg)
Doxycycline, 100 mg orally daily for children >8 yrs •	
(2.2 mg/kg/day).
Chloroquine base, 5 mg/kg base orally up to •	
300 mg weekly for sensitive regions only (7.5 mg/kg 
chloroquine phosphate)
Mycobacterium 
tuberculosis
 Isoniazid-sensitive TST reaction >5 mm or prior positive TST 
result without treatment; or regardless of 
current TST result and previous treatment, 
close contact with any person who has 
contagious TB. TB disease must be excluded 
before start of treatment.
Isoniazid, 10–15 mg/kg body weight (max •	
300 mg) orally daily for 9 mos (AII); or 
20–30 mg/kg body weight (max 900 mg) 
orally 2 times weekly for 9 mos (BII)
Rifampin, 10–20 mg/kg body weight (max 600 mg) •	
orally daily for 4–6 mos (BIII)
 Isoniazid-resistant Same as previous pathogen; increased 
probability of exposure to isoniazid-resistant TB
Rifampin, 10–20 mg/kg body weight (max •	
600 mg) orally daily for 4–6 mos (BIII)
Uncertain•	
Multidrug-
resistant 
(isoniazid and 
rifampin)
Same as previous pathogen; increased 
probability of exposure to multidrug-resistant TB
Choice of drugs requires consultation with •	
public health authorities and depends on 
susceptibility of isolate from source patient
Mycobacterium 
avium complex¶
For children aged >6 yrs with CD4 count of 
<50 cells/mm3; aged 2–5 yrs with CD4 count 
of <75 cells/mm3; aged 1–2 yrs with CD4 
count of <500 cells/mm3; aged <1 yr with CD4 
count of <750 cells/mm3
Clarithromycin, 7.5 mg/kg body weight •	
(max 500 mg) orally 2 times daily (AII), or 
azithromycin, 20 mg/kg body weight (max 
1200 mg) orally weekly (AII)
Azithromycin, 5 mg/kg body weight (max 250 mg) •	
orally daily (AII); children aged >6 yrs, rifabutin, 
300 mg orally daily (BI)
Varicella-zoster 
virus**
Substantial exposure to varicella or shingles 
with no history of varicella or zoster or 
seronegative status for VZV by a sensitive, 
specific antibody assay or lack of evidence for 
age-appropriate vaccination
Varicella-zoster immune globulin (VariZIG), •	
125 IU per 10 kg (max 625 IU) IM, 
administered within 96 hrs after exposure†† 
(AIII)
If VariZIG is not available or >96 hrs have passed •	
since exposures, some experts recommend 
prophylaxis with acylovir 20 mg/kg body weight 
(max 800 mg) per dose orally 4 times a day 
for 5–7 days. Another alternative to VariZIG is 
intravenous immune globulin (IVIG), 400 mg/kg, 
administered once. IVIG should be administered 
within 96 hrs after exposure (CIII)
Vaccine-preventable 
pathogens
Standard recommendations for HIV-exposed 
and HIV-infected children
Routine vaccinations (see Figures 1 and 2)
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TABLE 1. (Continued) Prophylaxis to prevent first episode of opportunistic infections among HIV-exposed and HIV-infected 
infants and children,  United States*†
Preventive regimen
Pathogen Indication First choice Alternative
Usually recommended
Toxoplasma 
gondii§§
Immunoglobulin G (IgG) antibody to 
Toxoplasma and severe immunosuppression: 
HIV-infected children aged <6 yrs with CD4 
<15%; HIV-infected children aged >6 yrs with 
CD4 <100 cells/mm3 (BIII)
TMP-SMX, 150/750 mg/m•	 2 body surface 
area daily orally in 2 divided doses (BIII)
Acceptable alternative dosage schedules •	
for same dosage (Al): single dose orally 3 
times weekly on consecutive days; 2 divided 
doses orally daily; or 2 divided doses orally 
3 times weekly on alternate days
Dapsone (children aged •	 >1 mos), 2 mg/kg body 
weight or 15 mg/m2 body surface area (max 25 mg) 
orally daily, PLUS pyrimethamine, 1 mg/kg body 
weight (max 25 mg) orally daily; PLUS leucovorin, 
5 mg orally every 3 days (BI)
Atovaquone (children aged 1–3 mos and >24 mos, •	
30 mg/kg body weight orally daily; children aged 
4–24 mos, 45 mg/kg body weight orally daily) with 
or without pyrimethamine, 1 mg/kg body weight or 
15 mg/m2 body surface area (max 25 mg) orally 
daily; PLUS leucovorin, 5 mg orally every 3 days 
(CIII)
Not recommended for most children; indicated for use only in unusual circumstances
Invasive bacterial 
infections
Hypogammaglobulinemia  
(i.e., IgG <400 mg/dL)
IVIG (400 mg/kg body weight every •	
2–4 wks) (AI)
 Cytomegalovirus CMV antibody positivity and severe 
immunosuppression (CD4 <50 cells/mm3)
Valganciclovir, 900 mg orally 1 time daily •	
with food for older children who can receive 
adult dosing (CIII) 
 * Abbreviations: HIV = human immunodeficiency virus; PCP = Pneumocystis pneumonia; TMP-SMX = trimethoprim-sulfamethoxazole; TST = tuberculin skin test; TB = tuberculosis; 
IM = intramuscularly;  IVIG = intravenous immune globulin; IgG = immunoglobulin G; CMV = cytomegalovirus; VZV = varicella-zoster virus; FDA = Food and Drug Administration.
 † Information in these guidelines might not represent FDA approval or FDA-approved labeling for products or indications. Specifically, the terms “safe” and “effective” might not be 
synonymous with the FDA-defined legal standards for product approval. Letters and roman numerals in parentheses after regimens indicate the strength of the recommendation 
and the quality of the evidence supporting it (see Box).
 § Daily trimethoprim-sulfamethoxazole (TMP-SMX) reduces the frequency of certain bacterial infections. TMP-SMX, dapsone-pyrimethamine, and possibly atovaquone (with or 
without pyrimethamine) protect against toxoplasmosis; however, data have not been prospectively collected. Compared with weekly dapsone, daily dapsone is associated with 
lower incidence of PCP but higher hematologic toxicity and mortality.  Patients receiving therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against PCP 
and do not need TMP-SMX.
 ¶ Substantial drug interactions can occur between rifamycins (i.e., rifampin and rifabutin) and protease inhibitors and non-nucleoside reverse transcriptase inhibitors. A specialist 
should be consulted.
 ** Children routinely being administered intravenous immune globulin (IVIG) should receive VariZIG if the last dose of IVIG was administered >21 days before exposure.
 †† As of 2007, VariZIG can be obtained only under a treatment Investigational New Drug protocol (1-800-843-7477, FFF Enterprises, Temecula, California.)
 §§ Protection against toxoplasmosis is provided by the preferred anti-Pneumocystis regimens and possibly by atovaquone.
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TABLE 2. Prophylaxis to prevent recurrence of opportunistic infections, after chemotherapy for acute disease, among HIV-exposed 
and HIV-infected infants and children, United States*†
Preventive regimen
Pathogen Indication First choice Alternative
Recommended as standard of care after completion of initial therapy
Pneumocystis 
pneumonia§
Prior PCP TMP-SMX, 150/750 mg/m2 body surface area 
daily (max: 320/1600 mg) orally divided into 
2 doses and administered 3 times weekly on 
consecutive days (AI)
Acceptable alternative dosage schedules 
for same dosage: single dose orally 3 times 
weekly on consecutive days; 2 divided doses 
orally daily; or 2 divided doses orally 3 times 
weekly on alternate days (Al)
Dapsone: children aged >1 mos, 2 mg/kg body 
weight (max 100 mg) orally daily or 4 mg/kg body 
weight (max 200 mg) orally weekly (BI)
Atovaquone: children aged 1–3 mos and >24 mos, 
30 mg/kg body weight orally daily; children aged 
4–24 mos, 45 mg/kg body weight orally daily (BI)
Aerosolized pentamidine: children aged >5 yrs, 
300 mg every mo by Respirgard II™ (Marquest, 
Englewood, CO) nebulizer (BI)
Toxoplasma 
gondii§
Before Toxoplasma encephalitis Sulfadiazine, 85–120 mg/kg body weight 
(max 2–4 g) daily orally divided into in 2–4 
doses; PLUS pyrimethamine, 1 mg/kg body 
weight or 15 mg/m2 body surface area (max 
25 mg) orally daily; PLUS leucovorin, 5 mg 
orally every 3 days (AI)
Clindamycin, 20–30 mg/kg body weight daily orally 
divided into 3–4 doses; PLUS pyrimethamine, 
1 mg/kg body weight or 15 mg/m2 body surface area 
(max 25 mg) orally daily; PLUS leucovorin, 5 mg 
orally every 3 days (BI)
Atovaquone (children aged 1–3 mos and >24 mos, 
30 mg/kg body weight orally daily; children aged 
4–24 mos, 45 mg/kg body weight orally daily) with 
or without pyrimethamine, 1 mg/kg body weight or 
15 mg/m2 body surface area (max 25 mg) orally daily; 
PLUS leucovorin, 5 mg orally every 3 days (CIII)
Mycobacterium 
avium complex¶
Prior disease Clarithromycin, 7.5 mg/kg body weight 
(max 500 mg) orally 2 times daily (AII); 
PLUS ethambutol, 15–25 mg/kg body weight 
(max 2.5 g) orally daily (AII); with or without 
rifabutin, 5 mg/kg body weight (max 300 mg) 
orally daily (CII)
Azithromycin, 5 mg/kg body weight (max 250 mg) 
orally daily (AII); PLUS ethambutol, 15–25 mg/kg 
body weight (max 2.5 g) orally daily (AII); with or 
without rifabutin, 5 mg/kg body weight (max 300 mg) 
orally daily (CII)
Coccidioides spp. Documented disease Fluconazole, 6 mg/kg body weight 
(max 400 mg) orally daily (AII)
Itraconazole, 2–5 mg/kg body weight (max 200 mg) 
orally per dose 2 times daily (AII)
Cryptococcus 
neoformans
Documented disease Fluconazole, 6 mg/kg body weight 
(max 200 mg) orally daily (AI)
Itraconazole oral solution, 5 mg/kg body weight 
(max 200 mg) orally daily (BI)
Histoplasma 
capsulatum
Documented disease Itraconazole oral solution, 5 mg/kg body 
weight (max 200 mg) orally per dose 
2 times daily (AII)
Fluconazole, 3–6 mg/kg body weight (max 200 mg) 
orally daily (CII)
Microsporidiosis Disseminated, nonocular infection caused 
by microsporidia other than Enterocytozoon 
bieneusi
Albendzaole, 7.5 mg/kg body weight (max 
400 mg/dose) per dose orally 2 times daily 
(AII) until immune reconstitution after initiation 
of HAART
Ocular infection Topical fumagillin bicylohexylammonium 
(Fumidil B), 3 mg/mL in saline (fumagillin 
70 μg/mL) eye drops—2 drops every 2 
hrs for 4 days, then 2 drops 4 times daily 
(investigational use only in United States) 
(BII); PLUS albendazole, 7.5 mg/kg body 
weight (max 400 mg/dose) orally 2 times daily 
to manage systemic infection (BIII)
Cytomegalovirus Prior retinitis, neurologic disease, or 
gastrointestinal disease with relapse
Ganciclovir, 5 mg/kg body weight IV daily 
(AI); or
Foscarnet, 90–120 mg/kg body weight IV 
daily (AI); or
Valganciclovir, 900 mg orally 1 time daily with 
food for older children who can receive adult 
dosing (AI)
(For retinitis) Ganciclovir sustained-release implant, 
every 6–9 mos; PLUS ganciclovir, 30 mg/kg body 
weight orally 3 times daily (BIII)
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TABLE 2. (Continued) Prophylaxis to prevent recurrence of opportunistic infections, after chemotherapy for acute disease, among 
HIV-exposed and HIV-infected infants and children, United States*†
Preventive regimen
Pathogen Indication First choice Alternative
Recommended only if subsequent episodes are frequent or severe
Invasive bacterial 
infections**
>2 infections in a 1-yr period TMP-SMX, 150/750 mg/m2 body surface area 
daily orally divided into in 2 doses (BI)
IVIG, 400 mg/kg body weight every 2–4 wks 
(BI)
Antibiotic chemoprophylaxis with another active 
agent (BIII)
Bartonellosis Frequent or severe recurrences Doxycycline, 2–4 mg/kg body weight 
(max 100–200 mg/day) per day orally 
1 time daily or divided into 2 doses (AIII)
One of the macrolide antibiotics (AIII)— e.g., 
azithromycin, 5–12 mg/kg body weight (max 
600 mg/day) orally 1 time daily; OR clarithromycin, 
15 mg/kg body weight (max 1 g/day) per day orally 
divided into 2 doses; OR erythromycin, 30–50 mg/kg 
body weight (max 2 g/day) per day orally divided into 
2 doses (AIII)
Candida 
(esophageal)
Frequent or severe recurrences Fluconazole, 3–6 mg/kg body weight 
(max 200 mg) orally daily (BI)
—
Herpes simplex 
virus
Frequent or severe recurrences Acyclovir, 20 mg/kg body weight (max 
400 mg/dose) per dose orally 2 times daily 
(AI)
Valacyclovir, 500 mg orally 2 times daily, OR 
famicilovir, 500 mg orally 2 times daily for children old 
enough to receive adult dosing (AI)
 * Information in these guidelines might not represent FDA approval or FDA-approved labeling for products or indications. Specifically, the terms “safe” and “effective” might not be 
synonymous with the FDA-defined legal standards for product approval. Letters and roman numerals in parentheses after regimens indicate the strength of the recommendations 
and the quality of evidence supporting it (see Box).
 † Abbreviations: HIV—human immunodeficiency virus; FDA—Food and Drug Administration; PCP—Pneumocystis pneumonia; TMP-SMX—trimethoprim-sulfamethoxazole; 
HAART—highly active antiretroviral treatment; IV—intravenous; IVIG—intravenous immune globulin.
 § Pyrimethamine plus sulfadiazine, and possibly atovaquone, confers protection against PCP as well as against toxoplasmosis. Although the clindamycin-plus-pyrimethamine or 
atovaquone-with/without-pyrimethamine regimens are recommended for adults, they have not been tested in children. However, these drugs are safe and are used for other 
infections in children.
 ¶ Substantial drug interactions might occur between rifabutin and protease inhibitors and non-nucleoside reverse transcriptase inhibitors. A specialist should be consulted.
 ** Antimicrobial prophylaxis should be chosen on the basis of microorganism identification and antibiotic susceptibility testing. TMP-SMX, if used, should be administered daily. 
Health-care providers should be cautious about using antibiotics solely for this purpose because of the potential for development of drug-resistant microorganisms. IVIG might 
not provide additional benefit to children receiving daily TMP/SMX but might be considered for children who have recurrent bacterial infections despite TMP-SMX prophylaxis. 
Choice of antibiotic prophylaxis versus IVIG also should involve consideration of adherence, ease of IV access, and cost. If IVIG is used, respiratory syncytial virus (RSV) IVIG 
(750 mg/kg body weight), not monoclonal RSV antibody, can be substituted for IVIG during the RSV season to provide broad anti-infective protection, if this product is available.
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TABLE 3. Criteria for discontinuing and restarting prophylaxis for opportunistic infections among HIV-exposed and HIV-infected 
infants and children, United States*
Opportunistic 
 illness
Criteria for discontinuing 
primary prophylaxis
Criteria for restarting 
primary prophylaxis
Criteria for discontinuing 
secondary prophylaxis
Criteria for restarting 
secondary prophylaxis
Pneumocystis 
pneumonia
Do not discontinue in children 
aged <1 yr
After >6 mos of HAART and
Age 1–5 yrs: CD4 percentage •	
>15% or count >500 cells/mm3 
for >3 consecutive mos (BII)
Age •	 >6 yrs: CD4 percentage 
>15% or count >200 cells/mm3 
for >3 consecutive mos (BII) 
Age 1–5 yrs: CD4 
percentage <15% or count 
<500 cells/mm3 (BIII)
Age >6 yrs: CD4 
percentage <15% or count 
<200 cells/mm3 (BIII)
If all of the following criteria fulfilled (CIII):
Completed •	 >6 mos of HAART
Age 1–5 yrs: CD4 percentage •	 >15% or count 
>500 cells/mm3 for >3 consecutive mos (BII)
Age •	 >6 yrs: CD4 percentage >15% or count 
>200 cells/mm3 for >3 consecutive mos (BII)
Age 1–5 yrs: CD4 percentage <15% 
or count <500 cells/mm3 or PCP 
recurrence (BIII)
Age >6 yrs: CD4 percentage <15% 
or count <200 cells/mm3 or PCP 
recurrence (BIII)
Toxoplasma 
gondii 
encephalitis
Do not discontinue in children 
aged <1 yr
After >6 mos of HAART and
Age 1–5 yrs: CD4 percentage •	
>15% for >3 consecutive mos 
(CIII)
Age •	 >6 yrs: CD4 percentage 
>15% or count >100–200 
cells/mm3 for >3 consecutive 
mos (CIII)
Age 1–5 yrs: CD4 
percentage <15% (CIII)
Age >6 yrs: CD4 
percentage <15% or count 
<100–200 cells/mm3 (CIII)
If all of the following criteria fulfilled (CIII):
Completed •	 >6 mos of HAART
Completed initial therapy for TE•	
Asymptomatic for TE•	
Age 1–5 yrs: CD4 percentage •	 >15% or count 
>500 cells/mm3 for >3 consecutive mos (CIII)
Age •	 >6 yrs: CD4 percentage >15% or count 
>200 cells/mm3 for >3 consecutive mos (CIII)
Age 1–5 yrs: CD4 percentage <15% 
or count <500 cells/mm3 (CIII)
Age >6 yrs: CD4 percentage <15% 
or count <200 cells/mm3 (CIII)
Mycobacterium 
avium complex 
disease
Do not discontinue in children 
aged <2 yrs
If age >2 yrs, after >6 mos 
of HAART and
Age 2–5 yrs: CD4 count •	
>200 cells/μL for >3 
consecutive mos (BII)
Age •	 >6 yrs: CD4 count 
>100 cells/μL for >3 
consecutive mos (BII)
Age 2–5 yrs: CD4 count 
<200 cells/mm3 (BIII)
Age >6 yrs: CD4 count 
<100 cells/mm3 (BIII)
If all of the following criteria fulfilled (CIII):
Completed •	 >6 mos of HAART
Completed at least 12 mos MAC therapy•	
Asymptomatic for signs and symptoms of MAC•	
Age 2–5 yrs: CD4 count >200 cells/mm•	 3 for 
>6 consecutive mos (BII)
Age •	 >6 yrs: CD4 count >100 cells/mm3 for 
>6 consecutive mos (BII)
Age 2–5 yrs: CD4 count 
<200 cells/mm3 (BII)
Age >6 yrs: CD4 count 
<100 cells/mm3 (BII)
Cytomegalovirus 
retinitis
Not applicable Not applicable If all of the following criteria fulfilled (CIII):
Completed •	 >6 mos of HAART.
Consultation with ophthalmologist•	
Age 1–5 yrs: CD4 percentage •	 >15% or count 
>500 cells/mm3 for >6 consecutive mos
Age•	  >6 yrs: CD4 count >100 cells/mm3 for 
>6 consecutive mos
Routine (every 3–6 mos) ophthalmologic •	
follow-up is recommended for early detection 
of relapse or immune restoration uveitis (AII)
Age 1–5 yrs: CD4 percentage <15% 
or count <500 cells/mm3 (BIII)
Age >6 yrs: CD4 percentage <15% 
or CD4 count <100 cells/mm3 (BIII) 
Cryptococcal 
meningitis
Not applicable Not applicable If all of the following criteria (BII) fulfilled:
Age •	 >6 yrs
Asymptomatic and received •	 >6 mos of 
secondary prophylaxis for crypotoccosis
Completed •	 >6 mos of HAART
CD4 count •	 >200 cells/mm3 for >6 mos
Age >6 yrs: CD4 count 
<200 cells/mm3 (AIII)
Histoplasma 
capsulatum 
infection
Not applicable Not applicable If all of the following criteria fulfilled (CIII):
Age •	 >6 yrs
Received •	 >1 yr itraconazole
Completed •	 >6 mos of HAART
CD4 count >150 cells/mm•	 3
Negative •	 Histoplasma blood cultures
Serum •	 Histoplasma antigen <2 ng/mL
Age >6 yrs: CD4 count 
<150 cells/mm3 (CIII)
* Abbreviations: HIV=human immunodeficiency virus; PCP=Pneumocystis pneumonia; HAART: highly active antiretroviral treatment; TE=Toxoplasma encephalitis; 
MAC=Mycobacterium avium complex.
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TABLE 4. Recommendations for treatment of opportunistic infections in HIV-exposed and HIV-infected infants and children, 
United States*†
Infection Preferred therapies and duration Alternative therapies Other options or issues
Bacterial infections
Bacterial pneumonia 
(Streptococcus 
pneumoniae; 
occasionally 
Staphylococcus 
aureus, 
Haemophilus 
influenzae, 
Pseudomonas 
aeruginosa)
Ceftriaxone, 80–100 mg/kg body weight per 
day (max 4 g/day) in 1 or 2 divided doses 
(AIII)
OR
Cefotaxime, 150–200 mg/kg body weight 
(max 8–10 g/day) per day divided into 3 or 4 
doses (AIII)
Cefuroxime, 100–150 mg/kg body weight 
(max 4–6 g/day) divided into 3 doses (AIII)
Add azithromycin for hospitalized patients to treat 
other common community-acquired pneumonia 
pathogens (e.g., Mycoplasma pneumoniae, 
Chlamydia pneumoniae).
Add clindamycin or vancomycin if methicillin-resistant 
S. aureus is suspected (choice based on local 
susceptibility patterns).
For patients with neutropenia, chronic lung disease 
other than asthma (e.g., lymphoid interstitial 
pneumonia, bronchiectasis) or indwelling venous 
catheter, consider regimen that includes activity 
against P. aeruginosa (e.g., cefepime instead of 
ceftriaxone).
Consider PCP in patients with severe pneumonia or 
more advanced HIV disease.
Consider evaluation for TB and cryptococcosis.
Bartonellosis Cutaneous bacillary angiomatosis infections:
Erythromycin, 30–50 mg/kg body weight •	
(max 2 g/day) per day orally divided 
into 2–4 doses, or if unable to take oral 
medication, 15–50 mg/kg body weight (max 
2 g/day) per day IV in divided doses 4 times 
a day (AII)
Doxycycline, 2–4 mg/kg body weight (max •	
100–200 mg/day) per day orally or IV once 
daily or divided into 2 doses (AII)
Treatment duration: 3 mos
Azithromycin, 5–12 mg/kg body weight (max 
600 mg/day) orally once daily (BIII)
Clarithromycin, 15 mg/kg body weight (max 
1 g/day) per day orally divided into 2 doses 
(BIII)
Severe Jarisch-Herxheimer–like reaction can occur in 
the first 48 hrs after treatment.
Long-term suppression with erythromycin or 
doxycycline may be considered in patients with 
relapse or reinfection (CIII).
CNS infections, bacillary peliosis, 
osteomyelitis, severe infections:
Doxycycline, 2–4 mg/kg body weight (max •	
100–200 mg/day) per day orally or IV once 
daily or divided into 2 doses (AIII)
Treatment duration: 4 mos
Rifampin, 20 mg/kg body weight (max 
600 mg/day) per day orally or IV once daily 
or divided into 2 doses can be used in 
combination with erythromycin or doxycycline 
in patients with more severe infections (BIII)
Syphilis Congenital: proven or highly probable 
disease:
Aqueous crystalline penicillin G, 100,000–•	
150,000 U/kg body weight per day, 
administered as 50,000 U/kg body weight IV 
every 12 hrs for the first 7 days of life, then 
every 8 hrs for a total of 10 days (AII)
If diagnosed after 1 mo of age, aqueous •	
penicillin G, 50,000 U/kg body weight per 
dose IV every 4–6 hrs for 10 days (AII) 
Acquired:
Early stage (primary, secondary, early latent):
Benzathine penicillin, 50,000 U/kg body •	
weight (max 2.4 million units) IM for 1 dose 
(AII)
Late latent stage:
Benzathine penicillin 50,000 U/kg body •	
weight (max 2.4 million units) IM once 
weekly for 3 doses (total 150,000 U/kg body 
weight; mzx 7.2  million units)(AIII)
Neurosyphilis (including ocular):
Aqueous penicillin G, 200,000–300,000 •	
U/kg body weight IV every 6 hrs (max 
18–24 million units per day) for 10–14 days 
(AII)
Congenital:
Alternative for proven or highly probable •	
disease (less desirable if CNS involved):
Procaine penicillin G, 50,000 U/kg body  —
weight IM once daily for 10 days (BII)
Infants with possible congenital syphilis •	
(maternal treatment and response 
adequate, normal physical examination, 
normal cerebrospinal fluid (CSF) studies, 
but serum quantitative nontreponemal 
serologic titer that is the same or 4-fold 
higher than maternal titer):
Benzathine penicillin G, 50,000 U/kg  —
body weight IM in a single dose (max 
2.4 million units) (BII)
For treatment of congenital syphilis, repeat entire 
course of treatment if even 1 day of treatment is 
missed.
Children with congenital syphilis should be 
evaluated at 1, 2, 3, 6, and 12 mos of age and have 
nontreponemal testing at 3, 6, and 12 mos after 
conclusion of therapy or until test becomes negative 
(AIII).
Children with increasing titers or persistently positive 
titers (even if low levels) at age 6–12 mos should be 
evaluated and considered for retreatment (AIII).
Children and adolescents with acquired syphilis 
should have clinical and serologic response 
monitored at 3, 6, 9, 12, and 24 mos after therapy 
(AIII).
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Mycobacterial infections
Mycobacterium 
tuberculosis 
Intensive phase (8 wks) (AI):
Isoniazid, 10–15 mg/kg body weight (max 
300 mg/day) orally once daily; PLUS rifampin, 
10–20 mg/kg body weight (max 600 mg/day) 
orally once daily; PLUS pyrazinamide, 
20–40 mg/kg (max 2 g/day) body weight 
orally once daily; PLUS ethambutol, 
15–25 mg/kg body weight (max 2.5 g/day) 
orally once daily (AI)
Continuation phase (for drug- susceptible 
TB) (AI):
Daily:•	
Isoniazid, 10–15 mg/kg body weight  —
(max 300 mg/day) orally once daily; 
PLUS rifampin, 10–20 mg/kg body 
weight (max 600 mg/day) orally once 
daily (AI)
Intermittent:•	
Isoniazid, 20–30 mg/kg body weight  —
(max 900 mg/day) orally once daily 
3 times weekly; PLUS rifampin, 
10–20 mg/kg body weight (max 
600 mg/day) orally once daily 3 times 
weekly (AI); administration of the drugs 
twice weekly can be considered only for 
children who are not immunosuppressed 
(i.e., CD4 >15% or >100 cells/μL who 
are >6 yrs old) (CIII) 
Treatment duration (drug-sensitive TB) (AIII):
Pulmonary TB: 9 mos for HIV-infected child •	
(6 mos if not HIV-infected)
Extrapulmonary TB: 12 mos •	
Alternative drug for rifampin is rifabutin, 
10–20 mg/kg body weight (max 300 mg/day) 
orally once daily (same dose is for intermittent 
2 or 3 times weekly regimen) (BIII)
Alternative drug for ethambutol is 
streptomycin, 20–40 mg/kg body weight 
(max 1 g/day) IM once daily (or 20 mg/kg 
as intermittent 2 or 3 times weekly regimen) 
(BIII)
Ethionamide, 15–20 mg/kg body weight orally 
(max 1 g/day) divided into 2 or 3 doses per 
day should be used for TB meningitis (AIII)
Drug-resistant TB:
Resistance to isoniazid alone:•	
Discontinue isoniazid —
Rifampin PLUS pyrazinamide PLUS  —
ethambutol (ethionamide or streptomycin 
can be substituted for ethambutol if 
M. tuberculosis isolate is susceptible to 
these agents) (BII)
Resistance to rifampin alone:•	
Discontinue rifampin —
Isoniazid PLUS pyrazinamide PLUS  —
ethambutol PLUS streptomycin for first 
2 mos, followed by continuation phase 
of isoniazid PLUS pyrazinamide PLUS 
ethambutol to complete 12- to 18-mo 
course (BIII)
For older adolescents: isoniazid PLUS  —
pyrazinamide PLUS ethambutol PLUS 
a fluoroquinolone for 2 mos, followed 
by isoniazid PLUS ethambutol PLUS 
a fluoroquinolone to complete 12- to 
18-mo course (BIII)
Multidrug resistance:•	
Therapy should be based on resistance  —
pattern (of child or of source case 
when child’s isolate is not available), 
and children should be managed in 
consultation with an expert (AIII)
Treatment duration (drug-resistant TB) (AIII):
Single drug: isoniazid-resistant TB: •	
9–12 mos (BII)
Single drug: rifampin-resistant TB: •	
12–18 mos (BIII)
Multidrug-resistant TB: 18–24 mos after •	
culture conversion in children with 
bacteriologic confirmation; ≥12 mos in 
children who were culture-negative at 
treatment initiation.
Directly observed therapy should be standard of care 
for children with TB (AII)
Potential drug interactions should be carefully 
reviewed
In antiretroviral-naïve child, initiate therapy for TB 
2–8 wks before starting antiretroviral drugs (BII); 
for children already receiving antiretroviral therapy 
in whom TB is diagnosed, the child’s antiretroviral 
regimen should be reviewed and altered, if needed, 
to ensure optimal treatment for both TB and HIV 
and to minimize potential toxicities and drug-drug 
interactions (AIII).
For children with severe immunosuppression 
(CD4 <15% or children >6 yrs old, <100 cell/μL), 
continuation phase for drug-susceptible TB should 
include either daily or thrice-weekly treatment; 
twice-weekly regimens should not be used 
because they may lead to rifamycin resistance in 
immunosuppressed patients (AII).
Pyridoxine should be administered if isoniazid or 
cycloserine is administered (AII).
Adjunctive treatment with corticosteroids is indicated 
for children with CNS disease (AII) and can be 
considered for children with pleural or pericardial 
effusions, severe miliary disease, and significant 
endobronchial disease (BIII).
Children receiving ethambutol who are old enough 
to undergo routine eye testing should have monthly 
monitoring of visual acuity and color discrimination 
(AIII).
Thiacetazone can cause severe or fatal reactions 
in HIV-infected children, including rash and aplastic 
anemia, and should not be used (EIII).
For drug-resistant strains, ≥2 drugs to which the 
isolate is susceptible should be administered 
(minimum of 3 drugs should be administered through 
the continuation phase of therapy).
Second-line drugs for multidrug-resistant TB:
Amikacin, 15–30 mg/kg body weight (max 1 g/day) 
IM once daily.
Capreomycin, 15–30 mg/kg body weight (max 
1 g/day) IM once daily.
Ciprofloxacin, 10–15 mg/kg body weight orally twice 
daily (max 1.5 g/day); levofloxicin, 500–1000 mg 
orally once daily; OR moxifloxacin, 400 mg orally 
once daily (fluoroquinolones are not labeled for use 
in children <18 yrs old because of concerns about 
potential effects on cartilage; use in younger persons 
requires assessment of potential risks and benefits) 
(CIII).
Cycloserine, 10–20 mg/kg body weight (max 1 g/day) 
orally once daily.
Ethionamide/prothionamide, 15–20 mg/kg body 
weight (max 1 g/day) orally in 2–3 divided doses.
Kanamycin, 15–30 mg/kg body weight (max 1 g/day) 
IM once daily.
Para-aminosalicylic acid, 200–300 mg/kg body weight 
orally divided into 3–4 doses per day (max 10 g/day).
Streptomycin, 20–40 mg/kg body weight (max 
1 g/day) IM once daily.
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Mycobacterium 
avium complex 
Initial treatment (≥2 drugs) (AI):
Clarithromycin, 7.5–15 mg/kg body weight •	
(max 500 mg/dose) orally twice daily (AI); 
PLUS ethambutol, 15–25 mg/kg body 
weight (max 2.5 g/day) orally once daily 
(AI), followed by chronic suppressive 
therapy
For severe disease, add rifabutin, •	
10–20 mg/kg body weight (max 
300 mg/day) orally once daily (CI)
Azithromycin, 10–12 mg/kg body weight (max 
500 mg/day) orally once daily if intolerant to 
clarithromycin (AII)
If rifabutin cannot be administered (or if a 
fourth drug is needed for patients with more 
severe symptoms or disseminated disease): 
ciprofloxacin, 10–15 mg/kg body weight orally 
twice daily (max 1.5 g/day); OR levofloxicin, 
500 mg orally once daily; OR amikacin, 
15–30 mg/kg body weight IV in 1 or 2 divided 
doses (max 1.5 g/day) (CIII) 
Combination therapy with a minimum of 2 drugs is 
recommended (AI).
Clofazamine is associated with increased mortality in 
HIV-infected adults and should not be used (EII).
Children receiving ethambutol who are old enough 
to undergo routine eye testing should have monthly 
monitoring of visual acuity and color discrimination 
(AIII).
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin) 
are not labeled for use in children <18 yrs because of 
concerns about potential effects on cartilage; use in 
younger persons requires an assessment of potential 
risks and benefits (CIII).
Chronic suppressive therapy (secondary prophylaxis) 
is recommended in children and adults after initial 
therapy (Table 2).
Fungal infections
Aspergillosis Voriconazole, 6–8 mg/kg body weight per 
dose IV or 8 mg/kg body weight (max 400 mg) 
per dose orally twice daily on day 1, followed 
by 7 mg/kg body weight (max 200 mg) per 
dose IV or orally twice daily (AI)
Treatment duration: ≥12 wks, but treatment 
duration should be individualized for each 
patient according to clinical response
Amphotericin B deoxycholate, 1.0–1.5 mg/kg 
body weight IV once daily (AIII)
Lipid formulations of amphotericin B, 5 mg/kg 
body weight IV once daily (AIII)
Caspofungin, 70 mg/m2 body surface area 
(max 70 mg) IV as loading dose, then 
50 mg/m2 body surface area (max 50 mg) 
IV once daily (CIII)
Potential for significant pharmacokinetic interactions 
between protease inhibitors or non-nucleoside 
reverse transcriptase inhibitors with voriconazole 
and should be used cautiously in these situations. 
Consider therapeutic drug monitoring and dosage 
adjustment if necessary.
Candidiasis Oropharyngeal disease:
Fluconazole, 3–6 mg/kg body weight •	
(max 400 mg/dose) orally once daily (AI)
Itraconazole cyclodextrin oral solution, •	
2.5 mg/kg body weight orally twice daily 
(max 200 mg/day) (AI)
Clotrimazole trouches, 10 mg troche orally •	
4 times daily (BII)
Nystatin suspension: 4–6 mL orally 4 times •	
daily; OR 1–2 200,000 U flavored pastilles 
orally 4–5 times daily (BII)
Treatment duration: 7–14 days
Esophageal disease:
Fluconazole, 6 mg/kg body weight orally •	
once on day 1, then 3–6 mg/kg body weight 
(max 400 mg/dose) orally once daily (AI)
Itraconazole cyclodextrin oral solution, •	
2.5 mg/kg body weight orally twice daily or 
5.0 mg/kg body weight orally once daily (AI)
Treatment duration: minimum of 4–21 days
Invasive disease:
Amphotericin B, 0.5–1.5 mg/kg body weight •	
IV once daily (AI)
Treatment duration: based on presence of 
deep tissue foci and clinical response; in 
patients with candidemia, treat until 2–3 wks 
after last by positive blood culture (AIII)
Oropharyngeal disease (fluconazole-
refractory):
Itraconazole cyclodextrin oral solution, •	
2.5 mg/kg body weight orally twice daily 
(max 200–400 mg/day) (AI)
Amphotericin B oral suspension, 1 mL •	
(100 mg/mL) orally 4 times daily (BII) 
Esophageal disease:
Amphotericin B, 0.3–0.5 mg/kg body weight •	
IV once daily (BII) 
Invasive disease:
Fluconazole, 5–6 mg/kg body weight IV •	
or orally twice daily (max 600 mg/day) 
for minimum 4 wks (if uncomplicated 
C. albicans candidemia) (AI)
Lipid formulations of amphotericin B, •	
5 mg/kg body weight IV once daily (BII)
Amphotericin B (according to preferred •	
therapy dose) PLUS flucytosine, 
100–150 mg/kg body weight orally divided 
into 4 doses for severe invasive disease, 
especially involving the CNS (CIII)
Itraconazole cyclodextrin oral solution should not be 
used interchangeably with itraconazole capsules. 
Itraconazole capsules are generally ineffective for 
treating esophageal disease (DII).
Central venous catheters should be removed when 
feasible in HIV-infected children with fungemia (AII).
Fluconazole should not be used for empiric treatment of 
fungemia because resistance of non-albicans Candida 
species to fluconazole has been reported (EIII).
In uncomplicated catheter-associated C. albicans 
candidemia, an initial course of amphotericin B followed 
by fluconazole to complete treatment can be used (BIII).
Amphotericin B initiation doses
Mild to moderate disease: initiate at 0.25–•	
0.5 mg/kg body weight IV once daily, then increase 
as tolerated to 0.5–1.5 mg/kg body weight IV once 
daily (BIII).
Severe disease: initiate treatment at•	  target daily 
dose (BIII). 
After stabilization and resolution of fever on 
daily therapy for children with invasive disease, 
amphotericin B can be administered as 1.5 mg/kg 
body weight IV once every other day (BIII).
Lipid formulation of amphotericin B may be used in 
patients with renal insufficiency or infusion-related 
toxicity to amphotericin B (BII).
Voriconazole has been used to treat 
esophageal candidiasis in a small number of 
immunocompromised children without HIV infection; 
because of limited experience in children, data 
are insufficient to recommend use of this drug for 
esophageal or disseminated candidiasis (CIII).
Caspofungin has been used to treat esophageal 
and invasive candidiasis in adults; however, data in 
children are limited, and definitive pediatric dose has 
not been defined (CIII).
Flucytosine dose should be adjusted to keep drug 
levels 40–60 μg/mL.
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Coccidioides spp. Diffuse pulmonary or disseminated non-
meningitic disease:
Amphotericin B, 0.5–1.0 mg/kg body weight •	
IV once daily until clinical improvement 
(minimum of several wks) (AII) 
Meningeal infection:
Fluconazole, 5–6 mg/kg body weight IV or •	
orally twice daily (max 800 mg/day) (AII)
Diffuse pulmonary or disseminated non-
meningitic disease (in stable patient):
Fluconazole, 5–6 mg/kg body weight IV or •	
orally twice daily (max 800 mg/day) (BIII)
Itraconazole, 5–10 mg/kg body weight IV •	
or orally twice daily for 3 days, followed by 
2–5 mg/kg body weight orally twice daily 
(max 400 mg/day) (BIII) 
Meningeal infection (unresponsive to 
fluconazole):
Amphotericin B PLUS intrathecal •	
amphotericin B (CI)
Surgical debridement of bone and lung lesions may 
be helpful
Some experts add triazole to amphotericin B therapy 
and continue triazole once amphotericin B is stopped 
(BIII)
May consider voriconazole, capsofungin, or 
posaconazole; or combinations, although experience 
in children is limited, and definitive pediatric dose has 
not been defined (CIII)
Options should be discussed with an expert in 
treating coccidioidomycosis
Chronic suppressive therapy (secondary prophylaxis) 
with fluconazole or itraconazole is recommended 
for adults and children after initial induction therapy 
(Table 2)
Cryptococcus 
neoformans 
CNS disease:
Acute therapy (minimum 2-wk induction •	
followed by consolidation therapy)
Amphotericin B, 0.7–1.0 mg/kg body  —
weight (or liposomal amphotericin B, 
6 mg/kg body weight) IV daily; PLUS 
flucytosine, 100 mg/kg body weight orally 
daily divided 4 times a day (AI); or
Liposomal amphotericin B, 4–6 mg/kg  —
body weight IV once daily (especially 
in children with renal insufficiency or 
infusion-related toxicity to amphotericin 
B); PLUS flucytosine, 100 mg/kg body 
weight orally daily divided 4 times a day 
(AII)
Consolidation therapy (followed by chronic •	
suppressive therapy):
Fluconazole, 12 mg/kg body weight on  —
day 1 and then 6–12 mg/kg body weight 
(max 800 mg) daily IV or orally for a 
minimum of 8 wks (AI) 
Localized disease including isolated 
pulmonary disease (CNS not involved)
Fluconazole, 12 mg/kg body weight on day •	
1 and then 6–12 mg/kg body weight (max 
600 mg) IV or orally daily (AIII)
Treatment duration: length of initial therapy 
for non-CNS disease depends on site and 
severity of infection and clinical response.
Disseminated disease (CNS not involved) or 
severe, pulmonary disease
Amphotericin B, 0.7–1.0 mg/kg body •	
weight; OR amphotericin liposomal, 
3–5 mg/kg body weight; OR amphotericin 
lipid complex, 5 mg/kg body weight IV once 
daily (± flucytosine) (AIII)
Treatment duration: length of initial therapy 
for non-CNS disease depends on site and 
severity of infection and clinical response.
CNS disease:
Acute therapy (minimum 2-wk induction •	
followed by consolidation therapy):
Liposomal amphotericin B, 4–6 mg/kg  —
body weight IV once daily (especially 
in children with renal insufficiency or 
infusion-related toxicity to amphotericin 
B) (AII)
Amphotericin B, 0.7–1.5 mg/kg body  —
weight IV once daily (if flucytosine not 
tolerated) (BI)
Fluconazole, 12 mg/kg body weight on  —
day 1 and then 6–12 mg/kg body weight 
(max 800 mg) IV or orally daily; PLUS 
flucytosine, 100 mg/kg body weight orally 
daily divided 4 times a day (BII) (offered 
only if amphotericin B-based therapy not 
tolerated) 
Consolidation therapy (followed by chronic 
suppressive therapy):
Itraconazole, 5–10 mg/kg per day once •	
or twice daily (max 200 mg/dose) for a 
minimum of 8 wks (BI). A loading dose 
(calculated twice daily dose is administered 
3 times daily) for the first 3 days (max 
200 mg/dose; 600 mg/day). See comment 
on itraconazole under “Other options/
Issues.” 
Localized disease including isolated 
pulmonary disease (CNS not involved)
Amphotericin B, 0.7–1.0 mg/kg body •	
weight; OR amphotericin liposomal, 
3–5 mg/kg body weight; OR amphotericin 
lipid complex, 5 mg/kg body weight IV daily 
(AIII) 
Disseminated disease (CNS not involved) or 
severe pulmonary disease:
Fluconazole, 12 mg/kg body weight on day •	
1 and then 6–12 mg/kg body weight (max 
600 mg) IV or orally once daily (AIII)
In patients with meningitis, CSF culture should be 
negative before initiation of consolidation therapy.
Overall in vitro resistance to antifungal agents used 
to treat cryptococcosis remains uncommon. Newer 
azoles (voriconazole, posaconazole, ravuconazole) 
are all very active in vitro against C. neoformans, but 
published clinical experience is limited about their 
use for cryptococcosis.
Liquid preparation of itraconazole (if tolerated) 
preferable (but more expensive) over tablet 
formulation because of better bioavailability (BIII).
Serum concentrations of itraconazole should be 
monitored to optimize drug dosing.
Amphotericin B may increase toxicity of flucytosine 
by increasing cellular uptake or impairing its renal 
excretion or both.
Flucytosine dose should be adjusted to keep drug 
levels at 40–60 μg/mL.
Oral acetazolamide should not be used to reduce 
intracranial pressure in cryptococcal meningitis (DIII).
Chronic suppressive therapy (secondary prophylaxis) 
with fluconazole is recommended for adults and 
childrens after initial therapy (Table 2).
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Histoplasma 
capsulatum 
Mild disseminated disease:
Itraconazole oral solution: initial loading •	
dose of 2–5 mg/kg body weight per dose 
(max 200 mg) orally 3 times daily for first 
3 days of therapy, followed by 2–5 mg/kg 
body weight (max 200 mg) per dose twice 
daily for 12 mos (AII)
Moderately severe to severe disseminated 
disease:
Acute therapy (minimum 1- to 2-wk •	
induction, longer if clinical improvement is 
delayed, followed by consolidation therapy)
Lipsomal amphotericin B, 3 mg/kg body  —
weight IV once daily (AI) 
Consolidation therapy (followed by chronic •	
suppressive therapy):
Itraconazole oral solution: initial loading  —
dose of 2–5 mg/kg body weight per dose 
(max 200 mg) orally 3 times daily for first 
3 days of therapy, followed by 2–5 mg/kg 
body weight (max 200 mg) per dose 
twice daily for 12 mos (AII) 
CNS infection
Acute therapy (4–6 wks, followed by •	
consolidation therapy):
Lipsomal amphotericin B, 5 mg/kg body  —
weight IV once daily (AII)
Consolidation therapy (followed by chronic •	
suppressive therapy):
Itraconazole oral solution: initial loading  —
dose of 2–5 mg/kg body weight per 
dose (max 200 mg) orally 3 times daily 
for first 3 days of therapy, followed by 
2–5 mg/kg body weight (max 200 mg) 
per dose twice daily for ≥12 mos and 
until histoplasmal antigen is no longer 
detected (AII)
Moderately severe to severe disseminated 
disease or CNS Infection:
Acute therapy (minimum 1- to 2-wk •	
induction, longer if clinical improvement is 
delayed or at least 4–6 wks if CNS involved, 
followed by consolidation therapy):
Amphotericin B deoxycholate, 1 mg/kg  —
body weight IV once daily (AIII)
Urine antigen should be monitored to identify relapse.
Serum concentrations of itraconazole should be 
monitored and reach 1 μg/mL at steady-state. Levels 
exceeding 10 μg/mL should be followed by dose 
reduction.
Urine antigen should be monitored to identify relapse.
High relapse rate with CNS infection occurs in adults, 
and longer therapy may be required; treatment in 
children is anecdotal, and expert consultation should 
be considered
Chronic suppressive therapy (secondary prophylaxis) 
with itraconazole is recommended for adults and 
children after initial therapy (Table 2).
Pneumocystis 
pneumonia
TMP-SMX, 15–20 mg/kg body weight TMP; 
PLUS 75–100 mg/kg body weight SMX 
daily IV or orally in 3–4 divided doses (AI) 
(after acute pneumonitis resolved in mild 
to moderate disease, IV TMP-SMX may be 
changed to oral)
Treatment duration (followed by chronic 
suppressive therapy): 21 days (AII)
Alternative therapeutic regimens (if patient is 
TMP-SMX intolerant or clinical treatment fails 
after 5–7 days of TMP-SMX therapy):
Pentamidine, 4 mg/kg body weight IV once •	
daily is first choice alternative regimen 
(AI) (pentamidine may be changed to 
atovaquone after 7–10 days IV therapy 
[BIII])
Atovaquone, 30–40 mg/kg body weight •	
(max 1500 mg/day) daily orally in 2 divided 
doses with food for patients from birth to 
3 mos and >24 mos of age (BI). For infants 
aged 3–24 mos, an increased dose of 
45 mg/kg body weight daily in 2 divided 
doses with food is needed (AII)
Dapsone, 2 mg/kg body weight orally once daily (max 
100 mg/day) PLUS TMP, 15 mg/kg body weight orally 
per day divided into 3 doses has been used in adults 
(BI), but data in children are limited (CIII).
Primaquine base, 0.3 mg/kg body weight orally once 
daily (max 30 mg/day), PLUS clindamycin, 10 mg/kg 
body weight IV or orally (max 600 mg IV and 300–
450 mg orally) every 6 hrs has been used in adults 
(BI), but data in children are not available (CIII).
Indications for corticosteroids (AI):
PaO2 <70 mmHg at room air or alveolar-arterial •	
oxygen gradient >35 mm Hg.
Prednisone dose: 1 mg/kg body weight orally twice •	
daily for 5 days, then 0.5–1.0 mg/kg body weight 
orally twice daily for 5 days, then 0.5 mg/kg body 
weight orally once daily for days 11–21. 
Chronic suppressive therapy (secondary prophylaxis) 
with TMP/SMX is recommended for children and 
adults after initial therapy (Table 2) (AI).
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Parasitic infections
Cryptosporidiosis Effective HAART; immune reconstitution may 
lead to microbiologic and clinical response 
(AII)
No consistently effective therapy exists for 
cryptosporidiosis in HIV-infected persons; 
optimized HAART and a trial of nitazoxanide 
can be considered:
Nitazoxanide (data from immuno competent •	
children) (BI), HIV-uninfected; (CIII), 
HIV-infected) in combination with effective 
HAARTy:
1–3 yr: 100 mg orally twice daily —
4–11 yr: 200 mg orally twice daily —
>12 yr: 500 mg orally twice daily —
Treatment duration: trial of <14 days
Supportive care: hydration, correct electrolyte 
abnormalities, nutritional support (AIII).
Antimotility agents (e.g., loperamide) should be used 
with caution among young children (CIII).
Malaria Uncomplicated Plasmodium falciparum OR 
unknown malarial species from
Chloroquine-resistant area (all other malarial •	
areas or unknown region)
— Atovaquone-proguanil (Malarone™) 
(pediatric tablets 62.5 mg/25 mg; adult 
tablets 250 mg/100 mg adult tabs) (AI)
– 5–8 kg: 2 peds tabs x 3 days
– 9–10 kg: 3 peds tabs x 3 days
– 11–20 kg: 4 peds tabs or 1 adult 
tab x 3 days
– 21–30 kg: 2 adult tabs x 3 days
– 31–40 kg: 3 adult tabs x 3 days
– >40 kg: 4 adult tabs x 3 days
Chloroquine-sensitive region (north of the •	
Panama Canal):
— Chloroquine phosphate, 16.6 mg/kg 
(10 mg/kg body weight base) (max 
1000 mg) orally once, then 8.3 mg/kg 
body weight (max 500 mg) orally at 6, 
24, 48 hrs (total dose = 41.6 mg/kg (AI) 
chloroquine phosphate [max 2500 mg] 
= 25 mg/kg chloroquine base) (AI)
P. vivax, P. ovale, P. malariae (all areas 
except Papua New Guinea, Indonesia)
Initial therapy (followed by antirelapse therapy)•	
Chloroquine phosphate, 16.6 mg (10 mg/kg  —
body weight base) (max 1000 mg) orally 
once, then 8.3 mg/kg body weight 
(max 500 mg) orally at 6, 24, 48 hrs (total 
dose = 41.6 mg/kg body weight chloroquine 
phosphate [max 2500 mg] = 25 mg/kg body 
weight chloroquine base) (AI)
Antirelapse therapy for•	  P. ovale, P. vivax:
Primaquine, 0.5 mg base/kg body  —
weight (max 30 mg base) orally daily for 
14 days (AI)
Uncomplicated P. falciparum OR unknown 
malaria species, chloroquine-resistant (all 
other malarial areas or unknown region):
Mefloquine (Larium™) (250-g tablets •	
only),15 mg/kg body weight (max 750 mg) 
orally once, then 10 mg/kg body weight 
(max 500 mg) orally 12 hrs later
Quinine sulfate,10 mg/kg body weight (max •	
650 mg) orally every 8 hrs for 3–7 days; 
PLUS clindamycin, 20 mg/kg body weight 
daily orally divided into 3 doses every 8 hrs 
for 7 days
Chloroquine phosphate is the only formulation of 
chloroquine available in the United States. 10 mg of 
chloroquine phosphate = 6 mg of chloroquine base.
In combination with quinine, an alternative to 
clindamycin is doxycycline in persons >8 yrs of age. 
Doxycycline 2.2 mg/kg (max: 100 mg) orally twice 
daily for 7 days.
Papua New Guinea has widespread chloroquine-
resistant P. vivax; thus, patients with malaria who 
have traveled there should be treated as having 
chloroquine-resistant malaria
Before primaquine is administered,glucose-6-
phosphate dehydrogenase status must be verified. 
Primaquine typically is administered after the initial 
chloroquine blood-phase therapy, not in combination.
The most updated prevention and treatment 
recommendations for specific malarial regions 
are available at http://www.cdc.gov/malaria/pdf/
treatmenttable.pdf.
Severe malaria
Quinidine gluconate, 10 mg/kg body •	
weight IV loading dose over 1–2 hrs, then 
0.02 mg/kg/minute infusion for >24 hrs 
(Treatment duration: 7 days for patients 
who were in Southeast Asia or Oceania; 
otherwise 3 days); PLUS doxycycline, 
100 mg per dose orally every 12 hrs for 
7 days, OR clindamycin, 20 mg/kg body 
weight daily orally divided into 3 doses 
every 8 hrs for 7 days. Quinidine gluconate 
10 mg = 6.25 mg quinidine base (AI)
Severe malaria:
Quinidine, 6.25 mg base/kg body weight •	
IV loading dose over 1–2 hrs, then 
0.0125 mg/kg/minute infusion (Treatment 
duration: 7 days for patients who have 
been in Southeast Asia or Oceania; 
otherwise 3 days); PLUS doxycycline, 
100 mg per dose orally every 12 hrs for 
7 days, OR clindamycin, 20 mg/kg body 
weight daily orally, divided into 3 doses 
every 8 hrs for 7 days
Artesunate, 2.4 mg/kg body weight IV •	
bolus at 0, 12, 24 hrs, then once daily for 
7 days; when patient is able to take an oral 
regimen, can switch to either artesunate, 
2 mg/kg body weight orally once daily; 
PLUS doxycycline, 100 mg per dose orally 
every 12 hrs, OR mefloquine, 15 mg/kg 
body weight (max 750 mg) orally once, then 
10 mg/kg body weight (max 500 mg) orally 
once 12 hrs later
Quinidine gluconate is a class 1a anti-arrhythmic 
agent not typically stocked in pediatric hospitals. 
When regional supplies are not available, it can 
be obtained from Eli Lilly Company, telephone: 
800-821-0538; the CDC Malaria hotline may be 
of assistance (see below). Do not give quinidine 
gluconate as an IV bolus. Administration of 
quinidine gluconate IV should be monitored. Cardiac 
monitoring is required. Adverse events that can result 
from use of this drug at treatment doses include 
severe hypoglycemia, prolongation of the QT interval, 
ventricular arrhythmia, and hypotension.
Artesunate is available only from CDC quarantine 
stations as of July 2007. Contact the CDC Malaria 
Hotline, 770-488-7788, from 8 a.m. to 4:30 pm EST, 
or 770-488-7100 after hours and on weekends and 
holidays.
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children, United States*†
Infection Preferred therapies and duration Alternative therapies Other options or issues
Microsporidiosis Effective HAART: immune reconstitution may 
lead to microbiologic and clinical response 
(AII)
For disseminated (not ocular) and intestinal 
infection attributed to microsporidia other than 
Enterocytozoon bienuesi:
Albendazole, 7.5 mg/kg body weight (max •	
400 mg/dose) per dose orally twice daily 
(AII)
Treatment duration: continue until immune 
reconstitution after initiation of HAART (AIII) 
For ocular infection:
Topical fumagillin bicylohexylammonium •	
(Fumidil B), 3 mg/mL in saline (fumagillin 
70 μg/mL) eye drops–2 drops every 
2 hrs for 4 days, then 2 drops 4 times daily 
(investigational use only in United States) 
(BII); PLUS albendazole, 7.5 mg/kg body 
weight (max 400 mg/dose) orally twice daily 
for management of systemic infection (BIII)
Treatment duration: continue indefinitely to 
prevent recurrence or relapse (BIII)
Supportive care: hydration, correct electrolyte 
abnormalities, nutritional support (AIII).
Antimotility agents (e.g., loperamide) should be used 
with caution in young children (CIII).
Fumagillin (adult dose, 20 mg/dose orally 3 
times daily for 2 weeks), or TNP-470 (a synthetic 
analogue of fumagillin) recommended for treatment 
of infections because of Enterocytozoon bienuesi 
in HIV-infected adults, is unavailable in the United 
States, and data are unavailable on dosing in 
children (CIII).
Toxoplasma gondii Congenital toxoplasmosis (AII):
Pyrimethamine: loading dose, 2 mg/kg •	
body weight orally once daily for 2 days, 
then 1 mg/kg body weight orally once daily 
for 2–6 mos, then 1 mg/kg body weight 
orally 3 times weekly; PLUS leucovorin 
(folinic acid), 10 mg orally or IM with each 
dose of pyrimethamine; PLUS sulfadiazine, 
50 mg/kg body weight orally twice daily
Treatment duration: 12 mos (AII)
Acquired toxoplasmosis, acute induction 
therapy (followed by chronic suppressive 
therapy) (AI):
Pyrimethamine: loading dose, 2 mg/kg •	
body weight (max 50 mg) orally once daily 
for 3 days, then 1 mg/kg body weight (max 
25 mg) orally once daily; PLUS sulfadiazine, 
25–50 mg/kg body weight (max 1.0–
1.5 g/dose) orally per dose 4 times daily; 
PLUS leucovorin, 10–25 mg orally daily, 
followed by chronic suppressive therapy
Treatment duration (followed by chronic 
suppressive therapy): ≥6 wks (longer if 
clinical or radiologic disease is extensive or 
response in incomplete at 6 wks) (BII)
For sulfonamide-intolerant patients:
Clindamycin, 5–7.5 mg/kg body weight (max •	
600 mg/dose) orally or IV per dose 4 times 
a day can be substituted for sulfadiazine 
combined with pyrimethamine and 
leukovorin (AI)
Congenital toxoplasmosis:
For infants born to mothers with symptomatic •	
Toxoplasma infection during pregnancy, empiric 
therapy of the newborn should be strongly 
considered irrespective of the mother’s treatment 
during pregnancy (BIII). 
Acquired toxoplasmosis:
Pyrimethamine use requires complete blood count •	
monitoring at least weekly while patient is on daily 
dosing and at least monthly while on less than daily 
dosing (AIII)
TMP-SMX (5 mg/kg body weight TMP PLUS •	
25 mg/kg body weight SMX per dose IV or orally 
twice daily) has been used as an alternative to 
pyrimethamine-sulfadiazine in adults (BI) but has 
not been studied in children (CIII).
Atovaquone /(adults: 1.5 g orally  twice daily with •	
food) in regimens combined with pyrimethamine/
leukovorin; with sulfadiazine alone; or as a single 
agent in patients intolerant to both pyrimethamine 
and sulfadiazine has been used in adults (BII), but 
these regimens have not been studied in children 
(CIII).
Azithromycin (adults: 900–1200 mg/day) also has •	
been used in adults combined with pyrimethamine-
sulfadiazine (BII) but has not been studied in 
children (CIII).
Corticosteriods (e.g., prednisone or •	
dexamethasone) have been used in children with 
CNS disease when CSF protein is very elevated 
(>1000 mg/dL) or when the child has focal lesions 
with significant mass effects, with discontinuation 
as soon as clinically feasible (BIII).
Anticonvulsants should be administered to patients •	
with a history of seizures (AIII) and continue 
through the acute treatment, but they should not be 
used prophylactically (DIII).
Chronic suppressive therapy (secondary •	
prophylaxis) is recommended for adults and 
children after initial therapy (AI).
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Viral infections
Cytomegalovirus Symptomatic congenital infection with 
neurologic involvement:
Ganciclovir,•	  6 mg/kg body weight IV every 
12 hrs for 6 wks (BI)
Disseminated disease and retinitis:
Induction therapy (followed by chronic •	
suppressive therapy):
Ganciclovir, —  5 mg/kg body weight IV 
every 12 hrs for 14–21 days (may be 
increased to 7.5 mg/kg body weight IV 
twice daily), then 5 mg/kg per day for 
5–7 days per wk for chronic suppression 
(AI)
CNS disease (followed by chronic 
suppressive therapy):
Ganciclovir,•	  5 mg/kg body weight IV every 
12 hrs; PLUS foscarnet, 60 mg/kg body 
weight IV every 8 hrs, continued until 
symptoms improve (BII), followed by chronic 
suppression
Disseminated disease and retinitis:
Induction therapy (followed by chronic •	
suppressive therapy):
Foscarnet, 60 mg/kg body weight  —
IV every 8 hrs for 14–21 days, then 
90–120 mg/kg once a day for chronic 
suppression (AI)
Alternative for retinitis (followed by chronic •	
suppressive therapy):
IV ganciclovir PLUS IV foscarnet (at  —
above induction doses)—may be 
considered as initial induction therapy in 
children with sight-threatening disease 
(BIII)
Older children: ganciclovir intraocular  —
implant; PLUS oral ganciclovir, 30 mg/kg 
3 times daily (BIII), or if child is old 
enough to receive adult dosing, oral 
valganciclovir, 900 mg orally once daily 
(CIII)
Valganciclovir is used in adults to treat CMV retinitis: 
induction dosing in adults is 900 mg orally twice 
daily for 14–21 days, followed by once daily dosing 
as chronic suppressive therapy (AI); however, data 
on valganciclovir dosing in children are unavailable 
(CIII). Valganciclovir liquid formulation is not 
commercially available, and because pharmacokinetics, 
bioavailability, safety, and shelf-life of extemporaneously 
compounded valganciclovir are not known, such 
“homebrew” formulations should not be used (EIII).
Cidofovir also is used to treat CMV retinitis in adults: 
induction dosing in adults is 5 mg/kg body weight 
IV once weekly for 2 wks, followed by chronic 
suppressive therapy (AI); however, data on dosing in 
children are unavailable (CIII). Must be administered 
with probenecid and IV hydration.
Intravitreal injections not practical for most children (DIII).
Intraocular implant should not be used in children 
<3 yrs of age because of small size of eyes (EIII).
Combination ganciclovir and foscarnet is associated 
with substantial rates of adverse effects, and 
optimal treatment for neurologic disease in children 
is unknown, particularly those receiving optimized 
antiretroviral therapy.
Chronic suppressive therapy (secondary prophylaxis) is 
recommended for adults and children after initial therapy of 
disseminated disease or retinitis (Table 2) (AI).
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Hepatitis B virus Treatment required only for HBV (HIV 
treatment not required; avoid TDF, 3TC, and 
FTC):
Interferon-alfa, 3 million units/m•	 2 body 
surface area subcutaneously 3 times 
weekly for 1 wk, followed by dose escalation 
to 6 million units/m2 (max 10 million units/
dose), to complete a 24-wk course (BII); OR
Adefovir, 10 mg orally once daily for older •	
children who can receive adult dosing for a 
minimum of 12 mos (BII)
Treatment required for both HIV and HBV:
Lamivudine (3TC), 4 mg/kg body weight •	
orally (max 150 mg/dose) twice daily as part 
of a fully suppressive HAART regimen (BII)
Include tenofovir, 300 mg orally once daily, •	
as part of HAART regimen with 3TC for 
older children who can receive adult dosing 
(BII)
If child is on HAART containing 3TC or •	
emtricitabine (FTC) and has detectable 
HBV DNA (assume 3TC/FTC resistance):
If child is old enough to receive adult  —
dosing, continue 3TC (or FTC) (CIII); 
if child is old enough to receive adult 
dosing and not on tenofovir, add 
tenofovir, 300 mg orally once daily, as 
part of HAART regimen (BII); or add 
adefovir, 10 mg orally once daily, to 
HAART regimen (BII)
If child is not old enough to receive  —
adult dosing: administer 6-mo course 
of interferon-alfa as above in addition to 
HAART regimen (BII); continue 3TC (or 
FTC) (CIII)
Treatment for HIV alone:
HAART regimen that avoids the use of 3TC, •	
FTC, or tenofovir (BIII)
Interferon-alfa, 10 million units/m2 body 
surface area subcutaneously 3 times weekly 
for 6 mos (sometime used for retreatment of 
failed lower-dose interferon therapy) (CII)
Alternative for 3TC: FTC 6 mg/kg body weight 
(max 200 mg) once daily (BIII)
Indications for treatment include (BII):
Detectable serum HBV DNA, with or without •	
positive HBeAg, for >6 mos; and
Persistent (>6 mos) elevation of serum •	
transaminases (twice or more the upper limit of 
normal); or
Evidence of chronic hepatitis on liver biopsy. •	
Interferon-alfa is contraindicated in children with 
decompensated liver disease, significant cytopenias, 
severe renal, neuropsychiatric, or cardiac disorders, 
and autoimmune disease (EII).
Choice of HBV treatment options for HBV/HCV 
coinfected children depends on whether concurrent 
HIV treatment is warranted.
3TC and FTC have similar activity (and have cross-
resistance) and should not be administered together.
Tenofovir is not approved for use in HIV-infected 
children aged <18 yrs, and no pediatric formulation 
exists; it can be used for older HIV-infected children 
who can receive adult dosage.
Adefovir is not approved for use in children but is 
under study in HIV-uninfected children for treatment 
of chronic hepatitis B; can be considered for older 
HIV-infected children who can receive adult dosage.
IRIS may be manifested by dramatic increase in 
transaminases as CD4 counts rise within the first 
6–12 wks of HAART. Distinguishing between drug-
induced hepatotoxicity or other causes of hepatitis 
and IRIS may be difficult.
In children receiving 3TC, FTC, and/or tenofovir, clinical 
and laboratory exacerbations of hepatitis (flare) may 
occur if the drug is discontinued; thus, once anti-HBV/
HIV therapy has begun, it should be continued unless 
contraindicated or until the child has been treated for 
>6 mos after HBeAg seroconversion and can be closely 
monitored on discontinuation (BIII).
If anti-HBV therapy is discontinued and a flare 
occurs, reinstitution of therapy is recommended 
because a flare can be life threatening (BIII).
Entecavir and telbivudine have been approved for 
use in adults with HBV; no data exist on safety or 
efficacy of these medications in children.
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Hepatitis C virus Interferon-alfa PLUS ribavirin combination 
therapy (BIII):
Interferon-alfa–2a or –2b, 3–5 million units/•	
m2 body surface area subcutaneously or IM 
3 times weekly (max 3 million units/dose); 
PLUS
Ribavirin (oral), 15 mg/kg body weight daily •	
in 2 divided doses (fixed dose by weight 
recommended):
25–36 kg: 200 mg a.m. and p.m. —
>36–49 kg: 200 mg in a.m. and 400 mg  —
in p.m.
>49–61 kg: 400 mg in a.m. and p.m. —
>61–75 kg: 400 mg in a.m. and 600 mg  —
in p.m.
>75 kg: 600 mg in a.m. and p.m. —
Treatment duration: 48 wks, regardless of 
HCV genotype (BIII)
For children in whom ribavirin is 
contraindicated (e.g., who have unstable 
cardiopulmonary disease, preexisting anemia 
or hemoglobinopathy):
Interferon-alfa–2a or –2b, 3–5 million •	
units/m2 body surface area (max 3 million 
units/dose) subcutaneously or IM 3 times 
weekly (BII)
Length of treatment for HIV/HCV-coinfected children 
is unknown and based on recommendations for HIV/
HCV-coinfected adults (BIII).
Treatment of HCV in children <3 yrs generally is not 
recommended (DIII).
Indications for treatment are based on 
recommendations in HIV/ HCV-coinfected adults; 
because HCV therapy is more likely to be effective 
in younger patients and in patients without advanced 
disease or immunodeficiency, treatment should be 
considered for all HIV/HCV-infected children >3 yrs 
who have no contraindications for treatment (BIII).
IRIS may be manifested by dramatic increase in 
transaminases as CD4 counts rise within the first 
6–12 wks of HAART. Distinguishing between drug-
induced hepatotoxicity or other causes of hepatitis 
and IRIS may be difficult.
Interferon-alfa is contraindicated in children with 
decompensated liver disease, significant cytopenias, 
severe renal or cardiac disorders, and autoimmune 
disease (EII).
Ribavirin is contraindicated in children with unstable 
cardiopulmonary disease, severe preexisting anemia 
or hemoglobinopathy (EII).
Didanosine combined with ribavirin may lead to 
increased mitochondrial toxicities; concomitant use is 
contraindicated (EIII).
Ribavirin and zidovudine both are associated 
with anemia and when possible should not be 
administered together (DII).
Pegylated interferon-alfa is not approved for use 
in children, although it is under study; in adults, 
pegylated interferon-alfa–2a (180 μg) or –2b (1.5 
μg/kg) subcutaneously once weekly PLUS ribavirin 
is the treatment of choice in adults with chronic HCV 
hepatitis warranting treatment (AI).
Herpes Simplex 
virus
Neonatal CNS or disseminated disease:
Acyclovir, 20 mg/kg body weight IV per •	
dose 3 times daily for 21 days (AI)
Neonatal skin, eye, or mouth disease:
Acyclovir, 20 mg/kg body weight IV per •	
dose 3 times daily for 14 days (AI)
CNS or disseminated disease in children 
outside the neonatal period:
Acyclovir, 10 mg/kg body weight IV 3 times •	
daily for 21 days (AII)
Moderate to severe symptomatic 
gingivostomatitis:
Acyclovir, 5–10 mg/kg body•	  weight per dose 
IV 3 times daily (AI)
After lesions began to regress, change to •	
oral acyclovir (AI); continue therapy until 
lesions completely heal
For genital herpes:
In children <45 kg, Acyclovir, 20 mg/kg body•	  
weight (max 400 mg/dose) per dose orally 3 
times daily for 5–14 days (AI)
In adults and adolescents, •	
Acyclovir,400 mg/dose orally twice daily for 
5–14 days(AI)
Acyclovir-resistant HSV infection:
Foscarnet, 40 mg/kg body weight per dose •	
IV 3 times daily or 60 mg/kg body weight 
per dose IV twice daily (AI)
Mild symptomatic gingivostomatitis:
Acyclovir, 20 mg/kg body weight (max •	
400 mg/dose) per dose orally 3 times daily 
for 5–10 days (AI)
For neonatal CNS disease: repeat CSF HSV DNA 
PCR should be performed at days 19–21 of therapy; 
do not stop acyclovir until repeat CSF HSV DNA PCR 
is negative (BIII).
Valacyclovir is approved for use in adults and 
adolescents with mucocutaneous HSV at a dosage 
of 1 g orally twice daily (AI); no pediatric preparation 
exists, and data on dosing in children are limited; 
could be used by older children able to receive adult 
dosing.
Famciclovir is approved for use in adults and 
adolescents with mucocutaneous HSV infection at a 
dosage of 500 mg orally twice daily (AI); no pediatric 
preparation exists, and data on dosing in children are 
unavailable; could be used by older children able to 
receive adult dosing.
Suppressive secondary prophylaxis can be 
considered for children with severe and recurrent 
gingivostomatitis (AI).
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Human 
papillomavirus
Podofilox solution/gel (0.5%) applied topically 
twice daily for 3 consecutive days weekly for 
<4 wks (patient applied) (BIII)
Imiquimod cream (5%) applied topically at 
night for 3 nonconsecutive nights per week for 
up to 16 weeks and washed off 6–10 hours 
after each application (patient applied) (BII)
Trichloroacetic acid applied topically weekly 
for up to 3–6 wks (health-care provider 
applied) (BIII)
Podophyllin resin, 10%–25% suspension 
in tincture of benzoin, applied topically and 
washed off several hrs; later repeated weekly 
for 3–6 wks (CIII)
Individual external genital wart lesions can be 
removed by cryotherapy or electrodessication; 
may be repeated every 1–2 wks (BIII)
Veragen self-applied 3 times daily for up to 
16 wks (patient applied) (CIII)
Laser ablation or surgical excision for 
recalcitrant cases
Adequate topical anesthetics to the genital area 
should be administered before application of caustic 
modalities.
Intralesional interferon-alfa generally is not 
recommended because of high cost, difficult 
administration, and potential for systemic side effects 
(DIII).
Cidofovir topical gel (1%) is an experimental therapy 
studied in HIV-infected adults but is not commercially 
available and has limited use in children; systemic 
absorption can occur (CIII).
HAART has not been consistently associated with 
reduced risk for HPV-related cervical abnormalities in 
HIV-infected women.
Laryngeal papillomatosis generally requires referral 
to a pediatric otolaryngologist. Treatment is directed 
at maintaining the airway, rather than removal of 
all disease. Adjuvant therapy with interferon-alfa or 
intralesional cidofovir is being used investigationally 
for invasive disease (CIII).
Abnormal Pap smear cytology should be referred to 
colposcopy for diagnosis and management.
Varicella zoster virus Chickenpox:
No or moderate immune suppression (CDC •	
immunologic categories 1 and 2 [969A]) 
and mild varicella disease (oral [BIII]):
Acyclovir, 20 mg/kg body weight orally  —
per dose (max 800 mg/dose) 4 times 
daily for 7–10 days or until no new 
lesions for 48 hrs (AI)
Severe immune suppression (CDC •	
immunologic category 3 [969A]), IV [AIII]):
Acyclovir, 10 mg/kg body weight IV per  —
dose 3 times daily for 7–10 days or until 
no new lesions for 48 hrs (AI)
Zoster:
Trigeminal nerve involvement or extensive •	
multidermatomal zoster (intravenous [AII]):
Acyclovir, 10 mg/kg body weight IV  —
per dose 3 times daily until cutaneous 
lesions and visceral disease are clearly 
resolving, then can switch to oral 
acyclovir to complete 10- to 14-day 
course (AII)
Progressive outer retinal necrosis•	
Ganciclovir, 5 mg/kg body weight IV  —
every 12 hrs; PLUS foscarnet, 90 mg/kg 
body weight IV every 12 hrs; PLUS 
ganciclovir, 2 mg/0.05mL intravitreal 
twice weekly, and/or foscarnet 
1.2 mg/0.05mL intravitreal twice weekly 
(AIII)
Acute retinal necrosis:•	
Acyclovir, 10 mg/kg body weight IV 3  —
times daily for 10–14 days, followed by 
oral valacyclovir, 1 g per dose 3 times 
daily for 4–6 wks (for children old enough 
to receive adult dose); alternative oral 
acyclovir, 20 mg/kg body weight for 
4–6 wks (AIII)
For patients not responding to acyclovir:
Foscarnet, 40–60 mg/kg body weight IV per •	
dose 3 times daily for 7–10 days (AI)
Some experts base IV acyclovir dosing in children 
aged ≥1 yr on body surface area (500 mg/m2/dose IV 
every 8 hrs) instead of on body weight.
Valacyclovir is approved for use in adults and 
adolescents who have zoster at a dosage of 1 g 
orally twice daily for 7–10 days (AII); no pediatric 
preparation is available, and data on dosing in 
children are limited; could be used by older children 
able to receive adult dosing.
Famciclovir is approved for use in adults and 
adolescents who have zoster at a dosage of 500 mg 
orally 3 times daily for 7–10 days (AII); no pediatric 
preparation is available, and data on dosing in 
children are limited; could be used by older children 
able to receive adult dosing
Involvement of an experienced ophthalmologist with 
management of children with varicella zoster virus 
retinitis is strongly recommended (AIII)
* HIV=human immunodeficiency virus; PCP=Pneumocystis pneumonia; TB=tuberculosis; IV=intravenous; IV=intravenous; IM=intramuscularly; CSF=cerebrospinal fluid; 
CNS=central nervous system; TMP/SMX=trimethoprim-sulfamethoxazole; HAART=highly active antiretroviral therapy; CMV=cytomegalovirus. HBV=hepatitis B virus; 
HBeAg=hepatitis B e antigen; HCV=hepatitis C virus; IRIS=immune reconstitution inflammatory syndrome; PCR=polymerase chain reaction; HSV=herpes simplex virus; 
HPV=human papillomavirus
† Information in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for products or indications. Specifically, the terms safe 
and effective might not be synonymous with the FDA-defined legal standards for product approval. Letters and roman numerals in parentheses after regimens indicate the 
strength of the recommendations and the quality of evidence supporting it (see Box).
Vol. 58 / RR-11 Recommendations and Reports 143
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HIV-infected infants and children, United States*
Major toxicities†
Drug Preparations
Indicating need  
for medical attention
Indicating need  
for medical attention  
if persistent or bothersome Special instructions
Antifungal drugs
Amphotericin B 
Deoxycholate 
(Fungizone)
IV Frequent
Infusion-related reactions (fever/•	
chills, nausea/vomiting, hypotension, 
anaphylaxis)
Anemia•	
Hypokalemia•	
Renal function impairment•	
Thrombophlebitis (at injection site)•	
Less frequent/Rare
Blurred or double vision•	
Cardiac arrhythmias, usually with rapid •	
infusions
Hypersensitivity (rash)•	
Leukopenia•	
Polyneuropathy•	
Seizures•	
Thrombocytopenia•	
GI disturbance (nausea, 
vomiting, diarrhea, abdominal 
pain)
Headache
Infuse over 1–2 hrs; in patients with azotemia, 
hyperkalemia, or getting doses >1 mg/kg, infuse 
over 3–6 hrs.
Requires dose reduction in patients with 
impaired renal function.
Nephrotoxicity exacerbated with concomitant 
use of other nephrotoxic drugs; avoid when 
possible. Permanent nephrotoxicity related to 
cumulative dose.
Nephrotoxicity may be ameliorated by hydration 
with 0.9% saline IV over 30 min before the 
amphotericin B infusion.
Infusion-related reactions Less frequent in 
children than adults; onset usually 1–3 hrs after 
infusion; duration <1 hr; frequency decreases 
over time.
Pretreatment with acetaminophen and/or 
diphenhydramine may alleviate febrile reactions.
Amphotericin 
B lipid
complex
(Abelcet®)
IV More frequent
Infusion-related reactions (fever/chills, •	
nausea/vomiting, headache, nausea/
vomiting)
Less frequent
Anemia•	
Leukopenia•	
Respiratory distress•	
Thrombocytopenia•	
Renal function impairment•	
GI disturbance (loss of 
appetite, nausea, vomiting, 
diarrhea, abdominal pain)
Infuse diluted solution at rate of 2.5 mg/kg/hr.
In-line filters should not be used.
Use with caution with other bone-marrow–
suppressing drugs or nephrotoxic drugs; renal 
toxicity dose-dependent, but renal toxicity is less 
than with conventional amphotericin B.
Consider dose reduction in patients with 
impaired renal function.
Amphotericin B 
liposome
(AmBisome®)
IV More frequent
Fever, chills•	
Hypokalemia•	
Less frequent
Back pain•	
Chest pain•	
Dark urine•	
Dyspnea•	
Infusion-related reaction (fever/chills, •	
headache)
Jaundice•	
Renal function impairment•	
Rare
Anaphylactic reaction•	
GI disturbance (nausea, 
vomiting, diarrhea, abdominal 
pain)
Headache
Skin rash
Infuse over 2 hrs.
Consider dose reduction in patients with 
impaired renal function.
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Major toxicities†
Drug Preparations
Indicating need  
for medical attention
Indicating need  
for medical attention  
if persistent or bothersome Special instructions
Caspofungin
(Cancidas)
IV More frequent
Histamine-mediated symptoms (fever, •	
facial swelling, pruritis, bronchospasm)
Rare
Hypokalemia•	
Anaphylactic reaction•	
GI disturbances (nausea, 
vomiting, diarrhea)
Headache
Skin rash, facial flushing
Elevated liver transaminases
Thrombophelbitis
Requires dose adjustment in moderate to severe 
hepatic insufficiency.
IV infusion over 1 hr in normal saline (do not use 
diluents containing dextrose).
Flucytosine
(Ancobon)
Capsules:
 250 mg, 500 mg
More frequent
Bone marrow suppression (especially •	
leukopenia and thrombocytopenia)
Less frequent
Hepatotoxicity•	
Renal toxicity (including crystalluria)•	
Rare
Cardiac toxicity (ventricular •	
dysfunction, myocardial toxicity, 
cardiac arrest)
CNS symptoms (hallucinations, •	
seizures, peripheral neuropathy)
Anaphylaxis•	
GI disturbances (abdominal 
pain, constipation, diarrhea, 
anorexia, nausea, vomiting)
Elevated liver transaminases
Skin rash
Rare
CNS symptoms (headache, •	
drowsiness, confusion, 
vertigo)
Drug levels should be monitored and doses 
adjusted to maintain at 40–60 μg/mL.
Requires dose adjustment in patients with 
impaired renal function; use with extreme 
caution.
Fatal aplastic anemia and agranulocytosis have 
been Rarely reported.
Fluconazole
(Diflucan)
Oral suspension:
 10 mg/mL, 40 mg/mL
Tablets:
 50 mg, 100 mg, 
150 mg, 200 mg
IV
Infrequent
Hypersensitivity (fever, chills, skin •	
rash)
Rare
Agranulocytosis•	
Exfoliative skin disorders (including •	
Stevens-Johnson syndrome)
Hepatotoxicity•	
Thrombocytopenia•	
Frequent
GI disturbances (abdominal •	
pain, constipation, diarrhea, 
anorexia, nausea, vomiting)
Infrequent
CNS effects (dizziness, •	
drowsiness, headache)
Alopecia•	
May be administered orally without regard to 
meals.
Requires dose adjustment in patients with 
impaired renal function.
IV administration should be administered 1 time 
daily at rate <200 mg/hr.
Oral and IV doses are the same.
Multiple potential drug interactions.
Itraconazole
(Sporanox)
Oral solution:
 10 mg/mL
Capsules:
 100 mg
IV
Infrequent
Hypersensitivity (fever, chills, skin •	
rash)
Hypokalemia (can be associated with •	
cardiac arrhythmias)
Rare
Hepatotoxicity•	
Hematologic abnormalities •	
(thrombocytopenia, leukopenia) 
Frequent
GI disturbances (abdominal •	
pain, constipation, diarrhea, 
anorexia, nausea, vomiting)
Infrequent
CNS effects (dizziness, •	
drowsiness, headache)
Oral solution: give on an empty stomach as 
gastric acid increases absorption.
Capsules: administer after a full meal to 
increase absorption.
Itraconazole oral solution has 60% greater 
bioavailability than capsules, and the oral 
solution and capsules should not be used 
interchangeably.
IV infusion over 60 min.
Multiple potential drug interactions.
Posaconazole
(Noxafil)
Oral solution:
 40 mg/mL
Infrequent
Hypersensitivity (fever, chills, skin •	
rash)
Anaphylactoid reaction with IV infusion•	
Rare
Hepatotoxicity (including hepatic •	
failure)
Exfoliative skin disorders (including •	
Stevens-Johnson syndrome)
Renal dysfunction•	
Cardiac arrhythmias (QT prolongation, •	
torsades de pointes)
Hemolytic uremic syndrome•	
Pulmonary embolism•	
Bone marrow suppression
Muscular pain
Must be administered with meals. Adequate 
absorption depends on food for efficacy.
Liver function tests, renal function tests and 
electrolytes should be monitored while on 
therapy.
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Ketoconazole
(Nizoral)
Tablets:
 200 mg
Infrequent
Hypersensitivity (fever, chills, skin •	
rash)
Rare
Hepatotoxicity (including hepatic •	
failure)
Frequent
GI disturbances (abdominal •	
pain, constipation, diarrhea, 
anorexia, nausea, vomiting)
Infrequent
CNS effects (dizziness, •	
drowsiness, headache)
Rare
Gynecomastia•	
Impotence•	
Menstrual irregularities•	
Photophobia•	
Adverse GI effects occur less often when 
administered with food.
Drugs that decrease gastric acidity or 
sucralfate should be administered ≥2 hrs after 
ketoconazole.
Disulfiram reactions have occurred in patients 
ingesting alcohol.
Hepatotoxicity is an idiosyncratic reaction, 
usually reversible when stopping the drug, 
but Rare fatalities can occur any time during 
therapy; more common in females and adults 
>40 yrs, but cases reported in children.
High-dose ketoconazole suppresses 
corticosteroid secretion, lowers serum 
testosterone concentration (reversible).
Multiple potential drug interactions.
Voriconazole
(VFEND)
Tablets:
 50 mg, 200 mg
IV
Infrequent
Hypersensitivity (fever, chills, skin •	
rash)
Anaphylactoid reaction with IV infusion•	
Rare
Hepatotoxicity (including hepatic •	
failure)
Exfoliative skin disorders (including •	
Stevens-Johnson syndrome)
Renal dysfunction•	
Cardiac arrhythmias •	
More frequent
Visual changes, dose-•	
related (photophobia, blurry 
vision)
CNS effects (dizziness, •	
drowsiness, headache)
GI disturbances (abdominal •	
pain, constipation, diarrhea, 
anorexia, nausea, vomiting)
Rare
Gynecomastia•	
Approved for use in treating aspergillosis and 
serious fungal infections caused by Fusarium 
species and Scedosporium apiospermum in 
adults intolerant of or refractory to other therapy.
Oral tablets should be taken 1 hr before or after 
a meal.
Maximum infusion rate 3 mg/kg/hr over 1–2 hrs.
Oral administration to patients with impaired 
renal function if possible (accumulation 
of IV vehicle occurs in patients with renal 
insufficiency).
Dose adjustment needed if hepatic insufficiency.
Data in children not yet available.
Visual disturbances common (>30%) but 
transient and reversible when drug is 
discontinued.
Multiple potential drug interactions.
Anti-Pneumocystis drugs
Atovaquone
(Mepron)
Oral suspension:
 150 mg/mL
Frequent
Fever•	
Skin rash•	
Frequent
GI disturbances (nausea, •	
vomiting, diarrhea)
Headache•	
Cough•	
Insomnia•	
Should be administered with a meal to enhance 
absorption (bioavailability increases 3-fold when 
administered with high-fat meal).
Clindamycin
(Cleocin)
Oral solution:
 15 mg/mL
Capsules:
 75 mg, 150 mg, 
300 mg
IV
More frequent
Pseudomembranous colitis•	
Less frequent
Hypersensitivity (skin rash, redness, •	
pruritis)
Neutropenia•	
Thrombocytopenia•	
GI disturbances (abdominal 
pain, nausea, vomiting, 
diarrhea)
Fungal overgrowth, rectal and 
genital areas
IV preparation contains benzyl alcohol, not 
recommended for use in neonates.
IV preparation must be diluted before 
administration.
Capsule formulation should be taken with food 
or a full glass of water to avoid esophageal 
irritation.
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Dapsone Syrup (compassionate-
use investigational new 
drug):
 2 mg/mL
Tablets:
 25 mg, 100 mg
More frequent
Hemolytic anemia (especially if G6-PD •	
deficient)
Methemoglobinemia•	
Skin rash•	
Rare
Blood dyscrasias•	
Exfoliative skin disorders (including •	
Stevens-Johnson syndrome)
Hepatic toxicity•	
Mood or other mental changes•	
Peripheral neuritis•	
Hypersensitivity reaction (fever, rash, •	
jaundice, anemia)
CNS toxicity (headache, 
insomnia, nervousness)
GI disturbances (anorexia, 
nausea, vomiting)
Protect from light; dispense syrup in amber 
glass bottles.
Pentamidine
(Pentam)
IV
Aerosol
More frequent
Nephrotoxicity•	
Hypoglycemia•	
Hyperglycemia or diabetes mellitus•	
Elevated liver transaminases•	
Hypotension•	
Leukopenia or neutropenia•	
Thrombocytopenia•	
Less frequent
Anemia•	
Cardiac arrhythmias•	
Hypersensitivity (skin rash, fever)•	
Pancreatitis•	
Phlebitis•	
Sterile abscess (at site injection)•	
More frequent
Sneezing•	
Cough•	
More frequent
GI disturbances (anorexia, •	
nausea, vomiting, diarrhea)
Less frequent
Unpleasant metallic taste•	
More frequent
Bronchospasm•	
Rapid infusion can results in precipitous 
hypotension; IV infusion should be administered 
over ≥60 min (preferably 2 hrs).
Cytolytic effect on pancreatic beta islet 
cells, leading to insulin release, can result in 
prolonged severe hypoglycemia (usually occurs 
after 5–7 days’ therapy, but also can occur after 
discontinuation of drug); risk increases with 
higher dose, longer duration of therapy, and 
retreatment ≤3 mos.
Hyperglycemia and diabetes mellitus may occur 
up to several mos after drug discontinued.
Primaquine Tablets:
 15 mg (base)
More frequent
Hemolytic anemia (with G6-PD •	
deficiency)
Less frequent
Methemoglobinemia•	
Rare
Leukopenia•	
GI disturbances (nausea, 
vomiting)
Take with meals or antacids to minimize gastric 
irritation.
Store in light-resistant container.
Trimethoprim-
sulfamethoxazole
(TMP-SMX)
(Bactrim, Septra)
Oral suspension:
 TMP 8 mg/mL and 
SMX 40 mg/mL
Tablets, single strength:
 TMP 80 mg and SMX 
400 mg
Double strength:
 TMP 160 mg and SMX 
800 mg
IV
More frequent
Skin rash•	
Less frequent
Hypersensitivity reactions (skin rash, •	
fever)
Hematologic toxicity (leukopenia, •	
neutropenia, thrombocytopenia, 
anemia)
Rare
Exfoliative skin disorders (including •	
Stevens-Johnson syndrome)
Hemolytic anemia (with G6-PD •	
deficiency)
Methemoglobinemia•	
Renal toxicity (crystalluria, nephritis, •	
tubular necrosis)
CNS toxicity (aseptic meningitis)•	
Pseudomembranous colitis•	
Cholestatic hepatitis•	
Thyroid function disturbance•	
GI disturbances (anorexia, 
nausea, vomiting, diarrhea)
Requires dose adjustment in patients with 
impaired renal function.
Maintain adequate fluid intake to prevent 
crystalluria and stone formation (take with full 
glass of water).
Potential for photosensitivity skin reaction with 
sun exposure.
IV infusion over 60–90 min.
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Antimycobacterial drugs
Amikacin IV More frequent
Nephrotoxicity•	
Neurotoxicity (including muscle •	
twitching, seizures)
Ototoxicity, both auditory and vestibular•	
Less frequent
Hypersensitivity (skin rash, redness, •	
or swelling)
Rare
Neuromuscular blockade•	
Must be infused over 30–60 min to avoid 
neuromuscular blockade.
Requires dose adjustment in patients with 
impaired renal function.
Should monitor renal function and hearing 
periodically (e.g., monthly) in children on 
prolonged therapy.
Azithromycin
(Zithromax)
Oral suspension:
 20 mg/mL, 40 mg/mL
Capsules:
 250 mg, 600 mg
IV
More frequent
Thrombophlebitis (IV form)•	
Rare
Acute interstitial nephritis•	
Allergic reactions/anaphylaxis •	
(dyspnea, hives, rash)
Pseudomembranous colitis•	
GI disturbances (abdominal 
discomfort or pain, diarrhea, 
nausea, vomiting)
Dizziness, headache
Administer 1 hr before or 2 hrs after a meal; do 
not administer with aluminum- and magnesium-
containing antacids.
IV: should be infused at concentration of 
1 mg/mL over a 3-hr period or 2 mg/mL over 
a 1-hr period; should not be administered as a 
bolus.
Use with caution in patients who have hepatic 
function impairment (biliary excretion main route 
of elimination).
Potential drug interactions.
Capreomycin
(Capastat)
IM More frequent
Nephrotoxicity•	
Less frequent
Hypersensitivity (rash, fever)•	
Hypokalemia•	
Neuromuscular blockade•	
Ototoxicity, both auditory and •	
vestibular
Injection site pain, sterile abscess•	
Requires dose adjustment in patients with 
impaired renal function.
Administer only by deep IM injection into large 
muscle mass (superficial injections may result in 
sterile abscess).
Should monitor renal function and hearing 
periodically (e.g., monthly) in children on 
prolonged therapy.
Ciprofloxacin
(Cipro)
Oral suspension:
 50 mg/mL, 100 mg/mL
Tablets:
 100 mg, 250 mg,
 500 mg, 750 mg
IV
More frequent
QTc-interval prolongation•	
Less frequent
Phototoxicity•	
Rare
CNS stimulation•	
Hepatotoxicity•	
Hypersensitivity reactions (rash, •	
pruritis, exfoliative skin disorders 
including Stevens-Johnson syndrome, 
dyspnea, vasculitis)
Interstitial nephritis•	
Phlebitis (at injection sites)•	
Pseudomembranous colitis•	
Tendonitis or tendon rupture•	
More frequent
GI disturbances (abdominal •	
discomfort or pain, 
diarrhea, nausea, vomiting)
CNS toxicity (dizziness, •	
headache, insomnia, 
drowsiness)
Less frequent
Change in taste•	
Photosensitivity•	
Can be taken without regard to meals.
Avoid concurrent antacids or sucralfate (take 
≥6 hrs before or 2 hrs after ciprofloxacin).
Take with full glass of water to avoid crystalluria.
Possible phototoxicity reactions with sun 
exposure.
IV infusions should be over 1 hr.
Clarithromycin
(Biaxin)
Oral suspension:
 25 mg/mL, 50 mg/mL
Tablets:
 250 mg, 500 mg
Rare
Hepatotoxicity•	
Hypersensitivity reaction (rash, pruritis, •	
dyspnea)
Pseudomembranous colitis•	
Thrombocytopenia•	
Frequent
GI disturbances (abdominal •	
discomfort or pain, 
diarrhea, nausea, vomiting)
Infrequent
Abnormal taste sensation•	
Headache•	
Requires dose adjustment in patients with 
impaired renal function.
Can be administered without regard to meals.
Reconstituted suspension should not be 
refrigerated.
Potential drug interactions.
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Cycloserine
(Seromycin)
Capsules:
 250 mg
More frequent
CNS toxicity (including confusion, •	
anxiety)
Less frequent
Hypersensitivity (skin rash)•	
Peripheral neuropathy•	
Seizures•	
Psychosis•	
Rare
Cardiac arrhythmias•	
More frequent
Headache•	
Rare
Photosensitivity•	
Take with food to minimize gastric irritation.
Neurotoxicity is related to excessive serum 
concentrations; serum concentrations should be 
maintained at 25–30 μg/mL.
Do not administer to patients with severe renal 
impairment (because of increased risk for 
neurotoxicity).
Should monitor serum levels, if possible.
Should administer pyridoxine at the same time.
Ethambutol
(Myambutol)
Tablets:
 100 mg, 400 mg
Infrequent
Acute gouty arthritis (secondary to •	
hyperuricemia)
Rare
Hypersensitivity (rash, fever, joint pain)•	
Peripheral neuritis•	
Retrobulbar optic neuritis•	
GI disturbances (abdominal 
pain, anorexia, nausea, 
vomiting)
Confusion
Disorientation
Headache
Requires dose adjustment in patients with 
impaired renal function.
Take with food to minimize gastric irritation.
Monitor visual acuity and red-green color 
discrimination.
Avoid concomitant use of drugs with 
neurotoxicity.
Ethionamide
(Trecator-SC)
Tablets:
 250 mg
Infrequent
Hepatitis, jaundice•	
Peripheral neuritis•	
Psychiatric disturbances•	
Rare
Goiter or hypothyroidism•	
Hypoglycemia•	
Optic neuritis•	
Skin rash•	
More frequent
GI disturbances (anorexia, •	
metallic taste, nausea, 
vomiting, stomatitis)
Orthostatic hypotension•	
Rare
Gynecomastia•	
Avoid use of other neurotoxic drugs that could 
increase potential for peripheral neuropathy and 
optic neuritis.
Administration of pyridoxine may alleviate 
peripheral neuritis.
Take with food to minimize gastric irritation.
Isoniazid Oral syrup:
 10 mg/mL
Tablets:
 50 mg, 100 mg,
 300 mg
IM
More frequent
Hepatitis prodromal syndrome •	
(anorexia, weakness, vomiting)
Hepatitis•	
Peripheral neuritis•	
Rare
Blood dyscrasias•	
Hypersensitivity (fever, rash, joint pain)•	
Neurotoxicity (includes seizure)•	
Optic neuritis•	
GI disturbances (abdominal 
pain, nausea, vomiting, 
diarrhea)
Take with food to minimize gastric irritation.
Take ≥1 hr before aluminum-containing 
antacids.
Hepatitis less common in children.
Use with caution in patients who have hepatic 
function impairment, severe renal failure, or 
history of seizures.
Pyridoxine supplementation should be provided 
for all HIV-infected children.
Kanamycin Vials:
 75 mg/2 mL
 500 mg/2 mL
 1 g/3 mL
IM
More frequent
Nephrotoxicity•	
Neurotoxicity (including muscle •	
twitching, seizures)
Ototoxicity, both auditory and •	
vestibular
Less frequent
Hypersensitivity (skin rash, redness or •	
swelling)
Rare
Neuromuscular blockade•	
Must be infused over 30–60 min to avoid 
neuromuscular blockade.
Requires dose adjustment in patients with 
impaired renal function.
Should monitor renal function and hearing 
periodically (e.g., monthly) in children on 
prolonged therapy.
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P-aminosalicyclic 
acid
Delayed-release 
granules:
 4 g per packet
Rare
Hypersensitivity (fever, skin rash, •	
exfoliative dermatitis, infectious 
mononucleosis-like or lymphoma-
like syndrome, jaundice, hepatitis, 
pericarditis, vasculitis, hematologic 
abnormalities including hemolytic 
anemia, hypoglycemia, optic neuritis, 
encephalopathy, reduction in 
prothrombin)
Crystalluria•	
Hemolytic anemia•	
GI disturbances (abdominal 
pain, nausea, vomiting, 
diarrhea)
Should not be administered to patients with 
severe renal disease.
Drug should be discontinued at first sign 
suggesting hypersensitivity reaction (usually 
rash, fever, GI symptoms followed by jaundice).
Vitamin B12 therapy should be considered in 
patients receiving for >1 mo.
Administer granules by sprinkling on acidic 
foods (e.g., applesauce or yogurt) or a fruit drink 
(e.g., tomato juice or orange juice).
Maintain urine at neutral or alkaline pH to avoid 
crystalluria.
The granule soft “skeleton” may be seen in the 
stool.
Pyrazinamide Tablets:
 500 mg
More frequent
Arthralgia•	
Less frequent
Hepatotoxicity (dose-related)•	
Rare
Acute gouty arthritis secondary to •	
hyperuricemia
Skin rash, pruritis
Photosensitivity
Avoid in patients with severe hepatic 
impairment.
Rifabutin
(Mycobutin)
Capsules:
 150 mg
More frequent
Allergic reaction (rash, pruritis)•	
GI intolerance (anorexia, diarrhea, •	
dyspepsia, nausea, vomiting)
Neutropenia•	
Less frequent
Asthenia•	
Rare
Arthralgia, myalgia•	
Change in taste•	
Pseudojaundice•	
Thrombocytopenia•	
Uveitis •	
Headache
Insomnia
Preferably take on empty stomach, but 
may administer with food in patients with GI 
intolerance.
Contents of capsules may be mixed with 
applesauce if unable to swallow capsule.
May cause reddish to brown-orange color urine, 
feces, saliva, sweat, skin, or tears (can discolor 
soft contact lenses).
Uveitis seen with high-dose rifabutin (adults 
>300 mg/day) especially when combined with 
clarithromycin.
Multiple potential drug interactions.
Rifampin
(Fifadin)
Oral suspension:
 (not commercially 
available but can be 
prepared from cap-
sules of 1.2 g rifampin 
in 120 mL syrup)
Capsules:
 150 mg, 300 mg
IV
Infrequent
“Flu-like” syndrome•	
Rare
Blood dyscrasias•	
Hepatitis prodromal syndrome •	
(anorexia, nausea, vomiting, 
weakness)
Hepatitis•	
Interstitial nephritis•	
GI disturbances (abdominal 
pain, diarrhea)
Preferably take on empty stomach, but 
may administer with food in patients with GI 
intolerance; take with full glass of water.
Suspension formulation stable for 30 days.
May cause reddish to brown-orange color urine, 
feces, saliva, sweat, skin, or tears (can discolor 
soft contact lenses).
Multiple potential drug interactions.
Streptomycin IM More frequent
Nephrotoxicity•	
Neurotoxicity (including muscle •	
twitching, seizures)
Peripheral neuritis•	
Ototoxicity, both auditory and •	
vestibular
Less frequent
Hypersensitivity (skin rash, redness or •	
swelling)
Optic neuritis•	
Rare
Neuromuscular blockade•	
Usual route of administration is deep IM injection 
into large muscle mass.
For patients who cannot tolerate IM injections, 
dilute to 12–15 mg in 100 mL of 0.9% sodium 
chloride; must be infused over 30–60 min to 
avoid neuromuscular blockade.
Requires dose adjustment in patients with 
impaired renal function.
Should monitor renal function and hearing 
periodically (e.g., monthly) in children on 
prolonged therapy.
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Antiviral drugs
Acyclovir
(Zovirax)
Oral suspension:
 40 mg/mL
Capsules:
 200 mg
Tablets:
 400 mg, 800 mg
IV
More frequent
Phlebitis (at injection site when •	
administered IV)
Less frequent
Acute renal failure (parenteral use, •	
more common with rapid infusion)
Rare (parenteral form only)
Encephalopathy•	
Hematologic toxicity (leukopenia, •	
neutropenia, thrombocytopenia, 
anemia, hemolysis)
Crystalluria, hematuria•	
Disseminated intravascular coagulation•	
Hypotension•	
Neuropsychiatric toxicity (with high •	
doses)
Rare (parenteral and oral forms):
Rash (urticarial, exfoliative skin •	
disorders including Stevens-Johnson 
syndrome)
Anaphylaxis•	
Seizures•	
Elevated transaminase enzymes•	
Fever, hallucinations•	
Leukopenia•	
Lymphadenopathy•	
Peripheral edema•	
Visual abnormalities•	
More frequent
GI disturbances (anorexia, •	
diarrhea, nausea, vomiting)
Headache, lightheadness•	
Malaise•	
Less frequent (more marked 
in older adults) [irrelevant to 
this document]
Agitation•	
Alopecia•	
Dizziness•	
Myalgia, paresthesia•	
Somnolence•	
Requires dose adjustment in patients with renal 
impairment.
Avoid other nephrotoxic drugs.
Infusion concentrations of <7 mg/mL are 
recommended.
Should be infused slowly over 1 hr to avoid 
renal tubular damage; must be accompanied by 
adequate hydration.
Cidofovir
(Vistide)
IV More frequent
Nephrotoxicity•	
Neutropenia•	
Less frequent
Fever•	
Rare
Vision changes because of ocular •	
hypotony
GI disturbances (anorexia, 
diarrhea, nausea, vomiting)
Headache
Asthenia
Infuse over 1 hr.
Should not be used in patients with severe renal 
impairment.
Probenecid must be administered before each 
dose of cidofovir and 2 and 8 hrs after infusion.
Each dose must be administered with 1 liter of 
0.9% sodium injection, infused over 1–2 hrs 
immediately before cidofovir infusion; if the 
patient can tolerate the fluid load, a second liter 
should be started either at the beginning of the 
cidofovir infusion or immediately afterward.
Concurrent use of other nephrotoxic drugs 
should be avoided.
Foscarnet
(Foscarvir)
IV More frequent
Nephrotoxicity•	
Serum electrolyte abnormalities •	
(hypocalcemia, hypophosphatemia, 
hypomagnesemia, hypokalemia)
Less frequent
Hematologic toxicity (anemia, •	
granulocytopenia)
Neurotoxicity (muscle twitching, tremor, •	
seizures, tingling around mouth)
Cardiac abnormalities secondary to •	
electrolyte changes
Phlebitis (at site of injection)•	
Rare
Sores or ulcers mouth or throat•	
Frequent
GI disturbances (abdominal •	
pain, anorexia, nausea, 
vomiting)
Anxiety, confusion, •	
dizziness, headache
Fever•	
Requires dose adjustment in patients with 
impaired renal function.
Use adequate hydration to decrease 
nephrotoxicity.
Avoid concomitant use of other nephrotoxic 
drugs.
Monitor serum electrolytes.
IV solution of 24 mg/mL can be administered 
through central line but must dilute to 12 mg/mL 
if administered through peripheral line.
Must be administered at a constant rate by 
infusion pump over ≥2 hrs (or no faster than 
1 mg/kg/min).
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Ganciclovir
(Cytovene)
Capsules:
 250 mg, 500 mg
IV
More frequent
Granulocytopenia•	
Thrombocytopenia•	
Less frequent
Anemia•	
CNS effects (confusion, headache)•	
Hypersensitivity (fever, rash)•	
Elevated transaminase enzymes•	
Increase in creatinine, BUN•	
Phlebitis (at injection sites)•	
Rare
Retinal detachment•	
Seizures•	
Psychosis•	
GI disturbances (abdominal 
pain, anorexia, nausea, 
vomiting)
Requires dose adjustment in patients with renal 
impairment.
Avoid other nephrotoxic drugs.
IV infusion over 1 hr. In-line filter required.
Maintain good hydration.
Undiluted IV solution is alkaline (pH 11); use 
caution in handling and preparing solutions, and 
avoid contact with skin and mucus membranes.
Administer oral doses with food to increase 
absorption.
Interferon-alfa Parenteral 
(subcutaneous or IM 
use)
More frequent
Hematologic toxicity (leukopenia, •	
thrombocytopenia)
Neurotoxicity (confusion, depression, •	
insomnia, anxiety)
Injection erythema•	
Less frequent
Cardiovascular effects (chest pain, •	
hypertension, arrhythmias)
Hypoesthesia/paresthesia•	
Rare
Abnormality or loss of vision•	
Allergic reaction (rash, hives)•	
Hypothyroidism•	
Development of antinuclear antibodies•	
More frequent
Flu-like syndrome (myalgia, •	
arthralgia, fever, chills, 
headache, back pain, 
malaise, fatigue)
GI disturbances (abdominal •	
pain, anorexia, nausea, 
vomiting, diarrhea, 
dyspepsia)
Pharyngitis•	
Infrequent
Alopecia•	
Epistaxis•	
Severe adverse effects less common in children 
than adults.
Toxicity dose-related, with significant reduction 
over the first 4 mos of therapy.
For non-life–threatening reactions, reduce dose 
or temporarily discontinue drug and restart at 
low doses with stepwise increases.
If patients have visual complaints, 
ophthalmologic exam should be performed to 
detect possible retinal hemorrhage or retinal 
artery or vein obstruction.
Should not be used in children with 
decompenstated hepatic disease, significant 
cytopenia, autoimmune disease, or significant 
preexisting renal or cardiac disease.
If symptoms of hepatic decompensation occur 
(ascites, coagulopathy, jaundice), interferon-alfa 
should be discontinued.
Lamivudine
(Epivir)
Oral solution:
 10 mg/mL
Tablets:
 100 mg, 150 mg, 
300 mg
More frequent
Pancreatitis•	
Peripheral neuropathy/paresthesias•	
Less frequent
Hematologic toxicity (anemia, •	
neutropenia)
Skin rash•	
Infrequent
GI disturbances (abdominal •	
pain, nausea, vomiting)
Headache, insomnia•	
Dizziness, fatigue•	
Cough•	
Rare
Hair loss•	
Avoid use in patients with history of pancreatitis 
or peripheral neuropathy.
Requires dose adjustment in patients with renal 
impairment.
HIV/HBV coinfected children should not 
be treated with lamivudine monotherapy; 
lamivudine should be administered as part of 
potent combination regimen and the dose used 
for HIV treatment.
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Ribavirin Inhalation solution:
 6-g vial (oral solution 
and IV preparation not 
available commercially 
but can be prepared 
by diluting ribavirin 
inhalation product vial)
Capsules:
 200 mg (in kit with 
interferon-alfa)
More frequent
Hemolytic anemia (with associated •	
potential for increase in unconjugated 
bilirubin and uric acid)
Infrequent
Neutropenia•	
CNS effects (fatigue, 
headache, insomnia, 
depression)
GI disturbances (abdominal 
pain, nausea, vomiting)
Skin rash
After reconstitution, ribavirin oral solution stable 
for 24 hrs.
IV infusion should be over 15–20 min.
Should not be used in patients with severe renal 
impairment.
Should not be used as monotherapy for 
treatment of hepatitis C, but used in combination 
with interferon-alfa.
Intracellular phosphorylation of pyrimidine 
nucleoside analogues (zidovudine, stavudine, 
zalcitabine) decreased by ribavirin, may have 
antagonism, use with caution.
Enhances phosphorylation of didanosine, use 
with caution because of increased risk for 
pancreatitis/mitochondrial toxicity. 
Valacyclovir
(Valtrex)
Tablets:
 500 mg, 1 g (an oral 
suspension formula-
tion 50 mg/mL can be 
prepared in Ora-Sweet 
or Syrpalta syrups)
Less frequent
Dysmenorrhea•	
Thrombotic microangiopathy (high •	
dose)
More frequent
Headache, nausea•	
Less frequent
Arthralagia•	
Dizziness, fatigue•	
GI disturbances (diarrhea •	
or constipation, anorexia, 
abdominal pain, vomiting)
An oral suspension formulation can be prepared 
in Ora-Sweet or Syrpalta syrups (to yield a final 
concentration of 50 mg/mL of the hydrochloride 
salt); stable for 21 days in amber glass bottles.
Thrombotic thrombocytopenia purpura/hemolytic 
uremic syndrome has been reported in HIV-
infected adults with advanced disease receiving 
high (8 g/day) but not lower doses.
Valganciclovir
(Valcyte)
Tablets:
 450 mg
More frequent
Granulocytopenia•	
Thrombocytopenia•	
Less frequent
Anemia•	
CNS effects•	
Hypersensitivity (fever, rash)•	
Elevated transaminase enzymes•	
Increase in creatinine, BUN•	
GI disturbances (abdominal 
pain, anorexia, nausea, 
vomiting)
Requires dose adjustment in patients with renal 
impairment.
Avoid other nephrotoxic drugs.
Tablets should not be broken or crushed.
Antiparasitic drugs
Albendazole
(Albenza)
Tablets:
 200 mg
More frequent
Abnormal liver function results•	
Less frequent
Hypersensitivity (rash, pruritis)•	
Neutropenia (with high doses)•	
Rare
Pancytopenia•	
Infrequent
CNS effects (dizziness, •	
headache)
GI disturbances (abdominal •	
pain, diarrhea, nausea, 
vomiting)
Rare
Alopecia•	
Take with meals to increase absorption.
Nitazoxanide
(Alinia)
Oral suspension:
 20 mg/mL
Tablets (not yet 
commercially available):
 500 mg
More frequent
GI disturbances (abdominal •	
pain, nausea, diarrhea, 
vomiting)
Headache•	
Rare
Yellow sclera•	
Should be administered with food.
Pyrimethamine
(Daraprim)
Tablet:
 25 mg
Less frequent
Neutropenia•	
Thrombocytopenia•	
Megaloblastic anemia•	
Rare
Stevens Johnson syndrome•	
Skin rash To prevent hematologic toxicity, administer with 
leucovorin.
Sulfadiazine Tablet:
 500 mg
Rare
Crystalluria, renal failure•	
Bone marrow suppression/blood •	
dyscrasias
Severe hypersensitivity syndrome•	
GI disturbances (abdominal 
pain, diarrhea, nausea)
Ensure adequate fluid intake to avoid 
crystalluria.
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TABLE 5. (Continued) Preparations and major toxicities of drugs commonly used for treating opportunistic infections in HIV-
exposed and HIV-infected infants and children, United States*
Major toxicities†
Drug Preparations
Indicating need  
for medical attention
Indicating need  
for medical attention  
if persistent or bothersome Special instructions
Antimalarial drugs
Primaquine Tablets:
 15 mg (base)
More frequent
Hemolytic anemia (with G6-PD •	
deficiency)
Less frequent
Methemoglobinemia•	
Rare
Leukopenia•	
GI disturbances (nausea, 
vomiting)
Take with meals or antacids to minimize gastric 
irritation.
Store in light-resistant container.
Mefloquine Tablets:
 250 mg
More frequent
CNS (dizziness, vivid dreams, •	
insomnia)
Side effects less prominent 
in children
No pediatric tablets.
Bitter taste; use with marshmellows can mask 
taste.
Side effects requiring discontinuation ~4%.
Atovaquone/
Proguanil
Tablets:
 Pediatric tabs— 
62.5 mg/25 mg
 Adult tabs— 
250 mg/100 mg
Less frequent
Vomiting•	
Pruritis•	
Not for severe renal 
impairment
(GFR <30 mL/min)
Pediatric tablets available making dosing easier.
In adults, side effects similar to placebo.
Side effects requiring discontinuation ~1%–2%.
Doxycycline Tablets and Capsules:
 50, 75, 100 mg
Suspension:
 25 mg/5 mL oral sus-
pension, 50 mg/5 mL 
syrup
More frequent
GI irritation, pill esophagitis•	
Photosensitivity•	
Staining of teeth, use in 
persons >8 yrs
Photoonycholysis
Swallow with adequate amounts of fluids.
Milk decreases mean absorption by 30%.
Provides rickettsial and leptospirosis 
prophylaxis.
Chloroquine 
Phosphate
Tablets:
 500 mg
 250 mg
More frequent
Pruritis—common in persons of African •	
descent (25%–33%)
Psoriasis exacerbations Well tolerated at prophylaxis dosing.
Store in child-proof containers.
Can be toxic in overdose.
Bitter tasting.
Solution available worldwide, but not in United 
States.
Quinidine IV Serious
Cardiac arrhythmias•	
Hypoglycemia•	
Very frequent
Cinchonism = dose-
dependent effect with 
tinnitus, reversible high-
frequency hearing loss, 
deafness, vertigo, blurred 
vision, diplopia, photophobia, 
headache, confusion, 
delirium.
Nausea, diarrhea
Electrocardiogram monitoring is standard of 
care.
Do not give by bolus infusion.
If electrocardiogram changes observed, slow 
infusion rate.
Artesunate IV (available from 
CDC Malaria Hotline 
only: telephone: 
770-488-7788)
Approximately 40% less mortality than with 
quinidine use in severe malaria.
50% less hypoglycemia than with quinidine.
Antibacterial drugs (note: clarithromycin and azithromycin are listed under “Antimycobacterial drugs”)
Doxycycline Capsules:
 20, 50, 75, 100 mg
Tablets:
 20, 50, 100 mg
Syrup:
 50 mg/5 mL (60 mL)
Suspension:
 25 mg/5 mL (60 mL)
Injection:
 100, 200 mg
Uncommon
Increased intracranial pressure, •	
photosensitivity, hemolytic anemia, 
rash, and hypersensitivity reactions
GI disturbances (nausea, 
vomiting, abdominal cramps)
Use with caution in hepatic and renal disease.
IV doses should be infused over 1–4 hrs.
Patient should avoid prolonged exposure to 
direct sunlight (skin sensitivity).
Generally not recommended for use in children 
<8 yrs of age because of risk for tooth enamel 
hypoplasia and discoloration, unless benefit 
outweighs the risk.
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TABLE 5. (Continued) Preparations and major toxicities of drugs commonly used for treating opportunistic infections in HIV-
exposed and HIV-infected infants and children, United States*
Major toxicities†
Drug Preparations
Indicating need  
for medical attention
Indicating need  
for medical attention  
if persistent or bothersome Special instructions
Erythromycin Erythromycin base
Tablet:
 250, 333, 500 mg
Delayed-release tablet:
 250, 333, 500 mg
Delayed-release capsule:
 250 mg
Erythromycin ethyl 
succinate
Suspension:
 200, 400 mg/5 mL 
(100, 480 mL)
Oral drops:
 100 mg/2.5 mL
Chewable tablet:
 200 mg
Tablet:
 400 mg
Erythromycin estolate
Suspension:
 125, 250 mg/5 mL
Erythromycin stearate
Tablet:
 250, 500 mg
Erythromycin gluceptate
Injection:
 1,000 mg
Erythromycin lactobionate
Injection:
 500, 1000 mg
Uncommon
Estolate may cause cholestatic •	
jaundice, although hepatotoxicity is 
uncommon (2% of reported cases)
GI disturbances (nausea, 
vomiting, abdominal cramps)
Use with caution in liver disease.
Oral therapy should replace IV therapy as soon 
as possible.
Give oral doses after meals.
Parenteral administration should consist of a 
continuous drip or slow infusion over >60 min.
Adjust dose in renal failure.
Erythromycin should be used with caution in 
neonates; hypertrophic pyloric stenosis and life-
threatening episodes of ventricular tachycardia 
associated with prolonged QTc interval have 
been reported.
High potential for interaction with many 
antiretrovirals and other drugs.
* Abbreviations: CNS—central nervous system; GI—gastrointestinal; G6-PD—glucose-6-phosphate dehydrogenase deficiency; IM—intramuscular; IV—intravenous.
† The toxicities given were selected on the basis of their potential clinical significance and do not include all side effects reported for a particular drug.
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TABLE 6. Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Antifungal drugs
Amphotericin B
Amphotericin B lipid 
complex (Abelcet)
Amphotericin 
B liposome 
(AmBisome)
Potential for increased toxicity because 
of overlapping toxicity or side effect of 
amphotericin (e.g., hypokalemia):
Bone marrow suppressant drugs: 
corticosteroids, corticotropin
Cardiovascular drugs: digitalis glycosides
Diuretics: potassium depleting
Nephrotoxic drugs
Neuromuscular blocking drugs
Caspofungin Decreases caspofungin levels:
Anticonvulsant drugs: phenytoin
Antimycobacterial drugs: rifampin
Antiretroviral drugs: efavirenz, nevirapine, 
nelfinavir
Increases concomitant drug levels:
Anticancer: tacrolimus
Flucytosine Increases flucytosine levels:
Nephrotoxic drugs: medications that impair 
glomerular filtration
Ketoconazole Decreases ketoconazole levels:
Antiretroviral drugs: nevirapine
Increases concomitant drug levels:
Antihistamines: astemizole, terfenadine
Gastrointestinal drugs: cisapride
Sedatives/Hypnotics: midazolam, triazolam
Decreases ketoconazole levels:
Anticonvulsant drugs: phenytoin
Antimycobacterial drugs: isoniazid, rifampin
Decreases ketoconazole absorption:
Antiretroviral drugs: didanosine
Gastrointestinal drugs: antacids, 
anticholinergics/antispasmodics, histamine 
H2-receptor antagonists, omeprazole, 
sucralfate
Minerals: ferrous sulfate, zinc
Potential for increased toxicity because 
of overlapping toxicity:
Hepatotoxic drugs
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Anticonvulsant drugs: phenytoin
Antiretroviral drugs: indinavir
Cardiovascular drugs: digoxin
Immunosuppressant drugs: cyclosporine
Fluconazole Increases concomitant drug levels:
Antihistamines: terfenadine (with high-dose 
fluconazole)
Gastrointestinal drugs: cisapride
Decreases fluconazole levels:
Anticonvulsant drugs: phenytoin
Antimycobacterial drugs: rifampin
Increases concomitant drug levels:
Antidiabetes drugs: oral agents
Antimycobacterial drugs: rifabutin
Antidepressant drugs: amitriptyline
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Anticonvulsant drugs: phenytoin
Asthma drugs: theophylline
Immunosuppressant drugs: cyclosporin (with 
high dose fluconazole)
Sedatives/Hypnotics: midazolam
Itraconazole Increases concomitant drug levels:
Antihistamines: astemizole, terfenadine
Gastrointestinal drugs: cisapride
Sedatives/Hypnotics: midazolam, triazolam
Statins: lovastatin, simvastatin
Decreases itraconazole levels:
Anticonvulsant drugs: carbamazepine, 
phenytoin
Antimycobacterial drugs: rifampin
Decreases itraconazole absorption:
Antiretroviral drugs: didanosine
Gastrointestinal drugs: antacids, 
anticholinergics/ antispasmodics, histamine 
H2-receptor antagonists, omeprazole, 
sucralfate
Minerals: ferrous sulfate, zinc
Increases concomitant drug levels:
Antidiabetes drugs: oral agents
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Anticonvulsant drugs: carbamazepine, 
phenytoin
Cardiovascular drugs: digoxin
Immunosuppressant drugs: cyclosporin
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TABLE 6. (Continued) Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Posaconazole Increases posaconzaole levels:
Antihistamines: astemizole, terfenadine
Antimalarial: Halofantrine
Cardiovascular drugs: quinidine
Ergot alkaloids: ergotamine, dihydroergotamine
Gastrointestinal drugs: cisapride
Psychiatric drugs: pimozide
Increases posaconzaole levels:
Antihistamin astemizole, terfenadine
Antimalarial: Halofantrine
Cardiovascular drugs: quinidine
Ergot alkaloids: ergotamine, dihydroergotamine
Gastrointestinal drugs: cisapride
Psychiatric drugs: pimozide
May decrease posaconazole drug levels 
(avoid concomitant use unless benefits 
outweigh risks):
Anticonvulsant drugs: phenytoin
Antimycobacterial drugs: rifabutin
Gastrointestinal drugs: cimetidine
May increase concomitant drug levels:
Anticonvulsant drugs: phenytoin
Antihypertensives: (calcium channel blockers 
metabolized through CYP3A4):verapamil, 
diltiazem
Antimycobacterial drugs: rifabutin
Chemotherapeutic drugs (i.e. vinca alkaloids): 
vincristine and vinblastin
Immunosuppressant drugs: cyclosporin, 
sirolimus,tacrolimus,
Sedatives/Hypnotics: midazolam
Statins: (those metabolized by CYP34A)
Increased blood glucose levels with 
concomitant drug use; requires glucose 
monitoring:
Antidiabetic drugs: glipizide
May increase concomitant drug levels:
Anticonvulsant drugs: phenytoin
Amtihypertensives (calcium channel blockers 
metabolized through CYP3A4): verapamil, 
diltiazem
Antimycobacterial drugs: rifabutin
Chemotherapeutic drugs (i.e. vinca alkaloids): 
vincristine and vinblastin
Immunosuppressant drugs: cyclosporin, 
sirolimus,tacrolimus,
Sedatives/Hypnotics: midazolam
Statins: (those metabolized by CYP34A)
Voriconazole Decreases voriconazole levels:
Anticonvulsant drugs: carbamazepine, long-
acting barbiturates
Antimycobacterial drugs: rifabutin, rifampin
Increases concomitant drug levels:
Antihistamines: astemizole, terfenadine
Antimycobacterial drugs: rifabutin
Cardiovascular drugs: quinidine
Ergot alkaloids
Gastrointestinal drugs: cisapride
Immunosuppressant drugs: sirolimus
Psychiatric drugs: pimozide
Increases voriconazole levels:
Antiretroviral drugs: amprenavir, ritonavir, 
saquinavir
May increase or decrease voriconazole levels:
Antiretroviral drugs: delavirdine, efavirenz
Increases concomitant drug levels:
Antiretroviral drugs: amprenavir, nelfinavir, 
saquinavir, delavirdine
Antidiabetes drugs: oral
Statins
Increases concomitant drug levels:
Anticancer drugs: vinca alkaloids
Anticoagulant drugs: warfarin, coumarin 
derivatives
Anticonvulsant drugs: phenytoin
Cardiovascular drugs: felodipine (calcium 
channel blockers)
Gastrointestinal drugs: omeprazole
Immunosuppressant drugs: cyclosporin, 
tacrolimus
Sedatives/Hypnotics: midazolam, triazolam, 
alprazolam
Statins: lovastatin, simvastatin
Decreases voriconazole levels:
Anticonvulsant drugs: phenytoin
Anti-Pneumocystis drugs
Atovaquone Decreases atovoquone levels:
Antimycobacterial drugs: rifampin
Decreases atovaquone levels:
Antimycobacterial drugs: rifabutin 
Clindamycin Decreases clindamycin antibacterial efficacy:
Antibacterial drugs: chloramphenicol, 
erythromycins
Increases concomitant drug toxicity:
Anesthetics: hydrocarbon inhalation
Neuromuscular blocking drugs
Dapsone Increases dapsone levels:
Probenecid
Decreases dapsone levels:
Antimycobacterial drugs: rifampin
Decreases dapsone absorption:
Antiretroviral drugs: didanosine
Increases levels both drugs:
Antibacterial drugs: trimethoprim
Potential for increased toxicity because 
of overlapping toxicity:
Bone marrow suppressant drugs or drugs 
associated with hemolysis 
Pentamidine Potential for increased toxicity because 
of overlapping toxicity
Anti-emetic drugs: droperidol
Antiretroviral drugs: zalcitibine
Potential for increased toxicity because 
of overlapping toxicity:
Antiviral drugs: foscarnet
Antiretroviral drugs: didanosine
Bone marrow suppressant drugs
Nephrotoxic drugs
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TABLE 6. (Continued) Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Primaquine Potential for increased toxicity because 
of overlapping toxicity:
Antiprotozoal drugs: quinacrine
Potential for increased toxicity because 
of overlapping toxicity:
Bone marrow suppressant drugs or drugs 
associated with hemolysis
Nephrotoxic drugs
Trimethoprim-
sulfamethoxazole
Potential for increased toxicity because 
of overlapping toxicity:
Folate antagonists
Decreases trimethoprim levels:
Antimycobacterial drugs: rifampin
Increases levels both drugs:
Antibacteria drugsl: dapsone
Potential for increased toxicity because 
of overlapping toxicity:
Bone marrow suppressant drugs 
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Anticonvulsant drugs: phenytoin
Cardiovascular drugs: procainamide
Antimycobacterial drugs
Amikacin Potential for increased toxicity because 
of overlapping toxicity:
Antimycobacterial drugs: capreomycin
Potential for increased toxicity because 
of overlapping toxicity:
Anti-TB drugs (injectable): streptomycin, 
kanamycin
Nephrotoxic drugs
Neuromuscular blocking drugs
Ototoxic drug: loop diuretics
Azithromycin Decreases azithromycin absorption:
Gastrointestinal drugs: antacids
Increases concomitant drug levels:
Antihistamines: terfenadine
Ergot derivatives
Sedatives/Hypnotics: triazolam
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Anticonvulsant drugs: carbamazepine, 
phenytoin
Asthma drugs: theophylline
Cardiovascular drugs: digoxin
Immunosuppressant drugs: cyclosporin
Capreomycin Potential for increased toxicity because 
of overlapping toxicity:
Antibacterial drugs: aminoglycosides 
(parenteral)
Potential for increased toxicity because 
of overlapping toxicity:
Nephrotoxic drugs
Neuromuscular blocking drugs
Ototoxic drugs: loop diuretics
Ciprofloxacin Increases ciprofloxacin levels:
Probenecid
Decreases ciprofloxacin absorption:
Antiretroviral drugs: didanosine
Minerals: ferrous sulfate, zinc
Gastrointestinal drugs: antacids, sucralfate, 
magnesium-containing laxatives
Potential increased toxicity concomitant drug:
Antidiabetes drugs: sulfonylurea (glucose 
abnormalities, both hypoglycemia and 
hyperglycemia, mechanism unclear)
Increases concomitant drug levels:
Anticoagulant drugs: warfarin
Asthma drugs: aminophylline, oxtriphylline, 
theophylline
Immunosuppressant drugs: cyclosporin
Decreases concomitant drug levels:
Anticonvulsant drugs: phenytoin
Clarithromycin Increases concomitant drug levels:
Antihistamines: astemizole, terfenadine
Gastrointestinal drugs: cisapride
Psychiatric drugs: pimozide
Potential for increased toxicity because 
of overlapping toxicity:
Anti-emetic drugs: droperidol
Decreases clarithromycin levels:
Antimycobacterial drugs: rifabutin, rifampin
Antiretroviral drugs: zidovudine
Increases concomitant drug levels:
Anticoagulant drugs: warfarin, coumadin 
derivatives
Anticonvulsant drugs: carbamazapine
Cardiovascular drugs: digoxin
Asthma drugs: theophylline 
Cycloserine Potential for increased toxicity because 
of overlapping toxicity:
Antimycobacterial drugs: ethionamide, 
isoniazid
Increases concomitant drug levels:
Anticonvulsant drugs: phenytoin
Ethambutol Potential for increased toxicity because 
of overlapping toxicity:
Neurotoxic drugs
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TABLE 6. (Continued) Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Ethionamide Potential for increased toxicity because 
of overlapping toxicity:
Neurotoxic drugs
Antimycobacterial drugs: cycloserine, isoniazid
Increases concomitant drug levels:
Immunosuppressant drugs: cyclosporin
Isoniazid Decreases isoniazid levels:
Corticosteriods: glucocorticoids (e.g., 
prednisolone)
Decreases isoniazid absorption:
Gastrointestinal drugs: antacids
Increases concomitant drug levels:
Anesthetics: alfentanil
Decreases concomitant drug levels:
Antifungal drugs: ketoconazole
Potential for increased toxicity because 
of overlapping toxicity:
Antimycobacterial drugs: rifampin, cycloserine, 
ethionamide
Hepatotoxic drugs
Neurotoxic drugs
Increases concomitant drug levels:
Anticoagulant drugs: coumadin derivatives
Anticonvulsant drugs: carbamazepine, 
phenytoin
Asthma drugs: theophylline
Sedatives/Hypnotics: benzodiazepines
Kanamycin Potential for increased toxicity because 
of overlapping toxicity
Aminoglycosides: history of hypersensitivity or 
toxic reaction to any aminoglycoside
Diuretics (potent): ethacrynic acid, furosemide, 
meralluride sodium, sodium mercaptomerin, 
or mannitol (note: should not be administered 
concurrently)
Potential for increased toxicity because 
of overlapping toxicity (should be avoided)
Aminoglycosides: all, including paromomycin
Nephrotoxic and/or neurotoxic drugs: 
polymyxin B, bacitracin, colistin, amphotercin 
B, cisplatin, vancomycin
Decreases kanamycin levels:
Beta-lactam–type antibiotics: penicillins or 
cephalosporins
Pyrazinamide Potential for increased toxicity because 
of overlapping toxicity:
Antimycobacterial drugs: rifampin
Hepatotoxic drugs
Decreases concomitant drug levels:
Immunosuppressant drugs: cyclosporine
Rifabutin Decreases concomitant drug levels:
Antiretroviral drugs: delavirdine; saquinavir 
(hard gel capsule without higher-dose ritonavir 
boosting)
Decreases concomitant drug levels:
Antibacterial drugs: dapsone
Antifungal drugs: azoles (except for 
fluconazole)
Cardiovascular drugs: quinidine, verapamil 
(oral)
Contraceptives: oral
Corticosteriods 
Increases rifabutin levels:
Antiretroviral drugs: nevirapine; amprenavir, 
indinavir, nelfinavir, ritonavir, saquinavir in 
combination with higher dose ritonavir boost
Decreases rifabutin levels:
Antiretroviral drugs: efavirenz
Decreases concomitant drug levels:
Antibacterial drugs: chloramphenicol, dapsone
Anticonvulsant drugs: barbiturates, diazepam
Antidiabetes drugs: oral
Antilipid drugs: clofibrate
Antiretroviral drugs: nevirapine, efavirenz,
amprenavir, indinavir, nelfinavir, saquinavir 
(soft gel cap)
Asthma drugs: aminophylline, oxtriphylline, 
theophylline
Cardiovascular drugs: beta-adrenergic 
blockers, digitalis glycosides, quinidine, 
verapamil (oral)
Immunosuppressant drugs: cyclosporine
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TABLE 6. (Continued) Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Rifampin Decreases concomitant drug levels:
Contraceptives: oral
Antiretroviral drugs: delavirdine, amprenavir, 
indinavir, lopinavir/ritonavir, nelfinavir, 
saquinavir (hard or soft gel without higher-
dose ritonavir boosting), or dual protease 
low-dose ritonavir-boosted regimens
Decreases rifampin absorption:
Antimycobacterial drugs: clofazamine
Decreases concomitant drug levels:
Antibacterial drugs: dapsone, trimethoprim
Antiretroviral drugs: nevirapine (use only if 
other options not available and close virologic 
and immunologic monitoring can be done)
Antifungal drugs: azoles
Corticosteriods
Methadone
Potential for increased toxicity because 
of overlapping toxicity:
Bone marrow suppressant drugs
Antimycobacterial drugs: isoniazid, 
pyrazinamide
Hepatotoxic drugs
Decreases concomitant drug levels:
Antibacterial drugs: chloramphenicol
Anticoagulant drugs: warfarin, coumadin 
derivatives
Anticonvulsant drugs: barbiturates, diazepam, 
phenytoin
Antidiabetes drugs: oral
Antilipid drugs: clofibrate
Asthma drugs: aminophylline, oxtriphylline, 
theophylline
Cardiovascular drugs: beta-adrenergic 
blockers, digitalis glycosides, disopyramide, 
mexiletine, propafenone, quinidine, tocainide, 
verapamil (oral)
Immuosuppressant drugs: cyclosporine
Methadone
Streptomycin Potential for increased toxicity because 
of overlapping toxicity:
Antimycobacterial drugs: capreomycin
Potential for increased toxicity because 
of overlapping toxicity:
Nephrotoxic drugs
Neuromuscular blocking drugs
Ototoxic drugs
Antiviral drugs
Acyclovir 
(Valacyclovir)
Increases acyclovir levels:
Probenecid
Potential for increased toxicity because 
of overlapping toxicity:
Nephrotoxic drugs
Cidofovir Potential for increased toxicity because 
of overlapping toxicity:
Antibacterial drugs: aminoglycosides
Nephrotoxic drugs
Foscarnet Potential for increased toxicity because 
of overlapping toxicity:
Anesthetic adjuncts: droperidol
Antiviral drugs: cidofovir
Anti-Pneumocystis drugs: pentamidine
Potential for increased toxicity because 
of overlapping toxicity:
Nephrotoxic drugs
Ganciclovir 
(Valganciclovir)
Increases ganciclovir levels:
Probenecid
Increases concomitant drug levels:
Antiretroviral drugs: didanosine
Potential for increased toxicity because 
of overlapping toxicity or other mechanisms:
Antibacterial drugs: impenem-cilastatin
Antiretroviral drugs: zidovudine
Bone marrow suppressant drugs
Nephrotoxic drugs
Interferon-alfa Potential for increased toxicity because 
of overlapping toxicity:
Antiretroviral drugs: zidovudine
Bone marrow suppressant drugs
Increases concomitant drug levels:
Asthma drugs: theophylline
Sedative drugs: barbiturates
Ribavirin Increases concomitant level of active drug 
(potential for increased risk of pancreatitis and 
mitochondrial toxicity):
Antiretroviral drugs: didanosine
Decreases concomitant level of active drug:
Antiretroviral drugs: zidovudine, stavudine, 
zalcitabine
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TABLE 6. (Continued) Drug interactions of clinical significance*
Drug class and name Contraindicated drugs
Drugs that should  
be used with caution
Drugs that require plasma-level  
monitoring and/or dose adjustment
Antiparasitic drugs
Albendazole Increases albendazole levels:
Gastrointestinal drugs: Cimetidine
Corticosteroids
Anithelminhic drugs: praziquantel
Decreases concomitant drug levels:
Asthma drugs: theophylline
Nitazoxanide Potential for toxicity if concomitant use of 
highly protein-bound drugs with narrow 
therapeutic index, because of high (>99.9%) 
protein binding 
Paromomycin Potential for increased toxicity because 
of overlapping toxicity:
Neuromuscular blocking drugs
Decreases concomitant drug levels:
Cardiovascular drugs: digoxin
Antimalarial drugs
Atovaquone/
Proguanil
Decreases atovaquone levels
Antibacterial drugs: tetracycline
Antimycobacterial drugs: rifampin, rifabutin
Increases concomitant drug levels:
Antiretroviral drugs: Zidovudine
Mefloquine None Decreases concomitant drug levels
Antiretroviral drugs: Ritonavir (decreased 
ritonavir trough and area under curve) 
Artesunate None None
Quinidine Ritonavir
Other protease inhibitors (generally 
contraindicated, but in presence of life-
threatening, severe malaria and in the 
absence of other therapy, quinidine should 
be administered initially while artesunate is 
obtained from CDC)
Increases quinidine levels (may increase 
probability of arrthymia)
Antiretroviral drugs: Ritonavir 
Chloroquine None None
Primaquine None Potential for increased toxicity
Glucose-6-phosphate dehydrogenase 
deficiency oxidative drug use
Antibacterial drugs (Note: clarithromycin and azithromycin are listed under “antimycobacterial drugs”)
Doxycycline Increases doxycycline clearance:
Anticonvulsant drugs: phenytoin, 
carbamazepine
Antimycobacterial drugs: rifampin
Potential for increased toxicity of concomitant 
drug:
Antithrombotic drugs: warfarin
Erythromycin Gastroinetestinal drugs: cisapride Increases concomitant drug levels:
Anticonvulsants: carbamazepine, clozapine
Antiinflammtory drugs: cyclosporine, 
methylprednisolone
Asthma drugs: theophylline
Cardiac drugs: digoxin
* The drug interactions were selected on the basis of their potential clinical significance and are not inclusive of all potential drug interactions (see drug label for complete 
information about drug interactions).
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FIGURE 1. Recommended immunization schedule for HIV-infected* children aged 0–6 years — United States, 2009
For those who fall behind or start late, see the catch-up schedule
This schedule summarizes recommendations for routine administration 
of vaccines for HIV-infected children 0–6 years and indicates the recom-
mended ages for vaccine administration in this population for childhood 
vaccines licensed in the United States as of December 1, 2008. Any dose 
not administered at the recommended age should be administered at 
a subsequent visit, when indicated and feasible. Licensed combination 
vaccines may be used whenever any component of the combination is 
indicated and other components of the vaccine are not contraindicated and 
 1. Hepatitis B vaccine (HepB). (Minimum age: birth)
At birth:
Administer monovalent HepB to all newborns before hospital •	
discharge.
If mother is hepatitis B surface antigen (HBsAg)-positive, administer •	
HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 
hours after birth.
If mother’s HBsAg status is unknown, administer HepB within 12 hours •	
after birth. Determine mother’s HBsAg status as soon as possible and 
if HBsAg-positive, administer HBIG (at no later than age 1 week).
After the birth dose:
The HepB series should be completed with either monovalent HepB •	
or a combination vaccine containing HepB. The second dose should 
be administered at age 1 through 2 months. The final dose should be 
administered no earlier than age 24 weeks. Infants born to HBsAg-
positive mothers should be tested for HBsAg and antibody to HBsAg 
(anti-HBs) after completion of at least 3 doses of a licensed HepB 
series, at age 9 through 18 months (generally at the next well-child 
visit).
4-month dose:
It is permissible to administer 4 doses of HepB when combination •	
vaccines are administered after the birth dose. If monovalent HepB 
is used for doses after the birth dose, a dose at age 4 months is not 
needed.
* These guidelines also correspond to perinatally HIV-exposed children who 
are awaiting laboratory confirmation that they are HIV-uninfected.
 Vaccine         Age Birth
1
month
2
months
4
months
6
months
12
months
15
months
18
months
19–23
months
2–3
years
4–6
years
see 
footnote 1HepBHepB
RV RV RV2
Hib Hib Hib4
 Hepatitis B1
 Rotavirus2
 Haemophilus infl uenzae type b4
DTaP DTaP DTaP DTaP Diphtheria, Tetanus, Pertussis3 DTaP
MCVMeningococcal10
13
months
HepB
Hib
IPV IPV Inactivated Poliovirus IPVIPV
HepA SeriesHepatitis A9 HepA (2 doses)
PPSVPCV PCV PCV Pneumococcal
5 PCV
 Infl uenza6 TIV (Yearly)
 Measles, Mumps, Rubella7 Do not administer to severely immunosupressed (CD4+ T-lymphocyte percentages <15%) children
 Varicella8
Do not administer to severely immunosupressed (CD4+ age specifi c T-lymphocyte percentages <15%) children
Varicella Varicella
MMR MMR
see 
footnote 3
These recommendations should also be used for perinatally HIV-exposed children who are awaiting laboratory confi rmation that they are HIV-uninfected.
Range of recommended ages for vaccination
Certain high-risk groups
if approved by the Food and Drug Administration for that dose of the series. 
Providers should consult the relevant Advisory Committee on Immunization 
Practices statement for detailed recommendations. Clinically significant 
adverse events that follow immunization should be reported to the Vaccine 
Adverse Event Reporting System (VAERS). Guidance about how to obtain 
and complete a VAERS form is available at http://www.vaers.hhs.gov or 
telephone 800-822-7967.
Post-vaccination:
Testing is recommended for HIV-infected children and should be •	
performed 1 to 2 months after adminis tration of the last dose of the 
vaccine series using a method that allows determination of a protective 
level of anti-HBs (greater than or equal to 10 mIU/mL).
Children with anti-HBs levels of less than 10 mIU/mL after the primary •	
series should be revaccinated. Administering 3 doses on an appro-
priate schedule, followed by anti-HBs testing 1 to 2 months after the 
third dose, usually is more practical than serologic testing after one 
or more doses of vaccine.
Booster dose:
In HIV-infected children, the need for booster doses has not been •	
determined. Annual anti-HBs testing and booster doses when anti-
HBs levels decline to less than 10 mIU/mL should be considered in 
persons with ongoing risk for exposure. See MMWR 2005:54(No. 
RR-16).
 2. Rotavirus vaccine (RV). (Minimum age: 6 weeks)
Practitioners should consider the potential risks and benefits of •	
administering rotavirus vaccine to infants with known or suspected 
altered immunocompetence; consultation with an immunologist or 
infectious diseases specialist is advised. No safety or efficacy data 
are available for the administration of rotavirus vaccines to infants who 
are potentially immunocompromised, including those who are HIV-
positive. However, the following considerations support vaccination of 
HIV-exposed or HIV-infected infants: a) in infants born to HIV-positive 
mothers, the HIV diagnosis may not be established before the age of 
the first rotavirus vaccine dose (only 1.5%–3% of HIV-exposed infants 
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in the United States will eventually be determined to be HIV infected); 
and b) vaccine strains of rotavirus are considerably attenuated.
Administer the first dose at age 6 through 14 weeks (maximum age •	
14 weeks 6 days). Vaccination should not be initiated for infants aged 
15 weeks or older.
Administer the final dose in the series by age 8 months 0 days.•	
If Rotarix•	 ® is administered at ages 2 and 4 months, a dose at 
6 months is not indicated.
 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine 
(DTaP). (Minimum age: 6 weeks)
The fourth dose may be administered as early as age 12 months, •	
provided at least 6 months have elapsed since the third dose.
Administer the final dose in the series at age 4 through 6 years.•	
 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum 
age: 6 weeks)
If PRP-OMP (PedvaxHIB•	 ® or ComVax® [Hep B-Hib]) is administered 
at ages 2 and 4 months, a dose at age 6 months is not indicated.
TriHiBit•	 ® (DTaP/Hib) should not be used for doses at 2, 4 or 6 months 
of age but can be used as the final dose in children aged 12 months 
or older.
Clinicians and other health-care providers might consider use of Hib •	
among HIV-infected children aged 60 months and older who did not 
receive an age-appropriate Hib vaccination series by 60 months of 
age. See MMWR 2006;55(No. RR-15).
 5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal 
conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide 
vaccine [PPSV])
PCV is recommended for all HIV-infected children aged younger than •	
5 years. Children less than or equal to 23 months should be vacci-
nated according to the routine PCV schedule. For dosing intervals of 
children starting the vaccination schedule after age 2 months, see 
MMWR 2000;49(No. RR-9). For incompletely vaccinated children 
aged 24 through 59 months, administer 2 doses of PCV at least 8 
weeks apart. Children who have previously received 3 PCV doses 
need only 1 dose.
Administering PCV to HIV-infected children 5 years or older is not •	
contraindicated.
Children aged 2 years or older also should receive PPSV 2 or more •	
months after their last PCV dose.
 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated 
influenza vaccine [TIV])
Administer annually to HIV-infected children aged 6 months through •	
6 years and to all their eligible close contacts (including household 
members). Only TIV should be used for HIV-infected children.
For healthy nonpregnant close contacts aged 2 through 49 years, •	
either live, attenuated influenza vaccine (LAIV) or TIV may be used.
Children receiving TIV should receive 0.25 mL if aged 6 through 35 •	
months or 0.5 mL if aged 3 years or older.
Administer 2 doses (separated by at least 4 weeks) to children •	
aged younger than 9 years who are receiving influenza vaccine for 
the first time or who were vaccinated for the first time during the 
previous influenza season but received only 1 dose. See MMWR 
2008;57(No. RR-7).
 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 
12 months)
MMR is recommended for all asymptomatic HIV-infected children •	
who are not severely immunosuppressed and who lack evidence of 
measles immunity.
MMR for symptomatic HIV-infected children should be considered if •	
they do not have evidence of severe immunosuppression and lack 
evidence of measles immunity.
The first dose of MMR should be administered as soon as possible •	
after the first birthday. Consideration should be given to administering 
the second dose 1 month (i.e., a minimum of 28 days) after the first 
dose rather then waiting until age 4 through 6 years.
MMR and other measles-containing vaccines are not recommended •	
for HIV-infected children who have evidence of severe immunosup-
pression (CD4+ T-lymphocyte percentages less than 15%). See 
MMWR 1998;47(No. RR-8), “TABLE 2. Age-specific CD4+ T-lymphocye 
count and percent of total lymphocytes as criteria for severe immu-
nosuppression in persons infected with human immunodeficiency 
virus (HIV).”
Measles-mumps-rubella-varicella (MMRV) vaccine has not been stud-•	
ied in HIV-infected children and should not be substituted for MMR.
 8. Varicella vaccine. (Minimum age: 12 months)
Limited data are available on safety and immunogenicity of varicella •	
vaccine in HIV-infected children aged 1 through 8 years in CDC 
immunologic categories 1 and 2 (CD4+ age-specific T-lymphocyte 
percentages 15% or greater) and clinical categories N, A, and B.
Single-antigen varicella vaccine should be considered for HIV-infected •	
children who have CD4+ age-specific T-lymphocyte percentages 
15% or greater. Eligible children should receive 2 doses 3 months 
apart, with the first dose administered as soon as possible after the 
first birthday.
Varicella vaccine is not recommended for HIV-infected children who •	
have evidence of severe immunosuppression (CD4+ T-lymphocyte 
percentages less than 15%). See MMWR 2007;56(No. RR-4]).
MMRV vaccine has not been studied in HIV-infected children and •	
should not be substituted for single-antigen varicella vaccine.
 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
Administer to all children aged 12 through 23 months). The 2 doses •	
in the series should be administered at least 6 months apart.
Children not fully vaccinated by age 2 years can be vaccinated at •	
subsequent visits.
HepA is also recommended for children 24 months and older who live •	
in areas where vaccination programs target older children or who are 
at increased risk for infection See MMWR 2006;55(No. RR-7).
 10. Meningococcal vaccine. (Minimum age: 2 years for meningococcal 
conjugate vaccine [MCV] and for meningococcal polysaccharide vac-
cine [MPSV])
Administer MCV to children aged 2 through 6 years who have •	
terminal complement component deficiency, anatomic or func-
tional asplenia and certain other high-risk groups. See MMWR 
2007;56(48):1265–6.
Children who received MPSV 3 or more years previously and remain •	
at increased risk for meningococcal disease should be revaccinated 
with MCV.
Children with HIV most likely are at increased risk for meningococcal •	
disease but not to the extent as for invasive S. pneumoniae infection. 
Although the efficacy of MCV among HIV-infected children is unknown, 
providers may elect to vaccinate HIV-infected children.
For more information, see the catch-up schedule (http://www.cdc.gov/
vaccines/recs/schedules/child-schedule.htm#catchup)
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Range of recommended ages for vaccination
Certain high-risk groups
Catch-up immunization
7–10
years
11–12
years
13–14
years
15
years
16–18
years
see 
footnote
2
Diphtheria, Tetanus, Pertussis1
Human Papillomavirus2
see 
footnote
1
HPV (3 doses)
Tdap
HPV Series
Meningococcal3 MCV MCV MCV
Tdap
Pneumococcal5 PPSV
Infl uenza4 TIV (Yearly)
Inactivated Poliovirus8 IPV Series
Hepatitis B7 HepB Series
Hepatitis A6 HepA Series
Measles, Mumps, Rubella9
Varicella10
 Vaccine
    Age
Do not administer to severely immunosupressed (CD4+ T-lymphocyte percentages <15% or T-lymphocyte count <200 cells/µL) children or adolescents
Do not administer to severely immunosupressed (CD4+ age specifi c T-lymphocyte percentages <15% or T-lymphocyte count <200 cells/µL) children or adolescents
Varicella Series
MMR Series
FIGURE 2. Recommended immunization schedule for HIV-infected children aged 7–18 years — United States, 2009
This schedule summarizes recommendations for routine administration of 
vaccines for HIV-infected children and adolescents aged 7 through 18 years 
and indicates the recommended ages for vaccine administration for vaccines 
licensed in the United States as of December 1, 2008. Additional vaccines 
may be licensed and recommended after this immunization schedule is pub-
lished. Licensed combination vaccines may be used whenever a component 
of the combination is indicated and other components of the vaccine are 
 1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) 
(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)
Administer at age 11 or 12 years for those who have completed the •	
recommended childhood DTP/DTaP vaccination series and have not 
received a tetanus and diphtheria toxoid (Td) booster dose.
Adolescents aged 13 through 18 years who have not received Tdap •	
should receive a dose.
A 5-year interval from the last Td dose is encouraged when Tdap is •	
used as a booster dose; however, a shorter interval may be used if 
pertussis immunity is needed.
 2. Human papillomavirus vaccine (HPV) (Minimum age: 9 years, 
females only)
No data are available on immunogenicity, safety, and efficacy of HPV •	
vaccine in HIV-infected females. However, because quadrivalent HPV 
vaccine is a noninfectious vaccine, it can be administered to females 
who are immunosuppressed because of disease or medications, 
including HIV-infected females. However, the immune response and 
vaccine efficacy might be less than that in immunocompetent persons. 
See MMWR 2007;56(No. RR-2) and MMWR 2006;55(No. RR-15). 
Studies are ongoing in HIV-infected females.
Administer the first dose to females at age 11 or 12 years.•	
Administer the second dose 2 months after the first dose and the third •	
dose 6 months (at least 24 weeks) after the first dose.
Administer the series to females at age 13 through 18 years if not •	
previously vaccinated.
not contraindicated and if approved by the Food and Drug Administration 
for that dose of the series. Providers should consult the relevant Advisory 
Committee on Immunization Practices statement for detailed recommenda-
tions. Clinically significant adverse events that follow immunization should 
be reported to the Vaccine Adverse Event Reporting System (VAERS). 
Guidance about how to obtain and complete a VAERS form is available at 
http://www.vaers.hhs.gov or telephone 800-822-7967.
 3. Meningococcal vaccine (meningococcal conjugate vaccine [MCV])
Administer at age 11 or 12 years or at age 13 through 18 years if not •	
previously vaccinated.
Administer to previously unvaccinated college freshmen living in a •	
dormitory.
MCV is recommended for children aged 1 through 10 years who •	
have complement component deficiency, anatomic or functional 
asplenia, and certain other groups at high risk. See MMWR 2007; 
56(48);1265–6.
Persons who received •	 meningococcal polysaccharide vaccine 
(MPSV) 5 or more years previously and remain at increased risk for 
meningococcal disease should be revaccinated with MCV. See MMWR 
2005;54(No. RR-7).
HIV-infected patients likely are at increased risk for meningococcal •	
disease but not to the extent as for invasive Streptococcus pneu-
moniae infection. Although the efficacy of MCV among HIV-infected 
patients is unknown, HIV-infected patients aged 7 through 10 years 
who do not fit into the above groups may elect vaccination.
 4. Influenza vaccine (trivalent inactivated influenza vaccine [TIV])
Administer annually to HIV-infected children and adolescents aged •	
6 months through 18 years and to all eligible close contacts (includ-
ing household members). Only TIV should be used for HIV-infected 
persons.
For healthy nonpregnant close contacts aged 2 through 49 years, •	
either live, attenuated influenza vaccine (LAIV) or TIV may be used.
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Administer 2 doses (separated by at least 4 weeks) to children aged •	
younger than 9 years who are receiving influenza vaccine for the first 
time or who were vaccinated for the first time during the previous 
influenza season but received only 1 dose. All other children aged 
6 months through 18 years should receive 1 dose, See MMWR 
2008;57(No. RR-7).
 5. Pneumococcal vaccine (pneumococcal conjugate vaccine [PCV]; 
pneumococcal polysaccharide vaccine [PPSV])
If not previously vaccinated with PPSV, children and adolescents aged •	
7 through 18 years should receive 1 dose of PPSV.
If previously vaccinated with PPSV, a single revaccination should •	
be administered after 5 years. See MMWR 1997;46(No. RR-8) and 
MMWR 2000;49(No. RR-9).
Administering PCV to HIV-infected children 5 years or older is not •	
contraindicated.
 6. Hepatitis A vaccine (HepA)
Administer 2 doses at least 6 months apart.•	
HepA is recommended for children older than I year who live in •	
areas where vaccination programs target older children or who are at 
increased risk for infection. See MMWR 2006;55(No. RR-7).
 7. Hepatitis B vaccine (HepB)
Administer the 3-dose series to those who were not previously •	
vaccinated.
Postvaccination testing is recommended for HIV-infected persons. •	
Testing should be performed 1 to 2 months after administration of the 
last dose of the vaccine series using a method that allows determi-
nation of a protective level of antibody to hepatitis B surface antigen 
(anti-HBs) (greater than or equal to 10 mIU/mL). Persons found to 
have anti-HBs levels of less than 10 mIU/mL after the primary series 
should be revaccinated. Administration of 3-doses on an appropriate 
schedule, followed by anti-HBs testing 1 to 2 months after the third 
dose, usually is more practical than serologic testing after 1 or more 
doses of vaccine. Modified dosing regimens, including doubling of the 
standard antigen dose, might increase response rates. However, data 
are limited on response to these alternative vaccination schedules.
In HIV-infected persons, the need for booster doses has not been •	
determined. Annual anti-HB testing and booster doses when anti-HBs 
levels decline to less than 10 mIU/mL should be considered in persons 
with ongoing risk for exposure. See MMWR 2005:54(No. RR-16).
 8. Inactivated poliovirus vaccine (IPV)
For children who received an all-IPV or all-oral poliovirus (OPV) series, •	
a fourth dose is not necessary if the third dose was administered at 
age 4 years or older.
If both OPV and IPV were administered as part of a series, a total •	
of 4 doses should be administered, regardless of the child’s current 
age.
 9. Measles, mumps, and rubella vaccine (MMR)
If not previously vaccinated and eligible, administer 2 doses, or •	
administer the second dose for those who received only 1 dose, with 
at least 4 weeks between doses.
MMR is recommended for all asymptomatic HIV-infected children and •	
adolescents who do not have evidence of severe immunosuppression 
and who lack evidence of measles immunity.
MMR should be considered for symptomatic HIV-infected children and •	
adolescents who do not have evidence of severe immunosuppression 
and who lack evidence of measles immunity.
MMR and other measles-containing vaccines are not recommended •	
for HIV-infected children who have evidence of severe immuno-
suppression (CD4+ T-lymphocyte percentages less than 15% or 
T-lymphocyte count less than 200 cells/μL). See MMWR 1998;47(No. 
RR-8), “TABLE 2. Age-specific CD4+ T-lymphocye count and percent of 
total lymphocytes as criteria for severe immunosuppression in persons 
infected with human immunodeficiency virus (HIV).”
Measles-mumps-rubella-varicella (MMRV) vaccine has not been stud-•	
ied in HIV-infected children and should not be substituted for MMR.
 10. Varicella vaccine
Limited data are available on safety and immunogenicity of varicella •	
vaccine in HIV-infected children aged 1 through 8 years in CDC 
immunologic categories 1 and 2 (CD4+ T-lymphocyte percentages 
greater than or equal to 15%) and clinical categories N, A, and B. 
Single-antigen varicella vaccine should be considered for HIV-infected 
children aged 7 through 8 years with CD4+ T-lymphocyte percentages 
greater than or equal to 15% or age-specific T-lymphocyte count 
greater than or equal to 200 cells/μL and who lack evidence of immu-
nity. Eligible children should receive 2 doses 3 months apart.
Data are lacking on use of varicella vaccine in HIV-infected children 8 •	
years or older . However, on the basis of expert opinion, the safety of 
varicella vaccine in HIV-infected persons aged 8 years or older with 
similar levels of immune function (CD4+ age-specific T-lymphocyte 
percentages greater than or equal to 15% or T-lymphocyte count 
greater than or equal to 200 cells/μL) is likely to be similar to that of 
children aged less than 8 years. Immunogenicity might be lower in 
HIV-infected adolescents (and adults). However, weighing the risk 
for severe disease from wild varicella zoster virus and the potential 
benefit of vaccination, vaccination (2 doses administered 3 months 
apart) can be considered for children and adolescents aged 9 through 
18 years who lack evidence of immunity.
Varicella vaccine is not recommended for HIV-infected children or •	
adolescents who have evidence of severe immunosuppression (CD4+ 
age-specific T-lymphocyte percentages less than 15% or T-lymphocyte 
count less than 200 cells/μL).
MMRV vaccine has not been studied in HIV-infected children and •	
should not be substituted for single-antigen varicella vaccine.
For evidence of immunity guidance and other details, see •	 MMWR 
2007;56(No.RR-4).
Note: Haemophilus influenzae type b conjugate vaccine (Hib)
Hib conjugate vaccines are available in single- or combined-antigen 
preparations. Hib is recommended routinely for all children through age 59 
months. Clinicians and other health-care providers might consider use of 
Hib among HIV-infected children 60 months and older who did not receive 
an age-appropriate vaccine series before age 59 months. See MMWR 
2006:55(No. RR-15).
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Abbreviations and Acronyms
ACIP Advisory Committee on Immunization Practices
AIDS acquired immunodeficiency syndrome
anti-HCV antibody to hepatitis C virus
anti-HBc antibody to hepatitis B core antigen
anti-HBs hepatitis B surface antibody
ART antiretroviral therapy
ASCUS squamous cells of undetermined significance
BCG bacille Calmette-Guérin
CF complement fixation
CI confidence interval
CIN cervical intraepithelial neoplasia
CMV cytomegalovirus
CNS central nervous system
CT computed tomography
CSF cerebrospinal fluid
DOT directly observed therapy
EIA enzyme immunoassay
FDA Food and Drug Administration
FTA-ABS fluorescent treponemal antibody absorption
GI gastrointestinal
HAART highly active antiretroviral treatment
HBeAg hepatitis B virus early antigen-positive
HBIG hepatitis B immune globulin
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HIV human immunodeficiency virus
HHV human herpesvirus
HPV human papillomavirus
HSIL high-grade squamous intraepithelial lesions
HSV herpes simplex virus
IFA indirect fluorescent antibody
IM intramuscularly
IRIS immune reconstitution inflammatory syndrome
IV intravenous
IVIG intravenous immune globulin
JCV Jamestown Canyon virus
KS Kaposi sarcoma
LEEP loop electrosurgical excision procedure
LSIS low-grade SIL
LTBI latent tuberculosis infection
MAC Mycobacterium avium complex
MCV4 conjugated meningococcal vaccine
MDR TB multidrug-resistant tuberculosis
MPSV4 meningococcal polysaccharide vaccine
MRI magnetic resonance imaging
MRSA methicillin-resistant Staphylococcus aureus
NNRTI non-nucleoside reverse transcriptase inhibitor
OAR AIDS Research (OAR) of NIH
OI opportunistic infection
OPC oropharyngeal candidiasis
PACTG Pediatric AIDS Clinical Trials Group
PBMC peripheral blood mononuclear cell
PCP Pneumocystis jirovecii pneumonia
PCR polymerase chain reaction
PCV pneumococcal conjugate vaccine
PDH progressive disseminated histoplasmosis
PI protease inhibitor
PML progressive multifocal leukoencephalopathy
PPD purified protein derivative
PPSV pneumococcal polysaccharide vaccine following 
licensure of pneumococcal conjugate vaccine 
(PCV)
PPV pneumococcal polysaccharide vaccine
SIL squamous intra-epithelial lesions
TB tuberculosis
TE Toxoplasma encephalitis
TP-PA Treponema pallidum particle agglutination test
TST tuberculin skin test
TMP-SMX trimethoprim/sulfamethoxazole
VariZIG varicella zoster immune globulin currently in 
production
VDRL Venereal Disease Research Laboratory
VZIG varicella-zoster immune globulin, which is no 
longer produced
VZV varicella-zoster virus
XDR TB extensively drug-resistant TB
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1. HIV-infected children should receive live attenuated varicella 
vaccine…
A. under no circumstances.
B. if their CD4+ percentage is ≥25%, and their mother’s CD4+ per-
centage is also ≥15%.
C. if their CD4+ percentage is ≥15%.
D. if they are receiving highly active antiretroviral therapy.
2. HIV-infected children who are exposed to a person with varicella 
should…
A. receive live attenuated varicella vaccine.
B. receive acyclovir prophylaxis for 21 days.
C. be tested for the presence of varicella antibodies before any action 
is taken.
D. receive a one-time dose of either intravenous immunoglobulin or 
VariZig as prophylaxis.
3. HIV-infected children should receive regular intravenous immuno-
globulin prophylaxis…
A. if they have documented hypogammaglobulinemia.
B. from the time of diagnosis until age 5 years.
C. if they are in day care.
D. if they have had more than episodes of otitis media in 1 year while 
on highly-active antiretroviral therapy.
4. An HIV-exposed infant can be considered presumptively HIV 
uninfected if…
A. during pregnancy the mother had undetectable HIV virus while 
receiving highly active antiretroviral therapy.
B. at least two HIV-DNA-PCR are negative, with one test obtained 
at ≥2 weeks of age, and one test obtained at ≥4 weeks of age.
C. at least two HIV-DNA-PCR are negative, with one test obtained 
at ≥1 month of age, and one test obtained at ≥4 months of age.
D. an HIV-DNA-PCR obtained in the first week of life is negative.
5. Considerations which support administration of live rotavirus 
vaccine (Rotateq) to HIV-exposed infants include every one of the 
following except…
A. HIV diagnosis might not be established in infants born to HIV-
infected mothers before the age of the first rotavirus vaccine dose.
B. only 1.5%–3% of HIV exposed infants in the United States will 
eventually test HIV positive.
C. the incidence of rotavirus infection is higher among HIV-infected 
infants than in non-HIV-exposed infants.
D. Rotateq vaccine is considerably attenuated.
6. When opportunistic infections occur within 12 weeks of initiation 
of highly active antiretroviral therapy…
A. antiretroviral therapy should be continued and treatment for the 
OI initiated.
B. steroid therapy should be initiated.
C. they are usually acquired by recent frequent contact with HIV-
infected persons.
D. antiretroviral therapy should be discontinued, and genotype testing 
for antiretroviral resistance should be performed before resuming.
7. The best approach to reducing the risk for cryptosporidiosis from 
drinking water is…
A. primary prophylaxis with nitazoxanide in HIV-infected children 
with CD4+ percentage of <15%.
B. boiling drinking water.
C. the use of only bottled water.
D. treatment of water with iodine or chlorine.
8. Primary prophylaxis of serious bacterial infections in HIV-infected 
children…
A. need not be attempted.
B. is best accomplished with daily administration of trimethoprim-
sulfamethoxazole.
C. is best accomplished with weekly administration of azithromycin.
D. requires the addition of intravenous immunoglobulin in children 
whose CD4+ percentage is <15%.
9. Secondary prophylaxis for Mycobacterium avium complex (MAC) 
in HIV-infected children can be discontinued if (select the one that 
is false)…
A. a complete course of treatment for MAC has been administered.
B. microscopic examination of gastric aspirate reveals no acid-fast 
bacilli.
C. the child remains asymptomatic.
D. there has been a sustained recovery of CD4+ cell number to well 
above the age-specific target.
10. After immune reconstitution while on highly-active antiretroviral 
therapy, most secondary prophylaxis regimens in HIV-infected 
children can be discontinued. An exception is…
A. Mycobacterium avium.
B. Bartonella henselae.
C. Coccidioides immitis.
D. Cytomegalovirus.
11. Which best describes your professional activities?
A. Physician.
B. Nurse.
C. Health educator.
D. Office staff
E. Other.
12. I plan to use these recommendations as the basis for… (Indicate all 
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
Goal and Objectives
This goal of this report is to provide evidence-based guidelines for treatment of opportunistic pathogens that are common in human immunodeficiency 
virus (HIV)-exposed and HIV-infected children in the United States. This report provides guidelines for clinicians and health-care professionals regarding 
treatment of opportunistic pathogens in children. Upon completion of this activity, the reader should be able to 1) describe the differences between HIV-
infected children in the clinical presentation and laboratory diagnosis of HIV-associated opportunistic infections; 2) describe recommended treatment of 
HIV-related opportunistic infections in HIV-infected children; 3) describe recommendations for screening for M. tuberculosis infection in HIV-infected 
children; 4) describe treatment of suspected congenital syphilis in HIV-exposed infants and 5) describe recommendations for secondary chemoprophylaxis of 
HIV-infected children following infection with HIV-associated opportunistic pathogens.
To receive continuing education credits, please answer all of the following questions.
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13. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
14. After reading this report, I am confident I can describe the 
differences between HIV-infected children and adults in the 
clinical presentation and laboratory diagnosis of HIV-associated 
opportunistic infections.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
15. After reading this report, I am confident I can describe recommended 
treatment of HIV–related opportunistic infection in HIV infected 
children.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
16. After reading this report, I am confident I can describe recommen-
dations for screening for M. tuberculosis infection and diagnosis and 
treatment of M. tuberculosis disease in HIV-infected children.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
17. After reading this report, I am confident I can describe diagnosis and 
treatment of suspected congenital syphilis in HIV-exposed infants.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
18. After reading this report, I am confident I can describe recommen-
dations for secondary chemoprophylaxis of HIV-infected children 
following infection with HIV-associated opportunistic pathogens.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
19. The learning outcomes (objectives) were relevant to the goals of this 
report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
20. The instructional strategies used in this report (text, tables, and 
figures) helped me learn the material.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
21. The content was appropriate given the stated objectives of the report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
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Correct answers for questions 1–10.
1C; 2D; 3A; 4B; 5C; 6A; 7D; 8A; 9B; 10C.
22. The authors demonstrated expertise in the subject matter.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
23. Overall, the quality of the journal article was excellent.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
24. The availability of CE credit influenced my decision to participate 
in this activity.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
25. These recommendations will improve the quality of my practice.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
26. The MMWR format was conductive to learning this content.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
27. Do you feel this course was commercially biased? (indicate yes or 
no; if yes, please explain in the space provided)
A. Yes. B. No
28. How did you learn about the continuing education activity?
A. Internet
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal)
C. Coworker/supervisor
D. Conference presentation
E. MMWR subscription
F. Other
29. The content expert(s) demonstrated expertise in the subject matter.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Undecided.
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